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Abstract 
 
Background 
Currently, tumour response to radiotherapy cannot be predicted meaning that those patients 
with tumours resistant to the therapy endure the harmful side effects associated with 
ionising radiation in the absence of therapeutic gain. The aim of this project was to identify 
protein biomarkers predictive of radiotherapy response using comparative proteomic 
platforms to study radioresistant cell line models. The identification of such biomarkers 
will enable radiotherapy to be tailored on an individual patient basis and hence increase 
treatment efficacy.  
 
Methods 
Seven radioresistant (RR) cell line models derived from breast, head and neck (oral), and 
rectal cancers were investigated to identify differentially expressed proteins (DEPs) 
associated with radiotherapy resistance. This included the establishment of 2 RR rectal 
cancer cell line models and the proteomic analysis of 2 RR oral cancer cell lines and 2 RR 
rectal cancer cell lines. Proteomic analysis included 3 different platforms, namely antibody 
microarray, 2D MS and iTRAQ. Data mining of all biomarker discovery data, from all 7 
novel RR cell lines was carried out using Ingenuity Pathway Analysis (IPA) which 
identified canonical pathways associated with the data. Protein candidates from selected 
canonical pathways were confirmed by western blotting and assessed clinically using 
immunohistochemistry. 
 
Results 
Following the combination of all biomarker discovery data for all 7 RR cell lines, 373 
unique DEPs were successfully mapped onto the Ingenuity Knowledge Base, generating 
339 canonical pathways. Of these, 13 of the most relevant pathways were selected for 
further interpretation. Several proteasomal subunits were identified during the biomarker 
discovery phase and were mapped onto the protein ubiquitination pathway by IPA. DR4, 
was identified in 4/7 RR cell lines and was mapped onto the death receptor signalling 
pathway by IPA. Radiotherapy is typically thought to induce cellular apoptosis via the 
intrinsic (mitochondrial) pathway, therefore the repeated identification of the DR4 protein 
involved in the extrinsic apoptotic pathway has potentially lead to the discovery of a novel 
relationship between radiotherapy and the extrinsic death receptor pathway. The differential 
expression of both the 26S Proteasome and DR4 were confirmed by western blotting. 
Clinical assessment using immunohistochemistry revealed a significant association between 
expression of the 26S Proteasome and radioresistance in breast cancer. 
 
Discussion 
A large number of DEPs which may be associated with radiotherapy resistance in breast, 
oral and rectal cancers have been identified using comparative proteomic platforms. The 
protein ubiquitination pathway and the death receptor signalling pathway may play a 
significant role in radioresistance and proteins within these pathways may be putative 
biomarkers of radiotherapy response.  
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Chapter 1.  Introduction to radiotherapy 
1.1 Radiotherapy 
Over 50% of all cancer patients may benefit from receiving a treatment modality that 
includes radiotherapy. This can be employed in various different clinical regimens, given to 
various different tumour types, either as the primary therapy or in combination with other 
anti-cancer protocols. For example, treatment of head and neck squamous cell carcinoma 
(HNSCC) (e.g. oral and laryngeal cancers) in the neoadjuvant setting involves various 
options including radiotherapy with or without chemotherapy, and most recently the use of 
radiotherapy in combination with molecularly targeted agents, such as cetuximab, which 
function to inhibit EGFR activity (section 2.2.3.3) (Begg, 2012). Radiotherapy in the neo-
adjuvant setting for HNSCC can in some cases lead to cure. Rectal cancers also employ a 
pre-operative radiotherapy regimen with the aim being to shrink the tumour mass prior to 
surgery. The most commonly used regimen is a long-course regimen (section 5.2.5) 
combined with 5-fluorouracil (5-FU) based chemotherapy (Bosset et al., 2006, Julien and 
Thorson, 2010, Suarez et al., 2008, Allal et al., 2004). Adjuvant radiotherapy provides 
additional treatment post-surgery for example in breast cancer. Radiotherapy following 
breast conserving surgery, collectively known as breast conserving therapy (BCT), is used  
to eradicate any microscopic malignant cells which may be remaining and therefore provide 
risk of possible tumour recurrence. 
 Radiotherapy ultimately functions to damage cellular DNA. The treatment initiates 
its lethal affects through the fractionated delivery of high energy X-rays, resulting in the 
production of highly reactive free radicals, predominantly hydroxyl radicals, within the 
target tissue. Such free radicals lead to DNA damage through the formation of reactive 
 oxygen and nitrogen species, which result from oxidative respiration and/or products of 
lipid peroxidation. Radiotherapy has the ability to cause a broad spectrum of DNA damage, 
such as single-stranded breaks (SSBs) and double-stranded breaks (DSBs), alterations to 
bases, destruction of sugars and interstrand crosslinks (Houtgraaf et al., 2006). It is this 
damage that results in the activation of several transduction pathways. Such pathways 
function to detect genomic injury and lead to cell cycle arrest, allowing for DNA repair or, 
in cases where damage is too significant, induction of apoptosis to prevent the damaged  
DNA from further replication (Hoeijmakers, 2001, Damia and D'Incalci, 2007). 
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1.2 Maintaining Cellular Homeostasis 
Mammalian cells are continuously exposed to DNA damage from both endogenous insults, 
such as reactive oxygen species (ROS) and DNA replication errors, or exogenous stresses 
such as alkylating agents, chemical compounds, UV light or ionising radiation (Houtgraaf 
et al., 2006, Jalal et al., 2011b). Therefore, in order to maintain cellular homeostasis, a 
carefully orchestrated balance between cellular proliferation, repair and death is required. 
DNA lesions are rapidly detected during the cell cycling process (section 1.2.1), which in 
turn leads to the activation of the DNA damage response pathway (section 1.2.2), an 
intricate network of cell signalling pathways. It is through an effective DNA damage 
response, that the correct repair processes can be selected (section 1.2.3), or if damage is 
too significant initiation of apoptotic pathways (section 1.2.4) (Schmitt et al., 2007). 
1.2.1 Cell Cycle regulation 
There are a number of proteins involved in the tight regulation of the cell cycle. Such 
proteins, along with careful timing ensure that DNA is replicated correctly during the S 
phase and that identical chromosomes are segregated equally to the resultant daughter cells 
during the M phase (Sandal, 2002). Periods between these two phases are known as ‘gap’ 
phases of which there are two; G1 and G2. Cells in G1 can, before committing to DNA 
replication, enter a resting phase known as G0. Cells in this stage of the cycling process 
account for the major part of the non-growing, non-proliferating cells in the human body 
(Vermeulen et al., 2003). The transition between different phases is a hallmark of cell cycle 
regulation. In the presence of DNA damage, cells have several mechanisms of disrupting 
the cycling process to ensure the cell cycle does not proceed. These mechanisms are the 
quality control points of the cell cycle and are often referred to as checkpoints. There are 
four main checkpoints, namely the G1/S checkpoint, the intra-S-phase checkpoint, the G2/M 
checkpoint and finally the spindle checkpoint (Figure 1) (Molinari, 2000, Houtgraaf et al., 
2006). Both the G1/S and the G2/M checkpoint have the ability to arrest the cell cycle in the 
presence of DNA damage however, the intra-S-phase checkpoint differs since it has to 
manage replication intermediates and stalled replication forks, in addition to preventing the 
onset of mitosis, where DNA has not been fully replicated (Houtgraaf et al., 2006). The 
spindle checkpoint functions to ensure correct chromosomal segregation, inhibiting 
progression of the cell cycle if a fully functional mitotic spindle has not been formed 
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(Molinari, 2000). Also associated with quality control is the restriction point (R). This 
checkpoint, which occurs between mid and late G1 ensures that cells have received 
sufficient growth signals in order to replicate their DNA, and in turn pass through one 
round of complete cell division. If sufficient growth signals have been relayed, cells will 
pass through the R point, if not, cells will enter G0 (Novak and Tyson, 2004). Progression 
through the cell cycle occurs in a tightly controlled manner. Key regulatory proteins 
involved within this process are the cyclin-dependent kinases (CDKs), a family of 
serine/threonine protein kinases that drive forward cellular proliferation by the 
phosphorylation of specific substrates. Active CDKs are heterodimeric and consist of a 
CDK subunit bound to a cyclin subunit (Sandal, 2002, Harper and Elledge, 1996).Various 
combinations of cyclin/CDK complexes assemble during different phases of the cell cycle, 
all of which have specific activities essential for the progression through various cell cycle 
transitions. Inhibition of different CDKs occurs by one of two families; the INK4 family, 
comprising p16 
INK4a
, p15 
INK4b
, p18 
INK4c
 and p19 
INK4d
 or the CIP/KIP family, comprising 
p21 
cip1/waf1
, P27
 kip1
 and p57
 kip2 
(Malumbres and Barbacid, 2009, Carnero, 2002). All CDK 
inhibitors cause G1 arrest when over expressed in cells. Ordinarily, the relative abundance 
of CDK inhibitors present at any one time during the cycling process functions to set 
thresholds for cyclin-CDK activation that must be overcome in order for the cell cycle to 
continue (Carnero, 2002, Malumbres and Barbacid, 2009). 
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Figure 1: Cell cycle checkpoint control 
The cell cycle consists of 4 main checkpoints. The G1/S and the G2/M checkpoints have the 
ability to arrest the cell cycle in the presence of DNA damage. The intra-S-phase 
checkpoint is responsible for the management of replication folks and also functions to 
prevent mitosis in the absence of fully replicated DNA. Finally the spindle checkpoint 
functions to guarantee chromosomes have been correctly segregated to form a fully 
functional mitotic spindle (Houtgraaf et al., 2006, Molinari, 2000). The restriction point (R) 
is also involved in overall quality control, functioning to ensure that cells have received 
sufficient growth signals to pass a complete round of cell division (Novak and Tyson, 
2004) .  
 
1.2.2  DNA damage response pathway 
Exposure of human cells to DNA damaging agents such as ionising radiation activates the 
DNA damage response (DDR) pathway, ultimately inducing cell cycle arrest (section 
1.2.1). DNA damage leads to the recruitment of multiprotein (sensor) complexes namely, 
MRN (Mre11-Rad50-Nbs-1) and ATRP (ATR-interacting protein) which in turn lead to the 
activation of the important signal transducers (sensor kinases) ATM (ataxia telangiectasia 
mutated) and ATR (ATM and Rad3 related), both of which belong to the PI3K 
(phosphoinositide 3-kinase) – like kinase family (Ashwell and Zabludoff, 2008, Al-Ejeh et 
al., 2010). Recruitment of these sensor kinases by MRN and ATRP, to the site of DNA 
damage (Stolz et al., 2011) leads to the activation of several downstream proteins in the 
DDR pathway, for example the H2AX protein. The ATM/ATR phosphorylation of this 
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protein is essential for the accumulation of MDC1, the key regulator for the 
microenvironment at the site of damaged chromatin. Docking of MDC1 at the damaged site 
allows for the accumulation of multiple adaptor proteins such as BRCA1, NSB1 and 
53BP1. Accumulation of these proteins provides a platform for the amplification of the 
DDR signal, ensuring the efficient activation of the cell cycle checkpoints (Huen and Chen, 
2008). Depending on the type of DNA damage caused, checkpoint proteins 1 and 2 (Chk1 
and Chk2) are phosphorylated and hence activated by ATR and ATM respectively. It is 
generally accepted that ATR activation is driven by single stranded breaks (SSBs) resulting 
from stalled replication forks, whilst ATM is the main initiator of response to double strand 
breaks (DSBs) (Ashwell and Zabludoff, 2008). Whilst there are several regulators involved 
in the cell cycle’s response to DNA damage, the p53 tumour suppressor protein (encoded 
by the TP53 gene) and Chk2 are of particular importance (Darzynkiewicz et al., 2009). In 
the event of DNA damage, ATM is activated and recruited to the site of DNA damage by 
the MRN complex. The ATM kinase subsequently phosphorylates and activates Chk2. This 
activation of Chk2 leads to the phosphorylation of both p53 and MDM2 resulting in the 
stabilisation of p53 by disrupting its association with MDM2, an E3 ubiquitin-ligase protein 
that normally targets p53 for degradation by the 26S Proteasome by interaction with E1 
ubiquitin-activating enzyme and E2 ubiquitin-conjugating enzyme (Motegi et al., 2009, 
Smith et al., 2007, Cheng and Chen, 2010). Once active, p53 induces the transcription of 
p21
cip1/waf1
, a critical regulator of G1/S transition. Binding of p21
cip1/waf1
 to the G1/S 
cyclin/CDK complexes (cyclin E/CDK2 and cyclin D/CDK4) (Malumbres and Barbacid, 
2009) prevents the subsequent phosphorylation of the retinoblastoma protein (pRb). As a 
consequence, E2F remains bound to pRb preventing its transcription of growth stimulatory 
genes required for the progression of the cell through the G1/S phase of the cell cycle. In the 
case of the G2/M checkpoint, ATM results in the activation of both p53-induced 
transcription of p21
cip1/waf1
 and 14-3-3σ. The latter sequesters the cyclin B/CDK1 complex 
(Lossaint et al., 2011) in the cytoplasm, preventing the nuclear phosphorylation events 
needed for G2/M progression (Molinari, 2000, Kesari et al., 2011) (Figure 2). Halting of the 
cell cycle at the G1/S and G2/M checkpoint enables time for DNA repair processes to take 
place (section 1.2.3), or if damage is irreparable, apoptosis (1.2.4) (Raffoul et al., 2007). 
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Figure 2: The cell cycle and DNA damage response 
The cell cycle consists of 4 main phases G1, S, G2 and M. Transition between these 
different phases is the hallmark of cell cycle regulation. The cell cycling process is tightly 
regulated by the cyclin-dependent kinases (CDKs), which are themselves regulated by 
important proteins such as ATM and p53. In the event of DNA damage, ATM activates 
Chk2. Activated Chk2 then phosphorylates p53 and MDM2 resulting in the stabilisation of 
p53 by disrupting its association with MDM2. p53 then induces the transcription of 
p21
cip1/waf1
. Subsequent binding of p21
cip1/waf1
 to the G1/S cyclin/CDK complexes prevents 
transition of the cycle through the G1/S phase (Cheng and Chen, 2010).  At the G2/M 
checkpoint, ATM results in the activation of both p53-induced transcription of p21
cip1/waf1
 
and 14-3-3σ. The latter sequesters the cyclin B/CDK1 complex in the cytoplasm preventing 
the nuclear phosphorylation events needed for G2/M progression (Kesari et al., 2011). 
1.2.3 DNA damage repair 
The occurrence of DNA damage, if not repaired, can be a major contributor to both the 
initiation and subsequent development and progression of malignancy. Cells are equipped 
with DNA repair mechanisms enabling them to rectify, where possible, any DNA damage 
incurred. Several DNA repair systems have been described however, their specific 
utilisation is determined by the type of DNA damage. 
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1.2.3.1 Single strand break (SSB) repair 
SSBs are so named due to the fact that only one of the two strands forming the DNA 
double helix structure has incurred DNA damage. In order for DNA restoration to 
successfully take place, repair mechanisms require the utilisation of the intact 
complimentary strand to act as a template for correction. A number of repair mechanisms 
exist to repair SSBs and ultimately function to remove the damaged base and replace it with 
a base sequence complimentary to that of the undamaged strand. Whilst SSBs can be 
repaired by mechanisms such as mismatch repair (MMR) and nucleotide excision repair 
(NER), ionising radiation-induced SSBs are repaired primarily by base excision repair 
(BER) (discussed below). 
 
Base excision repair (BER) 
The BER pathway functions primarily to repair oxidative damage to the bases of DNA 
which have resulted from reactive oxygen species (ROS) produced from ionising radiation 
(Houtgraaf et al., 2006, Jalal et al., 2011a, Zhu et al., 2009). Upon recognition of damaged 
bases, the pathway proceeds to remove the modified bases(s) and subsequently replace the 
break with nucleotides complementary to the sequence of the intact strand. In this particular 
repair pathway initial, DNA damage is detected by a damage-specific DNA glycosylase 
(Hegde et al., 2008). The sugar-phosphate backbone of the DNA helix is then incised by 
AP endonuclease (APE1) activity, leaving behind a nick in the DNA strand with 5’-
deoxyribose phosphate (dRP) and 3’-OH ends. In the short-patch (SP) pathway of BER, 
DNA polymerase β (polβ) is thought to insert a single nucleotide into the repair gap, 
therefore removing the dRP moiety left behind by the endonuclease (Damia and D'Incalci, 
2007). SSBs induced by ionising radiation are recognised by the PARP1 protein which then 
recruits the XRCC1/DNA ligase III complex to catalyse the nick sealing step, resulting in 
the production of an intact strand (Powell et al., 2010). In long patch (LP) BER however, it 
is possible to insert several nucleotides, rather than just one into the repair gap, implicating 
the use of polβ and/or polδ/ε in gap synthesis. Endonuclease activity takes place by the 
employment of flap endonuclease 1 (FEN1) which subsequently removes the resulting 
short chain ‘flap’ (Sukhanova et al., 2005). The nicked DNA is then sealed by DNA ligase I 
(Figure 3). Both of these pathways can be initiated by either monofunctional or bifunctional 
glycosylases. Through use of these alternatives, the base lesion can be successfully 
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removed, simultaneously to the generation of a nick by their 3’-β-lyase action. The 
resultant moiety can be removed by APE1 which is then thought to predominantly lead to 
polβ-dependent SP-BER. Oxidised bases incurred by ionising radiation are mostly targeted 
by glycosylases of bifunctional nature (Hegde et al., 2008). 
 
 
 
Figure 3: The BER pathway 
DNA glycosylase enzymes detect initial DNA damage. AP endonuclease (APE1) activity 
then proceeds to excise the sugar-phosphate backbone of the DNA helix, leaving behind a 
nick in the DNA strand with 5’- dPR and 3’-OH ends. In short path (SP) repair, DNA 
polymerase β (polβ) inserts a single nucleotide into the repair gap. XRCC1/DNA Ligase III 
then function to catalyse the nick sealing step. In long path (LP) repair however, it is 
possible to insert several nucleotides into the repair gap, implicating the use of polβ and/or 
polδ/ε. Flap endonuclease 1 (FEN1) subsequently removes the short chain ‘flap’. The 
nicked DNA is then sealed by DNA Ligase I (Damia and D'Incalci, 2007, Sukhanova et al., 
2005). 
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1.2.3.2 Double strand break (DSB) repair 
While SSBs are generally simple to repair due to damage being limited to only one of the 
two complementary DNA strands, DSBs present more of a problem owing to both strands 
of the helical structure being severed. Successful repair of DSBs (or death of the cell if 
damage is too significant) is vital due to the generation of small mutations and deletions at 
the site of damage which may give rise to a high risk of subsequent tumour development. 
Whilst repair mechanisms for SSBs involve the use of an intact strand to act as a template 
for synthesis, DSBs create a complete severance of both DNA strands, and repair has to be 
achieved without the use of a complementary strand. DSBs can be repaired by non-
homologous end joining (NHEJ) or homologous recombination repair (HRR) (discussed 
below). 
 
Non-homologous end joining (NHEJ) 
NHEJ is a repair strategy characterised by its ability to join any two ends of exposed DNA, 
regardless of their individual base sequence.  In order for accurate repair this method does 
not rely on extensive homologous sequences but on microhomologies, short homologous 
sequences present on the ends of each strand. If the microhomologies of the two strands 
destined to be joined are compatible then DNA repair is successful. However, NHEJ is also 
prone to error due to this non template approach where by sequence alterations or deletions 
become incorporated into the newly formed DNA sequence (Valerie and Povirk, 2003). 
The NHEJ pathway requires the presence of the DNA-dependent protein kinase (DNA-PK) 
complex, important not only for its direct role in the NHEJ process, but also due to its 
involvement in cell cycle arrest, enabling DNA to be repaired (Park et al., 1999). DNA-PK 
is a nuclear serine-threonine protein made up of two main components, namely DNA-PKc, 
a 460-kDa catalytic subunit and Ku, a heterodimer of Ku70 and Ku80. Ku acts as a DNA 
binding component, and binds directly to DSBs via a preformed channel. Such interaction 
elicits conformational changes allowing for the recruitment of DNA-PKcs to the site of 
DNA damage, where attachment onto the free DNA strands initiates activation of the 
serine-threonine kinase. It is through activation of the kinase that DNA damage can then be 
repaired, through simple tethering and alignment of the 2 broken strands by the 
XCCR4/DNA ligase IV complex (Jalal et al., 2011a, Houtgraaf et al., 2006) (Figure 4). 
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Figure 4: The NHEJ pathway 
NHEJ is performed by the Ku protein, a heterodimer of Ku70 and Ku80, which bind to the 
free ends of a DSB. The two ends are then joined by DNA PKc and annealed by the 
XCCR4/DNA Ligase IV complex (Houtgraaf et al., 2006, Jalal et al., 2011a). 
 
The EGFR signal transduction pathway, possibly involving PI3K and AKT, may also be 
involved in modulating NHEJ via interaction with DNA-PK (Mukherjee et al., 2010, Meyn 
et al., 2009, Baumann et al., 2007, Bussink et al., 2008) (see section 2.2.3.3). 
 
Homologous recombination repair (HRR) 
In contrast to NHEJ, HRR is able to re-establish the original DNA sequence using the intact 
sister chromatid, and therefore can only be employed during the S or G2 phase of the cell 
cycle. With this repair mechanism, nuclease enzymes, initiated by the MRN (section 1.2.2) 
are employed to resect DNA at the break site allowing for exposure of ssDNA. The 
resulting ssDNA then becomes coated by the single-strand-binding protein, replication 
protein A (RPA), which in turn allows for the subsequent binding of RAD52. After 
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interaction with RAD52, the recombinase enzyme, RAD51 is then able to access the 
ssDNA-RPA complex. After assembly of an active nucleoprotein filament on the resected 
ssDNA tail of the first end, the complex then pairs with homologous dsDNA allowing for 
strand exchange to take place. RAD51 and/or RAD52 then promote the capture of the 
second-end ssDNA tail and in turn allow the two invading ends to function as primers for 
DNA resynthesis (Li and Heyer, 2008, Branzei and Foiani, 2008, Zou, 2010). Finally, the 
DNA junctions (Holliday junctions) are resolved to form two new DNA sequence 
molecules (Khanna and Jackson, 2001) (Figure 5). Studies have also shown that BRCA1, 
BRCA2 and PALB2 breast cancer susceptibility genes, have the ability to bind to RAD51 
and in doing so facilitate HRR processes (Powell and Kachnic, 2003). While it could be 
argued that this method is more reliable in terms of reducing risk of mutation, it is limited 
to those DSBs that have an identical sequence copy elsewhere within the genome (Obe et 
al., 2002). 
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Figure 5: The HRR pathway 
Nuclease enzymes, recruited by MRN, resect the DNA at the break site exposing ssDNA. 
Replication protein A (RPA) then coats the ssDNA allowing for the subsequent binding of 
RAD52. After interaction with RAD52, the recombinase enzyme RAD51 is then able to 
access the ssDNA-RPA complex. After assembly of an active nucleoprotein filament on the 
resected ssDNA tail of the first end, the complex is then able to pair with homologous 
dsDNA allowing for strand exchange. RAD51 and/or RAD52 then promote the capture of 
the second-end ssDNA tail, enabling the two invading ends to function as primers for DNA 
synthesis (Branzei and Foiani, 2008, Li and Heyer, 2008). The DNA junction (Holliday 
junctions) are then resolved to form two new DNA sequence molecules (Khanna and 
Jackson, 2001). 
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1.2.4 Apoptosis 
The death of malignant cells through insults such as ionising radiation, have been shown to 
be mediated through initiation of apoptosis within the target cell population (Debatin, 
2004). Apoptosis, also known as programmed cell death, is a distinct physiological method 
of cell destruction, and is a major factor involved in the maintenance of cellular 
homeostasis, by functioning to eliminate abundant, damaged or unwanted cells. There are 
two main pathways involved in the initiation of apoptosis, namely the ‘intrinsic’ pathway 
(also known as the ‘mitochondrial’ pathway) (section 1.2.4.1) and the ‘extrinsic’ pathway 
(section 1.2.4.2). Whilst these pathways are largely separate, they do converge at the 
activation of the executioner caspase 3. Irreparable DNA damage caused by ionising 
radiation is thought to lead to the activation of the intrinsic (mitochondrial) pathway 
(Wiezorek et al., 2010). 
1.2.4.1 Intrinsic apoptotic pathway 
Activation of the intrinsic apoptotic pathway occurs via p53. The pro-apoptotic proteins 
including PUMA and NOXA are upregulated by p53 and function to inhibit the anti-
apoptotic proteins BCL2 and MCL1 on the surface of the mitochondria (Wiezorek et al., 
2010, Danial, 2007, Ward et al., 2008). This releases the inhibition of the pro-apoptotic 
proteins BAX and BAK, allowing for the release of cytochrome C and SMAC/DIABLO 
(which antagonizes the activity of inhibitors-of-apoptosis (IAP) proteins) from the 
mitochondrial membrane. Cytochrome C then binds with apoptosis protease-activating 
factor-1  (Apaf-1)  to form the apoptosome which in turn functions to activate the cysteine-
dependent protease caspase 9 (Harrington et al., 2008). Once activated, caspase 9 proceeds 
to cleave and subsequently activate effector caspases 3, 6 and 7, ultimately leading to 
cellular disassembly (Figure 6). 
1.2.4.2 Extrinsic apoptotic pathway 
Whilst the intrinsic pathway is initiated by response to intracellular signals, the extrinsic 
pathway becomes activated upon binding of extracellular death ligands, such as TRAIL to 
their complementary death receptors such as DR4, which are exposed on the surface of the 
cell (Riedl and Shi, 2004). Binding of TRAIL to its receptor DR4 results in trimerisation of 
the receptor, and clustering of its death domain (DD), which subsequently enables the 
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intracellular adaptor molecule FADD (fas associated death domain) to bind (Harrington et 
al., 2008, Wiezorek et al., 2010). Once bound, DR4 undergoes conformational changes 
resulting in the formation of the death inducing signalling complex (DISC), which 
subsequently leads to the recruitment and cleavage of pro-caspase 8. These initiator 
caspases then in turn activate the downstream effector caspases 3, 6 and 7, thereby 
converging with the intrinsic pathway, and initiating the induction of apoptosis (Wiezorek 
et al., 2010) (Figure 6). 
 
It can be concluded that in order to maintain normal cellular homeostasis by efficient 
cellular phosphorylation and degradation (by the ubiquitin-proteasome pathway) processes, 
careful co-ordination, and tight regulation of the important protein mediators involved in 
the above pathways is essential. Table 1 illustrates those proteins, protein families and 
complexes involved in maintaining cellular homeostasis which, if malfunctioning in cancer 
cells, could potentially be associated with development of the radioresistant profile.   
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Figure 6: Intrinsic and extrinsic apoptotic pathways 
The intrinsic pathway is activated via p53 resulting in the up-regulation of pro-apoptotic 
proteins PUMA and NOXA. These proteins function to inhibit anti-apoptotic proteins 
BCL2 and MCL1 on the surface of the mitochondria (Danial, 2007, Wiezorek et al., 2010, 
Ward et al., 2008), resulting in the released inhibition of the pro-apoptotic proteins BAX 
and BAK. Cytochrome C and SMAC/DIABLO (which functions to inhibit the activity of 
inbibitors-of-apoptosis (IAP) proteins) are then released from the mitochondrial membrane. 
Cytochrome C binds with Apaf-1 to form the apoptosome which in turn functions to 
activate caspase 9 (Harrington et al., 2008), leading to subsequent activation of the caspase 
cascade, from which apoptosis follows. The extrinsic pathway is initiated by binding of 
extracellular death ligands, such as TRAIL to their complementary death receptors, such as 
DR4 (Riedl and Shi, 2004). Such binding leads to the clustering of the intracellular death 
domain enabling FADD to bind and hence leading to the subsequent formation of the 
 death inducing signalling complex (DISC). Formation of DISC leads to the activation of 
caspase 8 from the recruitment and cleavage of its pro-caspase. Subsequently, caspase 8 
leads to the activation of the effector caspases 3, 6 and 7 (a step which can be inhibited by 
c-FLIP), thereby converging with the intrinsic pathway, and initiating the induction of 
apoptosis (Wiezorek et al., 2010). 
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Table 1: Proteins (arranged alphabetically by gene name from the National Centre for 
Biotechnology Information database), protein families, complexes and pathways that 
could conceivably play a role in radiotherapy resistance (as mentioned in this 
Chapter). 
 
AKT (AKT1)                                                                             
APEX1 (APE1, REF1) 
APAF1 
ATM 
ATR 
BAK (BAK1) 
BAX 
BBC3 (PUMA) 
BCL2 
BRCA1 
BRCA2 
Caspases 
CDKs 
CDKis (e.g.CDKN1A/p21/WAF1) 
CHEK1 (CHK1) 
CHEK2 (CHK2) 
Cyclins 
Cytochrome C 
DIABLO (SMAC) 
DISC 
DR4 
E1 ubiquitin-activating enzymes (e.g. UBA1) 
E2 ubiquitin-conjugating enzymes (e.g. UBE2N) 
E3 ubiquitin-protein ligases (e.g. MDM2, UBR5) 
EGFR 
FADD 
FEN1 
IAPs (e.g. XIAP) 
LIG1 (DNA ligase I) 
LIG3 (DNA ligase III) 
LIG4 (DNA ligase IV) 
MCL1 
MRE11A 
NBN (NBS1) 
PALB2 
PARP1 
PIK3CA (PI3K) 
PMAIP1 (NOXA) 
PRKDC (DNA-PK) 
Proteasome components (e.g. PSMA, PSMB, PSMC, PSMD and PSME proteins) 
RAD50 
RAD51 
RAD52 
RBBP8 (CTIP) 
RPA (RpA-70) 
TP53 (P53) 
TRAIL (Apol2) 
XRCC1 
XRCC4 
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Chapter 2.  Potential biomarkers of radiotherapy 
resistance 
2.1 Radiotherapy resistance  
Radiotherapy plays an integral role in the comprehensive treatment regimens available for 
many malignant disorders. Irradiation can be employed as the sole treatment modality, or in 
combination with other anticancer protocols such as surgery, chemotherapy or targeted 
therapies. Exposure to ionising radiation (IR) ultimately aims to damage cellular DNA 
(whilst sparing normal tissue) through the production of highly reactive free radicals. Such 
radicals are the source of reactive oxygen species, which chemically react with DNA to 
produce both single-stranded DNA breaks (SSBs) and double-stranded DNA breaks 
(DSBs). Efficient repair of SSBs takes place through the recruitment of cellular enzymes 
however, DSBs are considered the most lethal amongst radiation induced DNA lesions, 
resulting in catastrophic consequences for the target cell, thus triggering cellular apoptosis 
(section 1.2.4). 
Radiotherapy is used to treat a variety of cancer types however, despite this, a 
proportion of tumours are inherently resistant to the treatment. To date there is limited 
knowledge relating to the underlying mechanisms of radiotherapy resistance however, it is 
generally accepted that treatment failure is probably due to multiple alterations within 
several different cellular transduction pathways. This therefore presents a major obstacle to 
the successful outcome for patients with cancer, and means that those whose tumours are 
resistant to therapy endure unnecessary treatment and harmful side effects for no 
therapeutic gain. Furthermore, in the neo-adjuvant setting, definitive treatment may be 
further delayed, potentially leading to resistant growth and increased morbidity. Due to 
such consequences created by the radioresistant phenotype, the search for predictive 
biomarkers that would highlight those at risk of treatment failure remains an area of intense 
study. The identification of such biomarkers, which could be utilised within clinical 
practice would allow for the individualisation of treatment, and ultimately improve patient 
outcome. In addition, the ability to identify a radioresistant tumour prior to therapy may 
allow for the introduction of a radiosensitiser, or a molecularly targeted inhibitor, which 
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could go some way towards reversing treatment resistance or increasing cellular sensitivity 
for that particular patient. 
2.2 ‘Classic’ putative predictive markers of radioresistance 
To date, substantial efforts have been made in order to try and elucidate the mechanisms of 
radioresistance, and in doing so identify putative biomarkers as both predictors of 
radiotherapy response, and as potential targets for therapeutic intervention. The literature 
supports a series of extensively studied biomarkers that have been highlighted as having 
potential clinical significance with radiotherapy response in solid tumours, hence being 
given the term ‘classic’ within this thesis. Such proteins have roles involved in DNA 
damage recognition, apoptosis, the cell cycle and cellular proliferation processes however, 
none have yet been validated for routine clinical use. 
2.2.1 DNA repair biomarkers 
One of the major mechanisms in which cancer cells become resistant to the effects of 
radiotherapy comes from the ability to successfully repair DNA lesions caused by the 
treatment, and hence escape apoptotic cell death. Several DNA repair pathways exist each 
functioning to participate in cellular survival. From this, it can therefore be hypothesised 
that enhanced DNA repair in tumour cells could result in resistance to radiotherapy.  
2.2.1.1 DNA-PK – Non-homologous end joining (NHEJ) 
DSBs resulting from treatment by ionising radiation are generally repaired by the NHEJ 
pathway (section1.2.3.2), of which DNA-PK plays a major role. DNA-PKs enable cellular 
processes such as p53 activation (Woo et al., 1998) and cell cycle arrest (Park et al., 1999) 
to take place, subsequently allowing time for the damaged DNA of tumour cells to be 
restored and hence, avoid the lethal effects of ionising radiation. Various studies have been 
conducted to investigate the role of the DNA-PK complex and radiotherapy resistance. A 
study by Shintani and colleagues investigating 7 oral squamous cell carcinoma (OSCC) cell 
lines and 42 OSCC patients treated with pre-operative radiotherapy was carried out, using 
both western blotting and immunohistochemistry to evaluate the expression levels of the 
DNA-PK complex proteins, DNA-PKc, Ku-70 and Ku-80. Results from the study found 
that expression of these proteins increased following radiotherapy and in turn correlated 
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with radiotherapy resistance (Shintani et al., 2003). Beskow et al carried out a small 
immunohistochemical study on a cohort of 22 patients with cervical carcinoma to also 
observe an increased expression of DNA-PK complex proteins in those tumours which had 
survived radiotherapy (Beskow et al., 2009). Targeted inhibition of DNA-PK, using a 
synthesised peptide representing the C terminus of Ku-80 and hence functioning to disrupt 
the interaction between the Ku complex and DNA-PKc, has been found to sensitise breast 
tumour cells to the effects of radiotherapy (Kim et al., 2002). Studies have also 
demonstrated the role of wortmannin, a fungal metabolite which functions to irreversibly 
inhibit members of the phosphatidylinositol-3 kinase related kinase (PIKK) family, 
including DNA-PK, in the successful radiosensitisation of various tumour cells including 
lung, colon and cervical carcinomas (Sarkaria et al., 1998, Rosenzweig et al., 1997, 
Hashimoto et al., 2003). However, due to general toxicity, poor solubility and low stability, 
wortmannin never reached clinical trials (Kong and Yamori, 2008). A recent study 
however, has demonstrated the radiosensitising effects of targeting DNA-PK using the 
micro-RNA, miR-101 (Yan et al., 2010).  A study by Zhuang and co-workers also found 
that glioma initiating cells could be radiosensitised by using RNA interference to knock-
down DNA-PK (Zhuang et al., 2011). 
2.2.2 Cell cycle and apoptotic biomarkers  
Both cell cycle progression (section 1.2.1) and apoptosis mechanisms (section 1.2.4) work 
together in order to maintain normal cellular homeostasis. Protein defects in one or both of 
these processes can result in the uncontrolled proliferation of damaged cells in addition to 
disordered apoptosis, resulting in the potential development of a cancerous phenotype. 
Defects within cell cycle and apoptotic processes enable cancer cells, typically harbouring 
various different mutations, to carry on developing due to having the ability to escape cell 
cycle checkpoints that would normally regulate and control their growth by subsequent cell 
death in the form of apoptosis. Under normal circumstances, radiotherapy functions to 
initiate apoptosis within a cell population, a process regulated by normal cell cycle 
functioning. It can therefore be hypothesised that a radioresistant phenotype could be 
generated from the abnormal functioning of cell cycle proteins, or the over-expression/ 
inhibition of those proteins required to prevent/promote the onset of apoptosis, respectively. 
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2.2.2.1 Bcl-2/Bax  
The Bcl-2 family of proteins are major regulators of the apoptotic pathway and include both 
pro-apoptotic members, Bad, Bak, Bax and Bid, and anti-apoptotic members, Bcl-2 and 
Bcl-xL. Whether or not a cell is destined for apoptosis is determined by the relative ratios 
of these apoptotic proteins. 
Studies have established links with radiotherapy resistance and the Bcl-2 family, in 
particular Bcl-2 and Bax. It can be thought that abnormal over-expression of anti-apoptotic 
proteins (Bcl-2) or down-regulation of pro-apoptotic proteins (Bax) could result in the 
formation of a radioresistant phenotype. It has been reported that Bax, a related homologue 
of Bcl-2, forms heterodimers with the Bcl-2 protein and in doing so functions to promote 
apoptosis (Lee et al., 1999). It could therefore by hypothesised that up-regulation of Bcl-2 
in combination with down-regulation of Bax would reduce the amount of apoptotic activity 
and hence, as a result increase resistance to radiotherapy, and vice versa.  This proposal was 
confirmed by Mackey and colleagues where an immunohistochemical study of 41 prostatic 
tumours demonstrated that tumours with an elevated Bcl-2/Bax ratio were at increased risk 
of failing radiotherapy (Mackey et al., 1998). Nix et al. investigated 124 tumours, all with 
early stage (T1-T2,N0) laryngeal squamous cell carcinoma, to reveal that resistance to 
neoadjuvant radiotherapy correlated with expression of Bcl-2 (p < 0.001) and decreased 
expression of Bax (p = 0.012). This suggested a possible decrease in apoptosis of damaged 
cells by radiotherapy, and as a result increased rates of radioresistance due to continued 
proliferation (Nix et al., 2005). It was later observed from a study using malignant glioma 
cells that the inhibition of Bcl-2 using the small organic compound HA14-1 increased 
sensitivity to radiotherapy. Results indicated that the sensitizing effect was lost if Bcl-2 
expression was ‘knocked-down', or if cells expressed a mutated form of Bax, therefore 
preventing its efficient interaction with Bcl-2 (Manero et al., 2006). In addition to this, Cao 
and co-workers achieved increased sensitivity to radiotherapy by transducing prostate 
cancer cells that expressed high levels of Bcl-2, using the phosphatase and tensin homolog 
(PTEN), a tumour suppressor gene (Cao et al., 2008). It would therefore suggest from the 
above studies that the ratio of Bcl-2/Bax may hold potential to be a predictive biomarker of 
radioresistance. 
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2.2.2.2 P53 status 
P53 is a tumour suppressor gene associated with cell cycle progression, DNA repair and 
apoptosis (Concin et al., 2000). Upon damage to cellular DNA by ionising radiation, 
normal, wild-type p53 becomes elevated and stabilised enabling it to act as a transcriptional 
regulator, to subsequently induce the expression of several other target proteins involved in 
the overall maintenance of cellular homeostasis (Dey et al., 2008). It can therefore be 
speculated, that cells which express a mutated form of the p53 gene, may show increased 
radioresistance due to the loss of p53-dependent cycle arrest or apoptosis. Concin and 
colleagues investigated this theory using three established ovarian carcinoma cell lines 
(Concin et al., 2000). The group found that the one cell line expressing wild-type p53 (PA-
1) displayed increased sensitivity to radiotherapy whilst the remaining two cell lines (Caov-
3 and SK-OV-3) displayed a mutated form of p53 and expressed increased resistance to 
radiotherapy. This trend was observed in two other radioresistance studies, one carried out 
on five human bladder cancer cell lines (Hinata et al., 2003) and the other investigating 47 
tumour specimens from patients with breast carcinoma (Turner et al., 2000). Both studies 
demonstrated a significant correlation with a mutated form of p53 and resistance to 
radiotherapy. However, despite these studies, there is also contradictory evidence to suggest 
that cells expressing mutated p53 genes are more sensitive to radiotherapy. Tada et al 
performed a study analysing the radiation response of cerebral glioblastomas harbouring 
p53 mutations (Tada et al., 1998). Results from the study found that of 36 patients treated 
with radiotherapy the re-growth free period, after treatment, was significantly longer (p < 
0.0001) than that of patients with tumours expressing wild-type p53, and that p53 mutation 
was the sole independent factor predictive of response. Such findings are thought to be due 
to the absence of p53-induced cell cycle arrest (section 1.2.2), which would therefore 
prevent the activation of DNA repair proteins, and hence drive the cell toward apoptosis. 
Due to the complex roles of p53 in cell cycle progression, DNA repair and apoptosis it is 
not unexpected that there is conflicting evidence as to its exact effects on radiotherapy 
response. However, due to its pivotal role in maintaining cellular homeostasis, its role as a 
potential biomarker of radioresistance warrants further future investigation.  
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2.2.3 Biomarkers associated with cellular proliferation  
Whilst defects within DNA damage repair, cell cycle progression and apoptosis have 
potentially contributed to radiotherapy resistance amongst various tumour types, the 
repopulation of surviving clonogenic tumour cells during a course of fractionated 
radiotherapy is also a problem affecting local tumour control. Tumours with the ability to 
rapidly proliferate may confer a survival advantage over slower growing tumours when it 
comes to treatment with radiotherapy. It is thought that this problem may be overcome by 
adjusting the fractionation regimen given to the tumour. It has been proposed that by 
targeting rapidly proliferating cells, over a much shorter time scale, using small fractions of 
radiotherapy (Bolger et al., 1996), cells would have a reduced ability to repair the sub-lethal 
damage induced before the next replication, therefore triggering apoptosis and death of the 
damaged cell. In this next section, those proteins implicated in tumour proliferation, and in 
doing so potentially aid in the development of radioresistance, are discussed. 
2.2.3.1 Vascular endothelial growth factor (VEGF) 
A tumour’s ability to continually grow and develop relies heavily on the existence of a 
sufficient blood supply, made possible by the creation of new blood vessels via 
angiogenesis. VEGF is an important signalling protein involved in the growth of such 
blood vessels, and its over-expression has been studied in relation to radiotherapy 
resistance (Willett et al., 2006). Manders and co-workers carried out an experiment to 
investigate VEGF association with radiotherapy resistance in patients diagnosed with node-
negative breast cancer (Manders et al., 2003). The study demonstrated that in those patients 
treated with breast-conserving surgery and adjuvant radiotherapy (n=221), high levels of 
VEGF expression were predictive of reduced relapse-free survival and overall survival. 
Tumours expressing high levels of VEGF, measured by the use of a quantitative ELISA 
test, demonstrated a reduced benefit from radiotherapy compared with those tumours with 
lower VEGF levels. When investigating those patients not treated with radiotherapy, high 
VEGF levels did not correlate with a worse survival, leading the authors to conclude that 
increased expression of VEGF would appear to predict for a reduced efficacy of 
radiotherapy in node-negative breast cancer. In addition to this study, Zlobec et al. also 
found increased levels of VEGF expression to be associated with radiotherapy resistance, in 
rectal cancer (Zlobec et al., 2005). Immunohistochemical staining was performed on 59 
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pre-irradiation biopsies from tumours showing complete response (ypT0), and no response, 
following pre-operative radiotherapy. Results revealed that the VEGF expression, from 
non-responsive tumours, was significantly (p = 0.0035) greater than the levels observed in 
completely responsive tumours. Forty seven percent of tumours with complete response to 
radiotherapy, demonstrated a VEGF expression of 10% or less, of that number 11 tumours 
were negative for the expression of VEGF. Fifty-two percent of non-responding tumours 
had VEGF expression score of ≥ 80%. Inhibition of VEGF using either sFlk-1 or SU5416, 
demonstrated complete reversal of tumour radioresistance (Geng et al., 2001). 
 Whilst VEGF, a pro-angiogenic factor, may lead to therapy resistance by the 
creation of a constant blood supply to the malignant tumour, hence allowing it to grow and 
develop, blood vessels created via this method are different and less well equipped for 
function than those making up the normal vasculature. This means that blood flow is often 
slow-moving and unbalanced, and can in fact result in the reduced delivery of oxygen to the 
tumour cells, and the formation of hypoxic regions within the tumour mass (Brown, 2000). 
Existence of these hypoxic regions has been shown to correlate with radiotherapy resistance 
(Wouters and Brown, 1997). Furthermore, expression of VEGF within malignant cells is 
up-regulated in hypoxic regions and this further contributes to a tumour’s ability to 
metastasise (Chiarotto and Hill, 1999, Spence et al., 2008) and resist the effects of 
radiotherapy. In order for a tumour to elicit maximum response to ionising radiation, 
oxygen must be present within the cells to ensure maximum biological damage (Overgaard 
et al., 2005). It is a well accepted fact that sufficiently oxygenated tumour cells are more 
sensitive, and therefore more responsive to the effects of radiotherapy due to the oxygen 
molecules reacting with the free-radical damage caused by the treatment, and in turn 
making it permanent, resulting in death of the affected cell. This subsequently led to the 
theory that the more hypoxic a tumour is, the more resistant to radiotherapy it would 
become. The existence of tumour hypoxia and the subsequent up-regulation of VEGF has 
provoked studies to investigate the effects of combining antiangiogenic agents with 
ionising radiation in order to improve efficacy of the treatment. Employment of this 
combination therapy is designed to improve tumour vasculature with antiangiogenic agents 
functioning to normalise the blood vessels which interact with the tumour, thereby 
increasing both blood and oxygen flow, which in turn could potentially increase tumour 
radiosensitivity (Willett et al., 2006, Kobayashi and Lin, 2006). However, controversy 
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remains over whether or not introduction of this therapy could in fact lead to treatment 
induced hypoxia and subsequent radioresistance. Debate arises from the notion that 
destruction of the blood vessels that supply the tumour could render it more resistant due to 
lack of oxygen. Furthermore, this effect may result in the selection of additional angiogenic 
cell populations which may themselves be resistant to inhibitors (Moeller et al., 2004, 
Wachsberger et al., 2003). In 2007, Oehler-Janne et al demonstrated the use of this 
combined therapy using allograft tumour models. Results from the study revealed that 
when using the inhibitor AEE788, either alone or in combination with ionising radiation, 
tumour oxygenation, and as a result radiotherapy response was greatly improved (Oehler-
Janne et al., 2007).  
2.2.3.2 HER-2  
The HER-2/neu/erbB2 oncogene (HER-2) is a transmembrane protein kinase receptor 
belonging to the epidermal growth factor receptor (EGFR) family (Stackhouse et al., 1998). 
The over-expression of HER-2 leads to the activation of various signalling pathways, which 
in turn support the growth, proliferation and overall survival of tumour cells (No et al., 
2009). HER-2 over-expression has been reported in several different cancer types, with 
approximately 30% of all breast cancers demonstrating increased expression of this 
oncogene (Slamon et al., 1987). In addition, various studies have reported links between 
HER-2 over-expression and increased resistance to ionising radiation. Pietras et al. 
performed in vitro studies on breast cancer cell lines and observed that human breast cancer 
cells with over-expression of HER-2 were more resistant to the effects of ionising radiation, 
however, this resistance could be reversed by treatment with an antibody to HER-2, namely 
rhu-MAb (Pietras et al., 1999). One year later, Rao and co-workers observed increased 
radiosensitivity using CI-1033, a small molecule inhibitor which functions to block the 
kinase activity of all four ERBB family members (EGFR, HER-2, HER-3 and HER-4) (Rao 
et al., 2000).  Furthermore, Stackhouse et al. radiosensitised tumour cells through 
transfection using an anti-erbB2 single-chain antibody (Stackhouse et al., 1998). Liang and 
colleagues found that the use of Trastuzumab (Herceptin), a humanised monoclonal 
antibody, already approved by the National Institute of Clinical Excellence (NICE) for the 
treatment of HER-2 positive breast cancer both alone or in combination with 
chemotherapy, was also effective at radiosensitising six breast cancer cell lines, all 
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expressing various levels of HER-2 (Liang et al., 2003). It can therefore be illustrated from 
the above, that HER-2 over-expression demonstrates strong correlation with a radioresistant 
phenotype however, inhibition of HER-2 promotes increased radiosensitivity. 
2.2.3.3 Epidermal growth factor receptor (EGFR) 
Whilst past literature has provided some strong evidence to support the role of the above 
proteins in their relation to radiotherapy resistance in solid tumours, little progress has been 
made in recent years to push these targets forward toward potential clinical use as putative 
predictive biomarkers. However, one protein, namely EGFR, has continued on into the 
forefront of radiation research, possibly owing to its already pivotal role in the mediation of 
several different cellular processes (Toulany and Rodemann, 2010). EGFR is a 
transmembrane receptor consisting of an extracellular ligand binding domain and an 
intracellular tyrosine kinase domain. Subsequent ligand binding by EGF and transforming 
growth factor alpha (TGFα) to the extracellular domain results in the dimerization of EGFR 
and hence triggers a cascade of intracellular signal transduction pathways, including the 
phosphatidylinositol-3-kinase (PI3-K)/AKT pathway and the RAS/RAF/MAPK pathway 
(Toulany and Rodemann, 2010, Bussink et al., 2008, Ciardiello and Tortora, 2008) 
(illustrated as part of Figure 7). Signalling via these pathways leads to the regulation of 
several different mechanisms controlling cell cycle progression, proliferation, 
transformation, differentiation, survival, oncogenesis, metastasis and angiogenesis 
(Doebele et al., 2010). 
EGFR is over expressed in a large variety of cancer types including head and neck, 
colorectal, breast, kidney, ovary, lung, prostate, bladder, brain and pancreatic carcinomas 
(Camp et al., 2005).  Studies have revealed that over expression of EGFR (Milas et al., 
2004, Thariat et al., 2007) or presence of the specific EGFR mutant, EGFRvIII (Mukherjee 
et al., 2009, Weppler et al., 2007) correlates with a more aggressive tumour progression, 
poor prognosis and increased resistance to radiotherapy. In light of such findings, the need 
to elucidate the mechanisms by which EGFR mediates tumour response to ionising 
radiation has, over the years, become an area of intense study.  
There is increasing evidence to suggest three possible mechanisms of EGFR-
mediated radioprotection (Chen and Nirodi, 2007) (Figure 7). The first mechanism includes 
the direct interaction of EGFR with DNA dependent protein kinase (DNA-PKc) (section 
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2.2.1.1). A series of studies have found that EGFR exists normally in the perinuclear space 
of un-irradiated cells and that exposure to ionising radiation instigates the ligand-
independent translocation of EGFR into the nucleoplasm. Here EGFR binds directly with 
the catalytic subunit, DNA-PKc and the regulatory subunits Ku70/80, and in doing so 
initiates radiotherapy induced activation of DNA-PKc, leading to the successful repair of 
DNA DSBs (Dittmann et al., 2005a, Bandyopadhyay et al., 1998). A recent study however 
found that cells expressing mutated EGFR demonstrated reduced DNA repair as a result of 
impaired nuclear localisation (Liccardi et al., 2011). 
Under normal circumstances, following ionising radiation, tumour cells undergo 
cell death in the form of apoptosis. A second mechanism of radioprotection therefore comes 
from EGFR-mediated activation of the PI3K/AKT pathway, which promotes resistance to 
radiotherapy through the blockade of apoptotic signalling pathways. A number of studies 
have reported that PI3K/AKT-mediated signalling enhanced expression of the 
mitochondrial anti-apoptotic proteins Bcl-xL and Mcl-1, and caspase inhibitor proteins 
such as c-FLIP isoforms (Kuo et al., 2001, Panka et al., 2001, Zhan and Han, 2004). In 
addition, phosphorylation of the pro-apoptotic protein Bad and human procaspase 9 by 
AKT, subsequently renders these proteins inactive during apoptotic processes (Li et al., 
2001). EGFR signalling through the PI3K/AKT pathway has also been shown to be linked 
to DNA-PKc regulation and hence DNA repair (Toulany et al., 2008). 
The RAS/RAF/MAPK pathway also has links with radiotherapy resistance, with its  
activation taking place through either surface receptor signalling or through point mutations 
of the RAS genes (e.g K-RAS), which ultimately lead to constitutively active RAS-
proteins. EGFR is a potent activator of the RAS/RAF/MAPK pathway and does so through 
either direct or indirect recruitment of growth factor receptor-bound protein 2 (GRB2) to 
the receptor tyrosine kinase domain. A complex formation with the RAS nucleotide 
exchange factor, Son of sevenless (Sos), mediated by GRB activation, leads to the 
subsequent activation of RAS. Once activated, RAS binds to RAF, triggering the 
phosphorylation of MEK1/2 and ERK1/2.  Translocation of Phospho-/ERK1/2 into the 
nucleus activates various transcription factors which function to regulate the expression of 
proliferation control genes (Toulany and Rodemann, 2010). The RAS/RAF/MAPK 
pathway, when constantly activated does mediate radioresistance (Bernhard et al., 2000, 
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Cengel et al., 2007). However, whilst the exact mechanism is not yet fully elucidated, it can 
be hypothesised that constitutively active RAS proteins not only lead to the stimulation of 
pro-proliferative MAPK pathways, therefore leading to the rapid repopulation of a tumour 
after radiotherapy, but also to the pro-survival properties associated with the PI3K-AKT 
pathway (Suy et al., 1997, Toulany and Rodemann, 2010). 
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Figure 7: The three mechanisms of EGFR-mediated radioprotection. 
A, One mechanism includes the direct interaction of EGFR with DNA-PKc and the 
regulatory subunits Ku70/80, and in doing so initiates radiotherapy induced activation of 
DNA-PKc, leading to the successful repair of DNA DSBs (Dittmann et al., 2005a, 
Bandyopadhyay et al., 1998). B, a second mechanism includes the EGFR-mediated 
activation of the PI3K/AKT pathway, which promotes resistance to radiotherapy through 
the blockade of apoptotic signalling pathways. Phosphorylation of the pro-apoptotic protein 
Bad and human procaspase 9 by AKT, renders these proteins inactive during apoptotic 
processes (Li et al., 2001). EGFR signalling through the PI3K/AKT pathway is also linked 
to DNA-PKc regulation and hence DNA repair (Toulany et al., 2008). C, a third 
mechanism includes activation of the RAS/RAF/MAPK pathway by where constitutively 
active RAS proteins not only lead to the stimulation of pro-proliferative MAPK pathways, 
therefore leading the rapid repopulation of a tumour after radiotherapy, but also to the pro-
survival properties associated with the PI3K-AKT pathway (Toulany and Rodemann, 2010, 
Suy et al., 1997). 
 
Given the pivotal role of EGFR in cancer development, and its contribution to the 
radioresistant phenotype, a promising role for EGFR inhibition has emerged. A variety of 
studies have taken place in order to investigate the effects of Cetuximab (Erbitux), an anti-
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EGFR monoclonal antibody, on mediating radiotherapy response. Jing and co-workers 
demonstrated that treatment with Cetuximab in combination with radiotherapy significantly 
increased rates of apoptosis (Jing et al., 2009). Liu and colleagues found that Cetuximab 
increased radiosensitivity by the down-regulation of MAPK activation (Liu et al., 2010), 
whilst other studies demonstrated increased sensitivity when the radiation-induced import 
of EGFR into the nucleus was inhibited (Dittmann et al., 2005b, Huang and Harari, 2000). 
However, perhaps one of the most pivotal studies came from Bonner and co-workers who 
carried out a multinational, randomised phase III trial of Cetuximab in advanced head and 
neck cancer combined with radiotherapy (Bonner et al., 2006). In this study, a total of 424 
patients with locoregionally advanced head and neck cancer were randomly assigned to 
treatment with either definitive radiation therapy alone (213 patients) or radiation therapy 
combined with weekly Cetuximab (211 patients). Results found that the median duration of 
local control was 24.4 months for those patients treated with the combined therapy 
compared to 14.9 months among those treated with radiotherapy alone. At a median follow 
up of 54 months, the median duration of survival was almost doubled for those patients 
who had received the combined therapy compared with radiotherapy alone (49 vs 29 
months, P=0.03). This landmark study is the first of its type to demonstrate clinical efficacy 
when combining Cetuximab with radiotherapy, in addition to the demonstration of a 
significant survival benefit through use of this treatment regimen. As a result, in March 
2006, regulatory approval was granted for the use of Cetuximab combined with 
radiotherapy in the treatment of locoregionally advanced head and neck cancer. Since then, 
this study has been further updated to report that the 5 year overall survival of those 
patients treated with the combined therapy was 45.6% as opposed to 36.4% for those 
patients treated with radiotherapy alone (Bonner et al., 2010). 
 In addition to Cetuximab, a number of studies have been carried out to investigate 
the role of Iressa (Gefitinib), a small molecule tyrosine kinase inhibitor (TKI), when 
combined with radiotherapy. In vitro studies revealed that radiosensitivity was increased 
when Iressa was used in combination with radiotherapy (Bianco et al., 2002, Colquhoun et 
al., 2007, Stea et al., 2003). However to date, only small scale clinical studies have 
investigated a treatment regimen that includes both Iressa and radiotherapy (Czito et al., 
2006, Van Waes et al., 2010). 
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The information discussed clearly outlines a key role for EGFR in the development of a 
radiotherapy resistant phenotype. In addition, the abnormal activation of the key signalling 
pathways, predominantly PI3K-AKT and RAS/RAF/MAPK, down-stream of EGFR 
promote further the problem of radioresistance through the constant mediation of cell 
survival. However, the continued and increasing investigation of EGFR, and the 
development of clinically relevant inhibitors to reverse radiotherapy resistance have added 
to and strengthened EGFR’s role in radiotherapy response, and in doing so have potentially 
moved EGFR a step further to possibly becoming a biomarker of radioresistance. 
2.3 ‘Emerging’ putative predictive markers of radioresistance 
2.3.1 Cancer stem cell markers 
An increasing number of studies have found that most, if not all solid tumours contain 
cancer stem cells (CSCs) or cancer initiating cells (CICs) that have the capability to 
regenerate a tumour (Alison et al., 2011, Baumann et al., 2008) that has previously been 
treated with anti-cancer therapy, including radiotherapy. Studies of glioma (Tamura et al., 
2010) and breast (Phillips et al., 2006) cancer cells have demonstrated that after 
radiotherapy, CSC/CICs have both survived the treatment, in addition to increasing in 
number and causing tumour recurrence. It has therefore been proposed that by tracking and 
targeting these cell populations, resistance to conventional cancer treatments could 
potentially be overcome (Baumann et al., 2008). CSCs avoid the lethal effects of ionising 
radiation through a number of mechanisms such as their inherent intrinsic radioresistance, 
their total number prior to receiving radiotherapy, their ability to recover and repair DNA 
damage, and their potential to repopulate a tumour in between treatment fractions (Krause 
et al., 2011). Hypoxic regions within a tumour also contribute to radioresistance of CSCs 
and hence local tumour control (Yaromina et al., 2010). One study demonstrated that 
extended exposure to hypoxic conditions promoted self renewal of both CSCs and non-
CSCs, however the hypoxic conditions also promoted a more-stem like phenotype in the 
non-stem cell population (Heddleston et al., 2009). Whilst there are no current markers 
which can predict the inherent radiosensitivity of a CSC, the expression of CD44 in 
laryngeal cancer has the potential to become a promising candidate for predicting local 
tumour control following treatment with radiotherapy. De Jong and colleagues analysed 
different gene signatures for hypoxia, proliferation and intrinsic radiosensitivity and 
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revealed that local tumour recurrence was associated with CD44 mRNA and CD44 
immunohistochemical expression. Genes monitoring cellular proliferation and 
radiosensitivity showed no correlation, whilst genes defining hypoxia showed a positive 
trend but did not reach statistical significance. CD44 expression as a predictor of outcome 
following radiotherapy was also confirmed by a data-driven approach, investigating over 
8000 genes. In addition, the study of 8 laryngeal cancer cell lines demonstrated a positive 
link between CD44 expression and in vitro plating efficiency, supporting the theory that 
CD44 expression correlates with the number of CSCs present, a parameter of which is 
important for predicting local tumour control (de Jong et al., 2010). Whilst this study 
reveals the potential of CD44 as a hopeful candidate biomarker in early stage laryngeal 
cancer, its positive correlation with tumour recurrence may not necessarily be true of other 
tumour types treated with radiotherapy due to varying tumour characteristics, including 
heterogeneity. The use of CD44 expression status either alone or in combination with other 
potential CSC markers as a predictor of radiotherapy response therefore necessitates further 
investigation in future experiments. 
 
In summary, whilst there are many studies that have attempted to elucidate further the 
mechanisms of radioresistance and local failure across varying tumour types, there is still 
no reliable panel of biomarkers with the potential to predict whether or not a tumour will 
respond positively to the effects of ionising radiation based on their expression. 
Nevertheless, despite this, the above studies have aided significantly in our understanding 
of how different protein expression levels may contribute towards a radioresistant 
phenotype, with EGFR in particular showing much promise.  
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Chapter 3.  Introduction to proteomic techniques for the 
identification of biomarkers of radiotherapy resistance 
3.1 Introduction to Proteomics 
For many years the genome has been the ‘popular’ choice for molecular exploration of 
human disease. From within one single gene, coded information is transcribed into mRNA, 
then subsequently processed, modified, spliced and translated in order to produce a plethora 
of different proteins, all starting from the same genetic material. The proteome however, 
coined in 1995, refers to all protein products expressed by an individual’s full genetic code. 
Proteomics describes the large-scale study of the proteome, and functions to bridge the gaps 
between what is encoded in the genome, and what is later translated into protein product 
(Engwegen et al., 2006). The introduction, and increasing popularity of proteomics has 
been fuelled by the various molecular limitations presented by both genomic and 
transcriptomic approaches. For example, mRNA expression levels do not entirely correlate 
with accurate protein concentrations, due to the opportunity for post translational 
modifications. Such modifications may in turn have a significant effect on the resulting 
biological function and activity of the protein e.g. its ability to develop resistance to 
radiotherapy. In addition, genetic mutations occurring within the genome itself may or may 
not have any bearing on the resulting mRNA or protein product. Alternative splicing events 
can also often lead to the development of several protein species from just one gene type 
(Figure 8). Studying at the proteome level allows for these modifications, possibly caused 
by the disease process itself, to be identified, the inherent advantage being that the 
identified protein is itself the biological endpoint.  A significant advantage of proteomics 
comes from its ability to characterise all, or a select number of proteins within a given cell, 
thus allowing protein alterations corresponding to a particular disease state to be considered 
and the stream of information within that particular protein network to be identified. It has 
been estimated that the human proteome comprises approximately 100,000 different 
polypeptides, which are derived from an estimated 40,000 genes in the human genome. It 
can therefore be regarded that the proteome offers both more complexity and specificity 
than studying the genome alone (Banks et al., 2000, Harrison et al., 2002).  
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Figure 8: The pathway of progression from gene to protein 
DNA is first transcribed into RNA, which is then alternatively spliced or edited to form 
mRNA. The resulting mRNA is then translated into the final protein product which can be 
regulated by additional mechanisms such as post-translational modifications (Graves and 
Haystead, 2002, Banks et al., 2000). 
 
Proteomic methodologies can be used as comparative tools to expose differences in protein 
expression (expression proteomics) between two samples, such as radiosensitive and 
radioresistant. Use of such techniques enables protein expression to be investigated from 
various different biological sources e.g. established cell lines, tissue, serum, blood etc, 
enabling both the discovery and validation of protein biomarkers from various different 
cancer types. It can therefore be thought that the introduction of proteomics as a global 
technique would significantly benefit several cancer researches. Whilst many proteomic 
techniques exist, current analysis methods can be grouped into gel-based and gel-free mass 
spectrometry (MS) methods and microarray-based methods. 
3.2 The Biomarker Discovery Pipeline 
Whilst a standard model for biomarker discovery using proteomic techniques does not 
necessarily exist, a widely used model, initially proposed by Rifai et al provides a robust 
platform for the successful discovery of novel protein biomarkers. The model consists 
largely of three main phases, (1) biomarker discovery, (2) confirmation and (3) validation. 
Biomarker discovery phases, such as MS or microarray-based approaches, involve the use 
of several different biological samples in order to generate several thousands of potential 
protein candidates. This data is then mined, for example using Ingenuity Pathway Analysis 
(IPA) in order to prioritise protein targets to take forward. Selected targets can then be 
confirmed using techniques such as Western blotting, which again reduces the number of 
 37 
 
potential candidates further, leaving only those that have successfully passed through the 
confirmation phase to be taken to the final stages of validation. At this stage, potential 
candidates are generally tested immunohistochemically on a large sample cohort of 
clinically relevant samples (Makawita and Diamandis, 2010, Rifai et al., 2006) (Figure 9).  
 
 
Figure 9: The biomarker discovery pipeline 
A variety of approaches can be employed in the discovery, confirmation and validation 
phases of the biomarker pipeline. See text for an explanation of methodologies. As 
candidates move through the pipeline, the number of potential protein biomarkers 
decreases, due to the elimination of any false positive results (Rifai et al., 2006). 
ICAT: Isotope-coded affinity tagging; IHC: Immunohistochemistry; iTRAQ: Isobaric tag 
for relative and absolute quantification; MRM: Multireaction monitoring; PAGE: 
Polyacrylamide gel electrophoresis; PMF: peptide mass fingerprint; SILAC: Stable isotope 
labelling by amino acids in cell culture; RPA: reverse phase array. 
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3.3 MS approaches: gel-based methods 
This type of method is most often used in combination with mass spectrometry, and 
functions to separate complex protein samples through the use of gel electrophoresis. Gel-
based approaches have for many years been considered the ‘gold standard’ approach for 
protein separation, offering the ability to screen protein expression on a large scale at a 
lower cost than gel-free proteomic methods (Chevalier, 2010). 
3.3.1 1D-PAGE separation 
One-dimensional-polyacrylamide gel electrophoresis (1D-PAGE) is used to separate 
proteins according to their molecular weight through use of a denaturing polyacrylamide 
gel. In order for effective separation to take place, proteins must first be extracted and 
resuspended in a suitable buffer, for example Laemmli buffer. Buffer for 1D separation 
must contain a detergent (e.g. sodium dodecyl sulphate, SDS) to both disrupt non-covalent 
bonds and solubilise membrane proteins; a reducing agent (e.g. β-mercaptoethanol) for 
cleaving protein disulphide bonds prior to SDS-PAGE; glycerol, to increase sample density 
enabling it to lay at the bottom of a gel sample well; protease inhibitors to protect the 
protein from digestion by protease enzymes; phosphatase inhibitors to block the action of 
phosphatase enzymes; and finally a dye (e.g. bromophenol blue) to allow for protein 
visualisation during gel loading and subsequent electrophoresis. A protein sample 
resuspended in the above buffer is then loaded into a polyacrylamide gel and separated out 
into bands. The presence of a molecular weight marker enables for the molecular weight of 
the specific protein to be estimated. 
3.3.2 2D-PAGE separation 
Two-dimensional gel electrophoresis, initially reported by O’Farrell over 25 years ago, 
separates proteins via two dimensions (O'Farrell, 1975); in the first dimension, based on 
their pH dependent, net charges (pI), in a process termed isoelectric focusing (IEF) and in 
the second dimension based on their molecular mass by polyacrylamide electrophoresis in 
the presence of sodium dodecyl sulphate (SDS) (Clark and Gutstein, 2008). Once 
separated, protein spots are visualised through staining, excised from the gel, digested and 
the resultant peptides analysed by mass spectrometry. 
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3.3.2.1 Sample preparation 
In order to take full advantage of the high-resolution ability 2D-PAGE has to offer, protein 
samples, extracted from either cell line or tissue samples, must be fully denatured, 
disaggregated, reduced and solubilised in order to break molecular interactions and to 
ensure that each visualised spot represents one polypeptide only. Sample solubilisation is 
carried out using a complex buffer containing chaotropes (e.g. urea and thiourea) to disrupt 
hydrogen bonds; a detergent (e.g. CHAPS); a reducing agent (e.g. DTT); ampholytes to 
ensure a stable pH gradient is established; protease and phosphatase inhibitors; and finally a 
dye (e.g. bromophenol blue) to allow for protein visualisation (Chevalier, 2010). 
3.3.2.2 First dimension: separation by Isoelectric Focusing 
IEF is used to separate proteins within a sample according to their isoelectric point (pI); the 
pH point at which a particular protein or molecule has no net electrical charge (Figure 10). 
Proteins have a positive charge at values below their pI, and a negative charge at values 
above their pI. IEF is a separation method based on these biochemical characteristics of 
proteins (Chevalier, 2010). Upon the application of an electric field, negatively charged 
ions moves towards the anode, whilst the positively charged ions move towards the 
cathode. When the proteins reach their specific pI (i.e. when their net charge is zero) within 
the pH gradient they become completely immobile and are subsequently focused (Gorg et 
al., 2009). First dimensional separation takes place with the use of immobilised pH gradient 
(IPG) strips which function to provide a stable pH gradient. Each IPG strip is a dry gel 
produced by the polymerisation of acrylamide monomers, linked by bis-acrylamide with 
molecules of linked immobilin. Immobilins are chemical compounds with non-amphoteric 
properties and are able to co-polymerise with the acrylamide gel resulting in the formation 
of a stable, immoblilsed pH gradient (Gorg et al., 2009, Gorg et al., 2004, Chevalier, 2010). 
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Figure 10: 1
st
 dimensional protein separation by isoelectric focusing (IEF) 
IPG strips are rehydrated with protein sample overnight in a rehydration tray. Following 
incubation, the rehydrated IPG strips are transferred into an IEF tray and placed into an IEF 
cell for 1
st
 dimensional separation by IEF. 
 
3.3.2.3 Second dimension: separation by molecular weight 
Following horizontal separation by IEF, proteins are further separated vertically by their 
molecular weight, using sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis 
(PAGE) (Figure 11). Prior to separation, IPG strips must first be equilibrated. During this 
step the IPG strips are saturated with SDS, a detergent, used to denature proteins (by 
disrupting hydrogen bonds) and give them a net negative charge, ensuring they travel 
towards the anode during electrophoresis. DTT is added to the buffer in order to maintain a 
reducing environment, and iodoacetamide (IAA) is added to prevent re-oxidation of 
disulphide bonds by alkylating reduced thiol groups. Once equilibrated the IPG strip is 
placed at the top of the gel, and embedded in 1% agarose, allowing the proteins to migrate 
through the gel and be separated according to their individual  molecular weight (Chevalier, 
2010). Protein resolution after separation is dependent upon factors such pH range and gel 
size. Whilst protein profiling using broad range IPG strips provides a general overview of 
protein expression, sufficient resolution needed for the effective separation of a large 
proportion of proteins in a complex mixture, requires the use of several increasingly 
narrow-range pH strips in combination with the largest gel size. Pre-fractionation steps also 
allow for a more complete proteome analysis however, pre-fractionation of protein 
mixtures combined with a series of narrow pH-range gels has significant time and cost 
implications (Lee and Pi, 2009, Gorg et al., 2009). 
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Figure 11: 2
nd
 dimensional protein separation by molecular weight  
IPG strips containing proteins separated by pI are placed onto the top of the SDS-PAGE 
gel. The IPG strip is then pushed down into the well at the top of the gel, secured by molten 
agarose. Proteins are then separated by molecular weight (Mw) and subsequently stained 
for visualisation using Coomassie blue stain. 
 
3.3.2.4  Protein visualisation 
Following protein separation by either 1D- or 2D-PAGE, proteins are stained allowing for 
visualisation and subsequent excision and quantitative analysis. A variety of different 
staining methods exist including silver, coomassie blue and fluorescent stains however, the 
chosen stain must be compatible with downstream mass spectrometry (MS). Whilst silver 
stain is the most sensitive staining method its compatibility with MS is far less compared 
with coomassie blue staining due to the presence of gluteraldehyde in the sensitisation 
solution (Dong et al., 2011). For this reason coomasssie blue is most often the stain of 
choice for proteins separated by electrophoresis. In addition, the stain is relatively 
inexpensive and easy to use, and has the ability to detect as little as 10 ng of protein (Gauci 
et al., 2011). 
3.3.2.5 Quantification and identification of differentially expressed proteins 
Differentially expressed proteins (DEPs) between two sample groups (e.g. ‘radiosensitive’ 
and ‘radioresistant’) can be identified and analysed following protein visualisation and 
scanning. For comparison studies at least 3 technical replicates should be performed and a 
mean taken, in order to reduce variability between gels. Two dimensional difference gel 
electrophoresis (2D-DIGE) uses dual colour fluorescent labelling, therefore allowing the 
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simultaneous electrophoresis of two differentially labelled samples in the same gel, hence 
reducing gel variability (Chevalier, 2010). Various commercially available software 
packages, such as PDQuest and Progenesis (Rosengren et al., 2003, Wheelock and 
Buckpitt, 2005) can be used to identify differentially expressed protein spots between the 
two sample groups. Both differences in spot intensity and pattern between the gels are 
identified by relative quantification. Once DEPs have been highlighted and located on the 
gel the corresponding protein spot can then be excised (manually or robotically) ready for 
protein digestion. 
3.3.2.6 In-gel digest 
Differentially expressed protein bands (separated by 1D-PAGE) or protein spots (separated 
by 2D-PAGE) can be digested into peptides in order to release the protein from the gel. 
Prior to protein digestion, protein spots must first undergo a series of washing steps with 
ammonium bicarbonate/acetonitrile solutions to remove any remaining stain from the gel. 
Proteins are then digested using an enzyme such as trypsin which cleaves the protein at the 
C-terminal of lysine and arginine residues (Olsen et al., 2004). Once digested into peptides 
analysis by mass spectrometry can then be undertaken. Protein identifications are 
subsequently produced based on database searching containing in silico tryptic peptides 
from known proteins (Canas et al., 2006). 
3.3.2.7 Mass spectrometry 
Since its introduction more than one hundred years ago, MS has been widely used as an 
analytical technique, offering excellent sensitivity and selectivity, in addition to providing 
the molecular weight or structural information of a compound or peptide in a very short 
time period (Canas et al., 2006). The overall aim of the mass spectrometer is to produce, 
and subsequently separate ions according to their mass-to-charge ratio (m/z). In order to 
make separations possible, an electromagnetic field must be generated inside the 
instrument, making ion movement inversely proportional to the overall mass of the ion and 
directly proportional to its electrical charge. A mass spectrum is then produced displaying 
the m/z ratio alongside the relative abundance of each ion. Every MS instrument consists of 
an ion source, for production of ions from the sample; at least one mass analyser, to 
separate ions according to their m/z ratio; a detector, to register the number of emerging 
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ions from the protein sample; and finally a computer, to both process and produce mass 
spectrum of the resulting data (Lane, 2005, Canas et al., 2006, Aebersold and Mann, 2003) 
(Figure 12).  
 
 
Figure 12: A simplified schematic of a MALDI-TOF MS arrangement. 
Peptide ions are directed through the mass analyser and separated according to their m/z 
ratio. The detector then measures the number of emerging ions from the sample and relays 
the information to a computer where a mass spectrum is produced. 
 
For peptides to be separated in an electromagnetic field, they must first be converted into 
ions and subsequently transferred into the gas phase by use of an ionisation source (Canas 
et al., 2006). The two most suited methods for the ionisation of peptides include 
electrospray ionisation (ESI) and matrix-assisted laser desorption/ionisation (MALDI). Ion 
formation takes place at atmospheric pressure using ESI whilst ion generation using 
MALDI yields the best results under vacuum conditions (Canas et al., 2006). 
MALDI, first developed in the 1980’s by Karas and Hillenkamp, is the ionisation 
method most commonly utilised when analysing differentially expressed protein spots 
identified from 2D-PAGE (Aebersold and Mann, 2003). Like ESI, it is a ‘soft ionisation’ 
technique, but unlike ESI, relies on the utilisation of a matrix solution to ionise the analyte 
using laser pulses. The most common matrices used in combination with MALDI protocols 
include α-cyano-4-hydroxycinnamic acid (CHCA) and 2,5-dihydroxybenzoic acid (DHB). 
The peptide sample to be analysed is co-crystallised with an excess of matrix solution 
which in turn absorbs the energy from the laser. Typical lasers include nitrogen lasers (337 
nm) (Lane, 2005, Mann et al., 2001, Lin et al., 2003) and neodymium:yttrium aluminium 
garnet (Nd:YAG) lasers. Recently Bruker Daltonics have introduced the Smartbeam
TM
 
laser, which incorporates the better attributes of the nitrogen and Nd:YAG lasers, ultimately 
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leading to improved peak intensity. Irradiation of the matrix by any one of the above lasers, 
results in rapid heating and sublimation of the matrix crystals. Subsequent expansion of the 
matrix into the gas phase takes with it intact analyte molecules ultimately leading to 
ionisation of the sample (Lane, 2005).  
 As ions exit the ion source, they pass through a mass analyser. The mass analyser 
functions to separate ions according to their m/z ratio, the key parameters of which include 
mass accuracy, mass range, resolution, sensitivity and the capability of performing tandem 
MS (section 3.3.2.9) (Lane, 2005). Ultimately, the information obtained from a specific 
experiment is determined by the performance of the mass analyser. Several different mass 
analysers exist, each being different in design and performance. The four most common 
include the ion trap, time-of-flight (TOF), quadrupole and Fourier transform ion cyclotron 
(FT-MS) analysers (Aebersold and Mann, 2003). 
The TOF mass analyser is most commonly coupled to the MALDI ionisation 
source, to generate peptide mass fingerprint (PMF) information on specific proteins. This 
analyser is well suited to the pulsed nature of MALDI, and with a high frequency laser, can 
produce high sample throughput with sensitivity extending to femtomole levels. Essentially 
the TOF mass analyser consists of a flight tube in high vacuum to ensure collisions do not 
occur before ions reach the detector. The ions generated from the peptide sample are 
accelerated by a strong electric field (typically 20 kV) (Canas et al., 2006). Ions of different 
mass are subsequently separated based on the time it takes to transverse the length of the 
flight tube and strike the detector. Ions of lower mass reach the detector before those of 
higher mass. The resulting TOF spectrum is a recording of the signal produced by the 
detector upon impact of each ion. A typical mass spectrum is achieved by incorporating the 
relationship between the time it takes to arrive at the detector (t) with the square root of the 
m/z ratio value of the ion (Canas et al., 2006). However, MALDI can result in decreased 
resolution by broadening peak width. This is caused by differences in energy distribution, 
by ions of the same mass. If ions of the same mass arrive at the detector at different times, 
due to differences in kinetic energy, it results in peak broadening and hence decreased 
resolution. To combat this problem two techniques were introduced. Firstly, delayed pulse 
extraction (or pulsed ion extraction). This allows for differences in kinetic energy between 
ions of similar m/z values to be corrected by enabling ions to expand in the field free region 
in the source, before a voltage pulse is applied. By using this method, ions with higher 
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initial energy (that would move faster through the flight tube) are exposed to less electric 
potential, whilst ions with lower initial energy (move slower through the flight tube) are 
exposed to more electric potential, hence enabling ions of the same mass to arrive at the 
detector together therefore increasing resolution by narrowing peak width. Secondly, 
resolution was increased further by the incorporation of an ion reflector at the end of the 
flight tube. The ion reflector is essentially a mirror that creates a retarding field to deflect 
ions, sending them back along the flight tube. Highly energetic ions penetrate the retarding 
field more deeply, enabling them to travel a longer flight path, and subsequently arrive at 
the detector at the same time as ions of the same mass, but with less energy (Lane, 2005). 
Once ions collide with the detector a PMF spectrum is produced (Figure 13). 
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Figure 13: A schematic of a reflectron TOF mass analyser 
The TOF mass analyser separates ions of different mass based on the time taken to 
transverse the flight tube and strike the detector. Mass resolution using the TOF mass 
analyser can be increased by (1) delayed pulse extraction, which corrects for differences in 
kinetic energy between ions of the same m/z value, by exposing them to different electric 
potentials and (2) the presence of an ion reflector, which creates a retarding field, and hence 
a longer flight path for ions of higher energy, subsequently enabling them to arrive at the 
detector at the same time as ions of similar mass, but with lower energy. 
3.3.2.8 Protein identification 
The PMF is essentially a list of masses for all the peptides within a sample. The selected 
PMF is submitted to a protein database search (using a search engine such as MASCOT), 
and compared with the predicted PMFs from theoretical tryptic digestion of all proteins in a 
database. If enough peptides from the theoretical spectrum match the mass of those in the 
real spectrum, the protein can be successfully identified. Two common databases used for 
protein identification include the National Centre for Biothechnology Information non-
redundant (NCBI nr) database and the SwissProt database. However, whilst PMF analysis 
is currently the most popular method for protein identification, due to its simplistic 
approach there are a number of draw-backs associated with its use. For example, a PMF 
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generates several peptides however, it is extremely rare to find one peptide that is 
completely unique to one protein, therefore requiring the need for several peptides from the 
same protein to enable identification. In addition, proteins containing post-translational 
modifications hinder PMF analysis as peptides from a modified protein will not match 
those of an unmodified protein. Also, protein mixtures present problems for PMF analysis 
when more than one individual protein is present within the same sample. Due to such 
complication, it is therefore sometimes necessary to subject selected ions to further 
fragmentation to provide an amino acid sequence, hence giving a more confident result (see 
section 3.3.2.9). 
3.3.2.9 Tandem mass spectrometry 
Tandem mass spectrometry (MS/MS) (e.g. TOF/TOF) can be used to determine the amino 
acid sequence of a peptide and as a result provides a powerful tool for the analysis of 
complex protein mixtures (Yates, 2000). MS/MS combines the use of two mass analysers 
and a collision cell enabling for the collection of structural data. With this particular 
approach, an individual m/z value from the first mass analyser can be isolated, dissociated, 
and the m/z values of the dissociation products can be determined through use of the second 
mass analyser. As a result of the dissociation process, covalent bonds fragment leaving 
behind a group of ions which dictate the molecular structure of the ion. Whilst several 
different fragmentation methods exist, collision-induced dissociation (CID) is one of the 
most common. The method functions to energetically activate ions to dissociate. The 
selected peptide ions enter the collision cell and are subsequently subjected to low energy 
collisions with inert gas molecules such as argon, resulting in energetic excitation of the 
ion. As the ions become excited, covalent bonds fragment, predominantly around the 
peptide amide bond. If the N-terminus remains charged, the fragments are designated as b-
ions. In contrast, if the C-terminus remains charged, the fragments are designated as y-ions. 
The collected b- and y-ions then have their respective m/z values determined by the second 
mass analyser (Yates, 2000, Canas et al., 2006, Lane, 2005), thus yielding amino acid 
sequence data and in turn increasing both accuracy and confidence in the overall protein 
identification.  
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3.3.3 Repeatedly identified differentially expressed proteins (RIDEPs) associated with 
2D-PAGE based experiments 
Recent investigation has highlighted the existence of repeatedly-identified differentially 
expressed proteins (RIDEPs) which have been recognised frequently throughout various 
2D-PAGE based experiments. Petrak and co-workers investigated the protein identities 
generated from 186 2-DE-based experiments, published in 3 recent volumes of Proteomics, 
and in doing so identified the ‘TOP 15’ RIDEPs derived from studies using both rodent and 
human samples (Petrak et al., 2008).Wang and colleagues added further support to these 
findings when investigating 66 biologically different experiments encompassing 20 tissue 
types from 5 different species (Wang et al., 2009). From this study a list of 44 RIDEPs was 
generated, 73% of which were included in the ‘TOP 15’ RIDEPs identified previously from 
Petrak and colleagues. Table 2 lists these ‘TOP 15’ RIDEPs. It has been hypothesised that 
RIDEPs have association with the cellular stress response, therefore interpretation of these 
proteins must exercise ‘extreme caution’ when prioritising which to take forward for the 
validation stage of the biomarker discovery pipeline (Petrak et al., 2008, Mariman, 2009, 
Wang et al., 2009). 
 
Table 2: A list of the ‘TOP 15’ RIDEPs identified from 2D-PAGE based experiments 
This table lists the ‘TOP 15’ RIDEPs highlighted by Petrak and colleagues. 2008 after 
studying 186 2D-PAGE based experiments from across 3 recent volumes of Proteomics. 
Further analysis of these proteins must be interpreted with caution. 
 
‘TOP 15’ RIDEPs 
HSP27 
(HSPB1) 
Enolase 1 Triosephosphate 
isomerise 
Pyruvate kinase 
M1/M2 
Peroxiredoxin 1 
Peroxiredoxin 2 Vimentin Annexin A4 HSC7 (HSPA8) Peptidyl-prolyl 
isomerise A 
Cytokeratin 8 
(KRT8) 
Cathepsin D ATP synthase 
beta subunit 
Grp/Bip 
(HSPA5) 
Rho GDI 1 
(ARHGDIA) 
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3.4 MS approaches: gel-free methods 
One of the main advantages of gel-based approaches is that they give a visual 
representation of proteins and DEP’s within each sample; however, there are some 
drawbacks associated with gel-based techniques. Co-migration of more than one protein or 
the inaccurate excision of a DEP spot from the gel may make subsequent identification 
difficult. In addition, 2DE may not be suitable for proteins that are highly acidic, basic or 
hydrophobic, and proteins which are very large or small may be difficult to capture in the 
analysis. Low-abundance proteins may be beyond the level of sensitivity of the detection 
(gel staining) method or may be masked by high-abundance proteins. Contamination with 
human keratins can be a problem owing to the many experimental stages (Keller et al., 
2008), and gel-based methods are generally low through-put. Subcellular prefractionation 
and the use of narrow-range pH IPG strips can be advantageous in reducing the complexity 
of the gel image; however, a smaller proportion of the total proteome would be under 
interrogation during each experiment. Therefore, owing to the disadvantages of gel-based 
approaches, there has been a move towards the employment of gel-free methods for the 
discovery phase of proteomics research.  
3.4.1 ESI MS 
For the analysis and identification of DEP’s from complex protein lysates in liquid form, a 
strategy involving high-performance liquid chromatography (HPLC) for separation, 
followed by ESI, coupled with MS/MS for peptide sequencing can be employed. A variety 
of mass analysers can be coupled to an ESI source, and these include quadrupole, ion trap 
or orbitrap systems (Yates et al., 2009). This gel-free approach is based on the high-
throughput ‘shotgun’ analysis of peptides from a complex liquid protein mixture, and can 
be used for the accurate identification of proteins. 
 ESI functions at atmospheric pressure to produce small, charged solvent droplets 
when a high electric potential is set between a capillary and the inlet to a mass 
spectrometer. These tiny charged droplets, generated at the exit of the electrospray needle 
pass down a pressure potential gradient towards the analyser region of the mass 
spectrometer (Ho et al., 2003). By using heat in the atmospheric pressure interface, or a 
warm nitrogen counter current, the charged droplets are continuously reduced in size, due 
to solvent evaporation, and hence the electric charge density on the surface increases. Once 
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the electric field strength within the charged droplet reaches a critical point, the ions 
(typically positively charged, using the capillary as an anode and the mass spectrometer 
inlet as the cathode) at the surface of the droplet are ejected into the gas phase (Ho et al., 
2003, Canas et al., 2006, Lin et al., 2003) . ESI produces mainly doubly charged ions of 
tryptic peptides, resulting in easy fragmentation with less activation energy, giving rise to 
information patterns for database searching (Canas et al., 2006). 
3.4.2 Quantitative Shotgun Proteomics 
In contrast to proteomic methods such as 2DE-PAGE/MS, conventional shotgun proteomic 
analysis was used only for the identification of proteins within a given sample. However, 
advances in MS technologies have enabled gel-free MS-based shotgun approaches to 
become quantitative allowing for the introduction of comparative proteomic experiments to 
reveal significant DEP’s, prior to their subsequent identification. A number of quantitative 
shotgun proteomic approaches have been described (Hodgkinson et al., 2010, Wilm, 2009).  
Isobaric tag for relative and absolute quantification (iTRAQ) analysis is a gel-free 
technique containing a set of 4 isobaric reagents, therefore enabling the analysis of 4 
protein samples simultaneously. Proteins are first digested into peptides using trypsin and 
labelled with different iTRAQ reagents. iTRAQ exploits the presence of an N-
hydroxysuccinimide (NHS) ester derivative to modify primary amino groups by linking a 
mass balance group (carbonyl group) and a reporter group (based on N-methylpiperazine) 
to proteolytic peptides via amide bond formation (Ross et al., 2004). Once labelled with 
individual iTRAQ reagents, the samples are then pooled and typically fractionated using 
strong cation exchange (SCX) and reverse phase HPLC before analysis by MS/MS. Due to 
the mass design of iTRAQ reagents, peptides which have been differentially labelled 
appear on MS scans as a single peak, therefore significantly decreasing the probability of 
peak overlapping. Database searching of the peptide fragmentation data, generated by 
MS/MS, leads to the identification of both the labelled peptide and its corresponding 
proteins. Fragmentation of the peptide tag releases the mass balancing carbonyl moiety as a 
neutral fragment, and in turn generates reporter ions of varying m/z (i.e. 114,115,116 and 
117) that are unique to the tag used to label each individual digest. Intensity measurements 
of these reporter ions, then in turn provides quantitative information on the target proteins 
(Ernoult et al., 2008). 
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 Whilst iTRAQ has been used in the investigation of radiotherapy resistance 
biomarkers, other MS-based quantitative labelling approaches also exist. Such methods 
include isotope-coded affinity tagging (ICAT) and stable isotope labelling by amino acids 
in cell culture (SILAC), which involves the labelling of proteins during cell culture, prior to 
MS.  
3.5 MS-free approaches: microarray-based methods 
Microarray-based screening methods represent a relatively novel technique in the field of 
proteomics, offering a powerful means of analysing the differential expression of hundreds 
of known proteins simultaneously (Borrebaeck and Wingren, 2009). Unlike MS based 
approaches the method does not rely on the identification of a specific protein through the 
use of a public database, but instead provides a complementary discovery method where 
either monoclonal antibodies (forward phase) or test samples (reverse phase) are 
immobilised as a microarray for simultaneous screening to take place. Antibody 
microarrays have become increasingly popular within the field of proteomics research, 
offering a high throughput discovery approach that can successfully overcome some of the 
difficulties associated with both gel-based and MS-based methods (Hodgkinson et al., 
2010, Brennan et al., 2010). It is however important to note that antibody microarrays 
cannot be considered a ‘global’ proteomic technique, as analysis is limited to the expression 
of proteins whose corresponding antibodies have been pre-selected for printing onto the 
slide. Various different antibodies relating to proteins with various different functions or 
signalling pathways can be printed onto the slide for analysis. 
 An antibody microarray is a collection of hundreds of antibodies spotted in an 
orderly fashion, at high density, onto a nitrocellulose-coated glass microscope slide. The 
surface of the slide is chemically modified in order to present functional groups for the 
covalent binding of the antibodies, allowing them to maintain their activity despite 
immobilisation. Antibody microarrays allow for the simultaneous comparison of protein 
expression of two different samples (e.g. radiotherapy-sensitive versus radiotherapy-
resistant). In order to do this, the targeted proteins are labelled directly with fluorescent 
dyes (typically Cy3 and Cy5), mixed together in equal quantities and co-incubated with the 
microarray slide. The labelled protein samples then competitively bind to the corresponding 
antibody spotted on the plate (Haab, 2005) (Figure 14). Whilst competitive assays have 
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benefits including linearity of response and dynamic range (Barry et al., 2003) one 
particular drawback of a label-based assay is that the fluorescent label may disrupt the 
antibody-antigen interaction (Haab, 2005, Sanchez-Carbayo, 2006). Due to such issues it is 
essential to fully optimise dye-to-protein molar ratios as under-labelled proteins impair the 
assays sensitivity, whilst over-labelled proteins may result in masking of the epitope and 
subsequently lower reactivity with the immobilised antibody (Wingren et al., 2007). A 
fluorescent scanner is used for slide analysis which measures the amount of dye (Cy3 
versus Cy5) present at each antibody spot by signal intensity. The relative amount of dye 
present is directly proportional to the amount of bound protein. It is at this point that DEP’s 
can be identified between the two samples and fold-changes calculated. A fold-change of ≥ 
1.8 is generally accepted as significant (Hodgkinson et al., 2011). As previously mentioned, 
an antibody microarray consists of hundreds of antibodies spotted onto a glass slide, 
therefore enabling the simultaneous analysis of expression of hundreds of proteins. One 
example of an antibody microarray in commercial use is the Panorama® Antibody 
Microarray-XPRESS Profiler725 from sigma Aldrich. This particular microarray consists 
of 725 antibodies each spotted in duplicate onto a nitrocellulose-coated glass slide and has 
the ability to analyse proteins involved in various different functions including apoptosis, 
cell-signalling, cell cycle control and cellular proliferation. However, whilst this method 
provides a platform for high through-put analysis of several protein expression profiles, its 
high cost and restriction to only those antibodies spotted onto the slide provides limitations 
to the use of this technique. 
3.5.1 Repeatedly identified differentially expressed proteins (RIDEPs) associated with 
microarray-based experiments. 
Until recently, only RIDEPs generated from 2-DE-based experiments had been reported 
within the literature. However, published data obtained by this group following the analysis 
of 13 individual antibody microarray experiments using the XPRESS Profiler725 (Sigma 
Aldrich) assay has identified a preliminary list of RIDEPs associated with this 
complementary proteomic platform (Hodgkinson et al., 2011). Following analysis of 
protein extract derived from tissue, cells and cell line models, a total of 13 RIDEPs, which 
appeared in at least 4/13 experiments were identified. It must be noted that none of this 13 
were previously identified as RIDEPs from 2D-PAGE based experiments (section 3.3.3).  
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Table 3 lists these RIDEPs. As with those RIDEPs associated with 2-DE based methods 
(section 3.3.3), thorough investigation of these proteins must take place in order to 
determine their true value as biomarkers of therapy resistance. 
 
 
Figure 14: The Antibody microarray workflow 
Protein is first extracted from the two samples of interest and labelled directly with 
fluorescent dyes Cy3 (e.g. radiosensitive; PN) and Cy5 (e.g. radioresistant; RR). Unbound 
dye is removed before the labelled samples are combined in equal quantities and incubated 
with the microarray slide. 
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Table 3: A preliminary list of RIDEPs associated with the XPRESS Profiler 725 assay. 
This table lists the 13 RIDEPSs identified from across 13 individual antibody microarray 
experiments carried out within our laboratory from across tissue, cell and cell line model 
studies (Hodgkinson et al., 2011). The antibody catalogue number (Sigma Aldrich) is 
indicated in brackets. Further analysis of these proteins must be interpreted with caution. 
 
RIDEP 
Zyxin (Ab# Z0337) BID (Ab# B3183) 
MyD88 (Ab# M9934) IKKa (Ab# I6139) 
BclxL (Ab# B9429) Condroitin sulphate (Ab# C8035) 
14 3 3 (Ab# T5942) Centrin (Ab# C7736) 
SLIPR MAGI3 (Ab# S4191/S1190) Pinin (Ab# P0084) 
Protein Kinase C (Ab# P5704) Smad4 (Ab# S3934) 
Siah2 (Ab# S7945) 
3.6 Confirmation and validation of putative biomarkers 
Whether the proteomic discovery phase is carried out using gel-based or gel-free MS 
approaches or microarray-based methodologies, the identification and differential 
expression of all putative biomarkers must be confirmed using further independent 
techniques (Paulovich et al., 2008). In addition to false discovery due to the use of a high 
throughput ‘omic’ technology there are now also a number of human RIDEPs (sections 
3.3.3 and 3.5.1) which require careful scrutinisation (Hodgkinson et al., 2011, Petrak et al., 
2008). 
3.6.1 Data mining 
The main aim of high-throughput technologies currently used within proteomic 
investigations, is to screen samples with the intent of generating hundreds of potentially 
interesting proteins, all of which require further confirmation and validation. Such further 
investigation methods are generally of higher accuracy but carried out on a smaller scale 
(Qian and Huang, 2005). Therefore, in order to identify and prioritise such proteins for 
further investigation, software is employed to interpret the data using knowledge databases. 
Ingenuity Pathway Analysis (IPA) (Ingenuity Systems Inc., USA) is one example of such 
software. Using this online facility, generated protein lists can be uploaded into the 
software, where they are then analysed against the Ingenuity Knowledge Base. The 
software then highlights all relationships (direct or indirect) between the candidate proteins 
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using different networks and canonical pathways for illustration. Through use of this 
software, researchers can carry out virtual investigations, helping to further understand and 
prioritise a selection of proteins for subsequent technical (section 3.6.2) and clinical 
validation (section 3.6.3).  
3.6.2 Western Blotting 
Semiquantitive Western blotting (also known as immunoblotting) coupled with 
densitometry analysis is a widely used method for the co-confirmation of differential 
expression and protein identification. Following protein extraction from either cell line or 
tissue origin, the first step of Western blotting is the separation of proteins by electrical 
charge using a polyacrylamide gel. A known quantity of protein extract is mixed with 
Laemmli buffer, containing sodium dodecyl sulphate (SDS) to unfold and reduce the 
proteins whilst giving them a net negative charge, and β-Mercaptoethanol to reduce 
disulphide bonds causing the protein to revert back to its primary conformation prior to 
separation. The protein sample is then loaded into the gel, separated by molecular weight 
and transferred onto a nitrocellulose membrane. Once proteins have transferred it is 
necessary to ‘block’ the free sites on the membrane using either bovine serum albumin or 
non-fat dried milk powder. This step ensures no non-specific binding of the probing 
antibody to the membrane (only to the protein of interest). A primary antibody, specific to a 
protein of interest, is then incubated with the membrane, enabling it to bind to its target 
protein if it is present. After a brief washing step to remove any unbound antibody, one 
commonly used method for the visualisation of protein expression is the use of 
chemiluminescence, employing a horseradish peroxidise (HRP) conjugated secondary. The 
HRP enables the production of a signal in the form of luminescence by catalysing the 
decomposition of the chemiluminescent reagent. Relative amount of protein can then be 
visualised by exposure to photographic film. The presence of an exposed band indicates the 
presence of the target protein within the sample, with band intensity being proportional to 
the amount of protein present. The photographic film can then undergo quantification using 
densitometry. During this process, target proteins are normalised against loading controls or 
anti-‘housekeeping’ antibodies (e.g anti-alpha tubulin, anti-beta actin or anti-GAPDH) 
which should demonstrate constant levels of expression within the protein sample. Through 
use of these loading controls, comparisons between band intensity produced by the primary 
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antibody can be made, enabling a quantitation of fold-change in expression to be 
calculated. However, Western blotting requires the availability of a reliable primary 
antibody specific to the precise protein identified from proteomic analysis. Where suitable 
antibodies do not exist, further analysis at the mRNA level using reverse transcriptase 
polymerase chain reaction (RT-PCR) or real time quantitative PCR (RTqPCR) can be 
employed for confirmation of differential transcript expression. If a quantitative or semi-
quantitative method is employed, which utilises an appropriate house-keeping gene/protein 
as the internal control reference within each sample, then a 2-fold difference in expression 
between samples is commonly regarded as significant. In vitro gene silencing through the 
use of small interfering RNA (siRNA) molecules to cause RNA interference (RNAi) is also 
frequently used to confirm the cellular effects of aberrant gene knockdown. Similarly, 
protein function blockade via small molecule inhibitors or monoclonal antibodies can be 
used to demonstrate the effects in vitro on signal transduction.   
3.6.3 Clinical validation 
In vitro confirmation of differential expression or functional effect within experimental test 
samples does not necessarily equate to clinical relevance (Paulovich et al., 2008). To 
validate those putative biomarkers that successfully pass through technical validation 
(section 3.6.2), the clinical significance must be tested using clinical samples with relevant 
clinical information. Frequently this is initially carried out using immunohistochemistry 
(IHC) on a series of retrospective archival tumour samples. IHC can be used to validate the 
expression and localisation of proteins in whole sections of formalin-fixed, paraffin-
embedded (FFPE) clinical tissue samples mounted on glass microscope slides. Whilst this 
particular method is low throughput an alternative high throughput approach in the form of 
a suitable tissue microarray (TMA) could be employed (Hassan et al., 2008). This method 
involves removing cores of tissue from hundreds of different formalin-fixed paraffin-
embedded (FFPE) samples and co-embedding the selected cores into a new TMA block 
enabling a single slide to be screened simultaneously for the expression of one particular 
protein using IHC. Alternative approaches for clinical validation, include the use of an 
ELISA, MS-based multireaction monitoring (MRM) or reverse phase assays (RPA) (Pan et 
al., 2009). 
 57 
 
3.7 Proteomic identification of putative radiotherapy resistance biomarkers 
There are a number of proteomic studies that have attempted to identify biomarkers 
associated with radiotherapy resistance. For each study the discovery data has been 
reviewed and human proteins identified using MS/MS have been assimilated by gene name 
in Appendix A. PMF data appears in Appendix A only if confirmatory techniques (e.g. 
Western blotting) were used to demonstrate the correct identification and differential 
expression of the protein. Those proteins which have undergone clinical validation by IHC 
are highlighted in Appendix A and the details given in section 3.7.2 (Scaife et al., 2011).  
3.7.1 Clinical tissue studies 
Owing to the technical challenges associated with clinical tissue analysis, the majority of 
proteomic studies of radiotherapy resistance have been carried out on cell line models. 
However, a single study to identify biomarkers of radiotherapy resistance using clinical 
tissue has been described (Allal et al., 2004). Tissue biopsy samples were collected from 17 
rectal cancer patients with T2-T3/N0-N1 tumours prior to fractionated RT treatment. 
Following a total dose of 50 Gy, the tumour response was assessed histopathologically. RR 
and RS tumour samples where then compared by proteomic analysis using 2DE (pH range 
4.5-5.5 and 5.5-6.7) and PMF. The putative identity of several DEP’s was reported, 
including annexin V (ANXA5), Kv channel interacting protein 3 (calsenilin; KCNIP3), 
tropomodulin 3 (TMOD3) and RAD51-like 3 (RAD51L3). No further work was carried out 
to confirm the identity and differential expression of these proteins. 
3.7.2 Cell line studies 
The majority of studies that have employed comparative proteomic methodologies in order 
to identify putative biomarkers associated with radiotherapy resistance have utilised novel 
radioresistant (RR) cancer cell lines as clinically relevant in vitro models. Established 
cancer cell lines can be subjected to fractionated doses of ionising radiation mimicking the 
relevant clinical schedule and total dose, in order to generate novel cell sub-lines that 
demonstrate a significant increase in radiotherapy resistance. It is hypothesised that the 
fractionated sub-lethal radiation dose will drive the selection of cell clones that carry RR 
properties and the abnormal constitutive (in)activation of key proteins associated with the 
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RR phenotype. The current collection of such published studies is outlined in chronological 
order below and the putative biomarkers identified have been assimilated in Appendix A.  
 A derivative RR sub-line of the H69 small cell lung cancer cell line was produced 
following a fractionated total radiation dose of 37.5 Gy (Henness et al., 2004). Differences 
in protein expression in this H69/R38 RR sub-line, compared with untreated parental cells, 
were then examined using 2DE (pH range 3-10) and MS/MS. The identities of nine human 
DEP’s were reported (Appendix A). 
 A derivative RR sub-line of the MCF-7 breast cancer cell line was produced 
following a fractionated total radiation dose of 60 Gy (Wang et al., 2005). Differences in 
protein expression in this MCF-7+FIR30 RR sub-line, compared with RS MCF-7 cells, 
were analysed using 2DE (pH range 3-10 and 4-7) and MS/MS (Appendix A). The identity 
of peroxiredoxin II was reported as a differentially expressed protein and further analysis 
was concentrated on this protein. The up-regulation of peroxiredoxinII in the MCF+FIR30 
RR sub-line was confirmed by Western blotting and gene silencing using siRNA restored 
partial radiosensitivity.  
 Derivative RR sub-lines of the LNCaP, PC3 and Du145 prostate cancer cell lines 
were produced following a total radiation dose of 10 Gy (Skvortsova et al., 2008). 
Differences in protein expression in the LNCaP-IRR, PC3-IRR and Du145-IRR RR sub-
lines, compared with the relevant parental cells, were assessed using 2D-DIGE (pH range 
3-10) coupled with MALDI-TOF/TOF-MS. The identity of over 20 human DEP’s, which 
were observed in membrane and cytosol sub-fractions from all three RR sub-lines, was 
reported (Appendix A).  The differential expression of APEX1, HSPA8, NME1, RAB11A 
and SERBP1 was validated by Western blotting. Furthermore, gene silencing of APEX1 by 
siRNA demonstrably enhanced radiosensitivity in all three of the RR cell sub-lines. 
 In our own group, derivative RR sub-lines of the MCF-7, MDA-MB-231 and T47D 
breast cancer cell lines were produced following a fractionated total radiation dose of 40 Gy 
(Smith et al., 2009). Differences in protein expression in the MCF-7RR, MDA-MB-231RR 
and T47DRR sub-lines, compared with relevant parental cells, were analysed using both 
iTRAQ and 2DE (pH range 4-7 and 7-10) combined with MALDI-TOF/TOF-MS. A small 
number of 2DE spots that were identified by PMF (MALDI-TOF-MS) and subsequently 
validated by Western blotting or RTqPCR were also described. In total the identity of over 
50 human DEP’s, which were observed in at least one of the three RR sub-lines, were 
 59 
 
reported (Appendix A). The differential expression of 11 putative biomarkers was 
confirmed by Western blotting or RTqPCR, 2 of which were clinically validated.  A 
number of proteins were associated with the 26S proteasome and a pilot 
immunohistochemical analysis of archival laryngeal cancers confirmed that the decreased 
expression of the 26S proteasome correlated with radiotherapy resistance. 
 A derivative RR sub-line of the CNE2 nasopharyngeal cancer (NPC) cell line was 
produced following fractionated radiation (Feng et al., 2010).  Differences in protein 
expression in the CHE2-IR RR sub-line, compared with parental cells, were assessed using 
2DE and MS/MS. The identities of over 20 human DEP’s were reported (Appendix A). The 
differential expression of HSPA5 (GRP78), SERPINB5, SFN (14-3-3 σ) and SOD2 was 
validated by Western blotting. In addition, the in vitro silencing of SFN (14-3-3 σ) by 
siRNA was associated with increased radiotherapy resistance. A pilot 
immunohistochemical analysis of archival NPC samples confirmed that the downregulation 
of SFN (14-3-3 σ) and SERPINB5 expression correlated with radiotherapy resistance, 
whilst the upregulation of HSPA5 (GRP78) and SOD2 expression correlated with 
radiotherapy resistance. This four-biomarker panel demonstrated 90% sensitivity and 88% 
specificity for the prediction of radiotherapy resistance in NPC samples. 
 Derivative RR sub-lines of the OECM1 (gingival epidermoid carcinoma) and KB 
(oral epidermoid carcinoma) cell lines, which are sub-types of head and neck cancer 
(HNC), were produced following a fractionated total radiation dose of 60 Gy (Lin et al., 
2010). Differences in protein expression in the OECM1-RR and KB-RR RR sub-lines, 
compared with the relevant parental cells, were assessed by pre-fractionation and 1-DE 
prior to identification of differentially expressed protein bands by peptide mass 
fingerprinting. The putative identity of 64 proteins was described from the membrane, 
cytosol or nuclear sub-fractions and 6 underwent further confirmatory work (Appendix A). 
The significant differential expression of HSPD1 (HSP60), HSPA5 (GRP78), RAB40B, 
HSP90B1 (GRP94, GP96) and GDF15 was confirmed by RT-PCR in both RR cell lines. 
Further, gene silencing of HSP90B1 by siRNA demonstrably enhanced radiosensitivity in 
HNC cell lines and in tumour xenografts. Interestingly, the same group had previously 
identified the differential expression of HSP90B1 (GRP94, GP96) in RR cell lines of NPC 
origin using expression microarray analysis (Chang et al., 2007). 
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 A derivative RR sub-line of the Hep-2 laryngeal cancer cell line was produced 
following a fractionated total radiation dose of 60 Gy (Kim et al., 2010). Differences in 
protein expression in this RR-Hep-2 RR sub-line, compared with parental cells, were 
analysed using 2-DE (pH 4-7) and PMF. The putative identity of 16 proteins was described 
and these underwent further confirmatory work. The significant differential expression of 
12 DEPs was demonstrated visually by Western blotting or RT-PCR in the RR cell line 
(Appendix A). Further analysis of CLIC1 by RT-qPCR, confocal microscopy and chemical 
inhibition established a functional role for this protein in the acquisition of the RR 
phenotype (Kim et al., 2010). 
 Derivative RR sub-lines of the FaDu and SCC25 head and neck carcinoma cell lines 
were produced following a total radiation dose of 100 Gy (Skvortsov et al., 2011). 
Differences in protein expression in the FaDu-IRR and SCC25-IRR sub-lines, compared 
with the relevant parental cells, were assessed using 2D-DIGE (pH range 3-10) coupled 
with MALDI-TOF/TOF-MS. The identity of over 30 DEP’s from both IRR sub-lines were 
reported (Appendix A). 
  
 
In summary, it is clear from Appendix A that a large number of human DEP’s have been 
identified in RR cell lines through use of proteomic techniques, some of which have been 
further confirmed using Western blotting, transcript analysis, RNA interference or 
immunohistochemistry. However, when comparing this list of putative biomarkers with 
those discussed in Chapter 2 and those hypothesised in Table 1 (Chapter 1) there is very 
little overlap in relation to individual biomarkers, pathways or common themes. In addition, 
none have yet been brought into routine clinical use, highlighting the need for increased 
research into the search for predictive biomarkers of radiotherapy resistance using 
proteomic methodologies. 
 
 
 
 
 
 61 
 
3.8 Project Aims 
The identification of a panel of protein biomarkers that can be used within the clinical 
setting to predict response to radiotherapy would be an extremely valuable tool when 
considering treatment options for patients diagnosed with cancer. Not only will it allow for 
treatment regimens to be tailored on an individual patient basis, but it will also spare those 
patients resistant to the treatment from the harmful side effects associated with radiotherapy 
in the absence of therapeutic gain. In addition, the identification of a panel of protein 
biomarkers will in turn aid in our understanding of the underlying mechanisms of 
radioresistance, and in doing so possibly provide potential therapeutic targets for future 
treatment protocols. 
The overall aim of this project is to use complementary proteomic methodologies for 
the identification of DEPs associated with radiotherapy resistance across three tumour 
types, namely breast, head and neck and rectal, using 7 novel cell line models. The specific 
aims of this project include: 
 The establishment of two novel radioresistant rectal cancer cell lines. 
 The identification of putative biomarkers of radiotherapy resistance using the 
biomarker discovery pipeline; 
- The generation of DEP’s using 2D-PAGE MALDI-TOF/TOF-MS, iTRAQ and 
antibody microarray analysis. 
- The performance of data mining using Ingenuity Pathway Analysis software to 
aid in prioritisation of DEP’s for further confirmation and validation. 
- The confirmation of DEP’s using semi-quantative Western blotting. 
- The clinical validation of DEP’s using immunohistochemistry in order to 
identify putative biomarkers of radiotherapy resistance. 
 To make recommendations regarding the study of key canonical pathways. 
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Chapter 4: 
Materials and Methods 
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Chapter 4.  Materials and Methods 
4.1 Cell culture 
Throughout periods of cell culture all equipment including the water bath, tissue culture 
hood and incubator were cleaned thoroughly using Virkon disinfectant and 70% alcohol to 
ensure a clean and sterile working area. In addition to this, contamination of cells was 
further prevented through the adoption of sterile technique which involved spraying all 
equipment with 70% alcohol prior to placing it into the Class II tissue culture hood. 
4.1.1 Cell lines 
Cell culture was performed using 7 commercially purchased cell lines; these included 3 
breast cancer cell lines: MCF-7, MDA-MB-231 (MDA) and T47D, 2 oral cancer cell lines: 
PE/CA-PJ41 (PJ41) and PE/CA-PJ49 (PJ49), and 2 rectal cancer cell lines: SW837 and 
HRA-19 (Table 4). 
4.1.2 Thawing cells 
Before thawing of cells, the appropriate RPMI or DMEM cell culture medium (Appendix 
B) was heated to 37 ˚C in a water bath for approximately 30 min. Once the medium had 
reached the correct temperature, a cryovial of frozen cells, stored in freezing medium 
(Appendix B), was removed from the -80 ˚C freezer, placed into a sealed plastic bag, and 
put into the heated water bath in order to thaw quickly. Once fully defrosted the contents of 
the vial were carefully transferred to a 30 ml sterile universal tube in the tissue culture 
hood, and 9 ml of cell culture medium was added (to make a 1:10 dilution) drop-by-drop to 
enable the cells time to adjust to their new environment. The resulting cell suspension was 
then pelleted by centrifugation at 1500 rpm for 3 min. The remaining supernatant was 
discarded and the pellet re-suspended in the relevant volume of fresh culture medium. The 
cell suspension was transferred into either a T25 (25 cm
2
) or a T75 (75 cm
2
) flask 
determined by the relative size of the cell pellet. The flask of cells was then placed in a 
humidified incubator at a constant temperature of 37 ˚C with an atmosphere of 5% CO2.  
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Table 4: Details of the 7 commercially purchased cancer cell lines. 
The 7 cancer cell lines consisted of 3 breast, 2 oral and 2 rectal cell lines. For each the name, catalogue number/repository, tissue of origin, 
morphology, molecular subtype (except PJ41 and PJ49) and the medium used for culture are given. All 7 cell lines were adherent. Additional 
cell line information can be found in Appendix C. 
 
Name of cell 
line 
Catalogue #/ 
repository 
Tissue of origin Morphology Molecular subtype 
Culture 
medium used 
MCF-7 
#HTB-22/ 
ATCC 
Breast Epithelial 
Luminal (ER
+
) (Boyan et al., 2003) 
RPMI 
MDA-MB-231 
(MDA) 
#92020424/ 
HPA cultures 
Breast Epithelial 
Triple Negative (ER
-
) (Pan et al., 2012) 
RPMI 
T47D 
#85102201/ 
HPA cultures 
Breast Epithelial 
Luminal (ER
+
) (Pink et al., 1996) 
RPMI 
PE/CAPJ41 
(PJ41) 
#98020207/ 
ECACC 
Oral squamous 
epithelium 
Epithelial 
--- 
RPMI 
PE/CAPJ49 
(PJ49) 
#00060606/ 
ECACC 
Oral (Tongue) Epithelial-like 
--- 
RPMI 
SW837 
#91031104/ 
HPA cultures 
Rectum Epithelial 
P53 mutant (Hashimoto et al., 2001) 
MMR proficient (Lengauer et al., 1997) 
RPMI 
HRA-19 
#10012802/ 
HPA cultures 
Rectum Epithelial 
P53 mutant (Liu and Bodmer, 2006) 
MMR proficient (Wheeler et al., 1999) 
DMEM 
 65 
 
4.1.3 Culturing cells 
Cells were cultured in RPMI or DMEM cell culture medium (Appendix B) and kept in an 
incubator at 37 ˚C with an atmosphere of 5% CO2. Cells were cultured in T75 flasks, which 
along with the medium were changed 3 times each week. Prior to each flask change, the 
medium was heated in the water bath to a temperature of 37 ˚C for approximately 30 min. 
Media was heated to ensure minimal amounts of stress were experienced by the cells. 
Trypsinisation was used in order to remove adherent cells from the flask. Three ml of 
TrypLE Select (#12563, Invitrogen), a recombinant enzyme used for the dissociation of 
adherent cells, was added to the flask, ensuring complete coverage over all of the cells, and 
subsequently incubated at 37 ˚C for approximately 4 min. Once incubated, the flasks were 
gently tapped in order to loosen the cells from the flask’s surface, and 7 ml of warmed 
medium was then added to inhibit the action of trypsin. The cell suspension was removed 
from the flask, transferred into a 30 ml sterile universal tube, and then centrifuged at 1500 
rpm for 3 min. Once completed, the tube was returned to the tissue culture hood, the 
supernatant removed and the remaining cell pellet re-suspended in the appropriate volume 
of medium and transferred into a fresh flask. 
4.1.4 Freezing cells 
When cells reached a confluence level of ~80%, they were suitable for freezing. Cells were 
frozen using a freezing medium consisting of 10% dimethyl sulphoxide (DMSO) (#D2650, 
Sigma Aldrich) in appropriate RPMI or DMEM medium (Appendix B). Cells were then 
centrifuged at 1500 rpm for 3 min, with the remaining pellet slowly resuspended in 1 ml of 
freezing medium. The cell suspension was then transferred into a cryovial and stored at -
80˚C, or alternatively liquid nitrogen at -135 ˚C for long term storage. 
4.2  The biomarker discovery pipeline 
Prior to starting this project the 7 cancer cell lines were all at varying stages within our 
biomarker discovery pipeline (Figure 15). The 3 breast and 2 oral cancer radioresistant 
(RR) cell sublines had previously been established (detailed in sections 4.4.1 and 4.4.2, 
respectively). The RR breast cancer cell sublines had undergone all methods of biomarker 
discovery (antibody microarray (AbMA), 2D MS and iTRAQ) whilst the oral cancer RR 
cell sublines had only undergone AbMA analysis. RR rectal cancer cell sublines had yet to 
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be established and begin the biomarker discovery pipeline. Figure 15 clearly differentiates 
between work that had previously been completed (blue arrows) and work that was to be 
carried out (red arrows) during the course of this project. 
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Figure 15: Progression through the biomarker discovery pipeline of the 7 RR cancer cell lines.  
Both breast and oral cancer radioresistant (RR) cell line derivatives had been established. RR breast cancer cell lines had completed the 
biomarker discovery phase whilst the oral RR cancer cell lines had only undergone antibody microarray analysis (AbMA). Rectal cancer cell 
lines had yet to begin any of this process. This figure outlines work that had previously been completed (blue arrows) and work that was to 
be carried out (red arrows) during this project. 
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4.3 Development of the novel radioresistant Rectal Cancer cell lines 
Radioresistant novel derivatives were developed from the rectal cancer cell lines SW-837 
and HRA-19 in collaboration with Mr Sajid Mehmood. Treatment resistance was produced 
by using clinically relevant doses of radiotherapy. Irradiation was performed at Castle Hill 
Hospital, Hull, UK in conjunction with a radiation physicist (Gary Liney or Matthew Bush) 
using X-rays produced by a clinical Linear Accelerator treatment machine (6 Mv) as 
described previously (Smith et al., 2009) (see Figure 16). A cradle was manufactured 
therefore allowing the vial containing the cell suspension to be suspended inside a water 
filled vessel (phantom) (see Figure 17). The purpose of this operation was to enable 
irradiation of cells to mimic the in vivo environment, with the surrounding water 
representing normal body tissue. The cradle was designed such that the vial containing the 
cell suspension was mounted precisely in the centre of the water filled phantom. From this 
assembly, it was calculated that the dose given to any cells at the centre of the vial 
represented that given to the cells throughout its total volume. Using this experimental set-
up it was possible to deliver consistent doses to the cell samples throughout the course of 
the study.  
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Figure 16: The experimental set-up required for the irradiation of cell populations.  
Irradiation was performed at Castle Hill Hospital, Hull, UK using X-rays produced by a clinical Linear Accelerator treatment machine. The 
vial containing the cell suspension was suspended in a water-filled vessel (phantom), which was arranged so that the X-rays were delivered 
to the centre of the phantom. 
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Figure 17: A schematic diagram of the phantom used during radiotherapy treatment. 
The cradle was designed such that the vial containing the cell suspension was mounted 
precisely in the centre of the water filled phantom. From this careful assembly, it was 
assumed that the dose given to any cells at the centre of the vial represented that given to 
the cells throughout its total volume.    
 
 
4.3.1 Cell counting 
Cells were harvested using enzymatic dissociation (see section 4.1.3) and resuspended in 6 
ml of RPMI or DMEM medium. Twenty five µl of the cell suspension was then mixed 
thoroughly with 25 µl 0.4% (w/v) trypan blue, giving a 1:1 concentration. Twenty five µl of 
this resultant cell suspension was applied to a haemocytometer under a glass coverslip. 
Cells were counted under a light microscope using a hand-held counter. Cells were counted 
in 5 squares, 4 corner squares and the central square of the grid (see Figure 18). The cell 
concentration per ml was calculated using the following formula: 
 
[(Σ(1+2+3+4+5)/5) x 2] x 104 = cells/ ml 
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Figure 18: Grid on haemocytometer used for cell counting.  
Cells were counted in 4 corner squares and the central square of the grid. The cell 
concentration per ml was then calculated. 
 
4.3.2 Modified colony counting assay for assessment of radiotherapy response 
Prior to establishing a radioresistant cell line, the inherent sensitivity of SW837 and HRA-
19 was first established. This was performed by constructing dose response curves (DRCs) 
for each cell line using doses ranging from 0-10 Gy. For each DRC cells were harvested by 
enzymatic dissociation as described in section 4.1.3, and 1x10
6
 cells were seeded in 
screwed-cap 7ml polypropylene containers. A total of 6 containers were used, each filled 
with 5ml of the cell suspension. The containers were then labelled with the dose of 
radiation each was going to receive i.e. 0 Gy, 2 Gy, 4 Gy, 6 Gy, 8 Gy and 10 Gy. The 
samples were then irradiated as described in section 4.3. A proportion of the cell suspension 
from each container, which corresponded to 1000 cells, was then removed and plated in 
triplicate into six well tissue culture plates. This was done in triplicate. The plates were then 
incubated at 37 ˚C for 12-14 days until control cells (0 Gy) reached a critical mass and 
individual colonies became distinguishable. At that point, the medium was removed and the 
cells were fixed in 3ml of ice cold Carnoy’s fixative (3:1 methanol: acetic acid) for 5 min. 
The cells were left to air-dry overnight. The following day, the cells were stained with 3ml 
0.005% crystal violet for 5 min. The residual stain was then removed in slowly running tap 
water and the plates left to air-dry. In order to calculate the number of surviving cells after 
each dose of radiotherapy the stained colonies were photographed using a 14 mega-pixel 
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camera in order to produce a high-resolution image. Colonies of cells of >50 in number 
were deemed to represent surviving cells from the original cell line. The plates were 
examined under a light microscope and a colony of 50 cells was identified. This was then 
correlated with the photographed image and a measurement taken. Any group of cells of 
this size or greater was then counted independently, in triplicate, by 2 people and an 
average taken. A DRC of number of colonies against dose of radiotherapy was then 
produced (section 4.3.3). 
4.3.3 Dose response curve for radiotherapy resistance 
Plating efficiency (PE) and survival fraction (SF) were calculated for both parental cell 
lines using the following formulas:  
 
PE = (Number of colonies counted/ number of cells plated) x 100 
SF = (PE of treated sample/ PE of control) x 100 
 
 A survival curve was then generated by plotting the SF (Y axis) against radiation dose (X 
axis). Each experiment was done in triplicate for each dose and a mean value of SF for each 
dose was calculated. The whole experiment was repeated and the mean SF of two 
independent experiments was plotted on the DRC. 
4.3.4 Incremental irradiation dose 
Results generated from the DRC enabled the selection of an appropriately high sub-lethal 
dose, which was used during a fortnightly fractionation regimen. For these experiments, 8 
Gy was selected for the SW-837 cell line, and 4Gy was selected for the HRA-19 cell line, a 
decision made based on the guidance from the DRC and also existing clinical treatment 
regimens. In these experiments, the parental cell line refers to the cell line which had 
received no radiotherapy, from which a radioresistant cell line was created. For each of the 
two cell lines, a sample of 6x10
6
 from the parental cell line was placed into a 7ml 
polypropylene container and made up to a volume of 5 ml with RPMI/DMEM culture 
medium. This was then taken to the Radiotherapy Department and dosed at 8 Gy (SW837) 
and 4 Gy (HRA-19). The cells were then returned to the incubator and allowed to grow 
before the next dose. The cells were checked under the light microscope, and when 
approximately 80% confluence was reached the cells were counted and a further 6x10
6
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were dosed. This process was repeated until a final total dose of 48 Gy was reached for 
both cell lines. 
4.3.5 Confirmation of radioresistance 
In order to determine whether the 48 Gy treated cell lines were more resistant to 
radiotherapy than their parental counterparts, a DRC was constructed, as per section 4.3.3 
and compared to the DRC for SW837 and HRA-19 parental cells using the Student’s t-test 
for statistical analysis. 
4.4 Previously established novel cell line derivatives 
4.4.1 Development of the novel radioresistant Breast Cancer cell lines 
Radioresistant novel derivatives (hereafter named MCF-7RR, MDARR and T47DRR) 
were previously developed from the three breast cancer cell lines MCF-7, MDA-MB-231 
and T47D following the same workflow as described in section 4.3. Each original cell line 
population received a total dose of 40 Gy administered in 2 Gy fractions. Modified colony 
counting assays were used to measure the in vitro response to ionising radiation following 
the same workflow as detailed in section 4.3.2. DRC’s for both parental and novel 
radioresistant derivatives were plotted as per section 4.3.3. Compared with the respective 
parental cells, the overall maximum resistance demonstrated by MCF-7RR, MDARR and 
T47DRR was 37-fold, 22-fold and 34-fold, respectively, all of which were observed at 8 
Gy (p ≤ 0.01; ANOVA). 
4.4.2 Development of the novel radioresistant Oral Cancer cell lines 
Radioresistant novel derivatives (hereafter named PJ41RR and PJ49RR) were previously 
developed from the two oral cancer cell lines PE/CAPJ41 and PE/CAPJ49 as described in 
section 4.3. PJ41RR received a total dose of 28 Gy and PJ49RR received a total dose of 24 
Gy, administered in 4 Gy fractions. Modified colony counting assays were used to measure 
the in vitro response to ionising radiation following the same workflow detailed in section 
4.3.2. DRC’s for both parental and novel radioresistant derivatives were plotted in the same 
way as discussed in section 4.3.3. Compared with the respective parental cells, the overall 
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maximum resistance demonstrated by PJ41RR and PJ49RR was 142-fold and 10.2- fold, 
respectively, both of which were observed at 6 Gy (p ≤ 0.05; Students t-test). 
4.5 The Panorama Antibody Microarray XPRESS725 Profiler 
The Panorama Antibody Microarray XPRESS725 Profiler (#XP725, Sigma-Aldrich) 
consisting of 725 antibodies (spotted in duplicate) (Appendix D) selected from various cell 
signalling canonical pathways was used to compare protein expression between parental 
cells, and radioresistant derivatives. Figure 19 gives an outline of the overall workflow for 
an antibody microarray experiment. 
 
 
Figure 19: Overall workflow of an antibody microarray experiment. 
An outline of the steps involved for the discovery of DEPs using antibody microarray. 
4.5.1 Protein Extraction  
Prior to starting protein extraction the following solutions were prepared: 
 Protease Inhibitor Cocktail: 0.3 ml of ddH2O was added to the vial provided 
(#P4495, Sigma Aldrich). The reconstituted solution was then stored at -20 ºC. 
 Benzonase Working Solution: 2 µl of Benzonase Ultrapure (#B8309, Sigma 
Aldrich) was added to 18 µl of Extraction/Labelling Buffer (provided in the kit). 
During the course of this experiment, polypropylene microcentrifuge tubes were used at all 
times in order to minimise contamination from plastics as well as to prevent 
proteins/peptides being retained on the surface of the tubes. Ultra-pure proteomics grade 
water was also used throughout. Protein was extracted from the cell lines using the 
Antibody Microarray Extraction/Labelling buffer provided in the kit. To each 10 ml of 
Extraction/Labelling buffer 50 µl of the previously prepared Protease Inhibitor Cocktail, 
100 µl of Phosphatase Inhibitor Cocktail II and 1.2 µl of the Benzonase Working Solution 
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was added and kept on ice until required. This solution was then referred to as Lysis Buffer 
A. Addition of these reagents functions to prevent the breakdown of the protein sample 
whilst Benzonase is added to remove any nucleic acid within the sample.  
Cultured cells at a confluence of approximately 80% were scraped from the bottom 
of the flask and transferred to a universal tube, centrifuged at 1500 rpm for 3 min, and 
resuspended in 5 ml of cold, sterile, phosphate buffered saline (PBS) for washing. Cells 
were then centrifuged and washed again in 5 ml PBS for a total of 2 washes to ensure all 
serum was washed away from the cells, and hence would not interfere with the subsequent 
down-stream experiment. Upon completion of the wash steps, the pelleted cells were 
resuspended in 1ml of cold PBS and transferred to a 2 ml microfuge tube. Cells were 
centrifuged at 3000 rpm for 3 min and the supernatant subsequently discarded. Cell extracts 
were resuspended in 1ml of Lysis Buffer A containing both protease and phosphatase 
inhibitors. Cells were then vortexed for 5 min in order to lyse the cells. Samples were 
placed on an end-over-end rotator at 4 ˚C and incubated for 5 min. On completion of the 
incubation, samples were briefly vortexed and centrifuged at 15,000 rpm for 2 min. The 
resultant pellet of cell debris was discarded, and the remaining supernatant transferred to 
pre-chilled microfuge tubes and stored at -80 ˚C until quantification. 
4.5.2 Protein Quantification 
Protein concentration was determined using the Bradford protein assay. The Bradford 
Reagent (#B6916, Sigma Aldrich) consists of Brilliant Blue G, a dye which forms 
complexes with protein in the solution causing a shift in the absorbance of the dye from 465 
to 595 nm after a short incubation. The absorbance of the sample is therefore proportional 
to the amount of protein in the sample. Eight protein standards ranging from 0.1-1.4 mg/ml 
using bovine serum albumin (BSA) were diluted in Lysis Buffer A in microcentrifuge 
tubes. Five µl of each BSA standard was then placed in separate wells of a 96-well plate. 
The protein extracts (from section 4.5.1) of unknown concentration were also diluted in 
Buffer A to ensure their concentrations fell within the linear range of 0.1-1.4 mg/ml. The 
extracts were then placed in separate wells of the 96-well plate at a volume of 5 µl. Three 
technical replicates were performed for each sample. After gentle mixing at room 
temperature, 250 µl of Bradford Reagent was added to each standard and sample. The 96-
well plate was then mixed for 30 sec on a spectrophotometer (Multiscan MS plate reader, 
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Labsystems) and incubated at room temperature for 5 min. Absorbance was measured at 
595 nm. The protein concentration of each known protein sample was plotted against the 
absorbance at 595 nm to produce a standard curve. The protein concentration of the 
samples was determined using the equation of the line. 
4.5.3 Protein Labelling 
Labelling of the protein sample was carried out in a darkened room due to the fluorescent 
dyes being sensitive to light. Protein extracts from parental cells were labelled with Cy3 
(#PA23001, GE Healthcare) fluorescent dye and protein extracts from the corresponding  
RR cell subline were labelled with Cy5 (#PA25001, GE Healthcare) fluorescent dye. Each 
extract had been previously diluted to 1 mg/ml in Lysis Buffer A. Labelling required the 
addition of 1 ml of protein extract to the respective dye vials. The vial was capped, mixed 
by vortexing and subsequently incubated for 30 min at room temperature. During this 30 
min incubation the vial was vortexed every 10 min. Any unbound dye was then removed 
using Sigma Spin Columns (#S0185-8EA, Sigma Aldrich), provided in the Antibody 
Microarray kit. Any storage buffer contained within the spin columns was removed by 
centrifugation for 2 min at 750 xg and discarded. One hundred and fifty µl of each of the 
labelled protein samples was then passed through the columns by centrifugation for 4 min 
at 750 xg and the elutes were retained. The elute is the labelled protein extract which is 
light-sensitive. The Bradford assay (section. 4.5.2) was performed for a second time to 
ensure protein concentration was still close to 1mg/ml. 
4.5.4 Determination of the Dye-to-Protein Molar Ratio 
The Dye to Protein Molar Ratio (D:P ratio) was determined by measuring the absorbance of 
the Cy3-labelled and Cy5-labelled protein extracts at 552 nm and 650 nm respectively. 
Lysis Buffer A was used as a blank. The calculation was specified in the Antibody 
Microarray kit as follows, with only samples achieving a D:P ratio of ≥ 2 being used. 
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Cy3 concentration (µM) = (A552 / 0.15) x 10 
Cy5 concentration (µM) = (A650 / 0.25) x 10 
Y (mg/ml) = protein concentration after labelling with fluorescent dyes 
 Protein concentration (µM) = (Y / 60,000) x 1,000,000 
D:P ratio = Cy3 or Cy5 concentration (µM) / Protein concentration of sample (µM) 
4.5.5 Antibody Incubation 
Antibody incubation with the array slide was carried out in a darkened room. Equal 
amounts of labelled protein sample (50-150 µg) were mixed with 5 ml of Array Incubation 
Buffer (supplied in the Antibody Microarray kit) and placed in well 1 of the quadriPERM 
Cell Culture vessel provided in the kit. The Antibody Microarray slide provided in the kit 
was washed briefly in PBS before incubation with the samples in well 1. The slide was 
incubated with the samples for 40 min on an orbital shaker at low speed, protected from the 
light. After this time 5 ml of Wash Buffer (supplied in the kit) was added to wells 2, 3 and 
4 with the slide being washed for 5 min on an orbital shaker in each well (total of 3 
washes). Well 5 was then filled with 5 ml of ultrapure distilled water and the slide was 
washed for 2 min. The slide was then allowed to air-dry for 30 min (protected from the 
light) before scanning (section 4.5.6). 
4.5.6 Scanning and Analysis 
A GenePix Personal 4100A Microarray Scanner (Axon Instruments) with 532 nm and 635 
nm lasers was used to scan the antibody microarray slide. GenePix Pro software (Axon 
Instruments) was used to align the slide and apply protein names in the form of a list with 
their respective location on the array slide. All antibody-protein spots were edited manually 
to ensure accurate analysis. Negative controls in the slide were flagged as negative. Acuity 
software (Axon Instruments) was used to identify differentially expressed proteins between 
the parental cells and the respective sample derivative. Normalisation was carried out based 
on the Lowess method, and spot criteria were applied to only include spots which contained 
<3% saturated pixels, spots with ‘relatively’ uniform intensity and background, those which 
were detectable above the background and those which were not flagged (as negative 
controls), as a quality control measure. Log ratios were given based on the relative 
intensities of each Cy3/Cy5 labelled protein extract. Fold changes of ≥1.8 were considered 
significant, and fold changes ≥1.5 were also recorded for each experiment as supporting 
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data  (Hodgkinson et al., 2011). Experiments were considered successful if the percentage 
of ‘substances matched’, provided by the software during analysis was ≥ 90, ensuring only 
slides of the highest quality were taken forward for data interpretation. The direction of fold 
change, showing an increase or decrease in expression of a particular protein was provided 
at the analysis stage. However, this information was not expressed in the results, as dye-
swap experiments were not performed due to significant cost implications. The direction of 
fold change was therefore confirmed technically using western blotting and clinically using 
immunohistochemistry. 
4.6 Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) coupled with 
matrix-assisted laser desorption/ionisation time-of-flight/time-of-flight (MALDI-
TOF/TOF) mass spectrometry 
Prior to the start of any 2D PAGE/MS experiment, extreme care was taken to ensure the 
avoidance of keratin contamination. Such control measures include the use of a dedicated 
lab and equipment, nitrile gloves and hair protection. In addition any plasticware used 
throughout each experiment was made from polypropylene in order to prevent the loss of 
protein/peptides that could hinder downstream experiments. Figure 20 gives an outline of 
the overall workflow for 2D-PAGE MALDI-TOF/TOF MS. 
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Figure 20: Overall workflow of a 2D-PAGE MALDI-TOF/TOF MS experiment 
An outline of the steps involved for the discovery of DEPs using 2D-PAGE MALDI-
TOF/TOF MS. 
 
4.6.1 Protein extraction 
Cultured cells (from the parent and respective RR subline), at a confluence of 
approximately 80%, were trypsinised, transferred to a universal tube, centrifuged at 1500 
rpm for 3 min, and resuspended in 5 ml of cold, sterile, phosphate buffered saline (PBS) for 
washing. Cells were then centrifuged and washed again in 5 ml PBS for a total of 5 washes 
to ensure all serum was washed away from the cells, and hence would not interfere with the 
subsequent down-stream experiment. Upon completion of the wash steps, the pelleted cells 
were resuspended in 1 ml of cold PBS and transferred to a 2 ml microfuge tube. Cells were 
centrifuged at 3000 rpm for 3 min and the supernatant subsequently discarded. Cell extracts 
were resuspended in 1 ml of 2D Extraction Buffer containing both protease and 
phosphatase inhibitors (see Appendix B). Cells were then vortexed for 5 min in order to 
lyse the cells. Samples were placed on an end-over-end rotator at 4 ˚C overnight (16 hours). 
On completion of the overnight incubation, samples were centrifuged at 15,000 rpm for 15 
min at 4˚C. The resultant pellet of cell debris was discarded, and the remaining supernatant 
transferred to pre-chilled microfuge tubes and stored at -80 ˚C until quantification. 
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4.6.2 ReadyPrepTM 2-D Cleanup Kit 
The ReadyPrep 2-D Cleanup Kit (#163-2130, Bio-Rad) was used for the preparation of 
protein samples prior to isoelectric focusing (IEF) (section 4.6.4). The kit functions to 
quantitatively precipitate and concentrate proteins in a sample whilst leaving behind salts, 
lipids and nucleic acids; components known to interfere with IEF. The kit was able to clean 
up 200 µl of sample per 1.5 ml microcentrifuge tube; the sample was therefore divided 
between microcentrifuge tubes before commencing. All reagents used were supplied in the 
kit, excluding dH2O (proteomic grade). Wash Reagent 2 was stored at -20 ˚C for one hour 
prior to use. Six hundred µl of Precipitating Agent 1 was added to each tube, vortexed and 
incubated on ice for 15 min. Six hundred µl of Precipitating Agent 2 was then added to 
each tube and mixed thoroughly by vortexing. The tubes were then centrifuged at 
maximum speed for 5 min to form a tight pellet. Being careful not to disturb the pellet, the 
remaining supernatant was removed by pipetting. The tubes were centrifuged for 15-30 
seconds for a second time, and any supernatant was carefully removed by pipetting. Forty 
µl of Wash Reagent 1 was then added to each tube, ensuring full coverage of the protein 
pellet. The tubes were then centrifuged at maximum speed for 5 min and the supernatant 
was removed by careful pipetting. Twenty five µl of dH2O (proteomic-grade) was then 
added to each tube and vortexed. One ml of pre-chilled (-20 ˚C) Wash Reagent 2 and 5 µl 
of Wash 2 Additive were added to each tube, and the tubes subsequently vortexed for 1 
min. The protein samples were incubated for 30 min at -20 ˚C. During the incubation the 
tubes were vortexed for 30 sec every 10 min. After the incubation period, the tubes were 
centrifuged at maximum speed for 5 min to form a tight pellet. The supernatant was then 
discarded by careful pipetting and centrifuged for a second time to ensure full removal of 
any remaining liquid. The protein pellet was then air-dried for a maximum of 5 min, and 
resuspended in 200 µl of fresh 2D Extraction Buffer by pipetting and vortexing for 1 min. 
Tubes were incubated at room temperature for 5 min, vortexed again for 1 min and 
centrifuged at maximum speed for 5 min. Samples which had been cleaned up using the 
ReadyPrep 2-D Cleanup Kit were subsequently quantified (section 4.6.3) using the 2D 
Quant Kit (#80-6483-56, GE Healthcare)  to ensure accurate loading of the sample (200 µg 
protein per gel) was achieved. 
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4.6.3 Protein quantification 
Proteins were quantified using the 2D Quant Kit (#80-6483-56, GE Healthcare), a kit 
chosen based upon reagent compatibility with following experiments. The assay is designed 
for accurate determination of protein concentration, of protein extracts which will be used 
for isoelectric focusing (IEF) and 2D-PAGE. The assay is based on the specific binding of 
copper ions to protein, with any unbound copper measured by absorbance. The colour 
intensity is inversely proportional to the protein concentration. Prior to performing the 
assay an appropriate volume of Working Colour Reagent was prepared by mixing 100 parts 
of Colour Reagent A with 1 part Colour Reagent B, as stated in the kit manual. Each 
individual assay required 1 ml of working colour reagent. Six standard protein samples 
were then prepared by adding various different volumes of a 2 mg/ml BSA solution to 1.5 
ml microcentrifuge tubes. 
Samples to be quantified were transferred into fresh microcentrifuge tubes at 
volumes of 2 µl and 5 µl. Two technical replicates were performed for each sample. Each 
tube received 500 µl Precipitant reagent and was then vortexed briefly and incubated at 
room temperature for 3 min. Five hundred µl of Co-Precipitant reagent was then added to 
each tube and vortexed to mix. The protein samples were then centrifuged at 10,000 xg for 
5 min to pellet the sample. The remaining supernatant was then decanted by pipetting. Once 
all visible liquid had been removed from the tubes, 100 µl of Copper Solution and 400 µl of 
dH2O were added to each of the tubes. The tubes were then vortexed briefly to re-suspend 
the precipitated proteins. At this point, 1 ml of Working Colour Reagent was added to each 
tube, mixed by inversion and incubated for 15-20 min at room temperature. Samples were 
pipetted onto a 96-well plate (200 µl in each well), and the absorbance of each sample read 
at 480 nm using a Multiscan plate reader (Labsystems). DH2O was used as a blank. The 
protein concentration of the samples was then calculated from the equation of the line 
produced from the standard curve. 
4.6.4 Isoelectric focusing 
Two hundred µg of protein sample (from the parent and respective RR subline) was 
pipetted along the back edge of a clean, dry Rehydration /Equilibration Tray (#165-4025, 
Bio-rad) at a volume of 185 µl. This was performed in triplicate for each sample. 
ReadyStrips IPG Strips (pH 4-7; 11 cm) (#163-2015, Bio-Rad) were rehydrated with the 
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sample by peeling off the coversheet and placing gel-side down into the channel containing 
the protein sample, ensuring equal coverage of sample along the strip. The strip and sample 
were then incubated for 1 hour to allow for maximum absorbance. Once incubated, 3 ml of 
mineral oil (#163-2129, Bio-rad) was added to each channel to prevent evaporation of the 
protein sample. IPG strips were subsequently incubated with the sample for 16 hours at 
room temperature. 
           Prior to its use, the Protean® IEF Tray (#165-4020, Bio-rad) was washed and dried 
thoroughly. Using forceps, paper electrode wicks (#165-4071, Bio-rad) were placed over 
each electrode in the tray, and 8 µl of dH2O was pipetted onto each. Each of the rehydrated 
IPG strips were transferred to the corresponding channel in the IEF tray, maintaining the 
gel-side down. Each strip was then covered with 3 ml mineral oil. The Protean® IEF Tray 
containing the strips was then transferred to the Protean® IEF Cell (#165-4001) and IEF 
then took place using the method suggested for 11cm IPG strips (Table 5).The procedure 
lasted a total of 5.5 hours. 
 
Table 5: Method programmed into the Protean® IEF Cell for an 11cm strip. 
 
Step Voltage Time Volt-Hours Ramp 
1 250 20 min - Linear 
2 8,000 2.5 hrs - Linear 
3 8,000 - 20,000 V-hr Rapid 
 
The focused IPG strips were then drained of any excess liquid and transferred to a clean, 
dry Rehydration/Equilibration tray gel-side up and stored at -80 ˚C until required for SDS-
PAGE (no longer than 1 month). 
4.6.5 Equilibration 
IPG strips were thawed until translucent and transferred to a clean, dry 
Rehydration/Equilibration tray, maintaining the gel-side up. Equilibration buffers (EB) 1 
and 2 (Appendix B) were prepared from stock EB (Appendix B). EB-1 and EB-2 contain 
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dithiothreitol (DTT) and iodoacetamide (IAA) respectively which function to ensure the 
effective separation of proteins in the 2
nd
 dimension by preventing the reformation of 
disulphide bonds by reduction and alkylation. Each IPG strip was incubated with 4 ml of 
EB-1 for 10 min on an orbital shaker. After the incubation, EB-1 was discarded and the 
strips were incubated with 4 ml of EB-2 under the same conditions but also covered with 
foil as IAA is light sensitive. During this time, 1% overlay agarose solution (Appendix B) 
was heated (on a medium heat) to melt it and maintain it in a liquid state. 
4.6.6 Sodium-dodecyl-sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Six Criterion
TM
 pre-cast gels (8-16% Tris-HCl polyacrylamide gel, 11cm) (#345-0105, Bio-
Rad), all of the same batch number were taken from their packaging and the plastic comb 
removed. Gels were prepared for use by rinsing the wells 3 times with ddH2O and blotting 
dry with filter paper. IPG strips were washed in Tris-glycine running buffer (#161-0772, 
Bio-Rad), blotted and placed at the top of the gel, gel-side up. The molten overlay agarose 
solution (Appendix B) was pipetted into the IPG strip well, and the strips were 
subsequently pushed down into the well ensuring no air bubbles were present. The gel was 
left for 5 min, giving time for the agarose to set. The gels were placed into a Criterion 2D 
Electrophoresis Cell (Bio-Rad), which was filled with Tris-glycine running buffer (#161-
0772, Bio-Rad). At this time, 10 µl of Precision Plus Protein Standards Dual Colour Marker 
(#161-0374, Bio-Rad) was added to its designated well. Electrophoresis was performed at a 
constant voltage of 200V, 500 mA and 300 W for 65 min. 
4.6.7 Protein staining 
Once electrophoresis was complete, each gel was removed from its casing and washed 3 
times for 5 min each with dH2O in a nalgene staining box on an orbital shaker. Bio-safe 
Coomassie Stain (#161-0787, Bio-Rad) was used to stain the proteins in the gel for 1 hour 
on an orbital shaker (shaking at a frequency of ~20 rpm). Following the incubation, the 
stain was discarded and the gels were de-stained for 16 hours in ddH2O at room 
temperature on an orbital shaker. After de-staining, the gels were again washed 3 times for 
5 min each. Gels were scanned using a GS800 calibrated densitometer (Bio-Rad) and 
imaged with Quantity One (Bio-Rad) software. Once scanning was complete, the gels were 
placed back into the nalgene staining boxes and stored in ddH2O (maximum 1 week). 
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4.6.8 PDQuest analysis software 
After staining and optical density scanning, the gels were analysed using PDQuest Analysis 
Software, a complex tool used to identify differentially expressed protein spots between 
groups of gels e.g. ‘test’ and ‘control’. Gels were ‘test’ (RR cell subline) and ‘control’ 
(respective parent cells) in triplicate. The required parameters were set for spot detection by 
identifying faint, small and clusters of protein spots. Spots were automatically detected and 
matched by the software, however all information generated was then manually edited in 
order to remove false spots, to include any missed spots, to distinguish spots hidden within 
a cluster and to modify any incorrect matches. Spots which contained more than one 
protein or which could not be matched with confidence were excluded. Manual editing took 
approximately 3 full days to complete. Correctly matched spots were then normalised using 
the “Total Quantity in Valid Spots” normalisation method. The software generated a 
dataset, and the criteria for differentially expressed spots was applied: only spots with a 
fold change ≥ 2 (between parent and RR gels), of 95% significance were identified. 
Boolean quantification and the Students t-test was the analysis tool used to identify and 
quantify any differentially expressed protein spots with a fold change ≥ 2. These spots were 
highlighted on the gels, and a histogram produced to illustrate differential protein 
expression between the two samples. 
4.6.9 Spot excision 
Gels (stored in dH2O) were transferred to ProteoWorks Plus Gel Cutting Sheets (#165-
7057, Bio-rad). Protein spots to be excised were carefully identified (using a printed, 
annotated image) and excised from 2-3 respective gels of the same sample type (e.g. 
radiotherapy-resistant gels) using a sterile disposable scalpel. Each cut was made as close to 
the edge of the spot as possible in order to reduce the amount of background gel and/or the 
excision of neighbouring spots. Each excised spot was transferred into a 0.5 ml Protein 
LoBind microcentrifuge tube (#022431064, Eppendorf). 
4.6.10 In-gel digestion 
In-gel digestion is a procedure used to digest proteins into peptides within a gel piece, and 
as a result release them. At this point it is essential to minimise sample loss and 
contamination (section 4.6) by following a basic protocol involving a limited number of 
steps. 
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Ammonium bicarbonate 100 mM stock solution was prepared by dissolving 0.395 g 
in 50 ml ddH2O. From this stock solution, 25 mM ammonium bicarbonate (50% 
acetonitrile (ACN)) and 25 mM ammonium bicarbonate (aq) were prepared. 
4.6.10.1 De-staining of gel pieces 
In order to de-stain gel pieces incubation with 100 µl of 25 mM ammonium bicarbonate 
(50% ACN) was carried out for 20 min at room temperature. The supernatant was then 
removed and the step repeated. Gel pieces were then washed by incubating with 100 µl of 
acetonitrile for 5 min at room temperature. Gel pieces were then dried by vacuum 
centrifugation for 20 min. 
4.6.10.2 Protein digestion 
Trypsin Gold (#V5280, Promega) was reconstituted with 50 mM acetic acid to a final 
concentration 0.1 mg/ml (stock). Twenty microlitres (2 µg) of stock Trypsin Gold solution 
was diluted with 80 µl of 25 mM ammonium bicarbonate (aq) [0.02 µg/µl]. Ten µl of this 
solution was then added to each eppendorf containing gel pieces. After allowing 5-10 min 
for the gel pieces to re-hydrate, they were covered with 5-15 µl of 25 mM ammonium 
bicarbonate (aq), keeping the volume as low as possible. The gel pieces were then 
incubated for 16 hours at 37 ºC, allowing for the proteins to be digested into peptides. 
4.6.11 Preparation of the MALDI matrix and plate spotting 
The MTP384 polished steel TF target plate (#209520, Bruker Daltonics) was cleaned by 
wiping with 2-propanol and ddH2O and sonicating in 2-propanol followed by 70% ddH2O: 
30% ACN and 0.1% Trifluoroacetic acid (TFA) solution as recommended by Bruker. The 
MALDI matrix consisted of a freshly prepared 5 mg/ml solution of 4-hydroxy-α-
cyanocinnamic acid (CHCA) (#70990, Fluka) in 50% ACN and 0.1% TFA (aq) (v/v). One 
µl of each peptide mixture was carefully spotted onto the plate, immediately followed by 1 
µl of the matrix solution. One µl of calibrant (pre-prepared by Adam Dowle, Department of 
Biology, University of York) consisting of six known peptides (section 4.6.12) was also 
spotted onto the designated locations on the plate followed by 1 µl of matrix solution. 
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4.6.12 MALDI-TOF/TOF Mass Spectrometry 
Positive-ion MALDI mass spectra were obtained through use of a Bruker UltraFlex III 
(Department of Biology, University of York) in reflectron mode, equipped with a Nd:YAG 
smart beam laser. Spectra were obtained using FlexControl (version 3.3, Bruker Daltonics) 
in AutoXecute mode and were acquired over a mass range of m/z 800-4000. Final mass 
spectra were externally calibrated against an adjacent spot containing six known peptides 
(des-Arg
1
-Bradykinin, 904.681; Angiotensin I, 1296.685; Glu
1
-Fibrinopeptide B, 1750.677; 
ACTH (1-17 clip), 2093.086; ACTH (18-39 clip), 2465.198; ACTH (7-38 clip), 3657.929.). 
One spot of calibrant served 8 sample spots (see Figure 21). 
 
 
Figure 21: Orientation of the target plate for MALDI-TOF-TOF MS. 
Calibrant was spotted for every 8 peptide sample spots. 
 
In order to acquire MS spectra, 50 laser shots were fired at 16 random positions to yield a 
total of 800 shots. For acquisition of MS/MS spectra, 500 shots were used for the precursor 
ion followed by 2500 shots for fragment ions. Monoisotopic masses were obtained using a 
SNAP averagine algorithm (C 4.9384, N 1.3577, O 1.4773, S 0.0417, H 7.7583) and a 
signal-to-noise threshold of 2. For each sample spot the 10 strongest peaks of interest, with 
a signal-to-noise threshold ≥ 30, were selected for MS/MS fragmentation. Fragmentation 
was performed in LIFT mode without the introduction of a collision gas (based on laser 
induced decomposition). The default calibration method was used for MS/MS spectra, 
which were baseline-subtracted and smoothed (Savitsky-Golay, width 0.15 m/z, cycles 4). 
Monoisotopic peak detection used a SNAP averagine algorithm (C 4.9384, N 1.3577, O 
1.4773, S 0.0417, H 7.7583) with a minimum signal-to-noise threshold of 6. Bruker 
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FlexAnalysis software (version 3.3) was used to perform the spectral processing and peak 
list generation for both the MS and MS/MS spectra. Tandem mass spectral data were 
submitted to Mascot (version 2.1, Matrix Science Ltd) for searching of the SwissProt 
Human protein database via the Bruker ProteinScape interface (version 2.3). Specified 
search criteria can be found in Table 6. A 95% confidence threshold (p < 0.05) was used for 
searching the MS/MS data. 
 
Table 6: Specified search criteria for protein identification 
 
Enzyme: Trypsin 
Number of missed cleavages: 1 
Fixed modifications: Carbamidomethyl (C) 
Variable modifications: Oxidation (M) 
Peptide tolerance: 250 ppm 
MS/MS tolerance: +/- 0.5 Da 
Instrument: MALDI- TOF-TOF 
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4.7 Isobaric tag for relative and absolute quantification (iTRAQ) 
Figure 22 gives an outline of the overall workflow of an iTRAQ experiment. 
 
 
Figure 22: Workflow of an iTRAQ experiment 
Whole protein was extracted from the sample source, denatured, reduced, alkylated and 
digested with trypsin. Samples were then labelled with iTRAQ reagents and combined. The 
combined sample was then separated by strong cation exchange chromatography and RP 
HPLC prior to analysis by MS/MS. 
 
 89 
 
4.7.1 Protein extraction 
Protein was extracted from cultured oral cancer cell lines (PJ41 and PJ49) and their 
radioresistant derivatives (PJ41 RR and PJ49 RR) as per section 4.6.1. 
4.7.2 Protein quantification 
Following extraction, proteins were quantified using the 2D Quant Kit (#80-6483-56, GE 
Healthcare) as detailed in section 4.6.3. 
4.7.3 ReadyPrepTM 2-D Cleanup Kit 
Following protein quantification, each protein sample was prepared for subsequent iTRAQ 
analysis using the ReadyPrep 2-D Cleanup Kit (#163-2130, Bio-Rad) as detailed in section 
4.6.2, however with a few minor adjustments. Briefly, 300 µl of Precipitating Agent 1 was 
added to each sample tube containing 80 µg of protein. Each tube was vortexed and 
incubated on ice for 15 min. Three hundred µl of Precipitating Agent 2 was then added to 
each tube and mixed thoroughly by vortexing. As in section 4.7.3 the tubes were 
centrifuged at maximum speed to form a tight pellet with any supernatant carefully 
removed by pipetting. Forty µl of Wash Reagent 1 was then added to each tube, ensuring 
full coverage of the protein pellet. The tubes were then centrifuged at maximum speed for 5 
min and the supernatant was removed by careful pipetting. Twenty five µl of dH2O 
(proteomic-grade) was then added to each tube and vortexed. One ml of pre-chilled (-20˚C) 
Wash Reagent 2 and 5 µl of Wash 2 Additive were added to each tube, and the tubes 
subsequently vortexed for 1 min. The protein samples were incubated for 30 min at -20 ˚C. 
During the incubation the tubes were vortexed for 30 sec every 10 min. After the incubation 
period, the tubes were centrifuged at maximum speed for 5 min to form a tight pellet. The 
supernatant was then discarded by careful pipetting and centrifuged for a second time to 
ensure full removal of any remaining liquid. At this point, the protein sample tubes were 
stored on dry ice and transported to the Institute of Cancer Therapeutics, University of 
Bradford where they were processed approximately 2 hours later. 
 
4.7.4 Protein digestion 
Prior to protein digestion the following solutions were prepared (by Dr.Chris Sutton, 
Institute of Cancer Therapeutics, University of Bradford): 
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Solution Ingredients 
400 mM ammonium bicarbonate (Stock)  1.5812 g in 50 ml HPLC water 
8 M Urea in 400 mM ammonium 
bicarbonate 
 480.48 mg urea 
 0.5 ml 400 mM ammonium 
bicarbonate (Stock) 
 Vortexed, made to 1 ml with 400 
mM ammonium bicarbonate (Stock) 
Trypsin buffer (360 mM ammonium 
bicarbonate, 10% acetonitrile (ACN)). 
 720 µl of 400 mM ammonium 
bicarbonate 
 80 µl 100% ACN 
DTT (1M = 154 mg/ml in HPLC water – 
prepared fresh (stock)) 
50 mM DTT prepared from stock 
 5 µl of 1 M DTT 
 95 µl of HPLC water 
Trypsin (prepared fresh at 1 mg/ml in 
2% ACN, 0.05% TFA) 
Working solution: 
 0.1 mg/ml in trypsin buffer 
IAA  - prepared fresh 
 56 mg/ml resuspended in 3 ml of 
HPLC water (100 mM) 
Solvent A  2% ACN with 0.05% TFA 
Solvent B  80% ACN with 0.05% TFA 
Matrix working solution 
 1.056 ml 2:1 ethanol/acetone 
 120 µl CHCA stock (saturated 
solution of CHCA in 30% ACN, 
0.011% TFA) 
 12 µl 100 mM ammonium phosphate 
 12 µl 10% TFA 
 
 
Each 80 µg protein pellet was resuspended in 5 µl of 8 M urea, 400 mM ammonium 
bicarbonate in order to solubilise the protein. Proteins were reduced by adding 1 µl of 50 
mM DTT to each eluate, vortexing briefly, and incubating in a water bath at 80 ˚C for 20 
min. Proteins were then alkylated by the addition of 1 µl of 100 mM IAA. The samples 
were vortexed, briefly centrifuged at full speed and incubated in the dark at room 
temperature for 20 min. Trypsin buffer (13 µl) was then added to each sample in order to 
dilute the urea prior to protein digestion, followed by the addition of 2 µl of modified 
sequencing grade trypsin (#1418025, Roche) (1 mg/ml). Each sample was vortexed briefly 
and incubated at 37 ˚C for 16 hours. Following incubation the sample tubes were placed on 
ice to prevent the reaction from continuing. At this point, a small aliquot (0.5 µl) of 
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digested sample was diluted 10-fold in 10% ACN and analysed manually by MS (collection 
of 2000 shots at a laser intensity of ~30%) to ensure that the protein had successfully been 
digested into peptides (by observation of several peptide peaks). Apomyoglobin (#A8673, 
Sigma Aldrich) ± trypsin, myoglobin alone and trypsin alone were used as controls. Prior to 
the start of any MS analysis the target plate (MTP AnchorChip 800/384 target plate 
(#209514, Bruker Daltonics)) was prepared as follows: 
 
STEP 1: 1 acetone wash 
STEP 2: Sonication of the target plate for 15 min using 50% methanol 
STEP 3: 1 wash with 100% methanol 
STEP 4: 1 wash with HPLC water 
STEP 5: Air-dry the plate  
 
Following manual analysis, each of the samples was then desalted (to prevent interference 
with the subsequent experiment) on a C18 reverse phase LC cartridge (#220-0010-A, 
Kinesis) as follows:  
 
STEP 1: The cartridge was prepared using 100% methanol (1x1ml) 
STEP 2: The cartridge was equilibrated using solvent A (2x1ml) 
STEP 3: The sample was added to the cartridge 
STEP 4: The cartridge was washed through using solvent A (2x1ml) 
STEP 5: Peptides were eluted (by passive hydrostatic pressure) using solvent B (1x1 ml) 
into a clean eppendorf tube 
 
Samples were then lyophilised (45 ºC) to dryness and resuspended in 10 µl of 1M triethyl 
ammonium bicarbonate (TEAB) containing 0.1% SDS.  
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4.7.5 iTRAQ labelling 
The iTRAQ Reagent-4Plex Kit (#4352135, ABSciex) was used for sample labelling. 
iTRAQ vials were removed from the freezer and allowed to adjust to room temperature 
prior to labelling. Following the manufactures guidelines, the contents of each vial was 
reconstituted with 70 µl of ethanol. The vials were subsequently vortexed and centrifuged 
briefly. The content of one iTRAQ vial was then transferred to one digested sample tube as 
detailed: 
 
PJ41 PN iTRAQ label 114 
PJ41 RR iTRAQ label  115 
PJ49 PN iTRAQ label 116 
PJ49 RR iTRAQ label 117 
 
A further 10 µl of ethanol was added to each iTRAQ vial to remove residual reagent. The 
vial was again vortexed and centrifuged before the remaining reagent was added to the 
corresponding sample tube. Each tube containing the sample-iTRAQ mixture was vortexed 
thoroughly and centrifuged at full speed for 1 min. The pH of the mixture was then tested 
(using litmus paper) and adjusted to pH 7-10 if required, by adding 1M TEAB. The sample-
iTRAQ mixtures were then incubated at room temperature for 2 hours to allow the labelling 
reaction to take place. Following incubation, each mixture was pH tested again, and 
adjusted to pH 7-10 if required using 1M TEAB. In order to hydrolyse each iTRAQ 
reagent, and therefore prevent a reaction with peptides from the other sample sub-groups 
when later combined, 50 µl of HPLC water was added to each sample-iTRAQ mixture. The 
tubes were then vortexed and centrifuged at full speed before being combined into 1 sample 
tube. In order to ensure no sample was lost, 25 µl of HPLC water was added to each of the 
4 sample tubes, vortexed, centrifuged and then added to the tube containing the combined 
sample-iTRAQ mixture. The combined labelled samples were then lyophilised (45 ºC) and 
stored at 4 ˚C overnight prior to separation by strong cation exchange. 
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4.7.6 Strong cation exchange (SCX)  
Prior to beginning SCX, the following buffers were prepared by (Dr.Chris Sutton, Institute 
of Cancer Therapeutics, University of Bradford): 
 
Solution Ingredients 
SCX loading buffer  (LB) (50 ml) – pH3  
 10 mM potassium di-hydrogen 
phosphate (KH2PO4) in 25% ACN 
 0.068 g (KH2PO4) in 50 ml 25% 
ACN 
 Adjusted to pH3 with approximately 
25 µl HCl (conc) 
Elution buffers (2 ml each) – pH3  
(varying amounts of potassium chloride 
(KCl) was added to LB to achieve the 
required concentrations) 
 LB + 30 mM – 4.47 mg (KCl) 
 LB + 60 mM – 8.95 mg (KCl) 
 LB + 90 mM – 13.42 mg (KCl) 
 LB + 150 mM – 22.37 mg (KCl) 
 LB + 500 mM – 74.55 mg (KCl) 
 LB + 1M – 149.10 mg (KCl) 
 
 
The strong cation exchange LC cartridge (#530-0005-A, Kinesis) was wetted/washed using 
1 ml HPLC water. One ml (x2) of loading buffer was then passed through the cartridge, 
using a syringe to push through. The combined labelled sample mixture was then 
resuspended in 600 µl of SCX loading buffer. The pH of the sample was adjusted to pH 
2.5-3 by adding 10% TFA. The sample was then pipetted into the SCX cartridge to begin 
chromatography. The sample passed through the cartridge by passive hydrostatic pressure 
enabling the positively charged peptides to bind to the negatively charged column. The 
sample flow-through was collected in a new eppendorf tube (labelled FT1). In order to 
prevent the loss of any sample, a further 600 µl of SCX loading buffer was added to the 
combined sample tube, vortexed, centrifuged and transferred to the SCX cartridge and the 
flow-through was collected in eppendorf tube FT1 by passive hydrostatic pressure. The 
flow-through sample FT1 was then stored at 4 ºC. In order to remove any residual material, 
1 ml of loading buffer was passed through the cartridge by passive hydrostatic pressure. As 
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before, the flow-through (FT2) was collected and stored at 4 ºC. In order to elute the 
peptides, 500 µl of elution buffer (LB + 30 mM) was added to the cartridge and collected 
into a 2.2 ml eppendorf by passive hydrostatic pressure (E1). This process was repeated 
using LB + 60 mM, LB +90 mM, LB + 150 mM, LB + 500 mM and LB + 1M to generate 
elutes E2, E3, E4, E5 and E6, respectively. For each of the 6 collected fractions, 1.5 ml of 
RP C18 solvent A was added to dilute the ACN concentration prior to C18 desalt. Each tube 
was vortexed thoroughly. The SCX fractions E1-E6 and FT1 were desalted, lyophilised to 
dryness and stored at -20 ˚C prior to reverse phase nanoHPLC (section 4.7.7). 
4.7.7 Reverse Phase NanoHPLC 
Desalted fractions E1-E6 (section 4.7.6) were resuspended in 13 µl of 10% ACN and 
applied to a nanoscale reverse phase HPLC using an LC Packings UltiMate 3000 capillary 
high-performance liquid chromatography system (Dionex). An aliquot (0.5 µl) of each 
fraction was diluted 10-fold and analysed by manual MALDI MS (collection of 2000 shots 
at a laser intensity of ~30%). Following confirmation of successful labelling (determined 
by the presence of the iTRAQ modifications), 6.5 µl of each sample was automatically 
injected into the LC system via a sample loop (carrier solvent, 0.05% trifluoroacetic acid 
into a C18 300µm x 5mm x 5µm, 100Å PepMap pre-column (#160321, LC Packings)). 
Once on the column the carrier solvent was used to subsequently wash the sample for 3.5 
min at a flow rate of 300nl/min. The washed sample was then transferred into a C18, 75µm 
x 15 cm, 3µm, 100Å PepMap column (LC Packings) which was equilibrated using 2% 
ACN with 0.05% TFA (mobile phase A). After a period of 6 min post-injection the mobile 
phase was modified (automatically) to include 10% mobile phase B (80% ACN with 0.05% 
TFA), this contribution then increased linearly to 28% until a post-injection time of 81 min 
was reached, at which point 100% mobile phase B was introduced (automatically) until a 
post-injection time of 86 min. The column was then re-equilibrated using mobile phase A 
until the run was complete at 100 min post-injection. During the LC run, 384, 15 second 
(75nl) fractions were spotted onto a MTP AnchorChip 800/384 target plate (#209514, 
Bruker Daltonics) using a Proteineer FC fraction collector (Bruker Daltonics). The position 
of the target was calibrated prior to each run. Each fraction was co-eluted onto the target 
plate with 1.2 µl of CHCA matrix solution. Peptide Calibration Standard II (#222570, 
Bruker Daltonics) consisting of 9 known peptides (Angiotensin I, Angiotensin II, Substrate 
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P, Bombesin, ACTH (1-17 clip), ACTH (18-39 clip), Somatostatin 28, Bradykinin 
fragment 1-7 and Renin Substrate Tetradecapeptide porcine) covering a mass range of m/z 
700-3200 Da, was applied between every group of 4 fractions. 
4.7.8 MALDI-TOF/TOF MS and protein identification 
Positive-ion MALDI mass spectra were obtained using a Bruker UltraFlex II (Institute of 
Cancer Therapeutics, University of Bradford) in reflectron mode, equipped with a 200Hz 
smartbeam laser. Spectral analysis was performed in fully automated mode using WarpLC 
software (version 1.3), which encompassed data acquisition (FlexControl version 3.4) and 
peak detection (FlexAnalysis version 3.4) using the SNAP peak detection algorithm, 
initially in the MS mode screening LC fractions between 700-4000Da (400 shots per 
fraction) in order to generate a non-redundant list of peptides (minimum signal-to-noise 
threshold of 7). External calibration for each 4 surrounding fractions was carried out during 
MS analysis. Each peptide was then subject to MS/MS analysis using LIFT mode 
(FlexControl version 3.4) to acquire 1500 shots per spectrum. The default calibration 
method was used for MS/MS spectra, which were baseline-subtracted and smoothed 
(Savitsky-Golay) using SNAP peak detection algorithms. Tandem mass spectral data were 
submitted to Mascot (version 2.2, Matrix Science Ltd) for searching of the SwissProt 
Human protein database. Mascot search parameters are listed in Table 7. A 95% confidence 
threshold (p < 0.05) was used for searching the MS/MS data, which corresponded to a 
Mascot score of ≥ 28. ProteinScape software (version 3.0, Bruker Daltonics) was used to 
compile all 6 LC MALDI runs into one single non-redundant protein list (consisting of at 
least one unique peptide with a Mascot score of ≥ 28.  
 
Table 7: Specified search criteria for protein identification (iTRAQ) 
Enzyme: Trypsin 
Number of missed cleavages: 2 
Fixed modifications: Carbamidomethyl (C), iTRAQ (K), iTRAQ 
N-term 
Variable modifications: Oxidation (M) 
Peptide tolerance: 100 ppm 
MS/MS tolerance: +/- 0.7 Da 
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4.7.9 Data analysis 
The non-redundant protein list was filtered manually in ProteinScape to ensure at least one 
unique peptide with a Mascot score of ≥ 28 was present for each isoform of the same 
protein, and that all peptides not ranked first were removed from the dataset. The final 
refined list comprised a non-redundant profile of proteins associated with the 2 oral cancer 
RR cell lines (PJ41RR and PJ49RR). In order to determine which proteins were 
significantly differentially expressed between the parent and radioresistant derivative from 
each cell line, iTRAQ reporter ion ratios were determined for each individual protein 
identification – PJ41RR/PJ41PN = 115/114; PJ49RR/PJ49PN = 117/116. The data was 
then normalised by dividing each individual ratio by the mean ratio of the dataset. The 
selection of significantly differentially expressed proteins, between the parent and 
radioresistant sub-line, was based on ± 1 standard deviation of the data. 
4.8 Ingenuity Pathway Analysis (IPA) 
All data generated by antibody microarray analysis, 2D-PAGE MALDI-TOF/TOF MS and 
iTRAQ was analysed using IPA (Ingenuity Systems, www.ingenuity.com). Each data set, 
containing a list of gene names checked against the SwissProt and NCBI databases was 
uploaded into the IPA software online.  
 The Ingenuity Knowledge Base is the core technology and repository behind IPA, 
providing a bank of all biological and chemical information, functional annotations and 
modelled relationships for several genes, proteins, cells, tissues, complexes etc. The 
Ingenuity Knowledge Base is a comprehensive database which has pooled accurate 
information from several sources. This information is all manually reviewed and split into 4 
sub-groups: (1) Ingenuity® Expert Findings, which consists of experimentally 
demonstrated information; (2) Ingenuity® ExpertAssist Findings, information from 
recently published literature; (3) Ingenuity® Expert Knowledge, information curated from 
a team of Ingenuity scientists describing signalling and metabolic pathways; (4) Ingenuity® 
Supported Third Party Information, selected from a range of various sources and databases 
including Entrez Gene, RefSeq and Gene Ontology. 
 In order to generate networks, each gene from the uploaded dataset was mapped to 
the corresponding gene within the Ingenuity Knowledge Base, and an ‘annotated dataset’ 
was generated. ‘Network eligible’ genes, i.e. those genes which were successfully mapped 
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into the Ingenuity Knowledge Base were subsequently overlaid onto a global molecular 
network generated from data contained within the Ingenuity Knowledge Base.  
 IPA software allowed for the identification of different pathways which were 
associated with the uploaded dataset. The canonical pathway analysis tool involved the 
identification of pathways within the IPA canonical pathway information bank, which had 
the most significant association with molecules included in the dataset. IPA analysis 
parameters are listed in Table 8. 
 
Table 8: IPA analysis parameters 
 
IPA analysis parameters 
General settings: 
 Ingenuity Knowledge Base (genes only) 
 Direct relationships 
 Endogenous chemicals (untick) 
 Molecules per network (max) – 140 
 Networks per analysis (max) – 25 
 
Data sources: 
 Data sources: ‘all’ 
 
Confidence: 
 Confidence: ‘experimentally observed’ 
 
Species: 
 Species: human 
 Relaxed filters 
 
Tissues and cell lines: 
 Tissues and cell lines: ‘all’ 
 Relaxed filters 
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4.9 Western blotting 
Figure 23 gives an outline of the overall workflow for semi-quantitative western blotting. 
 
Figure 23: Overall workflow of a western blot experiment. 
An outline of the steps involved in the confirmation of DEPs using semi-quantitative 
western blotting. 
 
4.9.1 Protein Extraction 
Western blot (WB) extraction buffer was prepared (see Appendix B). To each 1 ml of WB 
extraction buffer 10 µl each of Protease Inhibitor (#80-6501-23, Amersham Biosciences), 
Phosphatase Inhibitor Cocktail 1 (#P2850, Sigma Aldrich) and Phosphatase Inhibitor 
Cocktail 2 (#P5726, Sigma Aldrich) was added, along with 50 µl of 2-Mercaptoethanol 
(#M-7522, Sigma Aldrich). Cultured cells at a confluence of approximately 80% were 
trypsinised (3 ml), transferred to a 30 ml universal tube, centrifuged at 1500 rpm for 3 min, 
and resuspended in 5 ml of cold, sterile PBS for washing. Cells were then centrifuged and 
washed again in 5 ml PBS for a total of 3 washes to ensure all serum was washed away 
from the cells. Upon completion of the wash steps, the pelleted cells were resuspended in 1 
ml of cold PBS and transferred to a 2 ml microfuge tube. Cells were centrifuged at 3000 
rpm for 3 min and the supernatant subsequently discarded. Cell extracts were resuspended 
in 125 µl-1 ml of WB extraction buffer, depending on the size of the cell pellet. Cells were 
then vortexed for 5 min in order to lyse the cells. Samples were placed on an end-over-end 
rotator at 4 ˚C overnight (16 hours). On completion of the overnight incubation, samples 
were centrifuged at 15,000 rpm for 15 min at 4 ˚C. The resultant pellet of cell debris was 
discarded, and the remaining supernatant transferred to pre-chilled microfuge tubes and 
stored at -80 ˚C until quantification. 
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4.9.2 Protein Quantification 
Protein quantification was performed using the RCDC (Reducing agent Compatible, 
Detergent Compatible) Protein Quantification Kit (#500-0119 to -0122, Bio-rad), chosen 
based on its compatibility with components used within Western blotting. Prior to starting 
the assay, 5 BSA protein standards were prepared by diluting a 2 mg/ml stock of BSA with 
dH2O in microcentrifuge tubes. Protein standards ranged from 0.25 to 1.5 mg/ml, as 
recommended in the assay protocol. If samples to be quantified were stored at -80 ˚C they 
were allowed to thaw, then after vortexing, diluted to 1:2, 1:5 and 1:10 dilutions, ensuring 
that the resultant protein concentration fell within the assay range. One hundred and twenty 
five µl of RC Reagent I was added to each tube, vortexed and incubated for 1 min at room 
temperature. RC Reagent II was then added to each tube at a volume of 125 µl, vortexed 
and centrifuged at 15,000 rpm for 5 min to form a tight pellet. The supernatant was 
discarded and the tube containing the pellet was inverted on absorbent paper to ensure 
removal of any remaining liquid. At this point, Working Reagent A was prepared by adding 
20 µl of Reagent S to every 1 ml of Reagent A. Working Reagent A was added to each tube 
at a volume of 127 µl. Each tube was vortexed to re-suspend the protein. One ml of 
Reagent B was added to each tube and incubated for 15 min at room temperature. 
Following incubation, 200 µl of each sample was transferred to a 96-well plate and the 
optical density read at 690 nm using a Multiscan plate reader (Labsystems). 
4.9.3 One-dimensional gel electrophoresis 
Protein extracts for electrophoresis were diluted in 0.5 ml microcentrifuge tubes using WB 
extraction buffer (see Appendix B) containing 5% 2-mercaptoethanol (#M-7522, Sigma 
Aldrich).  Each dilution was calculated to achieve a final volume of 25 µl containing 20 µg 
of protein. Once diluted, the protein extracts were denatured by heating to 95 ˚C in a 
thermocycler for 5 min. The samples were then placed immediately on ice to prevent 
reversal of protein denaturation. They were then vortexed and centrifuged at maximum 
speed for 30 sec. Twenty µg of sample was then loaded into the appropriate well of a 12% 
Precise Protein Gel (#25222, Thermo Scientific). The gel was then placed into the running 
tank, and the tank was subsequently filled with Tris-HEPES-SDS running buffer (#28368, 
Thermo Scientific). Ten µl of pre-prepared Precision Plus Protein WesternC Standard 
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(#161-0376, Bio-Rad), covering molecular weight 10-250 kDa was added to a separate well 
in the gel. Gel electrophoresis took place at a constant voltage of 140 V for 40 min. 
4.9.4 Protein transfer onto nitrocellulose membrane 
For each experiment, nitrocellulose ‘iBlot gel transfer stacks’ (#IB3010-01, Invitrogen) 
were used. A disposable iBlot anode pack was opened and placed onto the transfer unit and 
the gels placed carefully on top ready for transfer onto the nitrocellulose membrane. Filter 
paper soaked in dH2O was then placed on top of the gels, with any air bubbles removed 
using the roller provided. The disposable cathode and sponge pack containing an electrode 
were then placed on top of the filter paper and the lid was then closed. A 7 minute program 
was run as recommended by the manufacturer, enabling the transfer of proteins from the 
gel onto the nitrocellulose membrane. Once the transfer was complete, the gel and other 
transfer components were discarded.  
4.9.5 Blocking of binding sites on the membrane 
After the protein samples had transferred to the membrane, the free binding sites on the 
membrane were blocked. Western blot blocking solutions of either 5% non fat dried milk 
solution (Marvel) or 5% BSA are most commonly used in this process. Twenty ml of the 
chosen blocking solution was added to a Nalgene staining box and incubated with the 
membrane on an orbital rocker for 1 hour at room temperature or 16 hours at 4 ˚C. A 
membrane blocking step is required to prevent non-specific background binding of the 
primary and/or secondary antibodies to the membrane. The blocking solution functions by 
binding to all of the sites on the membrane, leaving only the bound protein sample exposed 
to antibodies. 
4.9.6 Immunoblotting 
 The primary antibody to the protein of interest was diluted to its optimum concentration in 
blocking solution. The solution was incubated with the membrane for 2 hours at room 
temperature or 16 hours at 4 ˚C on an orbital shaker. Following incubation with the primary 
antibody, the membrane was washed 3 times for 5 min on an orbital shaker with TBS-
Tween20 (see Appendix B) to ensure complete removal of any unbound antibody. The 
membrane was then incubated with a HRP-conjugated secondary antibody to the animal the 
primary antibody was raised in. The chosen secondary antibody was then diluted to its 
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optimum concentration in blocking solution and incubated with the membrane for 1 hour at 
room temperature on an orbital shaker. For visualisation of the Precision Plus Protein 
WesternC Standard molecular weight marker, 1 µl of Precision Protein StrepTactin-HRP 
conjugate (#161-0381, Bio-Rad), compatible with chemiluminescence detection, was also 
added to the blocking solution containing the secondary antibody. After incubation, the 
membrane was again washed 3 times for 5 min on an orbital shaker using TBS-Tween20. 
Details of primary and secondary antibodies used can be found in Table 34, Chapter 9. 
4.9.7 Loading controls  
In order to assess equal loading of protein samples into the gel, and therefore allowing for 
accurate comparisons to be made between different samples, loading controls, i.e. proteins 
which should be present in all cells at equal concentrations, are probed for. The main 
loading controls, or ‘housekeeping proteins’ are Alpha-tubulin, Beta-actin and GAPDH. 
Antibody details and dilutions are given in Table 9. 
 
Table 9: Details and dilutions of loading controls. 
Loading controls, or ‘housekeeping proteins’ are found in equal concentrations in all cells, 
the most common of which include Alpha-tubulin (50 kDa), Beta-actin (40 kDa) and 
GAPDH (37 kDa). For Alpha-tubulin, a goat anti-mouse secondary antibody (#SC-2031 
Santa-Cruz) was used and for Beta-actin and GAPDH, a goat anti-rabbit secondary 
antibody (#SC-2030, Santa-Cruz) was used. Both secondary antibodies were used at a 
dilution of 1:1000 in 5% milk for 1 hour at room temperature. 
 
Loading control Concentration and 
blocking solution 
Incubation period Details 
Alpha-tubulin 1:2500 in 5% milk 2 hours Mouse monoclonal 
(#ab7291, Abcam) 
Beta-actin 1:2500 in 5% milk 2 hours Rabbit polyclonal 
(#ab8227, Abcam) 
GAPDH 1:2500 in 5% milk 2 hours Rabbit polyclonal 
(#ab9485, Abcam) 
 
4.9.8 Protein detection 
The Supersignal West Pico Chemiluminescent Substrate kit (#34078, Thermo Scientific) 
was used to visualise bound antibody. In order to do this, the membrane was incubated with 
equal amounts (5 ml) of Supersignal West Pico Stable Peroxide Solution and Supersignal 
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West Pico Luminal Enhancer Solution for 5 min in the dark with gentle agitation. The 
membrane was then placed between transparent plastic sheets and placed in an intensifying 
cassette with CL-XPosure Film (#34090, Thermo Scentific). After exposure the film was 
developed manually by sequential passages through GBX developer (Kodak), 2% acetic 
acid (Fisher) and GBX fixative (Kodak), all for approximately 30 secs with gentle 
agitation. The film was then allowed to air-dry before scanning and densitometry.  
4.9.9 Densitometry 
Films were scanned into Quantity One Software (BioRad) using a GS-800 calibrated 
densitometer (BioRad). Target bands were normalised to a loading control to account for 
variability. The normalised optical density of the target bands was then given allowing for 
the target protein expression to be compared between both the treated and untreated 
samples. This then allowed for the optical density of the target band to be recorded and the 
subsequent fold-change to be calculated. 
4.10 Sample selection for immunohistochemistry 
4.10.1 Archival breast cancer sample selection 
The archival breast cancer tissue samples analysed were as described previously (Elfadl et 
al., 2011). This study was approved by Hull and East Riding Local Research Ethics 
Committee (ref 10/03/216). Due to this being a non-interventional retrospective study using 
archival samples, informed patient consent was not required. A retrospective search of 
surgical oncology records between the years of 1988-2007 at Castle Hill Hospital was 
performed (by Miss Dalia ELFadl) in order to identify patients that had undergone breast 
conserving therapy (BCT). In this study, the ‘test’ group was selected to represent a 
‘radioresistant’ tumour, with those patients who had a local and/or regional recurrence 
following BCT for early stage (T1/T2, N0/N1) breast cancer being considered. 
Histopathology records for the primary tumour resection (wide local excision in all cases) 
were reviewed by a consultant in breast pathology. Primary tumour samples had to meet the 
following strict criteria in order to be selected for the radioresistant group: 
 A maximum of four years between completion of RT and the recurrence. 
 The primary tumour resection showed clear margins of excision of a least 1 mm. 
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 Recurrences were located within the same quadrant as the primary cancer or within 
the ipsilateral axillary lymph nodes (axillary recurrences were only included if 
axillary RT had already been given during BCT). 
 The recurrent disease resembled the primary tumour, with regards to the type of 
disease and oestrogen receptor (ER) status. 
 Samples were not considered for the radioresistant group if the primary tumour size 
was > 50 mm, or if there was evidence to suggest multifocal disease, involvement 
of the surgical margin or an extensive intraductal component since these factors are 
associated with an increase risk of local-recurrence. 
Those tumours selected for the control (radiosensitive) group were from patients who were 
free of disease 10 years following the completion of BCT. As above, samples were not 
considered for the radiosensitive group if the primary tumour size was > 50 mm, or if there 
was evidence of multifocal disease, involvement of the surgical margin or an extensive 
intraductal component. In total, 14 patients were selected for both the radiosensit ive and 
radioresistant groups.  
4.10.2 Archival head and neck (laryngeal) cancer sample selection 
Laryngeal cancer samples analysed were as described previously (Nix et al., 2005). Local 
Research Ethics committee approval was granted for the collection of both clinical data and 
archival pre-treatment laryngeal biopsy material, and the clinical sample collection was 
coordinated by Mr. Paul Nix. Databases held in ENT departments in England were 
searched for patients diagnosed with early stage (T1-T2 N0) laryngeal cancer and treated 
with single modality radiotherapy with curative intent (55-60 Gy in 20-25 fractions). 
According to their response to radiotherapy, patients were identified as having 
radiosensitive or radioresistant tumours. To reduce confounding variables, both groups 
were matched with regards to T stage, laryngeal subsite and smoking history. Tumours 
were staged according to TNM classification and were all clinically nodal negative (N0) 
and metastatic negative (M0) at the time of treatment. 
Tumour samples had to meet the following criteria to be selected for the radioresistant 
group: 
 The radiotherapy had to have been given as a single modality treatment with 
curative intent for a biopsy-proven squamous cell carcinoma of the larynx. 
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 Biopsy-proven recurrent squamous cell carcinoma, the recurrence occurring at the 
original anatomical site within 12 months of finishing a course of radiotherapy. 
Tumour samples had to meet the following criteria to be selected for the radiosensitive 
group: 
 The radiotherapy had to have been given as a single modality treatment with 
curative intent for a biopsy-proven squamous cell carcinoma of the larynx. 
 Post-treatment, patients had a minimum follow up of 3 years with no evidence of a 
recurrent laryngeal tumour. 
From the total series, a small subset were selected for both the radiosensitive and 
radioresistant groups. 
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4.10.3 Immunohistochemistry 
Figure 24 gives an outline of the overall workflow for an immunohistochemical 
experiment. 
 
 
Figure 24: Overall workflow of an immunohistochemical experiment. 
An outline of the steps involved for the clinical validation of DEPs by 
immunohistochemistry. 
 
4.10.3.1 De-waxing and rehydration 
Formalin-fixed, paraffin-embedded tissue samples were cut using a microtome into 4 µm 
sections, mounted onto Superfrost Plus microscope slides (#00594, Menzel-Glaser) and 
incubated overnight at 37 ºC. Tissue sections were de-waxed by incubating in warm 
Histoclear II (#HS-200, National Diagnostics) for 10 min, followed by two sequential 10 
sec incubations (with gentle agitation) in separate solutions of Histoclear II. Once de-
waxed, samples were rehydrated by incubating (with gentle agitation) for 10 sec in 100% 
ethanol. This was done to a total of 3 incubations, using 3 separate ethanol solutions. Once 
rehydrated, sections were rinsed in running tap water for 1 min. 
4.10.3.2 Blocking of endogenous peroxidase 
Methanol, containing 8 ml of 30% hydrogen peroxide was used to block endogenous 
peroxidase of red blood cells. The sections were incubated in this solution for 20 min and 
subsequently rinsed. 
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4.10.3.3 Antigenic site retrieval 
Antigenic site-retrieval was achieved by boiling slides in a stainless steel pressure cooker 
(Prestige) containing 1500 ml of 1:100 Antigen Unmasking Solution (#H-3300, Vector 
Laboratories) at full pressure (103 kPa) for 3 min. Slides were then cooled, rinsed and 
transferred into 1 x TBS (Appendix B). 
4.10.3.4 Blocking of non-specific binding sites within tissue sections 
Slides were assembled with coverplates into Sequenza racks (Shandon, Basingstoke, UK) 
ready for immunohistochemical staining. TBS-washes were used to ensure correct 
assembly of each slide. Non-specific binding sites within the tissue sections were blocked 
for 10 min by incubation with 100 µl of pre-diluted normal horse serum provided in the kit, 
where the R.T.U VECTASTAIN Universal Quick Kit (#PK-7800, Vector Laboratories Ltd) 
was used downstream. Where the StreptABComplex/HRP Duet Kit (#K0492, 
DakoCytomation) was used downstream, non-specific binding sites were blocked using 100 
µl of 1x casein (#SP-5020) in TBS. Slides were then washed twice for 5 min in TBS. 
4.10.3.5 Incubation with primary antibody 
If the R.T.U VECTASTAIN Universal Quick Kit (#PK-7800, Vector Laboratories Ltd) was 
used downstream, primary antibody was diluted to its optimum concentration in 1.5% 
normal horse serum (provided) in TBS. If the StreptABComplex/HRP Duet Kit (#K0492, 
DakoCytomation) was used downstream, primary antibody was diluted in 0.2x casein in 
TBS. Antibody details and dilutions used are provided in Table 35, Chapter 9. Each tissue 
section was incubated with 100 µl of diluted antibody for 2 hours at room temperature. 
Each immunohistochemical staining experiment contained one negative control of which 
primary antibody was omitted. The negative control was therefore incubated with 100 µl of 
either 1.5% normal horse serum of 0.2x caesin. Slides were then washed twice for 5 min in 
TBS. 
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4.10.3.6 Antibody detection 
Antibody was detected using 1 of 2 kits, the second of which has now been discontinued. 
 
The R.T.U VECTASTAIN Universal Quick Kit (#PK-7800, Vector Laboratories) 
One hundred µl of pre-diluted biotinylated pan-specific universal secondary antibody was 
incubated with each slide for 20 min. Slides were then subsequently washed for 5 min in 
TBS and incubated with 100 µl of pre-prepared streptavidin/peroxidise complex reagent for 
10 min. Slides were washed again for 5 min in TBS, dismantled from the Sequenza and 
transferred into a fresh pot of TBS. 
 
StreptABComplex/HRP Duet Kit (#K0492, DakoCytomation) 
Reagent C (biotinylated goat anti-mouse/rabbit secondary antibody) was diluted 1:100 in 
TBS. One hundred µl was then incubated with each slide for 30 min. Slides were then 
washed for 5 min in TBS. Reagent A (streptavidin) and Reagent B (biotinylated 
peroxidase) were diluted 1:100 (each) together in TBS. One hundred µl was incubated with 
each slide for 30 mins. Slides were washed again for 5 min in TBS, dismantled from the 
Sequenza and transferred into a fresh pot of TBS. 
4.10.3.7 Visualisation of antibody 
Antibody visualisation was achieved using 0.02% diaminobenzidine (DAB) in TBS 
containing 0.125% hydrogen peroxide. Slides were incubated in the solution and regularly 
monitored until brown staining of the tissue sections could be clearly seen under a light 
microscope. Due to the precipitation of DAB, this incubation period did not exceed 30 min. 
4.10.3.8 Enhance, counterstain and differentiate 
Staining contrast was enhanced by incubation in 0.5% copper sulphate in 0.9% sodium 
chloride solution for 5 min. Sections were then counterstained in filtered Harris 
Haematoxylin (#HHS32, Sigma Aldrich), by incubating (with gentle agitation) for 20 sec. 
Excess haematoxylin was removed by rinsing the slides in running tap water. The 
counterstain was differentiated by incubating (with gentle agitation) for 10 sec in acid 
alcohol (70% alcohol, 1% HCl (conc)), followed by washing slides in running tap water. 
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4.10.3.9 Dehydration, clearing and mounting 
Tissue sections were dehydrated by taking the slides through 3 sequential solutions of 
100% ethanol, with gentle agitation for 10 sec. Sections were then cleared in Histoclear II 
(#HS-200, National Diagnostics), by taking the slides through 3 separate solutions with 
gentle agitation for 10 sec in each. Histomount (#HS-103, National Diagnostics) was then 
used to mount slides onto cover-slips. Slides were then allowed to air-dry overnight. 
4.10.3.10 Scoring of tissue sections 
After observation of all immunostained slides across the sample series by light microscopy, 
individual scoring systems were developed which were unique to each staining localisation 
(see chapter 9). Slides were scored independently by at least 2 observers and any 
disagreement resolved through discussion of the slide, allowing a majority based score to 
be reached. For the breast series, any disagreements were resolved by a consultant in breast 
pathology. The Fishers Exact test was used to determine statistical significance between 
histological scores and radioresistance (section 4.10.3.11). 
 
4.10.3.11 The Fishers Exact test  
In order to test for statistical significance between immunohistochemical scores, a two-
tailed Fisher’s Exact test was performed. Histological scores were uploaded into 2x2 
contingency tables, enabling the exact probability (P) values to be determined. Association 
between radioresistance and histological score was deemed significant where P values were 
≤0.05. GraphPad software Inc (USA) (http://graphpad.com/quickcalcs/contingency1.cfm) 
was used to calculate P values and subsequently determine statistical significance. 
 
All other statistical methods used throughout this thesis are described within the relevant 
sections within this chapter. 
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Chapter 5: 
Development of novel radioresistant 
Rectal Cancer cell lines 
 
 
Chapter Aims: 
To create two novel rectal cancer cell lines (using fractionated doses of radiotherapy)  
which are significantly more resistant to the effects of radiotherapy than their 
corresponding parental counterparts, and in doing so enabling the proteomic comparison  
of the novel resistant cell lines to the parent. By doing this, valuable information  
can be gained as to how the protein expression of the cell sub-lines have changed  
and as a result become resistant to radiotherapy. 
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Chapter 5.  Development of novel radioresistant Rectal 
Cancer cell lines 
5.1 Introduction 
In order to identify putative predictive biomarkers of radiotherapy resistance, it is necessary 
to study radioresistant tumour samples. However, determining tumour response to 
radiotherapy can only take place following treatment, meaning that tumour sample 
collection may be from a tumour that is now itself radioresistant. Obtaining pre-treatment 
biopsies of this nature is often difficult, and the question is always raised as to whether or 
not the pre-treated sample contains any inherently resistant tumour cells, or whether 
radioresistance would only be induced following treatment with radiotherapy (Nix et al., 
2004). Additional factors such as storage, transport and handling of tumour tissue samples 
may also affect quality, hence questioning the subsequent value of the sample when trying 
to identify reliable biomarkers of radiotherapy resistance. 
 At present there is no standard definition of radioresistance, therefore making it 
difficult to assess exactly how radioresistant a tumour is. In addition, studying clinical 
samples of this nature is technically challenging for proteomics. However, a number of 
studies have created radioresistant cell line models which have been found to express a 
significant increase in radioresistance compared to their parental counterparts. A variety of 
tumour types including small cell lung (Henness et al., 2004), breast (Wang et al., 2005, 
Smith et al., 2009), prostate (Skvortsova et al., 2008), nasopharyngeal (Feng et al., 2010) 
and head and neck cancers (Lin et al., 2010, Kim et al., 2010, Skvortsov et al., 2011) have 
been investigated by proteomic methods using this model (section 3.7.2), meaning that in 
vivo problems such as sample handling and storage can be overcome. 
5.2 Materials and methods  
5.2.1 The biomarker discovery pipeline 
Prior to the start of this project, no previous work had been carried out to investigate 
potential predictive biomarkers of radioresistance in rectal cancer. The work in this chapter 
therefore aims to develop 2 rectal radioresistant (RR) derivatives which display significant 
resistance to radiotherapy than their parental counterparts (Figure 26). The overall 
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workflow for the establishment of the rectal RR novel derivatives is illustrated in Figure 25. 
These cell line models will then be compared in subsequent proteomic experiments in order 
to try and identify those protein biomarkers associated with the development of a 
radioresistant phenotype.  
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Figure 25: Overall workflow for the establishment of a RR novel derivative cell line. 
Cell lines were initially cultured to approximately 80% confluence and their inherent 
radiosensitivity assessed through use of a modified colony counting assay, the results of 
which are then plotted onto a DRC. An incremental dose of irradiation was then selected 
based on the initial DRC and clinical regimens used within the clinic. Once an appropriate 
dose has been determined, novel derivatives were established using fractionated 
radiotherapy at the selected dose. Once the final dose (48 Gy) had been reached a modified 
colony counting assay was carried out and the results plotted onto a DRC. At this point, 
statistical analysis in the form of the Students t-Test was used to confirm a statistical 
increase in radioresistance between the novel derivative and their corresponding parental 
cell lines. A final log-linear survival curve was then plotted to illustrate the surviving 
fraction of cells as a percentage at each irradiation dose. 
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Figure 26: Progression through the biomarker discovery pipeline of the 2 rectal cancer cell lines – establishing cell model 
As highlighted by the dashed box, the establishment of 2 novel radioresistant rectal cancer cell lines will be discussed during this chapter. 
The red arrow indicates that no work has been previously carried out on the rectal cancer cell lines prior to the start of this project.  
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5.2.2 Cell Lines 
An aliquot of SW837 and HRA-19, human rectal carcinoma cell lines were thawed and 
cultured as per sections 4.1.2 and 4.1.3. These particular cell lines were chosen due to their 
ready availability, ease of culture and their molecular subtype (Table 4). 
5.2.3 Modified colony counting assay for the assessment of inherent radiotherapy 
response 
Before establishment of the radioresistant cell lines could begin, the inherent sensitivity to 
radiotherapy of the 2 cell lines was first determined. This was performed by carrying out a 
modified colony counting assay for each cell line, the information of which could then be 
plotted onto an initial DRC and used (along with other factors) to select an incremental 
irradiation dose from which to create the novel radioresistant cell line. For each assay, cells 
were harvested (to a confluence of 80%) and counted as per section 4.3.1 and 1x10
6
 cells 
were placed into screwed-cap 7ml polypropylene containers. A total of 6 containers were 
used, each filled with 5ml of the cell suspension and labelled with the dose of radiation 
each was going to receive. The cells were then transported in a sealed bag, placed inside a 
polystyrene box, to the Radiotherapy Department at Castle Hill Hospital and dosed with 2 
Gy, 4 Gy, 6 Gy, 8 Gy and 10 Gy (1 dose as specified by the labelled vial) as detailed in 
section 4.3. It must be noted that cells receiving no treatment (0 Gy) were still transported. 
Following treatment, cells were returned to the lab and 1000 cells were removed from each 
container and cultured in triplicate for 12-14 days in six well tissue culture plates as per 
section 4.3.2. 
5.2.4 Dose response curve for the assessment of inherent radiosensitivity 
Plating efficiencies (PE) and survival fractions (SF) were calculated as per section 4.3.3. 
Log-linear survival curves were then generated by plotting the SF (Y axis) against the 
radiation dose (X axis) to illustrate the surviving fraction of cells as a percentage at each 
dose. The percentage was calculated by taking the number of surviving cells from the 
control group (0 Gy) to represent a survival fraction of 100%. Each subsequent survival 
fraction was calculated as a fraction of the control and a curve plotted. Each experiment 
was done in triplicate for each dose. The whole experiment was repeated twice for 
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confirmatory purposes and a final survival curve was constructed using the mean number of 
surviving cells at each dose of radiotherapy from across the 2 experiments. 
5.2.5 Development of the novel radioresistant cell lines 
Cells were cultured as per section 4.1.3 and subsequently transported to the Radiotherapy 
Department at Castle Hill Hospital for treatment with fractionated doses of radiotherapy 
(section 4.3). This was done at 2 weekly intervals, a timescale based on the health and 
confluence of the cells. An incremental dose of 8 Gy was used to treat the SW837 cell line 
and a dose of 4 Gy was used to treat the HRA-19 cell line. Selection of these doses enabled 
us to use a single passage before a further dose of radiation was required. Both cell lines 
were treated to a clinically relevant final dose of 48 Gy. Development of the novel 
radioresistant cell lines followed the long course neoadjuvant radiotherapy regimen for 
rectal cancers, which typically involves treatment with radiotherapy to a total dose of 45 to 
54 Gy. The novel cell line derived from SW837 was named SW837RR and the novel cell 
line derived from HRA-19 was named HRA-19RR. Figure 27 illustrates how a 
radioresistant cell subline is selected out using fractioned doses of radiotherapy. 
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Figure 27: Selecting out a radioresistant phenotype. 
Parental cells are cultured and irradiated with the first fractionated dose of radiotherapy. 
Cells are cultured again, with only those which have survived treatment continuing to grow. 
Cells are irradiated again then cultured, leaving behind only those cells which have 
survived. This process continues until the total dose of radiotherapy has been achieved, at 
which point the surviving population i.e. the novel radioresistant cells are cultured prior to 
protein extraction. 
 
5.2.6 Confirmation of radioresistance 
In order to determine whether significant radioresistance had been achieved between the 
parent and the novel derivative, a modified colony counting assay was carried out as per 
section 4.3.2 and initial DRC’s were constructed as per section 4.3.3. Each experiment was 
repeated twice for confirmatory purposes. The Student’s t-test was used to confirm any 
statistically significant increase in radioresistance for SW837RR and HRA-19RR in 
comparison to their parental counterparts. For visual comparison of both the parent and its 
corresponding novel radioresistant derivative, log-linear survival curves were constructed. 
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5.3 Results 
5.3.1 Modified colony counting assays for the assessment of inherent radiotherapy 
response 
Modified colony counting assays were successfully carried out on both parental cell lines 
(SW837 and HRA-19) to assess their inherent sensitivity to ionising radiation. The raw 
colony counting data for each cell line is given in Appendix E-H. Only those colonies 
consisting of ≥ 50 cells (see Figure 28) were counted and included in the overall analysis.  
 
 
Figure 28: An example of a colony 
Only colonies consisting of ≥ 50 individual cells were counted and included in the overall 
analysis. This colony (A) (x400 magnification), identified from a parent sample at 0 Gy 
(B), was used as a reference colony throughout the counting process. Any colony that 
appeared smaller by eye was not counted. 
 
Figure 29 shows the final log-linear survival curves for both SW837 and HRA-19 as 
determined by a modified colony counting assay. The curves were constructed by plotting 
the mean number of surviving cells at each dose of radiotherapy from across 2 independent 
experiments. As expected, due to greater levels of cell killing, the overall surviving fraction 
of the cell population significantly decreased as the radiation dose increased. When 
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comparing both survival curves it can be seen that SW837 shows lower levels of 
radiosensitivity at 2, 4 and 6 Gy in comparison to HRA-19. This initial dose response data 
found HRA-19 to show decreased radiosensitivity at 8Gy. Complete cell death for both 
parental cell lines occurred at 10 Gy. 
 
 
Figure 29: The final log-linear curve to show the response to radiotherapy of the two 
parental cell lines over a dose range of 0-10 Gy. 
Each point represents of the mean number of surviving cells from 6 replicates across 2 
independent experiments. SW837 shows decreased levels of radiosensitivity at 2, 4 and 6 
Gy when compared to HRA-19. This initial dose response data shows HRA-19 to show 
decreased radiosensitivity at 8 Gy. All cells, from both cell lines were killed at 10 Gy. 
 
5.3.2 Incremental dose of radiotherapy 
Both SW837 and HRA-19 cell lines received a total dose of 48Gy (section 5.2.5), 
mimicking as closely as possible the long-course dosing regimen given to patients with 
rectal cancer within the clinic (section 5.2.5). The DRC results of SW837 and HRA-19 
(Figure 29) suggested that a fractionated dose of 8 Gy may be suitable for both cell lines. A 
dose of 8 Gy was both clinically relevant and was enough to achieve significant cell death 
without killing all of the cell population (see raw colony counts in Appendix E-H) hence 
enabling the surviving cells to continue growing ready for the next dose. However, whilst 
the SW837 cell line appeared to cope well with the selected dosing regimen, as indicated by 
a sufficient number of surviving cells, it became increasingly apparent during the course of 
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the experiment that continued exposure to 8Gy fractions was not suitable for HRA-19, due 
to significantly increased levels of cell death between fractions. Therefore, due to the 
decreased number of cells surviving each irradiation dose, the decision was made to reduce 
each treatment fraction to fortnightly doses of 4 Gy (to a total of 48 Gy) for the HRA-19 
cell line. 
5.3.3 Confirmation of radioresistance 
 Figure 30 and Figure 31 show the experimental layout of one of the two modified colony 
counting assays set up for SW837 and SW837 (48 Gy), and HRA-19 and HRA-19 (48 Gy), 
respectively. It can be clearly seen that the SW837 cell line, and the novel derivative, show 
increased resistance to the effects of radiotherapy when compared to the HRA-19 cell line 
as distinguished from the greater number of colonies formed at each dose (see also 
Appendix E-H). As expected the greatest number of cells survived when exposed to no 
radiation in both cell lines. Both figures clearly illustrate that an increase in radiation dose 
lead to a decrease in subsequent colony formation. 
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Figure 30: Experimental layout of a modified colony counting assay for SW837 and SW837 (48 Gy). 
Both SW837 and SW837 (48 Gy) were irradiated with a range of doses (0-10 Gy). One thousand cells from each dose were then seeded into 
6 well tissue culture plates. Colonies that formed after 12-14 days were fixed, stained and counted in order to calculate the survival fractions. 
Each dose was plated in triplicate and each experiment was duplicated for confirmatory purposes. Both modified colony counting assays for 
SW837 and SW837 (48 Gy) were carried out at the same time, as 1 experiment. It was observed that the cell population at 0 Gy for the 
SW837 (48 Gy) formed much larger colonies than SW837 at 0 Gy, a difference possibly owing to changes in proliferation rate of the novel 
derivative.  
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Figure 31: Experimental layout of a modified colony counting assay for HRA-19 and HRA-19 (48 Gy). 
Both HRA-19 and HRA-19 (48 Gy) were irradiated with a range of doses (0-10 Gy). One thousand cells from each dose were then seeded 
into 6 well tissue culture plates. Colonies that formed after 12-14 days were fixed, stained and counted in order to calculate the survival 
fractions. Each dose was plated in triplicate and each experiment was duplicated for confirmatory purposes. Both modified colony counting 
assays for HRA-19 and HRA-19 (48 Gy) were carried out at the same time, as 1 experiment. 
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Figure 32 shows the final log-linear survival curves for SW837 as compared with its novel 
RR (48 Gy) derivative, hereafter termed SW837RR, as determined by a modified colony 
counting assay. SW837 RR was significantly more radioresistant than its parental 
counterpart at 4, 6, 8 and 10 Gy (p≤ 0.05; Students t-test) giving a maximal 31-fold 
increase in resistance at 10 Gy Table 10. 
 
 
Figure 32: The final log-linear curve illustrating the difference in radiosensitivity 
between SW837 and SW837 RR. 
Each point represents the mean number of surviving cells from 6 replicates across 2 
independent experiments. Compared to its parental corresponding cell line, SW837 RR (48 
Gy) demonstrated a significant increase in survival at 4, 6, 8 and 10 Gy (p≤ 0.05; Students 
t-test) with a maximal 31-fold increase in resistance observed at 10 Gy. 
 
Table 10: Statistical confirmation of radioresistance for SW837RR compared with 
SW837. 
Statistical analysis using the Students t-test confirmed significant radioresistance (p≤ 0.05) 
between the novel derivative (SW837RR) and its corresponding parental cell line (SW837) 
at doses of 4, 6, 8 and 10 Gy (shaded). A maximal 31-fold increase in resistance was 
observed at 10 Gy. 
 
Dose 0 Gy 2 Gy 4 Gy 6 Gy 8 Gy 10Gy 
p-value 1 0.978 0.020 0.001 0.000 2.92x10
-5
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Figure 33 shows the final log-linear survival curves for HRA-19 as compared with its novel 
RR (48 Gy) derivative, hereafter termed HRA-19 RR, as determined by a modified colony 
counting assay.  HRA-19 RR was significantly more resistant than its parental counterpart 
at 4, 6 and 8 Gy (p≤ 0.05; Students t-test). A 4.2-fold increase in resistance was observed at 
8 Gy (Table 11). 
 
 
 
Figure 33: The final log-linear curve illustrating the difference in radiosensitivity 
between HRA-19 and HRA-19 RR as determined by a modified colony counting assay.  
Each of the points represents the mean of 6 replicates from 2 independent experiments.  
Compared to its parental corresponding cell line, HRA-19 RR (48 Gy) demonstrated a 
significant increase in survival at doses of 4, 6 and 8 Gy (p≤ 0.05; Students t-test). At 8 Gy, 
a 4.2 fold increase in resistance was observed.  
 
 
Table 11: Statistical confirmation of radioresistance for HRA-19RR compared with 
HRA-19. 
Statistical analysis using the Students t-test confirmed significant radioresistance (p≤ 0.05) 
between the novel derivative (HRA-19RR) and its corresponding parental cell line (HRA-
19) at doses of 4, 6 and 8 Gy (shaded). A 4.2-fold increase in resistance was observed at 8 
Gy. 
 
Dose 0 Gy 2 Gy 4 Gy 6 Gy 8 Gy 10Gy 
p-value 1 0.074 0.000 0.003 0.001 0.059 
Fold change 1 1.2 2.8 3.5 4.2 59 
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5.4 Discussion 
Radiotherapy plays a major role in the treatment of rectal cancer. However, despite its 
overall success, there are still a number of tumours which fail to respond to the treatment, 
hence representing a major obstacle to the successful outcome of those patients. In order to 
try and elucidate the mechanisms of radioresistance, 2 novel rectal cancer cell sublines 
which are significantly more resistant to the effects of radiotherapy than their 
corresponding parental counterparts, have been established. Through analysis of these cell 
sublines it is hoped that valuable information can be obtained to reveal how the protein 
expression of the novel derivatives have changed, and as a result become resistant to 
radiotherapy. 
Two rectal cancer cells lines, namely SW837 and HRA-19 were commercially 
purchased and irradiated to a total dose of 48 Gy, employing a long-course fractionated 
treatment regimen to closely mimic that used within the clinical setting. A dose adjustment 
from 8 Gy to 4 Gy for the HRA-19 cell line, generated an improved balance between cell 
death and survival, hence allowing subsequent fractionated treatment of the cell line to 
continue. 
Throughout the initial culturing process, prior to any radiotherapy treatment, it was 
observed that, for unknown reasons, HRA-19 was slightly slower to proliferate than 
SW837. However, during treatment, both SW837 RR and HRA-19 RR proliferated at a 
significantly slower rate than their parental counterparts, possibly owing to the time 
required to pause the cell cycle and repair any sublethal DNA damage caused by the 
ionising radiation, and also as expected, a subpopulation of the cells would die after each 
dose.   
It can be seen from Figure 30 and Figure 31 (and the data given in Appendix E-H) 
that there was considerable difference in the amount of colony formation between SW837 
and HRA-19 and their radioresistant derivatives, SW837RR and HRA-19RR. Significantly 
more colonies had formed from the SW837 cell line when compared to HRA-19. Such a 
difference could be owing to the fact that HRA-19 had increased sensitivity to ionising 
radiation, hence the change to a 4 Gy dosing regimen. However, considering that less 
colonies formed at 0 Gy in HRA-19 when compared to SW837, it would suggest that HRA-
19 as a cell line is more sensitive to any changing environmental factors (e.g. changing 
temperature, handling etc) regardless of its exposure to radiotherapy. It was also observed 
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that SW837 RR formed much larger colonies than its parental counterpart at 0 Gy. This 
may be due to a change in proliferation rate once the novel derivative had been fully 
established. It could be hypothesised that significant proteomic changes had occurred 
within SW837 RR which may have lead to the increased expression of those proteins 
required for cellular proliferation.  
As it can be seen from Figure 32 (SW837 vs SW837 RR) and Figure 33 (HRA-19 
vs HRA-19 RR) a significant level of radioresistance has been achieved between each 
novel derivative and its corresponding parent. SW837RR was significantly more 
radioresistant at doses of 4, 6, 8 and 10 Gy (p ≤ 0.05; Student’s t-test) and HRA-19RR was 
significantly more radioresistant at doses of 4, 6 and 8 Gy (p ≤ 0.05; Student’s t-test). Now 
fully established, these radioresistant rectal cancer cell sublines can undergo biomarker 
discovery by comparison with their parental counterparts in Chapter 7.  
It is hoped that through the use of complementary proteomic screen techniques, 
those proteins associated with the radioresistant phenotype which subsequently contribute 
to treatment failure can be successfully identified.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 126 
 
 
 Chapter 6: 
Identification of radiotherapy 
resistance biomarkers in Head and 
Neck Cancer 
 
 
 
 
Chapter Aims: 
 
To utilise the antibody microarray, 2D-PAGE MALDI-TOF/TOF MS and iTRAQ 
proteomic platforms to identify putative biomarkers of radiotherapy resistance in oral 
cancer, completing the discovery phase of the biomarker discovery pipeline. 
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Chapter 6.  Identification of radiotherapy resistance 
biomarkers in Head and Neck Cancer 
6.1 Introduction 
Head and Neck squamous cell carcinoma (HNSCC) poses a major global health problem, 
ranked the sixth most prevalent cancer worldwide, with approximately 600,000 new 
malignancies diagnosed each year (Roberg et al., 2007). The overall 5-year survival rates of 
patients diagnosed with HNSCC is approximately 50%, of which radiotherapy resistance, 
in part, contributes (approximately 20%) (Yang et al., 2011). With the survival rates of 
HNSCC being the lowest of the major cancer types (Hardisson, 2003), the need for 
improved treatment regimens is essential (Begg, 2012). 
 Current treatment regimens for HNSCC include a variety of options as mentioned in 
section 1.1. Radiotherapy is clearly a preferred option for the primary treatment of early 
stage head and neck cancers due to its ability to preserve both anatomical structure and 
function (Nix et al., 2004), however, treatment resistance does occur in a large number of 
patients, often resulting in the need for ‘salvage surgery’ if a cure is hoped to be achieved 
(Nix et al., 2004). Despite the lack of routine biomarkers with the ability to predict tumour 
response to radiotherapy, markers such as Bcl-2 overexpression (Nix et al., 2005), p53 
mutational status (Mineta et al., 1998) and,  most promisingly, EGFR expression (Bonner et 
al., 2006), have been factors implicated in radioresistant head and neck cancers to date.  
6.1.1 Previous development of the novel radioresistant oral cancer cell lines 
In order to study proteins associated with radioresistance in head and neck cancer, 2 oral 
cancer radioresistant derivatives had been previously established from their corresponding 
parental cell lines PJ41 and PJ49 (see Table 4) as described in section 4.4.2 (J Murphy, L 
Cawkwell; unpublished data). Figure 34 shows the final log-linear survival curves for both 
cell lines (PJ41 and PJ49) compared with their respective novel RR derivatives (PJ41RR 
and PJ49RR), as determined by a modified colony counting assay. PJ41RR was 
significantly more radioresistant than its parental counterpart at 2, 4, 6, 8 and 10 Gy (p≤ 
0.05; Student’s t-test), with a 142-fold increase in resistance observed at 6 Gy. PJ49RR was 
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significantly more radioresistant than its parent at 2, 4, 6, and 8 Gy (p≤0.05; Student’s t-
test) with a maximal 10.2-fold increase in resistance observed at 6 Gy. 
 
 
Figure 34: The final log-linear curve illustrating the difference in radiosensitivity 
between the 2 oral cancer cell lines (PJ41 and PJ49) and their novel radioresistant 
derivatives (PJ41RR and PJ49RR) as determined by a modified colony counting 
assay.  
Each of the points represents the mean of 6 replicates from 2 independent experiments.  
PJ41RR was significantly more radioresistant at 2, 4, 6, 8 and 10 Gy (p≤0.05; Students t-
test) whilst PJ49RR was significantly more resistant at 2, 4, 6 and 8 Gy (p≤0.05; Students t-
test). Both RR cell lines achieved a maximal fold change increase at 6 Gy; 142-fold 
(PJ41RR) and 10.2-fold (PJ49RR). 
 
This chapter aims to study the mechanisms of radioresistance using these 2 oral 
squamous cell carcinoma cell lines and their radioresistant derivatives. Comparative protein 
profiling of these cancer cell lines during this chapter will utilise proteomic platforms 
namely 2D-PAGE MALDI-TOF/TOF MS and iTRAQ as described previously in Chapter 
3. Data derived from these platforms will enable the identification of those proteins which 
may be associated with the development of a radioresistant phenotype. 
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6.2 Materials and Methods 
6.2.1 The biomarker discovery pipeline 
Prior to the start of this project, the following work relating to this chapter (i.e discovery of 
radioresistance biomarkers) had previously been completed: 
 The purchasing of 2 oral cancer cell lines, namely, PE/CAPJ41 (PJ41) and 
PE/CAPJ49 (PJ49) and their novel radioresistant derivatives established.  
 The first stage of the biomarker discovery phase in the form of antibody microarray 
analysis (see Chapter 8). 
Data newly obtained during the course of this project and therefore presented within this 
chapter, includes that derived from both 2D-PAGE MALDI-TOF/TOF MS and iTRAQ 
(see Figure 35).  
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Figure 35: Progression through the biomarker discovery pipeline of the 2 oral cancer cell lines – biomarker discovery 
Work highlighted by the dashed box will be discussed during this chapter. As indicated by the blue arrow, the cell lines and their 
radioresistant derivatives had been previously established prior to the start of this project. Antibody microarray analysis had also taken place. 
Work carried out during the course of this project, as highlighted by the red arrow, includes 2D-PAGE MALDI-TOF/TOF MS and iTRAQ. 
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6.2.2 2D-PAGE MALDI-TOF/TOF MS 
6.2.2.1 Protein extraction 
Protein was extracted according to section 4.6.1.  
6.2.2.2 Protein clean-up and quantification 
Protein samples were cleaned-up as detailed in section 4.6.2 and quantified as described in 
section 4.6.3. 
6.2.2.3 1st dimensional separation by IEF 
IEF took place using the 3-step program highlighted in section 4.6.4.  
6.2.2.4 2nd dimensional separation by SDS-PAGE 
Following IEF, proteins were reduced and alkylated as per section 4.6.5 and subsequently 
separated by SDS-PAGE (section 4.6.6). 
6.2.2.5 Protein staining 
Protein spots were stained and subsequently visualised as described in section 4.6.7. 
6.2.2.6 PDQuest analysis 
Significant DEPs were identified using PDQuest software as detailed in section 4.6.8.  
6.2.2.7 Spot excision and in-gel digest 
DEPs were excised from the gel as per section 4.6.9, and subsequently digested as per 
section 4.6.10. 
6.2.2.8 MALDI-TOF/TOF MS for protein identification 
Each peptide sample was spotted onto the target plate as per section 4.6.11. Proteins were 
then identified as detailed in section 4.6.12. 
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6.2.3 iTRAQ 
6.2.3.1 Protein extraction 
Protein was extracted as detailed in section 4.6.1.  
6.2.3.2 Protein quantification and clean-up 
Protein samples were quantified as described in section 4.6.3, and cleaned-up as detailed in 
section 4.7.3.  
6.2.3.3 Protein digestion 
Proteins samples were digested as per section 4.7.4. 
6.2.3.4 iTRAQ labelling 
iTRAQ labelling was carried out as described in section 4.7.5.  
6.2.3.5 Strong cation exchange (SCX)  
Samples were subjected to SCX as per section 4.7.6. 
6.2.3.6 Reverse Phase NanoHPLC 
Reverse phase nano-HPLC was carried out as detailed in section 4.7.7.  
6.2.3.7 MALDI-TOF/TOF MS  and protein identification 
MALDI –TOF/TOF MS was used for protein identification as per section 4.7.8.  
6.2.3.8 Data analysis 
Data was analysed according to section 4.7.9. 
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6.3 Results 
6.3.1 2D-PAGE MALDI-TOF/TOF MS 
6.3.1.1 2D PAGE 
A total of 2 comparative experiments were performed (PJ41PN v PJ41RR and PJ49PN v 
PJ49RR) in order to identify DEPs associated with the radioresistant phenotypes. For each 
of the 2 experiments proteins were separated in the 1
st
 dimension by IEF and then in the 2
nd
 
dimension by SDS-PAGE. Each separation process was done in triplicate in order to 
produce 3 replicate gels for each cell subtype within a sample pair. Figure 36 gives 1 
example of a PJ41 and PJ41RR coomassie stained 2D-PAGE gel. Figure 37 gives an 
example of 1 PJ49 and 1 PJ49RR coomassie stained 2D-PAGE gel. 
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Figure 36: Coomassie stained 2D-PAGE gels for PJ41 and PJ41RR. 
Proteins were first separated by pI in a pH range of 4-7, then vertically by molecular weight 
on an 11cm polyacrylamide gel. Image A shows an example of 1 out of 3 PJ41 gels. Image 
B shows an example of 1 out of 3 PJ41RR gels. 
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Figure 37: Coomassie stained 2D-PAGE gels for PJ49 and PJ49RR. 
Proteins were first separated by pI in a pH range of 4-7, then vertically by molecular weight 
on an 11cm polyacrylamide gel. Image A shows an example of 1 out of 3 PJ49 gels. Image 
B shows an example of 1 out of 3 PJ49RR gels. 
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6.3.1.2 PDQuest analysis 
Following optical density scanning of the protein stained gels, the resultant protein profiles 
were analysed using PDQuest analysis software in order to identify DEPs between the 
parent and radioresistant samples. Table 12 details the total number of matched protein 
spots per experiment, the total number of DEPs identified, and also the number of DEPs 
that were found to be up- and down-regulated in the radioresistant sample by the PDQuest 
software.   
 
Table 12: The total number of protein spots matched by PDQuest in relation to the 
total number of DEPs identified from both PJ41RR and PJ49RR cell lines. 
Of the total number of DEPs identified from PDQuest for both RR cell lines, 81% were up-
regulated and 19% were down-regulated in the PJ41RR cell line. In contrast, 31% were up-
regulated and 69% were down-regulated in the PJ49RR cell line. 
 
RR cell 
line 
Total number of 
protein spots 
matched by 
PDQuest 
Total number of 
DEPs identified 
by PDQuest 
Total number of 
DEPs up-
regulated in RR 
cell line 
Total number 
of DEPs down-
regulated in RR 
cell line 
PJ41RR 557 42 (7%) 34 (81%) 8 (19%) 
PJ49RR 501 36 (7%) 11 (31%) 25 (69%) 
Total 1058 78 45 33 
 
A selection of DEPs that were identified by PDQuest (and subsequently excised for further 
analysis) for PJ41RR and PJ49RR are shown in Figure 38 and Figure 39, respectively. 
 
 
 
 
 
 137 
 
  
  
 
 
  
  
Figure 38: DEPs and their corresponding histograms identified by PDQuest software 
for PJ41 and PJ41RR. 
Ten protein spots identified as DEPs (≥ 2-fold; p< 0.05) by PDQuest. The DEPs are 
highlighted within the yellow box. The corresponding histograms highlight the change in 
expression which was calculated by taking an average from the 3 gels for PJ41 (PN - red) 
and PJ41RR (RR - green) samples.  
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Figure 39: DEPs and their corresponding histograms identified by PDQuest software 
for PJ49 and PJ49RR. 
Ten protein spots identified as DEPs (≥ 2-fold; p< 0.05) by PDQuest. The DEPs are 
highlighted within the yellow box. The corresponding histograms help to highlight the 
change in expression which was calculated by taking an average from the 3 gels for PJ49 
(PN - red) and PJ49RR (RR - green) samples. 
 
6.3.1.3 Selection of DEPs to excise from the gel 
Despite the total number of DEPs identified by the software for each experiment, only a 
fraction of these were excised from the gel and digested for subsequent identification by 
MALDI-TOF/TOF MS. In order to be completely confident in the protein identification 
process and hence limit false discovery rates, stringent criteria were applied when deciding 
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which spots to excise from the gel and take forward to MS. In order to try and ensure that 
one protein spot would equate to only one protein identification during MS analysis, DEPs 
that appeared within a cluster of spots or overlapped with another spot, DEPs that were in a 
streak or smear, and also DEPs that didn’t appear to be composed of only one protein 
(when further investigated using the 3D viewer tool within PDQuest) were not excised 
from the gel. In addition to these criteria, extremely small or weak DEPs that could not be 
clearly identified by eye, were not excised from the gel. Based on these factors, Table 13 
details the total number of DEPs identified by PDQuest for each experiment, and of this 
total how many were successfully excised from the gel. 
 
Table 13: The total number of DEPs identified by PDQuest in relation to the number 
excised. 
Of the total number of DEPs identified by PDQuest, 10 (23%) were excised for the PJ41 
experiment, and 20 (56%) were excised for the PJ49 experiment.  
 
RR cell 
line 
Total number of 
DEPs identified by 
PDQuest 
Total number of DEPs 
excised from the gel 
Number of protein 
identifications by 
MALDI-TOF/TOF 
MS 
PJ41RR 42 10 (23%) 9 (90%) 
PJ49RR 36 20 (56%) 18 (90%) 
Total 78 30 27 
 
6.3.1.4 A MASCOT Summary Report 
Following analysis by MS, the resultant peptide mass fingerprints (PMFs) are submitted to 
a protein database search (using a search engine such as MASCOT) for subsequent 
identification. Figure 40 gives an example of a MASCOT Summary Report containing all 
essential information relating to that specific protein.  
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Figure 40:An example of a Mascot peptide summary page 
All information relating to the identified protein is given on the Mascot peptide summary 
page. Important information (underlined in yellow) includes the protein accession number, 
the mass of the matched protein (which should be compared with the 2D-PAGE gel to 
ensure this value is close to that expected), the protein score, the number of peptides 
significantly (‘expect value ≤ 0.05’) matched (in this example, 6 peptides are matched 4 of 
which are significantly matched), the specific protein name and gene name, the amino acid 
sequence of the significantly matched peptides in addition to their individual scores, 
‘expect values’ and mass error values (ppm).  
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The ‘protein view’ page (obtained by clicking on the protein accession number) (Figure 41) 
gives details of the protein pI and the percentage sequence coverage. From this page, 
additional information including mass spectra can be obtained for further detail. 
 
6.3.1.5 Protein identifications with only one peptide match 
A protein identification may result from several peptide matches, or a single peptide match.  
A greater number of peptides matched to a specific protein identification, provides a more 
confident result, however the ‘expect’ value, which acts as an indicator of how likely the 
peptide match occurred by chance (with a lower value indicating a more confident result) is 
also a factor to be considered. For proteins with only a single peptide match, additional 
supporting data in the form of annotated spectra and/or fragment ion lists can be accessed 
from within the MASCOT search engine. 
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Figure 41: An example protein view page. 
For each identified protein, the protein view page can be obtained by clicking on the protein 
accession number on the Mascot protein summary report. The protein view page gives 
details of the protein’s individual pI and its percentage sequence coverage. The amino acid 
sequence for the entire protein is given, the matched sequences of which are highlighted in 
bold red.  
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6.3.1.6 DEPs identified by MALDI-TOF/TOF MS. 
A total of 25 unique DEPs were identified from the 2 oral cancer cell line experiments. 
Table 14 lists these proteins, along with their corresponding gene names and direction of 
expression change in the radioresistant samples. Appendix I lists these proteins in addition 
to information gained from the MASCOT summary report.  
 
Table 14: DEPs associated with the PJ41RR and PJ49RR cell lines, identified by 2D-
PAGE MALDI-TOF/TOF MS. 
From the 2 experiments a total of 25 unique proteins were differentially expressed. Those 
proteins which are up-regulated (↑) and down-regulated (↓) in the radioresistant (RR) 
phenotype are highlighted. Proteins (≥2-fold in expression change) are listed alphabetically 
by gene name and have at least one peptide match. Those protein identifications based on a 
single peptide match are highlighted 
(1P).
 Proteins identified as RIDEPs (section 3.3.3) are 
highlighted (*).  
 
RR cell line Protein name Gene name 
Direction of 
expression 
change in 
RR 
PJ49RR Annexin A3 ANXA3 ↑ 
PJ49RR Annexin A8 ANXA8 ↓ 
PJ49RR Coactosin-like protein COTL1 ↓ 
PJ41RR Heterogeneous nuclear ribonucleoproteins C1/C2 HNRNPC ↑ 
PJ49RR Heat shock protein beta-1 * HSPB1 ↑ 
PJ49RR Keratin, type I cytoskeletal 15 KRT15 ↓ 
PJ41RR Keratin, type I cytoskeletal 17 KRT17 ↑ 
PJ41RR Keratin, type I cytoskeletal 19 KRT19 ↓ 
PJ41RR 
Keratin, type II cytoskeletal 8 * KRT8 
↑ 
PJ49RR ↓ 
PJ49RR Alpha-soluble NSF attachment protein NAPA ↓ 
PJ49RR Protein NDRG1 NDRG1 ↑ 
PJ49RR Protein-L-isoaspartate (D-aspartate) O-
methyltransferase  
(1P)
 
PCMT1 
 
↓ 
PJ49RR Serine/threonine-protein phosphatase PP1-beta 
catalytic subunit 
PPP1CB 
 
↓ 
PJ49RR Peroxiredoxin-2 * PRDX2 ↓ 
PJ49RR 26S proteasome non-ATPase regulatory subunit 11 PSMD11 ↓ 
PJ49RR 26S proteasome non-ATPase regulatory subunit 13 PSMD13 ↓ 
PJ49RR Proteasome activator complex subunit 2 PSME2 ↓ 
PJ41RR 
Reticulocalbin-1 RCN1 
↑ 
PJ41RR ↓ 
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PJ41RR Protein S100-A6 
(1P)
 S100A6 ↑ 
PJ41RR Protein S100-A9 S100A9 ↑ 
PJ41RR Plasminogen activator inhibitor 2 SERPINB2 ↑ 
PJ49RR Triosephosphate isomerise TPI1 ↑ 
PJ49RR Tropomyosin alpha-1 chain 
(1P)
 TPM1 ↓ 
PJ49RR Tropomyosin alpha-4 chain TPM4 ↓ 
PJ49RR Thioredoxin domain-containing protein 4 TXNDC4 ↓ 
 
6.3.2 iTRAQ 
From a total of 6 LC-MALDI MS/MS analyses, collected from the 6 SCX fractions from 4 
cell sublines (PJ41, PJ41RR, PJ49, PJ49RR), a non-redundant list of 516 proteins was 
identified, with at least 2 peptides matched for each. Proteins within the data which were 
differentially expressed between parental and radioresistant cell lines were identified using 
iTRAQ ratios; PJ41RR/PJ41PN = 115/114; PJ49RR/PJ49PN = 117/116. Following 
normalisation, the standard deviation was calculated for each dataset; PJ41RR/PJ41PN = 
0.37 and PJ49RR/PJ49PN = 0.20. The proteins that were significantly up- or down-
regulated within each of the 2 datasets were identified as those whose ratios were, for 
PJ41RR, < 0.73 and > 1.37- fold, and for PJ49RR < 0.83 and > 1.21- fold (+/- 1 standard 
deviation of the mean). Table 15 lists the number of DEPs identified for the PJ41RR and 
PJ49RR cell lines.  
 
Table 15: The total number of DEPs identified by iTRAQ for the PJ41RR and 
PJ49RR cell lines. 
Of the total number of DEPs identified for PJ41RR, 26 were up-regulated and 48 were 
down-regulated. Of the total number of DEPs identified for PJ49RR, 32 were up-regulated 
and 50 were down-regulated. 
 
RR cell line 
Total number of 
DEPs identified 
Total number of 
DEPs up-regulated 
in RR cell line 
Total number of 
DEPs down-
regulated in RR cell 
line 
PJ41RR 74 26 48 
PJ49RR 82 32 50 
Total 156 58 98 
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Table 16 lists the total number of proteins identified by iTRAQ along with their gene name 
and direction of expression change. The full set of quantitative data (including molecular 
weight, pI, accession number, ion scores, number of peptides matched) is given in 
Appendix J and K.  
 
Table 16: DEPs associated with the PJ41RR and PJ49RR cell lines, identified by 
iTRAQ. 
From the 2 experiments a total of 156 DEPs were identified. Fifteen of these DEPs were 
identified in both cell lines. Those that were up-regulated (↑) and those that were down-
regulated (↓) in the radioresistant phenotype are highlighted. Significantly expressed 
proteins (+/- 1 standard deviation of the data) are listed alphabetically by gene name along 
with their corresponding fold change value. There are currently no RIDEPs associated with 
the iTRAQ platform. 
 
RR cell line Protein name Gene name 
Direction of 
expression change 
in RR 
PJ41RR Alanyl-tRNA synthetase, cytoplasmic AARS ↑ 1.39 
PJ41RR Low molecular weight phosphotyrosine 
protein phosphatase 
ACP1 ↑ 6.35 
PJ41RR 
Alpha-centractin ACTR1A 
↑ 1.88  
PJ49RR ↓ 0.78 
PJ41RR Neuroblast differentiation-associated 
protein AHNAK 
AHNAK ↓ 0.66 
PJ41RR Adenylate kinase 2, mitochondrial AK2 ↓ 0.60 
PJ49RR Aldehyde dehydrogenase family 1 
member A3 
ALDH1A3 ↓ 0.75 
PJ49RR Annexin A5 ANXA5 ↓ 0.75 
PJ49RR Rho guanine nucleotide exchange factor 1 ARHGEF1 ↓ 0.71 
PJ41RR Actin-related protein 2/3 complex subunit 
2 
ARPC2 ↓ 0.66 
PJ49RR Large proline-rich protein BAG6 BAG6 ↓ 0.72 
PJ41RR Barrier-to-autointegration factor BANF1 ↑ 1.69 
PJ41RR BolA-like protein 2 BOLA2 ↑ 1.38 
PJ41RR Ribosome biogenesis protein BOP1 BOP1 ↓ 0.66 
PJ41RR 
Calmodulin-like protein 3 CALML3 
↓ 0.38   
PJ49RR ↓ 0.58 
PJ49RR Calpain-1 catalytic subunit CAPN1 ↓ 0.76 
PJ49RR Caveolin-1 CAV1 ↑ 1.21 
PJ41RR Core-binding factor subunit beta CBFB ↑ 1.37 
PJ41RR Chromobox protein homolog 3 CBX3 ↓ 0.57 
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PJ41RR Putative coiled-coil domain-containing 
protein 26 
CCDC26 ↓ 0.51 
PJ49RR T-complex protein 1 subunit theta CCT8 ↓ 0.82 
PJ49RR CD44 antigen CD44 ↓ 0.74 
PJ41RR 
Cyclin-dependent kinase 12 CDK12 
↓ 0.41  
PJ49RR ↓ 0.55 
PJ49RR Cofilin-1 CFL1 ↑ 1.25 
PJ49RR Cellular nucleic acid-binding protein CNBP ↓ 0.52 
PJ49RR Collagen alpha-1(VII) chain COL7A1 ↑ 1.33 
PJ49RR Coactosin-like protein COTL1 ↓ 0.71 
PJ49RR Cathepsin D CTSD ↓ 0.62 
PJ41RR 
Src substrate cortactin CTTN 
↑ 1.86  
PJ49RR ↑ 1.40 
PJ41RR Dipeptidyl peptidase 3 DPP3 ↓ 0.72 
PJ41RR 
Cytoplasmic dynein 2 heavy chain 1 DYNC2H1 
↓ 0.70  
PJ49RR ↓ 0.79 
PJ41RR Elongation factor 1-alpha 1 EEF1A1 ↓ 0.66 
PJ49RR EF-hand domain-containing protein D2 EFHD2 ↑ 1.26 
PJ49RR Epidermal growth factor receptor EGFR ↑ 1.72 
PJ41RR Eukaryotic translation initiation factor 
5A-1 
EIF5A ↑ 1.63 
PJ49RR Emerin EMD ↑ 1.42 
PJ41RR Echinoderm microtubule-associated 
protein-like 2 
EML2 ↑ 1.56 
PJ49RR Bifunctional aminoacyl-tRNA synthetase EPRS ↓ 0.81 
PJ49RR ERO1-like protein alpha ERO1L ↑ 1.66 
PJ49RR Endoplasmic reticulum resident protein 44 ERP44 ↓ 0.68 
PJ49RR Ezrin EZR ↓ 0.81 
PJ41RR Protein FAM83H FAM83H ↓ 0.70 
PJ41RR Fragile X mental retardation syndrome-
related protein 1 
FXR1 ↓ 0.51 
PJ41RR Tyrosine-protein kinase Fyn FYN ↓ 0.55 
PJ41RR Ras GTPase-activating protein-binding 
protein 1 
G3BP1 ↓ 0.69 
PJ41RR Glucose-6-phosphate 1-dehydrogenase G6PD ↓ 0.48 
PJ49RR Rab GDP dissociation inhibitor alpha GDI1 ↑ 1.86 
PJ49RR PERQ amino acid-rich with GYF domain-
containing protein 2 
GIGYF2 ↓ 0.79 
PJ41RR Guanine nucleotide-binding protein G(s) 
subunit alpha isoforms short 
GNAS ↓ 0.72 
PJ41RR Glucose-6-phosphate isomerise GPI ↓ 0.56 
PJ49RR Gelsolin GSN ↓ 0.74 
PJ49RR Trifunctional enzyme subunit alpha, 
mitochondrial 
HADHA ↓ 0.71 
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PJ49RR Histone deacetylase 1 HDAC1 ↓ 0.71 
PJ49RR HLA class I histocompatibility antigen, 
A-74 alpha  
HLA-A ↓ 0.78 
PJ49RR HLA class I histocompatibility antigen, 
Cw-12 alpha 
HLA-C ↓ 0.81 
PJ41RR Hematological and neurological expressed 
1 protein 
HN1 ↑ 1.38 
PJ49RR Heat shock protein HSP 90-beta HSP90AB1 ↑ 1.22 
PJ49RR Heat shock protein beta-1 HSPB1 ↑ 1.45 
PJ49RR 10 kDa heat shock protein, mitochondrial HSPE1 ↑ 1.21 
PJ41RR Hypoxia up-regulated protein 1 HYOU1 ↑ 1.78 
PJ41RR Isoleucyl-tRNA synthetase, cytoplasmic IARS ↓ 0.63 
PJ41RR Insulin-like growth factor 2 mRNA-
binding protein 2 
IGF2BP2 ↓ 0.51 
PJ49RR Interleukin enhancer-binding factor 3 ILF3 ↑ 1.30 
PJ41RR Junction plakoglobin JUP ↑ 1.78 
PJ41RR Importin subunit alpha-2 KPNA2 ↓ 0.36 
PJ49RR Keratin, type I cuticular Ha7 KRT37 ↓ 0.76 
PJ49RR Keratin, type II cytoskeletal 6A KRT6A ↓ 0.82 
PJ49RR Keratin, type II cytoskeletal 6B KRT6B ↓ 0.82 
PJ49RR Keratin, type II cytoskeletal 8 KRT8 ↓ 0.82 
PJ41RR Ladinin-1 LAD1 ↓ 0.57 
PJ49RR Laminin subunit gamma-2 LAMC2 ↓ 0.64 
PJ49RR Leucyl-tRNA synthetase, cytoplasmic LARS ↑ 1.28 
PJ49RR L-lactate dehydrogenase A chain LDHA ↑ 1.25 
PJ49RR L-lactate dehydrogenase B chain LDHB ↑ 1.21 
PJ49RR Galectin-1 LGALS1 ↑ 1.32 
PJ41RR Galectin-3 LGALS3 ↓ 0.66 
PJ49RR LIM domain and actin-binding protein 1 LIMA1 ↓ 0.75 
PJ41RR 
Leukotriene A-4 hydrolase LTA4H 
↓ 0.61  
PJ49RR ↓ 0.51 
PJ41RR Myristoylated alanine-rich C-kinase 
substrate 
MARCKS 
↓ 0.69   
PJ49RR ↓ 0.79 
PJ41RR 
DNA replication licensing factor MCM3 MCM3 
↑ 1.63   
PJ49RR ↓ 0.81 
PJ49RR Macrophage migration inhibitory factor MIF ↑ 1.26 
PJ41RR 
Metallothionein-1X MT1X 
↓ 0.37  
PJ49RR ↓ 0.61 
PJ49RR Myoferlin MYOF ↓ 0.79 
PJ49RR NADH dehydrogenase [ubiquinone] 1 
beta subcomplex subunit 9 
NDUFB9 ↓ 0.78 
PJ41RR NSFL1 cofactor p47 NSFL1C ↓ 0.57 
PJ41RR tRNA (cytosine(34)-C(5))-
methyltransferase 
NSUN2 ↓ 0.59 
 148 
 
PJ49RR Nuclear pore complex protein Nup107 NUP107 ↑ 4.07 
PJ41RR Ubiquitin thioesterase OTUB1 OTUB1 ↓ 0.70 
PJ41RR Programmed cell death protein 6 PDCD6 ↓ 0.52 
PJ41RR Profilin-2 PFN2 ↑ 1.40 
PJ41RR Phosphoglycerate mutase 1 PGAM1 ↓ 0.48 
PJ41RR 6-phosphogluconate dehydrogenase, 
decarboxylating 
PGD ↓ 0.65 
PJ49RR Phosphoglycerate kinase 1 PGK1 ↑ 1.35 
PJ49RR PHD finger-like domain-containing 
protein 5A 
PHF5A ↓ 0.78 
PJ49RR Plakophilin-3 PKP3 ↓ 0.55 
PJ41RR 
Perilipin-3 PLIN3 
↓ 0.64   
PJ49RR ↓ 0.65 
PJ41RR 
Plexin-B2 PLXNB2 
↑ 2.13   
PJ49RR ↓ 0.22 
PJ49RR Protein phosphatase 1 regulatory subunit 
12A 
PPP1R12A ↓ 0.76 
PJ41RR Protein phosphatase 1 regulatory subunit 
14B 
PPP1R14B ↑ 4.26 
PJ49RR Peroxiredoxin-2 PRDX2 ↑ 1.21 
PJ49RR Peroxiredoxin-4 PRDX4 ↓ 0.71 
PJ41RR 
Proteasome subunit alpha type-1 PSMA1 
↑ 1.42 / 
PJ49RR ↓ 0.81 
PJ41RR Proteasome activator complex subunit 1 PSME1 ↓ 0.72 
PJ49RR Apoptosis-associated speck-like protein 
containing a CARD 
PYCARD ↓ 0.82 
PJ41RR GTP-binding nuclear protein Ran RAN ↓ 0.51 
PJ49RR RNA-binding protein 39 RBM39 ↑ 1.23 
PJ49RR Regulator of chromosome condensation RCC1 ↑ 1.21 
PJ49RR Transforming protein RhoA RHOA ↓ 0.76 
PJ41RR 40S ribosomal protein S21 RPS21 ↑ 2.63 
PJ41RR 40S ribosomal protein S3a RPS3A ↓ 0.47 
PJ41RR 40S ribosomal protein S8 RPS8 ↓ 0.72 
PJ49RR Ribosome-binding protein 1 RRBP1 ↓ 0.81 
PJ49RR Reticulon-4 RTN4 ↓ 0.81 
PJ41RR 
U4/U6.U5 tri-snRNP-associated protein 1 SART1 
↓ 0.52   
PJ49RR ↑ 1.35 
PJ49RR Lysosome membrane protein 2 SCARB2 ↑ 1.22 
PJ49RR Serpin B6 SERPINB6 ↑ 1.62 
PJ41RR Serpin H1 SERPINH1 ↓ 0.66 
PJ41RR Splicing factor 1 SF1 ↓ 0.60 
PJ41RR Splicing factor 3A subunit 2 SF3A2 ↑ 1.82 
PJ41RR Splicing factor 3B subunit 3 SF3B3 ↑ 1.54 
PJ41RR Sideroflexin-3 SFXN3 ↓ 0.67 
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PJ49RR Serine hydroxymethyltransferase, 
cytosolic 
SHMT1 ↑ 1.62 
PJ41RR Solute carrier family 2, facilitated glucose 
transporter member 1 
SLC2A1 ↑ 1.80 
PJ41RR Structural maintenance of chromosomes 
protein 4 
SMC4 ↑ 1.53 
PJ41RR Serine/arginine-rich splicing factor 3 SRSF3 ↑ 1.51 
PJ41RR Serine/arginine-rich splicing factor 7 SRSF7 ↑ 1.73 
PJ49RR Stomatin-like protein 2 STOML2 ↑ 1.25 
PJ49RR Serine-threonine kinase receptor-
associated protein 
STRAP ↓ 0.81 
PJ49RR Threonyl-tRNA synthetase, cytoplasmic TARS ↓ 0.79 
PJ49RR Tubulin-specific chaperone A TBCA ↑1.29 
PJ41RR Lamina-associated polypeptide 2, isoform 
alpha 
TMPO ↑ 1.57 
PJ49RR Triosephosphate isomerise TPI1 ↑ 1.33 
PJ41RR Tubulin--tyrosine ligase-like protein 12 TTLL12 ↓ 0.61 
PJ41RR Ubiquitin-conjugating enzyme E2 N UBE2N ↓ 0.71 
PJ41RR 
Regulator of nonsense transcripts 1 UPF1 
↓ 0.40   
PJ49RR ↓ 0.61 
PJ49RR Voltage-dependent anion-selective 
channel protein 1 
VDAC1 ↑ 1.53 
PJ49RR Voltage-dependent anion-selective 
channel protein 2 
VDAC2 ↑ 1.52 
PJ41RR Tyrosyl-tRNA synthetase, cytoplasmic YARS ↓ 0.72 
PJ41RR Nuclease-sensitive element-binding 
protein 1 
YBX1 ↓ 0.36 
PJ41RR 14-3-3 protein gamma YWHAG ↓ 0.67 
PJ41RR 14-3-3 protein eta YWHAH ↓ 0.71 
PJ41RR 
Zinc finger protein 469 ZNF469 
↑ 1.38  
PJ49RR ↓ 0.78 
6.4 Discussion 
Protein was successfully extracted from the 2 oral cancer cell lines and their radioresistant 
derivatives, and subsequently analysed using 2 comparative proteomic platforms in order to 
identify DEPs associated with the radioresistant phenotype. 
 
Following both 2D-PAGE MS experiments, a total of 25 DEPs were identified (Table 14). 
From this final list, 3 RIDEPs, namely Heat shock protein beta 1 (HSPB1), Peroxiredoxin 2 
(PRDX2) and Keratin 8 (KRT8) were identified. Keratin 8 was the only DEP discovered in 
both RR cell lines. From this dataset, none of the ‘classic’ putative biomarkers discussed in 
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Chapter 2 were identified, as were none of the proteins listed as hypothetical biomarkers of 
RR (Table 1). However, 6 proteins from the dataset were also listed amongst those which 
were significantly associated with radioresistance from proteomic studies within the 
literature (Appendix A). 
 iTRAQ analysis of the 2 oral cancer samples revealed there to be 156 DEPs 
associated with the radioresistant phenotype. Of this 156, 15 proteins (shown in Table 16) 
were identified in both experiments, to generate a list of 141 unique DEPs. EGFR, 
discussed as a ‘classic’ putative biomarker in section 2.2.3.3, Chapter 2 was identified in 
the dataset, as was cyclin dependent kinase highlighted in Table 1 as a protein which could 
be hypothetically associated with radioresistance. A total of 12 proteins were common with 
those listed in Appendix A (proteins significantly associated with radioresistance from 
proteomic studies within the literature). 
 General findings from either one or both proteomic platforms including RIDEPs 
and keratin contamination will be discussed in Chapter 10. 
 
All of the DEPs associated with radioresistance generated from both 2D-PAGE MALDI-
TOF/TOF MS and iTRAQ presented within this chapter will now be taken forward to the 
data mining phase of the biomarker discovery pipeline (Chapter 8) where any common 
biomarkers/pathways will be highlighted. 
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Chapter 7.  Identification of radiotherapy resistance 
biomarkers in Rectal Cancer 
7.1 Introduction 
Rectal cancer remains one of the leading causes of cancer related deaths worldwide (Pfeifer 
et al., 2009). Globally ranked the third most common malignancy, there are approximately 
18000 newly diagnosed cases and around 6000 deaths per year in the UK alone (Cancer 
Statistics – Cancer Research UK). Due to surgical limitations resulting from the pelvic 
position of the rectum, and hence subsequent risk of local relapse and poor overall survival 
rates, pre-operative radiotherapy has become a treatment regimen widely used to 
complement surgery over the last 20 years (Glimelius, 2002, Allal et al., 2004). Use of pre-
operative radiotherapy in the treatment of rectal cancers has significantly decreased 
morbidity, predominantly caused by uncontrolled pelvic growth, in addition to overall 
survival. Improved preservation of anal sphincter function following surgery is also a 
significant benefit of using radiotherapy in a pre-operative setting (Sebag-Montefiore et al., 
2009). 
Despite the various treatment options available to rectal cancer patients (section 1.1) 
treatment with radiotherapy has been found to decrease local recurrence rates in only 50% 
of cases (Nagtegaal et al., 2005) hence highlighting the need for predictive biomarkers of 
radiotherapy response. To date, no significant breakthrough has been made towards the 
establishment of a panel of clinically relevant predictive biomarkers in rectal cancer 
however, this chapter aims to identify proteins associated with radioresistance through the 
study of 2 novel radioresistant rectal cancer cell lines (Chapter 5), utilising the antibody 
microarray and 2D-PAGE MALDI-TOF/TOF MS platforms. 
7.2 Materials and Methods 
7.2.1 The biomarker discovery pipeline 
Prior to starting this project, no previous work had been carried out on rectal cancer within 
our laboratory. Chapter 5 marked the beginning of the biomarker discovery pipeline for two 
rectal cancer cell lines through establishment of the 2 novel radioresistant derivatives, 
which displayed significant resistance to radiotherapy than their corresponding parental 
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counterparts. Now fully established, these cell lines and their novel derivates will undergo 
direct comparison in the biomarker discovery phase in order to identify those proteins 
associated with the radioresistant phenotype. Due to time constraints, only antibody 
microarray and 2D-PAGE MALDI-TOF/TOF MS have been utilised within this chapter 
(Figure 42). 
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Figure 42: Progression through the biomarker discovery pipeline of the 2 rectal cancer cell lines – biomarker discovery 
Work highlighted in the dashed box will be discussed during this chapter. As indicated by the red arrow, no work had been previously 
carried out on rectal cancer prior to the start of this project. Due to time constraints, iTRAQ could not take place during the course of this 
project, therefore only data derived from antibody microarray and 2D-PAGE MALDI-TOF/TOF MS will be discussed during this chapter. 
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7.2.2 Antibody microarray analysis 
The Panorama Antibody Microarray XPRESS725 Profiler (#XP725, Sigma Aldrich) was 
used to compare protein expression between parental, and radioresistant derivatives for 
both SW837 and HRA-19 cell lines as described in section 4.5. The hybridised slide was 
scanned using 532 nm and 635 nm lasers as shown in Figure 43. Work carried out during 
this experiment was done in collaboration with Mr Sajid Mehmood. The experiment was 
supervised and all data was checked by Dr Victoria Hodgkinson based on her significant 
experience in antibody microarray analysis.  
 
 
Figure 43: An example antibody microarray slide following hybridisation with 
fluorescently labelled protein sample. 
A: The parental sample labelled with the Cy3 fluorescent dye and scanned at 635 nm. B: 
The radioresistant sample labelled with the Cy5 fluorescent dye and scanned at 532 nm. C: 
Final image constructed by the layering of Cy3 and Cy5 images. This final image gives a 
ratio enabling the relative intensity of each dye to be determined for each specific antibody. 
Differences in relative intensity of ≥ 1.8-fold represents significant differential expression 
of that particular protein. 
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7.2.3 2D-PAGE MALDI-TOF/TOF MS 
7.2.3.1 Protein extraction 
Protein was extracted as per section 4.6.1.  
7.2.3.2 Protein clean-up and quantification 
Protein samples were cleaned-up (section 4.6.2) and quantified as per section 4.6.3. 
7.2.3.3 1st dimensional separation by IEF 
IEF took place using the 3-step program detailed in section 4.6.4. 
7.2.3.4 2nd dimensional separation by SDS-PAGE 
Following IEF, proteins were reduced and alkylated as in section 4.6.5 and separated by 
SDS-PAGE as per section 4.6.6. 
7.2.3.5 Protein staining 
Protein spots were stained and visualised as detailed in section 4.6.7. 
7.2.3.6 PDQuest analysis 
Significant DEPs were identified using PDQuest software as per section 4.6.8. 
7.2.3.7 Spot excision and in-gel digest 
DEPs were excised from the gel (section 4.6.9) and digested as per section 4.6.10. 
7.2.3.8 MALDI-TOF/TOF MS for protein identification 
Each peptide sample was spotted onto the target plate as per section 4.6.11. Proteins were 
subsequently identified as detailed in section 4.6.12. 
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7.3 Results 
7.3.1 Antibody Microarray analysis   
A total of 2 antibody microarray experiments (comparing SW837 with SW837RR, and 
HRA-19 with HRA-19RR) were carried out in order to identify DEPs associated with 
radioresistance, based on protein expression levels. From the 2 experiments a total of 130 
DEPs were identified (Table 17). Of this total, 59 DEPs with a fold change ≥ 1.8 were 
identified from both experiments. Of the 130 DEPs identified, 8 have been highlighted as 
RIDEPs (Table 17) (discussed previously in section 3.5.1). 
 
 
Table 17: DEPs associated with the SW837RR and HRA-19RR cell lines, identified by 
antibody microarray analysis. 
Those values that represent a significant fold change in expression (≥ 1.8) have been 
highlighted in bold. Supporting data ≥ 1.5 has also been included for proteins with a ≥ 1.8 
fold in expression. Protein fold changes that did not meet the level of significance (---) or 
did not pass analysis criteria () are also highlighted. Those proteins which were not linked 
to a specific gene name are labelled (ns) and RIDEPs are labelled (*). 
 
Ab # Protein Name Gene Name SW837RR  
 
HRA-19RR 
 
C8979 Cytohesin1 CYTH1 4.54 4.24 
G4170 GRP75 HSPA9 5.88 2.57 
D1286 Desmosomal Protein  ns 5.09 2.88 
J3774 JAK1 JAK1 4.88 2.93 
C7464 Cyclin D1 CCND1 4.20 3.38 
B7810 BOB1 OBF1 POU2AF1 3.40 3.97 
P4868 p53DINP1SIP TP53INP1 5.13 2.00 
R4653 hnRNPA2B1 HNRNPA2B1 3.50 2.86 
S7945 Siah2 * SIAH2 3.83 2.25 
T5530 Tau MAPT 3.58 2.15 
U0508 Ubiquitin ns 3.58 2.02 
M7802 MAP Kinase Activated 
Monophosphorylated 
ns 3.59 2.60 
M5670 MAP Kinase Erk1 Erk2 ns 2.97 3.05 
G4420 GRP94 HSP90B1 3.89 2.08 
S3934 Smad4 * SMAD4 3.25 2.50 
C6542 Caldesmon CALD1 2.96 2.75 
H2289 HSP 27 25 HSPB1 3.53 2.01 
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I1659 IFI16 IFI16 2.91 2.58 
P7607 Protein Phosphatase 1a PPP1CA 2.32 2.90 
I0783 ILK ILK 2.74 2.43 
C1862 Coilin COIL 2.62 2.48 
G6670 Growth Factor Independence 1 GFI1 2.57 2.52 
C0715 Cathepsin D CTSD 2.18 2.90 
P2860 PSF ns 2.26 2.76 
A9856 AP2 beta TFAP2B 1.97 3.04 
R2404 Raf1 cRaf RAF1 2.85 2.02 
T1948 TRF1 TERF1 2.49 2.25 
T3559 gTubulin ns 2.52 2.21 
B3170 Bcl2 BCL2 2.08 2.62 
A8469 Apaf1 APAF1 2.57 2.00 
H0913 Acetyl Histone H3 AcLys9 ns 2.18 2.37 
B7929 Bim BCL2L11 1.89 2.63 
M7318 MBD2ab MBD2 2.06 2.44 
T5201 b Tubulin ns 2.26 2.22 
B0436 BAF57 SMARCE1 2.61 1.87 
R5404 Rab9 RAB9A 2.28 2.18 
A4605 iASPP PPP1R13L 2.07 2.32 
C8035 Chondriotin Sulphate ACAN 1.90 2.43 
I6139 IKKa * CHUK 2.50 1.79 
D3813 DR4 TNFRSF10A 1.90 2.35 
C9358 Chk1 CHEK1 2.27 1.98 
R4777 Ran RAN 2.02 2.21 
C2081 aCatenin CTNNA1 2.09 2.11 
P6834 Proliferating Cell Protein Ki67 MKI67 1.91 2.28 
C2687 Calponin ns 2.01 2.14 
J4750 JNK Activated Diphosphorylated JNK MAPK8 1.84 2.31 
P2859 p300 CBP KAT2B 1.94 2.16 
N9532 Nitric Oxide Synthase Endothelial eNOS NOS3 1.98 2.11 
T2949 mTOR FRAP1 2.12 1.97 
R6278 hnRNPU HNRNPU 2.26 1.82 
T8300 Tumour Necrosis Factor a TNF 2.19 1.81 
V7881 Vitronectin VTN 1.99 1.99 
I1907 ILK ILK 1.97 1.96 
N2786 Nedd28 NEDD8 1.92 2.00 
R5145 Rsk1 RPS6KA1 1.85 2.04 
C5987 CD40 CD40 2.04 1.81 
T6199 aTubulin TUBA4A 1.89 1.96 
C7488 CENPE CENPE 1.91 1.90 
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N2911 Nck2 NCK2 1.81 1.91 
M9934 MyD88 * MYD88 3.71 1.71 
R8274 RIP Receptor Interacting Protein RIPK1 3.68 1.71 
M8432 p38 MAP Kinase Non Activated MAPK14 3.33 1.70 
S4445 Sin3A SIN3A 2.59 1.75 
R4903 hnRNPL HNRNPL 1.74 2.29 
A5044 aActinin ACTN1 2.33 1.65 
N4142 Neurofilament 200 NEFH 1.76 2.22 
A8353 hABH3 ALKBH3 1.59 2.33 
P6248 Parkin PARK2 2.35 1.55 
N5287 Nuf2 NUF2 2.23 1.66 
S4047 S6 Kinase RPS6KB1 1.75 2.10 
R8653 ROCK2 ROCK2 2.12 1.71 
N5139 Neurofilament 68 NEFL 2.12 1.67 
D8168 Dystrophin DMD 1.77 2.02 
C3617 Casein Kinase 2b CSNK2B 1.79 1.96 
P8609 Serine Threonine Protein 
Phosphatase 
ns 1.55 2.19 
H9163 HDRP MITR HDAC9 1.74 1.95 
C8093 Connexin43 ns 2.04 1.62 
A3853 Actin ns 1.70 1.95 
C4481 Caspase 4 CASP4 2.08 1.56 
T0678 Tryptophane Hydroxylase ns 2.01 1.62 
F0305 FANCD2 FANCD2 1.88 1.72 
R5653 hnRNPQ ns 1.80 1.74 
M4528 MAP1b MAP1B 1.97 1.57 
A5968 AP1 JUN 1.99 1.54 
S8316 SUV39H1Histone Methyl 
Transferase 
SUV39H1 1.59 1.92 
T0825 Transportin 1 TNPO1 1.88 1.63 
E9653 Endothelial Cells ns 1.71 1.80 
N3038 Nanog NANOG 1.80 1.71 
C1926 Collagen Type IV ns 1.70 1.80 
V4505 Vinculin VCL 1.68 1.80 
N9657 Nitric Oxide Synthase Inducible 
iNOS 
NOS2 1.87 1.60 
Z0377 Zyxin * ZYX 1.60 1.86 
C7099 CaM Kinase Kinase a CaMKKa CAMK2A 1.81 1.62 
C6909 Cytokeratin 8 13 ns 1.86 1.53 
T7941 bTubulin IV TUBB4 1.55 1.82 
R5028 hnRNPC1C2 HNRNPC 1.82 1.52 
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C8854 Caspase 13 CASP13 7.93  
T9191 TRAIL TNFSF10  4.17 
P7609 Serine Threonine Protein 
Phosphatase.. 
PPP1CC 3.66  
D3566 DcR1 TNFRSF10C 2.83  
E1532 E2F6 E2F6 2.13  
T3067 TRAIL TNFSF10  2.11 
F1054 FOXC2 FOXC2 2.01  
P1601 Protein Kinase Ba AKT1 3.05 --- 
T5942 14 3 3 * YWHAQ 2.62 --- 
R5773 Raf1 RAF1 2.51 --- 
R8529 RALAR RALA --- 2.48 
B1559 Bmf BMF 2.41 --- 
T7076 Thimet Oligopeptidase 1 THOP1 2.34 --- 
D3563 DR3 TNFRSF25 2.31 --- 
E5900 cerbB4 ERBB4 --- 2.30 
A5355 ASC2 NCOA6 --- 2.26 
C8831 Cyclin B1 CCNB1 --- 2.21 
M7569 MTA2 MTA2 --- 2.16 
H0788 Acetyl phospho Histone H3 AL9 S10 ns 2.07 --- 
N9287 NBS1 Nibrin NBN --- 2.05 
C2238 Cdc14A CDC14A 2.01 --- 
S6324 SNX6 SNX6 --- 1.99 
C1985 Clathrin Light Chain ns 1.94 --- 
P0084 Pinin * PNN --- 1.94 
B9303 BAP1 BAP1 --- 1.93 
M6569 MBD1 MBD1 --- 1.92 
B1684 Bmf BMF 1.88 --- 
T2928 Tyrosin hydroxylase TH --- 1.86 
C8343 Cdk6 CDK6 --- 1.84 
P5367 Par4 Prostate Apoptosis Response 4 PAWR 1.82 --- 
E8767 cerbB3 ERBB3 --- 1.81 
C5588 Cyclin D1 CCND1 --- 1.80 
M8177 p38 MAPK activated 
diphosphorylated 
MAPK14 1.80 --- 
P8090 Protein Kinase C * PRKCH --- 1.80 
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7.3.2 2D-PAGE MALDI-TOF/TOF MS 
7.3.2.1 2D PAGE 
A total of 2 experiments were performed in order to identify DEPs associated with the 
radioresistant phenotypes (SW837RR and HRA-19RR). For each of the 2 experiments 
proteins were separated in the 1
st
 dimension by IEF and then in the 2
nd
 dimension by SDS-
PAGE. Each separation process was done in triplicate to produce 3 replicate gels for each 
cell subtype within a sample pair. Figure 44 gives an example of 1 SW837 and 1 
SW837RR coomassie stained 2D-PAGE gel. Figure 45 gives an example of 1 HRA-19 and 
1 HRA-19RR coomassie stained 2D-PAGE gel. 
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A 
 
B 
 
Figure 44: Coomassie stained 2D-PAGE gels for SW837 and SW837RR. 
Proteins were first separated by pI in a pH range of 4-7, then vertically by molecular weight 
on an 11cm polyacrylamide gel. Image A shows an example of 1 out of 3 SW837 gels. 
Image B shows an example of 1 out of 3 SW837RR gels. 
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A 
 
B 
 
Figure 45: Coomassie stained 2D-PAGE gels for HRA-19 and HRA-19RR. 
Proteins were first separated by pI in a pH range of 4-7, then vertically by molecular weight 
on an 11cm polyacrylamide gel. Image A shows an example of 1 out of 3 HRA-19 gels. 
Image B shows an example of 1 out of 3 HRA-19RR gels. 
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7.3.2.2 PDQuest analysis 
Following optical density scanning of the protein stained gels, the resultant profiles were 
analysed using PDQuest analysis software in order to identify DEPs between the parent and 
radioresistant samples. For each experiment, a varying number of DEPs were identified. 
Table 18 details the total number of matched protein spots per experiment, the total number 
of DEPs identified, and also the number of DEPs that were found to be up-regulated in the 
radioresistant sample by the PDQuest software. 
 
Table 18: The total number of protein spots matched by PDQuest in relation to the 
total number of DEPs identified from both SW837RR and HRA-19RR. 
Of the total number of DEPs identified from PDQuest for both RR cell lines, 75% were up-
regulated and 25% were down-regulated in the SW837RR cell line. For the HRA-19RR cell 
line, 56% of DEPs were up-regulated and 44% were down-regulated. 
 
RR cell 
line 
Total number of 
protein spots 
matched by 
PDQuest 
Total number of 
DEPs identified 
by PDQuest 
Total number of 
DEPs up-
regulated in the 
RR sample 
Total number of 
DEPs down-
regulated in the 
RR sample 
SW837RR 552 37 (7%) 28 (75%) 9 (25%) 
HRA-19RR 561 71 (13%) 40 (56%) 31 (44%) 
Total 1113 108 68 40 
 
A selection of DEPs that were identified by PDQuest (and subsequently excised for further 
analysis) for SW837RR and HRA-19RR are shown in Figure 46 and Figure 47, 
respectively. 
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Figure 46: DEPs and their corresponding histograms identified by PDQuest software 
for SW837 and SW837RR. 
Ten protein spots identified as DEPs (≥ 2-fold; p< 0.05) by PDQuest. The DEPs are 
highlighted within the yellow box. The corresponding histograms help to highlight the 
change in expression which was calculated by taking an average from the 3 gels for SW837 
(PN - red) and SW837RR (RR - green) samples. 
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Figure 47: DEPs and their corresponding histograms identified by PDQuest software 
for HRA-19 and HRA-19RR. 
Ten protein spots identified as DEPs (≥ 2-fold; p< 0.05) by PDQuest. The DEPs are 
highlighted within the yellow box. The corresponding histograms help to highlight the 
change in expression which was calculated by taking an average from the 3 gels for HRA-
19 (PN - red) and HRA-19RR (RR - green) samples. 
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7.3.2.3 Selection of DEPs to excise from the gel 
Not all of the DEPs identified by PDQuest were successfully excised from the gel. As 
discussed previously in section 6.3.1.3, DEPs which appeared within a cluster of spots or 
overlapped another spot, DEPs that were in a streak or smear, and also DEPs that didn’t 
appear to be composed of only one protein were not excised from the gel. Those small, or 
weak DEPs which were not clearly visible by eye were not excised from the gel. By 
applying such stringent criteria during spot excision, the false discovery rate at the MS 
stage will be significantly reduced allowing for increased confidence in the resultant protein 
identification. Table 19 details the total number of DEPs identified by PDQuest for each 
experiment, and of this total the number that were successfully excised from the gel. 
 
 
Table 19: The total number of DEPs identified by PDQuest in relation to the number 
excised. 
Of the total number of DEPs identified by PDQuest, 15 (41%) were excised for the SW837 
experiment, and 15 (21%) were excised for the HRA-19 experiment.  
 
RR cell 
line 
Total number of 
DEPs identified by 
PDQuest 
Total number of DEPs 
excised from the gel 
Number of protein 
identifications by 
MALDI-TOF/TOF 
MS 
SW837 37 15 (41%) 13 (86%) 
HRA-19 71 15 (21%) 14 (93%) 
Total 108 30 27 
 
 
7.3.2.4 DEPs identified by MALDI-TOF/TOF MS 
A total of 27 unique DEPs were successfully identified from the 2 experiments. An 
example of a MASCOT peptide summary report and a protein view page have been 
included previously (section 6.3.1.4). In addition, further information which can be 
obtained to increase the confidence of a protein ID with only one peptide match has been 
discussed in section 6.3.1.5. Table 20 lists the 27 DEPs identified from the 2 rectal cancer 
cell line experiments, along with their corresponding gene names and direction of 
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expression change in the radioresistant sample. Appendix L lists these 27 proteins in 
addition to information gained from the MASCOT summary report. 
 
Table 20: List of DEPs associated with the SW837RR and HRA-19RR cell lines, 
identified by 2D-PAGE MALDI-TOF/TOF MS. 
From the 2 experiments a total of 27unique proteins were differentially expressed. Those 
proteins which are up-regulated (↑) and down-regulated (↓) in the radioresistant (RR) 
phenotype are highlighted. Proteins (≥2-fold in expression change) are listed alphabetically 
by gene name and have at least one peptide match. Those protein identifications based on a 
single peptide match are highlighted 
(1P). 
Proteins previously identified as RIDEPS are 
highlighted (*).  
 
 
RR cell line Protein name Gene name 
Direction of 
expression 
change in 
RR 
HRA-19RR Actin, cytoplasmic 1 ACTB ↓ 
SW837RR Actin, cytoplasmic 2 ACTG1 ↓ 
HRA-19RR Serum albumin 
(1P)
 ALBU ↓ 
HRA-19RR Rho GDP-dissociation inhibitor 1* ARHGDIA ↑ 
HRA-19RR Complement component 1 Q subcomponent-
binding protein, mitochondrial 
C1QBP ↑ 
SW837RR Catechol O-methyltransferase COMT ↑ 
HRA-19RR Lambda-crystallin homolog CRYL1 ↑ 
SW837RR Fatty acid-binding protein, heart FABP3 ↓ 
SW837RR Lactoylglutathione lyase GLO1 ↑ 
SW837RR Glia maturation factor beta GMFB ↑ 
HRA-19RR Heterogeneous nuclear ribonucleoproteins C1/C2 
(1P)
 
HNRNPC ↓ 
SW837RR Heat shock protein beta-1* HSPB1 ↑ 
SW837RR Keratin, type I cytoskeletal 16 KRT16 ↓ 
SW837RR Keratin, type I cytoskeletal 19 KRT19 ↓ 
HRA-19RR Keratin, type II cytoskeletal 8 KRT8 ↓ 
HRA-19RR Leukotriene A-4 hydrolase 
(1P)
 LTA4H ↑ 
HRA-19RR Platelet-activating factor acetylhydrolase IB 
subunit beta 
PAFAH1B2 ↑ 
SW837RR Protein disulfide-isomerase A3 PDIA3 ↓ 
HRA-19RR Glucosidase 2 subunit beta PRKCSH ↑ 
HRA-19RR Prostaglandin E synthase 3 PTGES3 ↑ 
SW837RR Ran-specific GTPase-activating protein RANBP1 ↑ 
HRA-19RR c-Myc-responsive protein Rc RCL ↑ 
SW837RR Protein S100-A6 
(1P)
 S100A6 ↑ 
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HRA-19RR Serpin B5 SERPINB5 ↓ 
SW837RR Stathmin STMN1 ↑ 
HRA-19RR Tryptophanyl-tRNA synthetase, cytoplasmic WARS ↑ 
SW837RR 14-3-3 protein gamma YWHAG ↑ 
7.4 Discussion 
Protein was successfully extracted from the 2 rectal cancer cell lines and their radioresistant 
derivatives, and subsequently analysed using 2 comparative proteomic platforms in order to 
identify DEPs associated with the radioresistant phenotype. 
Following both antibody microarray experiments, a total of 130 DEPs were 
identified, 59 of which were significantly (≥ 1.8 fold change in expression) expressed in 
both experiments (Table 17). Of the 130 DEPs identified, 8 RIDEPs (section 3.5.1) were 
identified, namely Siah2, Smad4 and iKKa, MyD88, Zyxin, 14 3 3, Pinin and Protein 
kinase C. Further analysis of these proteins will be interpreted with caution. From the list of 
DEPs, the ‘classic’ putative predictive markers Cyclin D1 and Bcl2 discussed in Chapter 2 
were identified, supporting further their involvement with a radioresistant phenotype. In 
addition, Bcl2 was listed in Table 1 (hypothetical biomarkers of RR) along with Apaf1, 
Chk1, TRAIL and DR4 which were also identified in the list of 130 DEPs. Comparison of 
these 130 DEPs with those proteins listed in Appendix A (proteins significantly associated 
with radioresistance from proteomic studies within the literature) revealed 8 proteins in 
common. 
 Following 2D-PAGE MS experiments, a total of 27 DEPs were identified (Table 
20). As predicted from the previous experiments discussed in Chapter 6, this final 27 was 
reduced from an initial 108 DEPs identified by PDQuest, due to factors discussed in section 
6.3.1.3. From this final list of DEPs only 2 RIDEPS (section 3.3.3) namely, Rho GDP-
dissociation inhibitor 1 (ARHGDIA) and Heat shock protein beta-1 (HSPB1) were 
identified. None of the same proteins were identified from both RR cell lines. The dataset 
highlighted none of the ‘classic’ putative biomarkers discussed in Chapter 2. There were 
also no proteins in common with Table 1 (hypothetical biomarkers of RR) however, 1 
protein SERPINB5 was listed in Appendix A (proteins significantly associated with 
radioresistance from proteomic studies within the literature).  
 
 170 
 
Following the biomarker discovery phase, the DEPs identified from both antibody 
microarray and 2D-PAGE MALDI-TOF/TOF MS during the course of this chapter in 
addition to the DEPs identified from the 2 proteomic techniques in Chapter 6, will now be 
submitted to Ingenuity Pathway Analysis (IPA) software for the data mining phase of the 
biomarker discovery pipeline. Further interpretation of these protein lists through use of 
IPA will enable DEPs to be mapped onto their most relevant biological pathway, and in 
doing so highlight those proteins common to the same pathways. Use of this information 
will aid in the prioritisation of which proteins to take forward for both confirmation and 
clinical validation phases.  
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Chapter 8: 
Data mining 
 
 
 
 
 
 
Chapter Aim: 
To analyse further data generated from the biomarker discovery phase for breast,  
oral and rectal cancer, enabling the prioritisation and selection of DEPs to be taken  
forward to the confirmation and clinical validation phase. 
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Chapter 8.  Data mining 
8.1 Introduction to data mining 
Proteomics is becoming an increasingly popular tool in the field of cancer research, 
providing the ability to investigate the molecular mechanisms which contribute to therapy 
resistance, through study of the entire proteome. Despite this, most proteomic 
methodologies focus on generating large lists of DEPs with no means of identifying or 
understanding how these proteins relate to, or interact with one another in a biological 
context. Therefore, in order to gain greater insight into the clinical relevance behind these 
large protein lists, and subsequently select out and prioritise the most interesting proteins 
for further investigation, enhanced interpretation through use of data mining tools is 
essential. 
8.1.1 Data mining approaches 
There are several data mining approaches available that can group proteins by function, 
interaction networks and pathways. Examples include DAVID, PANTHER, PPI spider, 
Reactome, STRING, MINT, Cytoscape and Ingenuity Pathway analysis (IPA), amongst 
several others (Antonov et al., 2009, Croft et al., 2011, Malik et al., 2010, Deighton et al., 
2010). IPA operates through the interrogation of a manually constructed (section 4.8) 
Ingenuity Knowledge Base (updated weekly) which enables protein data to be organised 
into the most relevant protein networks and canonical pathways, in addition to detailing 
common protein functions and protein-to-protein interactions, either in a direct or indirect 
context. Use of IPA enables complex data (like that derived from proteomics and 
microarray analysis) to be mapped within complex biological systems and hence provides 
the wealth of information needed to select the most clinically relevant targets for further 
investigation. 
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8.2 Materials and methods 
8.2.1 The biomarker discovery pipeline 
Prior to beginning this project, none of the data generated from the biomarker discovery 
phase using the novel radioresistant breast, oral or rectal cancer cell sublines had been 
subjected to further interpretation using data mining methods. Therefore, all data presented 
within this chapter has been derived during the course of this project (Figure 48). 
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Figure 48: Progression through the biomarker discovery pipeline of the breast, oral and rectal cancer cell lines – data mining 
Work highlighted by the dashed box will be discussed during this chapter. As indicated by the red arrows, no data mining of the breast, oral 
or rectal cancer putative biomarkers discovered using the novel RR cell sublines had been carried out prior to the start of this project. 
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8.2.2 Protein selection for data mining 
8.2.2.1 Biomarker discovery data 
Protein targets identified from breast, oral and rectal cancers, covering 7 RR cancer cell 
lines have been subjected to data mining by IPA. Table 21 clearly highlights the 7 RR cell 
lines, in addition to the proteomic platforms (AbMA/2D MS/ iTRAQ) that have been used 
to identify DEPs. It is important to note that the 3 novel breast cancer RR derivatives 
(MCF-7RR, MDA-MB-231RR and T47DRR) had been previously established (Smith et 
al., 2009) and biomarker discovery using all 3 proteomic platforms carried out (Table 21, 
Figure 48) prior to the start of this project. AbMA analysis for the RR oral cancer cell lines 
(PJ41RR and PJ49RR) had also taken place (Table 21, Figure 48). All other protein targets 
identified from 2D MS and iTRAQ for the RR oral cancer cell lines, and AbMA and 2D 
MS for the RR rectal cancer cell lines (SW837RR and HRA-19RR) have been presented in 
Chapters 6 and 7, respectively. Also, DEPs identified by proteomic studies using RR cell 
lines from the literature have been previously reviewed by myself (Scaife et al., 2011) and 
analysed, with the addition of one further recent study (post publication). The cancer types 
and proteomic methods used to identify DEPs in these studies are listed in Appendix A. 
DEPs identified by 2D MS and iTRAQ for the 3 RR breast cancer cell lines discussed 
within this thesis have been published (Smith et al., 2009), and therefore form part of the 
literature base. Therefore, the term ‘literature’ used within this chapter, refers to data 
obtained externally to this group only. 
From the DEPs uploaded into IPA, 16 different data combinations were analysed as 
presented in the relevant sections during this chapter.  
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Table 21: DEPs uploaded into IPA  
DEPs listed in the relevant tables were uploaded into IPA for data analysis. At this point, 
any DEPs with a non-specific gene name (‘ns’ from AbMA data) or any duplicate protein 
entries were removed prior to analysis.  
 
Cell line type Method DEPs 
Breast Cancer  
(MCF-7RR, MDARR, T47DRR) 
AbMA Appendix M 
2D MS Appendix N (Smith et al., 2009) 
iTRAQ Appendix O (Smith et al., 2009) 
Oral Cancer 
(PJ41RR, PJ49RR) 
AbMA Appendix P 
2D MS Table 14, section 6.3.1.6 
iTRAQ Table 16, section 6.3.2 
Rectal Cancer 
(SW837RR, HRA-19RR) 
AbMA Table 17, section 7.3.1 
2D MS Table 20, section 7.3.2.4 
iTRAQ NOT PERFORMED 
Literature 
(excludes data from this group) 
Proteomic 
methods 
Appendix A (Scaife et al., 2011) 
 
8.2.3 IPA analysis 
Biomarker discovery data was analysed using IPA (Ingenuity Systems, 
www.ingenuity.com) as detailed in section 4.8. 
8.3 Results 
8.3.1 Biomarker discovery data 
DEPs were identified within the biomarker discovery phase for the breast, oral and rectal 
cancer types, from across a total of 7 RR cell lines. Table 22 lists those DEPs which have 
been identified in 2 or more of the 7 RR cell lines by antibody microarray. Table 23 lists 
the DEPs identified in 2 or more of the RR cell lines by 2D MS. Table 24 lists those DEPs 
which have been identified in 2 or more of the 7 RR cell lines by iTRAQ. Cross matching 
between proteomic platforms identified only ALDOA to be seen in more than one cell line, 
namely the breast RR cell lines, MCF-7 and T47D, identified by iTRAQ and 2D MS 
platforms, respectively. Table 25 lists those DEPs which have been identified in at least 2/3 
tumour types. 
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Table 22: DEPs identified in 2 or more of the 7 RR cell lines by antibody microarray. 
A total of 70 DEPs were identified in 2 or more of the 7 RR cell lines by the AbMA platform (Table 21). DEPs have been listed 
alphabetically by gene name. Only those values that represent a significant fold change in expression (≥ 1.8) have been listed. Protein fold 
changes that did not meet the level of significance or did not pass analysis criteria are highlighted (---). Proteins previously identified as 
RIDEPs (section 3.5.1) are highlighted (*).  
 
Ab# Protein Name Gene Name 
Breast Oral Rectal 
MCF-7 
RR 
MDARR T47DRR PJ41RR PJ49RR 
SW837 
RR 
HRA-19 
RR 
C8035 Chondroitin Sulphate * ACAN --- --- --- 2.30 1.98 1.90 2.43 
A5979 ARP3 ACTR3 1.83 2.21 --- 
    
P1601 Protein Kinase B alpha AKT1 --- --- --- --- 2.01 3.05 --- 
A4475 Annexin VII ANXA7 --- --- --- 3.61 3.74 --- --- 
A8469 Apaf1 APAF1 --- --- --- --- --- 2.57 2.00 
B3170 Bcl2 BCL2 --- --- --- --- --- 2.08 2.62 
B7929 Bim BCL2L11 --- --- --- --- --- 1.89 2.63 
B3183 BID * BID --- --- --- 2.05 2.33 --- --- 
B1684 Bmf BMF --- --- 1.89 --- --- 1.88 --- 
B9310 BUBR1 BUB1B --- --- --- 2.58 1.84 --- --- 
S4945 SynCAM CADM1 2.18 --- 2.3 --- --- --- --- 
C6542 Caldesmon CALD1 --- --- --- --- --- 2.96 2.75 
C8854 Caspase 13 (ERICE) CASP13 --- --- 1.83 --- --- 7.93 --- 
C7464 Cyclin D1 CCND1 --- --- --- --- --- 4.20 3.38 
C5987 CD40 CD40 --- --- --- --- --- 2.04 1.81 
C7488 CENPE CENPE --- --- --- --- --- 1.91 1.90 
C9358 Chk1 CHEK1 --- 2.19 --- --- --- 2.27 1.98 
I6139 IKKa * CHUK --- --- --- --- 2.29 2.50 1.79 
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C1862 Coilin COIL --- --- 1.87 --- --- 2.62 2.48 
C2081 aCatenin CTNNA1 --- --- --- --- --- 2.09 2.11 
C0715 Cathepsin D CTSD --- --- --- --- --- 2.18 2.90 
C8979 Cytohesin1 CYTH1 --- --- --- --- --- 4.54 4.24 
E8767 c-erbB-3 ERBB3 --- --- 1.95 --- --- --- 1.81 
T2949 mTOR FRAP1 --- --- --- --- --- 2.12 1.97 
G6670 Growth Factor Independence-1 GFI1 2.3 2.49 --- --- --- 2.57 2.52 
R4653 hnRNPA2B1 HNRNPA2B1 --- --- --- --- --- 3.50 2.86 
R6278 hnRNP-U HNRNPU 3.64 --- --- --- --- 2.26 1.82 
G4420 GRP94 HSP90B1 --- --- --- --- --- 3.89 2.08 
G4170 GRP75 HSPA9 --- 1.84 --- --- --- 5.88 2.57 
H2289 HSP 27 25 HSPB1 --- --- --- --- --- 3.53 2.01 
I1659 IFI16 IFI16 --- --- --- --- --- 2.91 2.58 
I0783 ILK ILK --- --- --- --- --- 2.74 2.43 
J3774 JAK1 JAK1 --- --- --- --- --- 4.88 2.93 
P2859 p300 CBP KAT2B --- --- --- --- --- 1.94 2.16 
I9658 Importin alpha 1 KPNA2 3.77 --- 2.1 --- --- --- --- 
J4750 JNK Activated Diphosphorylated JNK MAPK8 --- --- --- --- --- 1.84 2.31 
T5530 Tau MAPT --- --- --- --- --- 3.58 2.15 
M7318 MBD2ab MBD2 --- --- --- --- --- 2.06 2.44 
P6834 Proliferating Cell Protein Ki-67 MKI67 --- --- 2.44 --- --- 1.91 2.28 
M3566 MTBP MTBP --- --- 1.99 --- 2.05 --- --- 
M9934 MyD88 * MYD88 2.02 --- 2.08 --- --- 3.71 --- 
N2911 Nck2 NCK2 --- --- --- --- --- 1.81 1.91 
N2786 Nedd28 NEDD8 --- --- --- --- --- 1.92 2.00 
N9532 Nitric Oxide Synthase Endothelial eNOS NOS3 --- --- --- --- --- 1.98 2.11 
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P9498 PIAS-x PIAS2 --- 2.21 2.4 --- --- --- --- 
B7810 BOB1 OBF1 POU2AF1 --- --- --- --- --- 3.40 3.97 
P7607 Protein Phosphatase 1a PPP1CA --- --- --- --- --- 2.32 2.90 
P7609 
Serine/Threonine Protein Phosphatase 1 
gamma 1 
PPP1CC --- --- --- 2.25 3.64 3.66 --- 
A4605 iASPP PPP1R13L --- --- --- --- --- 2.07 2.32 
P5359 
Serine/Threonine Protein Phosphatase 2 A/B 
gamma 
PPP2R2C --- --- --- 2.48 2.08 --- --- 
P5704 Protein Kinase C (PKC) * PRKCB 1.91 1.92 --- 2.10 --- --- --- 
F9051 phospho FAK (pSer772) PTK2 --- --- 1.82 1.80 --- 
  
R5404 Rab9 RAB9A --- --- --- --- --- 2.28 2.18 
R8029 Rad17 RAD17 --- --- --- 2.19 2.01 --- --- 
R2404 Raf1 cRaf RAF1 --- --- --- --- --- 2.85 2.02 
R4777 Ran RAN --- --- --- --- --- 2.02 2.21 
R5145 Rsk1 RPS6KA1 --- --- --- --- --- 1.85 2.04 
S7945 Siah2 * SIAH2 --- 1.92 2.05 2.10 --- 3.83 2.25 
S3934 Smad4 * SMAD4 1.96 1.81 --- --- --- 3.25 2.50 
B0436 BAF57 SMARCE1 --- --- --- --- --- 2.61 1.87 
S8316 SUV39H1 Histone Methyltransferase SUV39H1 1.88 --- 2.03 --- --- 1.59 1.92 
T1948 TRF1 TERF1 --- --- --- --- --- 2.49 2.25 
A9856 AP2 beta TFAP2B --- --- --- --- --- 1.97 3.04 
T8300 Tumour Necrosis Factor a TNF --- --- --- --- --- 2.19 1.81 
D3813 DR4 TNFRSF10A 4.84 --- 5.01 --- --- 1.90 2.35 
T9191 TRAIL TNFSF10 --- --- --- 2.07 --- --- 4.17 
P4868 p53DINP1SIP TP53INP1 --- --- --- --- --- 5.13 2.00 
T6199 aTubulin TUBA4A --- --- --- --- --- 1.89 1.96 
V7881 Vitronectin VTN --- --- --- --- --- 1.99 1.99 
Z0377 Zyxin * ZYX --- 3.07 2.99 --- --- --- 1.86 
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Table 23: DEPs identified in 2 or more of the 7 RR cell lines by 2D MS. 
A total of 8 DEPs were identified in 2 or more of the 7 RR cell lines by the 2D MS platform (Table 21). DEPs (≥2-fold in expression 
change) are listed alphabetically by gene name. Proteins that are up-regulated (↑) and down-regulated (↓) in the radioresistant (RR) 
phenotype are labelled. Proteins not identified as a DEP in a particular cell line are highlighted (---). Proteins previously identified as 
RIDEPS (section 3.3.3) are highlighted (*). 
 
Protein Name Gene Name 
Breast Oral Rectal 
MCF-7 
RR 
MDARR T47DRR PJ41RR PJ49RR 
SW837 
RR 
HRA-19 
RR 
Aspartyl-tRNA synthetase DARS --- ↓ ↑ --- --- --- --- 
Heterogeneous nuclear ribonucleoproteins C1/C2 HNRNPC --- --- --- ↑ --- --- ↓ 
Heat shock protein beta-1 * HSPB1 --- --- --- --- ↑ ↑ --- 
Keratin 19 KRT19 --- --- --- ↓ --- ↓ --- 
Keratin 8 * KRT8  --- --- --- ↑ ↓ --- ↓ 
Proteasome activator subunit 2 (PA28 beta) PSME2 ↓ --- --- --- ↓ --- --- 
Protein S100-A6 S100A6 --- --- --- ↑ --- ↑ --- 
Triosephosphate isomerise 1 * TPI1 ↓ ↓ --- --- ↑ --- --- 
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Table 24: DEPs identified in at least 2/5 RR cell lines by iTRAQ. 
A total of 19 DEPs were identified in at least 2/5 RR cell lines by the iTRAQ platform (Table 21). DEPs (≥ 2 fold in expression change) for 
the RR breast cancer cell lines, and DEPs (+/- 1 standard deviation of the data) for the RR oral cancer cell lines are listed alphabetically by 
gene name. Proteins that are up-regulated (↑) and down-regulated (↓) in the radioresistant (RR) phenotype are labelled. Proteins not 
identified in a particular cell line are highlighted (---). 
 
Protein Name Gene Name 
Breast Oral 
MCF-7RR MDARR T47DRR PJ41RR PJ49RR 
Alpha-centractin ACTR1A --- --- --- ↑ ↓ 
Neuroblast differentiation-association protein AHNAK --- ↓ --- ↓ --- 
Calmodulin-like protein 3 CALML3 --- --- --- ↓ ↓ 
Cyclin-dependent kinase 12 CDK12 --- --- --- ↓ ↓ 
Src substrate cortactin CTTN --- --- --- ↑ ↑ 
Cytoplasmic dynein 2 heavy chain 1 DYNC2H1 --- --- --- ↓ ↓ 
Filamin A, alpha (actin binding protein 280) FLNA ↓ ↓ --- --- --- 
Keratin 8 KRT8 ↓ --- --- --- ↓ 
Leukotriene A4 hydrolase LTA4H --- --- --- ↓ ↓ 
Myristoylated alanine-rich C-kinase substrate MARCKS --- --- --- ↓ ↓ 
DNA replication licensing factor MCM3 MCM3 --- --- --- ↑ ↓ 
Metallothionein -1X MT1X --- --- --- ↓ ↓ 
Perilipin-3 PLIN3 --- --- --- ↓ ↓ 
Plexin-B2 PLXNB2 --- --- --- ↑ ↓ 
Proteasome subunit alpha type-1 PSMA1 --- --- --- ↑ ↓ 
U4/U6.US tri-snRNP-associated protein 1 SART1 --- --- --- ↓ ↑ 
Triosephosphate isomerise TPI1 ↓ --- --- --- ↑ 
Regulator of nonsense transcripts UPF1 --- --- --- ↓ ↓ 
Zinc finger protein 469 ZNF469 --- --- --- ↑ ↓ 
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Table 25: DEPs highlighted in at least 2/3 cancer types. 
Following the combination of all DEPs identified from all proteomic platforms (antibody microarray, 2D MS and iTRAQ) and all 3 cancer 
types, a total of 45 DEPs were identified in ≥ 2 cancer types. Of this number 3 DEPS (shaded grey) were seen in all 3 cancer types. Those 
DEPs identified by antibody microarray (√), 2D MS (√) and iTRAQ (√) are labelled. RIDEPS identified by antibody microarray (section 
3.5.1) are labelled (
AM
) and RIDEPs identified by 2D MS (section 3.3.3) are labelled (
2D
).  
 
Protein Name Gene Name 
Breast Oral Rectal 
MCF-7 
RR 
MDARR T47DRR PJ41RR PJ49RR 
SW837 
RR 
HRA-19 
RR 
Chondroitin Sulfate 
AM
 ACAN       √ √ √ √ 
Actin, cytoplasmic 1 ACTB √           √ 
Neuroblast differentiation-associated protein AHNAK AHNAK   √   √       
Protein Kinase B alpha AKT1         √ √   
Bmf BMF     √     √   
CaM Kinase II alpha CAMK2A √         √   
Chk1 CHEK1   √       √ √ 
IKKa 
AM
 CHUK         √ √ √ 
Coilin COIL     √     √ √ 
Cathepsin D CTSD         √ √ √ 
cerbB3 ERBB3     √       √ 
Growth Factor Independence 1 GFI1 √ √       √ √ 
Histone Deacetylase 5  HDAC5 √       √     
Heterogeneous nuclear ribonucleoprotein A2/B1 isoform 
B1 
HNRNPA2B1 √         √ √ 
Heterogeneous nuclear ribonucleoproteins C1/C2 HNRNPC       √   √ √ 
hnRNP-U HNRNPU √         √ √ 
Heat shock 90-kDa protein 1 beta HSP90AB1     √   √     
Heat shock protein 90-kDa beta (Grp94), member 1 HSP90B1 √         √ √ 
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Heat shock 70-kDa protein 9 precursor HSPA9 √ √       √ √ 
Heat shock protein beta-1 
2D
 HSPB1         √ √ √ √ √ 
Importin alpha 1 KPNA2 √   √ √       
Keratin, type I cytoskeletal 19  KRT19 √     √   √   
Keratin, type II cytoskeletal 8  
2D
 KRT8 √     √ √ √   √ 
Leukotriene A-4 hydrolase LTA4H       √  √   √ 
p38 MAP Kinase  MAPK14   √       √ √ 
Proliferating Cell Protein Ki67 MKI67     √     √ √ 
MTBP MTBP     √   √     
MyD88 
AM
 MYD88 √   √     √   
Par4 Prostate Apoptosis Response 4 PAWR     √     √   
Protein disulfide-isomerase A3 PDIA3 √         √   
Serine/Threonine Protein Phosphatase 1 gamma 1 PPP1CC       √ √ √   
Protein Kinase C 
AM
 PRKCB √ √   √       
Proteasome activator complex subunit 1  PSME1 √     √       
Proteasome activator complex subunit 2 PSME2 √       √     
Phospho-FAK (pSer910) PTK2     √ √       
GTP-binding nuclear protein Ran RAN       √   √ √ 
Protein S100-A6  S100A6       √   √   
Siah2  
AM
 SIAH2   √ √ √   √ √ 
Smad4 
AM
 SMAD4 √ √       √ √ 
SUV39H1 Histone Methyltransferase SUV39H1 √   √     √ √ 
DR4 TNFRSF10A √   √     √ √ 
TRAIL TNFSF10       √     √ 
Triosephosphate isomerase 1 
2D
 TPI1 √ √ √      √ √     
14-3-3 protein gamma YWHAG       √   √   
Zyxin 
AM
 ZYX   √ √       √ 
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Table 22 - Table 25 provide an initial manual review of the DEPs identified from the 
breast, oral and rectal RR cancer cell lines prior to IPA analysis. It is through use of these 
tables that proteins identified more than once can be highlighted, as once the data is 
uploaded into IPA all duplicate protein entries are lost, along with the significance of that 
particular protein within the dataset. However, this manual review of the dataset provides 
no information regarding the functions and links between each of the protein targets, hence 
the need for subsequent IPA. 
8.3.2 IPA  – ‘Complementarity of the proteomic platforms’ 
DEPs identified from the 7 breast, oral and rectal RR cell lines (Table 21) were uploaded 
into IPA to initially assess the complementary nature of the 3 proteomic platforms (AbMA, 
2D MS, and iTRAQ). This investigation involved grouping together and subsequently 
uploading data from all 3 cancer types, but from the same proteomic platform as illustrated 
in Figure 49. Following individual analysis in this way, all data was combined and analysed 
as one dataset, in order to determine how DEPs generated from each method contributed to 
the outcome of the dataset overall.  
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Figure 49: Consort chart of the data analysed to assess the complementarity of the proteomic platforms. 
DEPs incorporated from all cancer types but identified by the same proteomic platform were first analysed. The 3 individual datasets were 
then combined and analysed again. Whilst the data is not presented from the 3 individual analyses, it was essential to carry out these initial 
intermediary steps in order to ensure that no potentially important pathways were lost when the data was combined. Table 21 gives the 
location of all listed DEPs within this thesis.  
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Following the combination of all data, a total of 373 DEPs were successfully mapped onto 
the Ingenuity Knowledge Base. This generated 339 significant canonical pathways. Due to 
the enormity of data output, 13 of the most relevant pathways were selected for further 
investigation, as listed in Table 26 (presented in more depth in section 8.3.3). The selected 
pathways chosen contained 9 or more mapped DEPs, in addition to being pathways that if 
malfunctioning, could potentially lead to the development of therapy resistance. The aim 
was to then assess the complementarity of the 3 proteomic platforms, based on the DEPs 
mapped onto these 13 pathways (Table 26), in order to answer the following questions: 
 
Q1: Did certain platforms identify proteins which dominated certain pathways? 
Q2: Were any proteins identified by more than one platform to create any significant   
overlap? 
 
At this point, it is important to note that DEPs generated from the antibody microarray 
platform were a result of the pre-selected antibodies spotted onto the AbMA slide. The 
selected 725 antibodies present on the Panorama Antibody Microarray XPRESS725 
profiler kit (#XP725, Sigma Aldrich) were based on proteins involved in canonical cell 
signalling pathways. Therefore it is to be expected that during any combined data analysis, 
some protein clustering towards certain pathways would be apparent, and hence cause a 
degree of bias towards particular pathways. 
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Table 26: The most relevant canonical pathways selected for further interpretation 
from the combined dataset of all 3 tumour types and all 3 proteomic platforms. 
From the 339 canonical pathways identified from the dataset, the 13 listed in this table are 
those considered to be of most relevance in relation to the number of DEPs mapped and 
potential radiotherapy resistance mechanisms. Pathways are listed according to the number 
of DEPs mapped and are colour coded by theme; cell cycle regulation and DDR (orange), 
apoptosis (purple), general cancer cell signalling (green), protein degradation (blue). The 
pathway ratio represents the significance of association between the dataset and the 
canonical pathway. 
 
Canonical pathway 
Number of DEPs 
mapped 
Pathway ratio 
Protein Ubiquitination Pathway (Figure 63) 24 9.13E-02 
PI3K/AKT Signalling (Figure 58) 21 1.64E-01 
p53 Signalling (Figure 55) 19 2.0E-01 
ERK/MAPK Signalling (Figure 59) 17 8.59E-02 
NF-κB Signalling (Figure 61) 17 1.0E-01 
VEGF Signalling (Figure 62) 15 1.65E-01 
Cyclins and Cell Cycle Regulation (Figure 53) 14 1.61E-01 
Apoptosis Signalling (Figure 57) 13 1.41E-01 
Death Receptor Signalling (Figure 56) 12 1.94E-01 
Cell Cycle: G1/S Checkpoint Regulation (Figure 51) 12 1.88E-01 
ATM Signalling (Figure 54) 11 1.86E-01 
Cell Cycle: G2/M DNA Damage Checkpoint 
Regulation (Figure 52) 
9 1.88E-01 
EGF Signalling (Figure 60) 9 1.88E-01 
 
 
After compiling all DEPs mapped onto the 13 most relevant pathways, a total of 101 
unique DEPs (duplicates removed) were identified. Table 27 lists, of this total the number 
of DEPs identified overall by AbMA, 2D MS and iTRAQ. 
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Table 27: The total number of unique DEPs identified overall from across the 13 most 
relevant canonical pathways. 
From a total of 101 unique DEPs identified overall, 70% were identified by the AbMA 
platform. 
 
 Proteomic platform 
 AbMA 2D MS iTRAQ 
Number of DEPs 
identified 
70 14 26 
Total as a 
percentage (%) 
70% 14% 25% 
 
 
For each of the 13 canonical pathways chosen, Table 28 displays for each pathway, the 
total number of DEPs identified by each proteomic method. 
 
Table 28: The total number of DEPs identified by each proteomic platform for each of 
the 13 most relevant canonical pathways. 
From the 13 pathways listed, all except 1 pathway labelled (*) were dominated by proteins 
identified by the AbMA platform. Pathways are colour coded by theme; cell cycle 
regulation and DDR (orange), apoptosis (purple), general cancer cell signalling (green), 
protein degradation (blue). 
 
Pathway 
Number of DEPs identified  
AbMA 2D MS iTRAQ 
Protein Ubiquitination Pathway * (Figure 63) 7 9 14 
PI3K/AKT Signalling (Figure 58) 17 2 5 
p53 Signalling (Figure 55) 17 1 1 
ERK/MAPK Signalling (Figure 59) 12 2 6 
NF-κB Signalling (Figure 61) 14 0 3 
VEGF Signalling (Figure 62) 12 2 2 
Cyclins and Cell Cycle Regulation (Figure 53) 13 0 1 
Apoptosis Signalling (Figure 57) 11 0 2 
Death Receptor Signalling (Figure 56) 12 1 1 
Cell Cycle: G1/S Checkpoint Regulation (Figure 51) 11 0 1 
ATM Signalling (Figure 54) 10 0 1 
Cell Cycle: G2/M DNA Damage Checkpoint 
Regulation (Figure 52) 
7 1 2 
EGF Signalling (Figure 60) 8 0 1 
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Based on the gene identifiers mapped onto each of the 13 most relevant pathways, Table 29 
lists those which were identified by 2 or more proteomic platforms. 
 
Table 29: DEPs mapped onto the 13 most relevant canonical pathways that were 
identified by 2 or more proteomic platforms. 
A total of 101 unique DEPs were identified from the 13 most relevant pathways identified 
by IPA. Of this number, only 8 DEPs were identified by 2 or more proteomic platforms. 
One DEP, was identified by all 3 proteomic platforms as labelled (*). 
 
Gene identifier 
Proteomic platform 
AbMA 2D MS iTRAQ 
ACTB --- √ √ 
HSP90AB1 --- √ √ 
HSP90B1 √ --- √ 
HSPA9 √ --- √ 
HSPB1* √ √ √ 
PPP1CB √ √ --- 
PSME1 --- √ √ 
YWHAG --- √ √ 
 
8.3.3 IPA – ‘Analysis of cancer type’ 
Following analysis of the 3 proteomic platforms, each cancer type, namely breast, oral and 
rectal was then analysed (Figure 50). Based on the 13 most relevant pathways selected 
previously (Table 26) it was possible to highlight which proteins, from which cancer types 
were involved in each of the 13 pathways, and from which proteomic platform they were 
identified. It was also possible to identify which DEPs if any, were common to more than 1 
cancer type, or if there was any DEP that appeared across all 3 cancer types, and may 
therefore have the potential to serve as a general biomarker of radioresistance, based on the 
13 pathways investigated. It was also apparent at this stage that some pathways were ‘semi 
duplicates’ of one another, with certain proteins appearing in several different pathways.  
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Figure 50: Consort chart of the data analysed to assess each cancer type. 
DEPs identified by each method for each cancer type were analysed individually, before being combined to represent all DEPs identified 
from each cancer type. All data from the 3 cancer types was then combined in one analysis (i.e. the same overall combination as shown in 
Figure 49, which was used to identify the 13 most relevant pathways). Whilst data from each intermediary step leading up to the overall 
combination analysis has not been presented, it is essential to carry out these initial analyses in order to ensure that no potentially important 
pathways were lost when the data was combined. Table 21 lists the location of all DEPs within this thesis.  
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8.3.3.1 Pathways associated with cell cycle regulation and DDR  
Defects within the cell cycle/cell cycle checkpoints, in addition to a disordered DDR, 
permits the continued survival and proliferation of damaged cells, and hence could 
potentially contribute to the development of therapy resistance. Figure 51 - Figure 55 
illustrate from the 13 selected, 5 canonical pathways associated with cell cycle regulation 
and DDR, identified by IPA analysis. For each figure, all gene names from the uploaded 
dataset that were mapped onto the pathway are listed. Additional colour charts are given for 
each pathway, with each coloured spot representing the total number of times that protein 
was identified (either from a different cell line or from the same cell line but from a 
different proteomic method). A key for all IPA pathways is given in Appendix Q. 
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Figure 51: Cell Cycle: G1/S Checkpoint Regulation 
A total of 12 DEPs were mapped onto the Cell Cycle: G1/S Checkpoint Regulation 
pathway as indicated above. Of these 12, 3 proteins were identified more than once. (Cell 
lines: Breast - MCF-7RR, MDARR, T47DRR; Oral - PJ41RR, PJ49RR; Rectal - 
SW837RR, HRA-19RR). Table 21 lists the location of all DEPs within this thesis. 
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Figure 52: Cell Cycle: G2/M DNA Damage Checkpoint Regulation 
A total of 9 DEPs were mapped onto the Cell Cycle: G2/M DNA damage Checkpoint 
Regulation pathway as indicated above. Of these 9, 4 proteins were identified more than 
once (Cell lines: Breast - MCF-7RR, MDARR, T47DRR; Oral - PJ41RR, PJ49RR; Rectal - 
SW837RR, HRA-19RR). Table 21 lists the location of all DEPs within this thesis. 
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Figure 53: Cyclins and Cell Cycle Regulation 
A total of 14 DEPs were mapped onto the Cyclins and Cell Cycle Regulation pathway as 
indicated above. Of these 14, 3 proteins were identified more than once (Cell lines: Breast - 
MCF-7RR, MDARR, T47DRR; Oral - PJ41RR, PJ49RR; Rectal - SW837RR, HRA-
19RR). Table 21 lists the location of all DEPs within this thesis. 
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Figure 54: ATM Signalling 
A total of 11 DEPs were mapped onto the ATM Signalling pathway as indicated above. Of 
these 11, 4 proteins were identified more than once (Cell lines: Breast - MCF-7RR, 
MDARR, T47DRR; Oral - PJ41RR, PJ49RR; Rectal - SW837RR, HRA-19RR). Table 21 
lists the location of all DEPs within this thesis. 
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Figure 55: p53 Signalling 
A total of 19 DEPs were mapped onto the p53 Signalling pathway as indicated above. Of 
these 19, 9 proteins were identified more than once (Cell lines: Breast - MCF-7RR, 
MDARR, T47DRR; Oral - PJ41RR, PJ49RR; Rectal - SW837RR, HRA-19RR). Table 21 
lists the location of all DEPs within this thesis. 
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8.3.3.2 Apoptosis related pathways 
Activation of the apoptotic pathway is the major mechanism by which treatment with 
ionising radiation leads to target cell death. There are 2 main pathways involved in the 
initiation of apoptosis, namely the intrinsic (or mitochondrial) pathway and the extrinsic 
pathway. It could be hypothesised that absent, or abnormal expression of proteins involved 
within these pathways may contribute to the development of radiotherapy resistance due to 
a lack of programmed cell death of damaged cell populations. Figure 56 and Figure 57 
illustrate 2 canonical pathways associated with apoptosis signalling, which were identified 
from IPA analysis. What was unexpected however, was the identification of the Death 
Receptor Signalling pathway (Figure 56), as this pathway, also known as the extrinsic 
apoptotic pathway is not typically activated by damage caused by radiotherapy.  
For each figure, all gene identifiers mapped onto each pathway from the uploaded 
dataset have been listed. Additional colour charts are given for each pathway, with each 
coloured spot representing the total number of times that protein was identified (either from 
a different cell line or from the same cell line but from a different proteomic method). A 
key for all IPA pathways is given in Appendix Q. 
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Figure 56: Death Receptor Signalling 
A total of 12 DEPs were mapped onto the Death Receptor Signalling pathway, as indicated 
above. Of these 12, 9 proteins were identified more than once (Cell lines: Breast - MCF-
7RR, MDARR, T47DRR; Oral - PJ41RR, PJ49RR; Rectal - SW837RR, HRA-19RR). 
Table 21 lists the location of all DEPs within this thesis. 
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 Figure 57: Apoptosis Signalling 
A total of 13 DEPs were mapped onto the Apoptosis Signalling pathway, as indicated 
above. Of these 13, 8 proteins were identified more than once (Cell lines: Breast - MCF-
7RR, MDARR, T47DRR; Oral - PJ41RR, PJ49RR; Rectal - SW837RR, HRA-19RR). 
Table 21 lists the location of all DEPs within this thesis. 
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8.3.3.3 General cancer cell signalling pathways 
Whilst the exact mechanism of radiotherapy resistance is not yet fully elucidated it is a well 
accepted fact that the development of this phenotype is most probably a result of multiple 
alterations which span across various cancer cell signalling pathways. Whilst there are 
several cancer cell signalling pathways that exist, this section illustrates the most relevant  
canonical pathways, identified from the IPA analysis of the uploaded dataset, which if 
functioning abnormally, could conceivably play a role in the development of 
radioresistance. Whilst the pathways presented in this section are not directly involved, they 
have association with the cell cycle, cell growth and proliferation and apoptosis pathways, 
in addition to having direct involvement with proteins discussed in Chapter 2, such as 
VEGF (section 2.2.3.1) and EGFR (section 2.2.3.3) which have already been extensively 
studied for their association with radiotherapy resistance. Figure 58 - Figure 62 illustrate 
the general cancer cell signalling pathways identified by IPA analysis, along with the gene 
identifiers and a colour chart with each coloured spot representing the total number of times 
that protein was identified (either from a different cell line or from the same cell line but 
from a different proteomic method). A key for all IPA pathways is given in Appendix Q. 
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 Figure 58: PI3K/AKT Signalling 
A total of 21 DEPs were mapped onto the PI3K/AKT Signalling pathway, as indicated 
above. Of these 21, 11 proteins were identified more than once (Cell lines: Breast - MCF-
7RR, MDARR, T47DRR; Oral - PJ41RR, PJ49RR; Rectal - SW837RR, HRA-19RR). 
Table 21 lists the location of all DEPs within this thesis. 
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Figure 59: ERK/MAPK Signalling 
A total of 17 DEPs were mapped onto the ERK/MAPK Signalling pathway, as indicated 
above. Of these 17, 8 proteins were identified more than once (Cell lines: Breast - MCF-
7RR, MDARR, T47DRR; Oral - PJ41RR, PJ49RR; Rectal - SW837RR, HRA-19RR). 
Table 21 lists the location of all DEPs within this thesis. 
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Figure 60: EGF Signalling 
A total of 9 DEPs were mapped onto the EGF Signalling pathway, as indicated above. Of 
this 9, 2 proteins were identified more than once (Cell lines: Breast - MCF-7RR, MDARR, 
T47DRR; Oral - PJ41RR, PJ49RR; Rectal - SW837RR, HRA-19RR). Table 21 lists the 
location of all DEPs within this thesis. 
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Figure 61: NFκB Signalling 
A total of 17 DEPs were mapped onto the NFκB Signalling pathway, as indicated above. Of these 
17, 7 proteins were identified more than once (Cell lines: Breast - MCF-7RR, MDARR, T47DRR; 
Oral - PJ41RR, PJ49RR; Rectal - SW837RR, HRA-19RR). Table 21 lists the location of all 
DEPs within this thesis. 
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Figure 62: VEGF Signalling 
A total of 15 DEPs were mapped onto the VEGF Signalling pathway. Of these 15, 5 
proteins were identified more than once (Cell lines: Breast - MCF-7RR, MDARR, 
T47DRR; Oral - PJ41RR, PJ49RR; Rectal - SW837RR, HRA-19RR). Table 21 lists the 
location of all DEPs within this thesis. 
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8.3.3.4 The Protein Ubiquitination pathway 
The protein ubiquitination pathway is the major pathway responsible for the degradation of 
not only redundant or damaged proteins, but also of many important regulatory proteins 
involved in processes such as cell cycle regulation, DNA damage repair and apoptosis. In 
order for proteins to be recognised and subsequently degraded in this pathway, they are 
normally first tagged by a polyubiquitin chain. It is this chain, made up of at least 4 
ubiquitin monomers, that allows for protein recognition by the 26S proteasome and hence 
subsequent degradation. Many studies have linked this pathway with the development of a 
cancerous phenotype due to the destruction of proteins such as p53, MDM2, p21
WAF1
, p27, 
DNA-PKc, BCL2 and BAX, however a small number of studies have also linked this 
pathway with the development of a RR phenotype (Smith et al., 2009, Elfadl et al., 2011) 
The protein ubiquitin pathway was identified as one of the top canonical pathways from the 
uploaded dataset in IPA analysis. Figure 63 illustrates this pathway, in addition to listing 
the gene identifiers mapped onto the pathway. As before, a colour chart has been given, 
with each coloured spot representing the total number of times that protein was identified 
(either from a different cell line or from the same cell line but from a different proteomic 
method). A key for the IPA pathway is given in Appendix Q. 
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Figure 63: Protein Ubiquitination Pathway 
A total of 24 DEPs were mapped onto the protein ubiquitin pathway. See Figure 64 for 
protein colour chart.  
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Figure 64: Protein Ubiquitination Pathway – protein colour chart 
Of the 24 proteins mapped onto the pathway (see Figure 63), 7 were identified in more than 
one cell line (Cell lines: Breast – MCF7-RR, MDARR, T47DRR; Oral – PJ41RR, PJ49RR; 
Rectal – SW837RR, HRA-19RR). Table 21 lists the location of the DEPs within this thesis. 
 
The colour coded charts for each of the 13 most relevant pathways (Figure 51 - Figure 64) 
revealed there to be no individual DEPs common to all tumour types (KRT8, KRT19 and 
SIAH2 (Table 25) were not mapped onto any of the 13 pathways), however, 21 individual 
DEPs, from those listed in Table 25 as being identified in at least 2/3 cancer types, were 
identified in the 13 pathways. These 21 proteins are listed in Table 30, a simplified version 
of Table 25, showing only the clear overlap between cancer type. The individual RR cell 
lines in which the protein was identified, along with the proteomic platform used can be 
found in Table 25. 
 An overall comparison of the 13 pathways highlighted several DEPs that were 
present in more than 1 pathway. The top 3 DEPs were ATM, present in 9/13 (69%) 
pathways, MAPK8, present in 6/13 (46%) pathways and RAF1, present in 6/13 (46%) 
pathways. 
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Table 30: DEPs identified in 2/3 tumour types from the 13 most relevant canonical 
pathways. 
Following the combination of all DEPs mapped onto the 13 pathways, 21 DEPs were 
identified in 2/3 cancer types. The exact cell line information and the platform used to 
identify each DEP can be found in Table 25. It can be observed from this table that there 
are 9 proteins common to breast and rectal, 6 proteins common to breast and oral, and 6 
proteins common to oral and rectal cancers. 
 
Protein Name Gene Name 
RR cancer type 
Breast Oral Rectal 
Actin, cytoplasmic 1 ACTB √  √ 
Protein Kinase B alpha AKT1  √ √ 
Chk1 CHEK1 √  √ 
IKKa CHUK  √ √ 
Histone Deacetylase 5  HDAC5 √ √  
Heat shock 90-kDa protein 1 beta HSP90AB1 √ √  
Heat shock protein 90-kDa beta (Grp94), 
member 1 
HSP90B1 √  √ 
Heat shock 70-kDa protein 9 precursor HSPA9 √  √ 
Heat shock protein beta-1  HSPB1  √ √ 
p38 MAP Kinase  MAPK14 √  √ 
MyD88 MYD88 √  √ 
Serine/Threonine Protein Phosphatase 1 
gamma 1 
PPP1CC  √ √ 
Protein Kinase C  PRKCB √ √  
Proteasome activator complex subunit 1  PSME1 √ √  
Proteasome activator complex subunit 2 PSME2 √ √  
Phospho-FAK (pSer910) PTK2 √ √  
Smad4 SMAD4 √  √ 
SUV39H1 Histone Methyltransferase SUV39H1 √  √ 
DR4 TNFRSF10A √  √ 
TRAIL TNFSF10  √ √ 
14-3-3 protein gamma YWHAG  √ √ 
Total number of DEPs 15 12 15 
Total as a percentage (%) 71% 57% 71% 
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8.3.4 IPA – ‘Supporting data from the literature’ 
DEPs identified from proteomic studies from within the literature (Table 21) were analysed 
by IPA. The aim of this was to measure whether or not data generated by other groups, 
either supported, or added anything new to the 13 most relevant pathways (Table 26) 
selected out in section 8.3.2. As mentioned in section 8.2.2.1, the term ‘literature’ used 
within this chapter refers only to data obtained externally to this group. DEPs from the 
literature were first analysed alone, then combined with the data presented within this thesis 
(Figure 65).  
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Figure 65: Consort chart of the data analysed to assess the support of the literature. 
Following the analysis of all data presented within this thesis, DEPs generated from proteomic studies from within the literature were 
introduced. The aim of this was to determine if the literature supported or added anything new to the 13 pathways selected in section 8.3.2. It 
must be noted that the term ‘literature’ refers only to data obtained externally to this group. The literature data was first analysed individually 
and then combined with the data from this thesis. Table 21 lists the location of all DEPs within this thesis. 
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Initial analysis of only the literature data identified 8/13 of the most relevant pathways 
discussed previously however, the number of DEPs mapped was significantly less (Table 
31). 
 
Table 31: Initial analysis of DEPs identified only from the literature compared with 
those identified from the 13 most relevant canonical pathways presented within this 
thesis. 
The total number of DEPs mapped onto the 8 relevant pathways is represented in black 
under the ‘literature’ column. Of this total, numbers labelled (n) represent the DEPs unique 
to the literature database, whilst numbers in (n) represent those DEPs which have 
overlapped with those presented within this thesis, but have also been independently 
identified from the literature. Pathways not identified following IPA of the literature 
database only are labelled (---). Appendix A gives details of the cancer types and proteomic 
methods used from the literature based studies. Pathways are colour coded by theme; cell 
cycle regulation and DDR (orange), apoptosis (purple), general cancer cell signalling 
(green), protein degradation (blue). 
 
Pathway 
Number of DEPs mapped 
Thesis Literature 
Protein Ubiquitination Pathway 24 14 (6) (8) 
PI3K/AKT Signalling 21 4   (3) (1) 
p53 Signalling 19 3   (2) (1) 
ERK/MAPK Signalling 17 --- 
NF-κB Signalling 17 --- 
VEGF Signalling 15 3   (1) (2) 
Cyclins and Cell Cycle Regulation 14 --- 
Apoptosis Signalling 13 --- 
Death Receptor Signalling 12 1   (0) (1) 
Cell Cycle: G1/S Checkpoint Regulation 12 1   (1) (0) 
ATM Signalling 11 1   (1) (0) 
Cell Cycle: G2/M DNA Damage Checkpoint Regulation 9 2   (2) (0) 
EGF Signalling 9 --- 
 
Data from the literature database was then combined with the data presented within this 
thesis and uploaded for further IPA (Figure 65). Appendix R illustrates the support that the 
literature database has given the 8/13 previously selected pathways.  
 Of particular note was the protein ubiquitination pathway. Combining data from this 
thesis, with that from the literature, added a total of 6 new DEPs (Table 31  and Figure 67) 
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to the pathway bringing the number of DEPs mapped to a total of 30. In addition, 8 DEPs 
(Table 31 and Figure 67) were identified that overlapped with those already presented from 
this thesis. This pathway has therefore been both developed and supported by information 
obtained from the literature. Figure 66 presents the updated protein ubiquitination pathway 
whilst Figure 67 displays the corresponding colour chart. On this chart all gene identifiers 
are listed as in Figure 63 but with the additional literature data presented. 
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Figure 66: The protein ubiquitination pathway – addition of literature. 
This pathway was both supported and developed by the literature, adding a total of 6 new 
DEPs unique to the literature database. 
 
 
 
 215 
 
 
Figure 67: Colour chart for the protein ubiquitination pathway – addition of literature 
Following the addition of the literature (Appendix A) to the IPA analysis, 30 DEPs were mapped onto the protein ubiquitination pathway. Of 
this 30, 6 DEPs were unique to the literature, whilst 8 DEPs (27%) overlapped with those previously presented within this thesis. Table 21 
lists the location of all DEPs within this thesis. 
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8.4 Discussion 
8.4.1 Biomarker discovery data 
Comparative proteomics was used to generate DEPs from 7 RR cancer cell lines originating 
from breast (3 RR cell lines), oral (2 RR cell lines) and rectal (2 RR cell lines) cancer types. 
Several of these DEPs were identified in > 1 cell line using the same proteomic platform 
(as shown in Table 22 -Table 24) however, 45 DEPs (listed in Table 25) were commonly 
identified in ≥ 2 different tumour types. Of this number, 3 DEPs, namely KRT8, KRT 19 
and SIAH2, were identified across all 3 tumour types. However, it must be noted that 
SIAH2 and KRT8, have been listed as a potential RIDEPs associated with antibody 
microarray (section 3.5.1) and 2D MS (section 3.3.3) based experiments, respectively. 
8.4.2 IPA – ‘Complementarity of the proteomic platforms’ 
In order to assess the complementary nature of the 3 proteomic platforms, data from all 3 
cancer types derived by the same method (either AbMA, 2D MS or iTRAQ) were uploaded 
into IPA. From this, 13 of the most relevant pathways (selected according to the number of 
DEPs mapped and also their potential contribution to therapy resistance if functioning 
abnormally) were selected for further interpretation. Based on the 101 unique DEPs 
mapped onto the 13 most relevant canonical pathways the answers to the following 
questions could be answered: 
 
Did certain platforms identify proteins which dominated certain pathways? 
From the most relevant 13 pathways, 12 were dominated by the 70% of DEPs that were 
identified by the AbMA platform (Table 28). This result was not unexpected however, due 
to the reasons discussed in 8.3.2. Based on the nature of the work in this thesis, canonical 
pathways relating to cell cycle regulation, DDR, apoptosis and cancer cell signalling 
networks would most likely be prioritised when selecting which proteins to validate further, 
due to the hypotheses that abnormalities of proteins within these pathways are potentially 
significant contributors of radiotherapy resistance. Therefore, whilst overall more DEPs 
were identified by the iTRAQ platform (176 DEPs), DEPs involved in the 13 most relevant 
pathways were dominated by those DEPs identified by AbMA analysis. 
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Were any proteins identified by more than one platform to create any significant overlap?  
Of the 101 unique proteins identified from the 13 pathways combined, only 8 DEPs were 
identified by more than one proteomic platform (Table 29) hence highlighting the need for 
all 3 complementary methods in order to maximise protein discovery. Traditionally, 2D-
PAGE has been the gold standard method used for the analysis of protein expression, the 
great advantage being its ability to provide a ‘snapshot’ of complex proteomes, in addition 
to requiring no prior knowledge for protein discovery. However, issues relating to lack of 
reproducibility, masking of lower abundant proteins, the unsuitable representation of highly 
acidic/basic and hydrophobic proteins as well as the time and labour required in order to 
carry out one experiment lead to the employment of the antibody microarray as an 
alternative, complementary method. The antibody microarray offers the ability to analyse 
the differential expression of hundreds of proteins simultaneously over a comparatively 
short time period, and unlike 2D-PAGE, provides a high-throughput approach without the 
need for a public database to identify a particular protein of interest, hence eliminating the 
chances of false protein discovery.  However, the wider application of this method is 
restricted in that only those proteins whose corresponding antibodies have been pre-
selected for printing onto the slide can be identified. With the above problems in mind, 
iTRAQ, a relatively new method was also employed to try to ‘capture’ those proteins which 
may not be identified from 2D-PAGE or antibody microarray, and in doing so complement 
the data allowing for the analysis of complex protein mixtures to be maximised. One of the 
main advantages of iTRAQ comes from its ability to multiplex up to eight different 
samples in parallel, enabling the identification and subsequent quantification of thousands 
of protein peptides in one experiment. Its large dynamic range allows for the identification 
of high and low abundant proteins, an issue that is often encountered during gel-based 
methods. However, drawbacks of this shotgun approach include the high cost implication, a 
factor also common to the antibody microarray, in addition to the lengthy sample 
processing, which like 2D-PAGE could potentially lead to increased experimental 
variation. However, despite the various pros and cons associated with each technique 
(highlighted in Table 32) it has been proven during this thesis, that a combination of all 3 
platforms has maximised biomarker discovery, proving that certain proteins, for example 
many of the proteins mapped onto the protein ubiquitination pathway, could not have been 
identified by using only 1 or 2 platforms alone.  
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Table 32: Advantages and disadvantages associated with AbMA, 2D MS and iTRAQ. 
This table provides a summary of the pros and cons of each of the three proteomic 
platforms. AbMA is labelled (√), 2D MS is labelled (√) and iTRAQ is labelled (√). 
 
Proteomic methods (AbMA, 2D MS, iTRAQ) 
Advantage Method Disadvantage Method 
Visual representation of the 
proteome 
√ Time consuming/labour intensive √√ 
High-throughput √√ Expensive √√ 
Analysis of different samples in 
parallel 
√ Limited identification of certain 
proteins 
√√√ 
Large dynamic range √ Need for a public database √√ 
8.4.3 IPA – ‘Analysis of cancer type’ 
Following analysis of the 3 proteomic platforms, each of the 3 cancer types (breast, oral, 
rectal) were then analysed. From the 13 most relevant pathways selected for further 
interpretation, the protein ubiquitination pathway had the largest number of DEPs mapped 
(24) whilst the Cell Cycle: G2/M DNA damage checkpoint regulation and the EGF 
signalling pathways had the least number of DEPs mapped (9 each) (Table 26). The colour 
coded charts (Figure 51 - Figure 63) for each of the 13 pathways revealed there to be no 
individual DEP common to all tumour types (KRT8, KRT19 and SIAH2 were not mapped 
onto any of the 13 pathways), however, 21 individual DEPs were identified in 2/3 cancer 
types as listed in Table 30. Looking at the pathways overall, all 13 contained DEPs 
originating from all cancer types (Figure 51 - Figure 63). Whilst the 13 pathways selected 
during this chapter were considered to be the most relevant in relation to the potential 
development of a radioresistant phenotype, a further 2 general cell signalling pathway 
possibilities may also require consideration in future work (Table 33). 
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Table 33: Additional IPA pathways which may also potentially contribute to 
radiotherapy resistance mechanisms. 
In addition to the 13 pathways selected during this chapter, the following 2 pathways may 
also require future investigation due to their roles in cancer cell signalling pathways. 
 
Canonical Pathway Total number of 
mapped DEPs 
Mapped DEPs Pathway ratio 
PTEN Signalling 15 AKT1, BCL-2, 
BCL2L11, CCND1, 
CHUK,CSNK2B, EGFR, 
ILK, MAGI3, MAPK1, 
PTEN, PTK2, RAF1, 
RPS6KB1, YWHAH 
1.21E-01 
mTOR Signalling 14 AKT1, ATM, EIF4A1, 
MAPK1, MTOR, 
PPP2R2C, PRKCB, 
PRKCH, RHOA, RPS21, 
RPSA3, RPS6KB1, 
RPS8 
7.41E-02 
 
8.4.4 IPA -  ‘Supporting data from the literature’ 
Following data analysis of all biomarker discovery data presented within this thesis, data 
obtained from the literature was introduced to see if, or how, it supported the 13 most 
relevant canonical pathways. Results from IPA revealed that the literature-based dataset 
strengthened 8/13 pathways, with highly noticeable impact on the Protein Ubiquitination 
Pathway (Figure 67). To this pathway, 6 DEPs unique to the literature were added, in 
addition to a further 8 DEPs which were both identified by the data presented within this 
thesis, as well as being independently identified by the literature. 
8.5 Conclusion 
Following complete IPA analysis of all DEPs associated with the RR phenotype, identified 
by proteomic methods, a selection of proteins identified in certain pathways will now be 
taken forward to the confirmation and clinical validation phase of the biomarker discovery 
pipeline (Chapter 9). 
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Chapter 9: 
Confirmation and clinical validation 
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Chapter 9.  Confirmation and clinical validation 
9.1 Confirmation of DEPs 
Once data mining of all protein targets discovered during the biomarker discovery phase 
has taken place, the prioritised proteins, selected for further investigation are carried 
forward to the confirmation phase. It is at this stage of the biomarker discovery pipeline 
that the differential expression of a specific protein, between radiosensitive and 
radioresistant cell lines, or clinical samples can be confirmed. One example of a technique 
commonly used during this phase of the biomarker discovery pipeline is western blotting, 
as described in section 3.6.2. 
9.2 Clinical validation of DEPs 
Those proteins which successfully pass through the confirmation stage of the biomarker 
discovery pipeline are then taken forward to clinical validation. It is at this phase that the 
true clinical relevance and predictive value of the selected protein targets can be determined 
through use of archival tumour tissue samples and detailed clinical information. 
Immunohistochemistry is a method well suited to the utilisation of archival tissue (section 
3.6.3) however, in order to determine the true value and reinforce the strength of each 
protein target as a potential putative biomarker of radiotherapy resistance, large sample 
cohorts are required. 
9.3 DEPs prioritised from IPA  
Of the 13 most relevant canonical pathways identified by IPA (Chapter 8), selected proteins 
identified in 2 pathways namely, the Protein Ubiquitination Pathway (Figure 63) and the 
Death Receptor Signalling pathway (Figure 56) were taken forward to the confirmation 
stage of the biomarker discovery pipeline. The Protein Ubiquitination Pathway was chosen 
due to being the most predominant of the 13 most relevant pathways, containing the largest 
number of mapped proteins, with 5 of these (PSMA1, PSMA2, PSMA7, PSMD11 and 
PSMD13) forming part of the 26S Proteasome complex. The introduction of data from the 
literature further supported this pathway by adding a further 4 unique proteasomal subunits 
(PSMB1, PSMC2, PSMC3 and PSMD14), whilst independently identifying 1 proteasomal 
subunit (PSMA1) which had already been discovered. It must be noted that due to discovery 
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of proteasomal subunits from the breast cancer RR cell lines by 2D MS, some preliminary 
confirmation had previously taken place (Smith et al., 2009) (see section 9.4). 
 A second pathway, the Death Receptor Signalling pathway was also of particular 
interest. This pathway also known as the extrinsic apoptotic pathway, induces apoptosis via 
binding of extracellular death receptors to their corresponding ligands. One DEP in 
particular which was identified within in this pathway, namely, TNFRSF10A (DR4), was 
identified in 4/7 RR cell lines during the biomarker discovery phase however, the 
identification of this protein was unexpected due to the concept that radiotherapy is 
typically thought to induce apoptosis via the intrinsic apoptotic pathway. Therefore, the 
identification of this protein in RR cell lines may possibly suggest a novel link between 
radiotherapy and the extrinsic Death Receptor Signalling pathway. 
The aim of this chapter therefore, was to carry forward the 26S Proteasome complex, 
and TNFRSF10A (DR4) for confirmation. DEPs that passed through the confirmation stage 
were then taken forward to validation in order to assess their differential expression in a 
clinical context. 
9.4 Previous confirmation and clinical validation 
Prior to the beginning of this project, some preliminary investigation of the 26S Proteasome 
had previously taken place. This included: 
 Confirmed down-regulation of the 26S Proteasome in the 3 RR breast cancer cell 
lines by western blotting (Smith et al., 2009). 
 Confirmed down-regulation of the 26S Proteasome by immunohistochemistry using 
a small immunohistochemical subset of archival laryngeal cancer samples (section 
4.10.2). Down-regulation of the 26S Proteasome was significantly associated with 
the radioresistant phenotype (p=0.05). 
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9.5 Materials and Methods 
9.5.1 The biomarker discovery pipeline 
Work to be presented within this chapter includes continued assessment of the 26S 
Proteasome and DR4 across the 3 cancer types, in order to evaluate their potential roles as 
biomarkers of radioresistance (Figure 68). 
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Figure 68: Progression through the biomarker discovery pipeline of the breast, oral and rectal cancer cell lines – confirmation and 
clinical validation. 
Work highlighted by the dashed box will be discussed during this chapter. No clinical validation took place for the rectal cancer RR cell 
lines during this thesis due to the unavailability of a suitable archival series. 
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9.5.2 Confirmation of DEPs by western blotting 
Western blotting was performed as described in section 4.9. Details of the primary 
antibodies used are listed in Table 34. 
 
Table 34: Details of the primary antibodies used for western blotting. 
The table lists those antibodies used to assess differential protein expression. For the 26S 
proteasome, a goat anti-mouse secondary antibody (#SC-2031 Santa-Cruz) was used and 
for PSMD11, PSMD13 and DR4, a goat anti-rabbit secondary antibody (#SC-2030, Santa-
Cruz) was used. Both secondary antibodies were used at a dilution of 1:1000 in 5% milk for 
1 hour at room temperature. To date, the proteasomal subunit antibodies PSMD11 and 
PSMD13 have not been fully optimised for western blotting. 
 
Antibody Concentration and 
blocking solution 
Incubation period Antibody details 
26S Proteasome 1:23 2 hours 
Mouse Monoclonal 
(#ab21165, Abcam) 
PSMD11 Not fully optimised 
Rabbit Polyclonal 
(#ab66346, Abcam) 
PSMD13 Not fully optimised 
Rabbit Polyclonal 
(#ab91429, Abcam) 
DR4 1:333 16 hours 
Rabbit Polyclonal 
(#ab8415, Abcam) 
 
9.5.3 Clinical validation of DEPs by immunohistochemistry 
9.5.3.1 Archival Samples 
Archival breast cancer tissue sections were used as previously described in section 4.10.1. 
In order to clinically validate proteins associated with radioresistant head and neck cancer 
cell lines, an archival series of laryngeal cancers, where radiotherapy was used with 
curative intent was available for study (Nix et al., 2005) as described in section 4.10.2. 
9.5.3.2 Immunohistochemistry 
Immunohistochemistry was performed as per section 4.10.3. Details of primary antibodies 
and the detection methods used for each antibody are given in Table 35. 
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Table 35: Primary antibodies used for immunohistochemical staining 
 
Antibody Dilution Antibody Details Detection Method 
26S Proteasome 1:50 
Mouse Monoclonal 
(#ab21165, Abcam) 
Dakocytomation 
DR4 1:50 
Mouse Monoclonal 
(#ab13890, Abcam) 
Vector Laboratories 
 
9.6 Results 
9.6.1 Confirmation of DEPs by western blotting 
9.6.1.1 The 26S Proteasome 
The first protein candidate selected for confirmation based on the pathways identified by 
IPA (Chapter 8) included the 26S Proteasome. Due to the number of different 26S 
proteasomal subunits identified from the dataset and subsequently mapped onto the Protein 
Ubiquitination Pathway during IPA, an antibody which recognised the 20S sub-complex 
within the 26S hetero-oligomeric protein complex, and the free cytosolic form of the 20S 
complex, was selected for use. This antibody therefore recognises PSMA and PSMB 
subunits due to their location within the 20S core. Whilst biomarker discovery experiments 
only identified proteasomal subunits in the breast (Smith et al., 2009) and oral RR cell 
lines, for the purpose of interest, this antibody was also applied to the rectal cancer RR cell 
lines. 
 Previously, western blotting demonstrated significant (≥ 2-fold) down-regulation of 
the 26S Proteasome in 3/3 breast RR cell sublines (Smith et al., 2009). This down-
regulation was also observed in 2/2 oral RR sub-lines (PJ41 and PJ49) (Figure 69). 
However, significant up-regulation of the 26S Proteasome in 1/2 of the rectal RR sub-lines 
(SW837) was observed (Figure 69). This trend was also observed in the second rectal RR 
sub-line however did not meet significance. The additional proteasomal subunits PSMD11 
and PSMD13 have not yet been fully optimised using western blotting. 
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Figure 69: Confirmation of the 26S Proteasome in the oral and rectal RR cancer cell 
lines using western blotting. 
The down-regulation of the 26S Proteasome was significantly (≥ 2 fold) associated with 
radioresistance in 2/2 of the oral RR cell lines (A). However, the up-regulation of the 26S 
Proteasome was significantly associated with radioresistance in 1/2 of the rectal RR cell 
lines (B). Alpha-tubulin and Beta-actin were used as loading controls. The 26S Proteasome 
antibody was used at an optimised concentration as shown in Table 34. PN – parental cell 
line; RR – radioresistant cell line. 
 
9.6.1.2 Death Receptor 4 (DR4) 
The second protein candidate selected for confirmation based on the pathways identified by 
IPA (Chapter 8) included DR4 (TNFRSF10A). Whilst biomarker discovery experiments 
only identified DR4 in the breast and rectal RR cell lines, for the purpose of interest, this 
antibody was also applied to the oral RR cell lines. 
 Western blotting demonstrated significant (≥ 2-fold) down-regulation of DR4 in 1/3 
breast RR sub-lines and 1/2 oral RR sub-lines. However, significant up-regulation of DR4 
in the SW837 rectal RR sub-line was observed. 
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Figure 70: Confirmation of DR4 in the breast, oral and rectal RR cell lines using 
western blotting. 
The down-regulation of DR4 was significantly ( ≥ 2-fold) associated with radioresistance in 
1/3 breast RR cell lines (A) and 1/2 oral RR cell lines (B). However, the up-regulation of 
DR4 was significantly associated with radioresistance in 1/2 rectal RR cell lines (C). The 
use of this antibody was unsuccessful on the HRA-19 rectal RR cell line. Alpha-tubulin, 
Beta-actin and GAPDH were used as loading controls. The DR4 antibody was used at an 
optimised concentration as shown in Table 34. PN – parental cell line; RR – radioresistant 
cell line. 
 
9.6.2 Clinical validation of DEPs by immunohistochemistry  
9.6.2.1 Clinical validation of DEPs in breast cancer 
The 26S Proteasome 
Following on from the previously published work which confirmed the significant down-
regulation of the 26S Proteasome to be associated with the RR phenotype in all 3 breast 
cancer cell lines (Smith et al., 2009) using western blotting, a small immunohistochemical 
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pilot study consisting of 14 test-samples (radioresistant group) and 14 control samples 
(radiosensitive group) was carried out (in collaboration with Miss Dalia ELFadl and Dr. 
Victoria Hodgkinson) in order to assess the differential expression of the 26S Proteasome 
in a clinical context (Elfadl et al., 2011). Assessment of slides took place by 3 independent 
scorers, with any discrepancies adjudicated by a consultant in breast pathology (Dr. Ervine 
Long). Following the assessment of slides, it was observed that when present, strong 
positive staining was localised predominantly to the cytoplasm, with occasional nuclear 
staining observed (Figure 71). Intensity of cytoplasmic staining was classed as negative 
(weak/no staining) and positive (strong staining). In total, 12/14 (85%) radioresistant 
samples demonstrated a decreased expression of the 26S Proteasome in the invasive 
carcinoma compared with 5/14 from the radiosensitive group. The decreased expression of 
the 26S Proteasome was significantly associated with the radioresistant group (p=0.018; 
Fishers exact test) (Elfadl et al., 2011). 
 
DR4 
DR4 was also significantly down-regulated in radioresistant samples in this same breast 
cancer pilot series (p=0.040; Fishers exact test) (personal communication Miss Dalia 
ElFadl/Dr Lynn Cawkwell). 
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Figure 71: Immunohistochemical analysis of the 26S Proteasome expression in 
invasive breast carcinoma cells. 
A: Strong positive staining of the 26S Proteasome present in the cytoplasm with occasional 
nuclear staining, representing high protein expression. B: Weak staining of the 26S 
Proteasome representing low protein expression. Normal breast tissue and lymphocytes 
demonstrated strong positive cytoplasmic staining and served as internal reference points. 
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9.6.2.2 Clinical validation of DEPs in laryngeal cancer. 
DR4 
During this thesis western blotting revealed the significant down-regulation of DR4 to be 
associated with radioresistance in 1/2 RR oral cancer cell lines (Figure 70). DR4 was 
therefore applied to the pilot series of laryngeal cancer samples (section 4.10.2) in order to 
assess the possible clinical relevance of DR4 expression. Assessment of the slides took 
place by 2 independent scorers with any discrepancies discussed in order to achieve a final 
consensus. Intensity of cytoplasmic staining was classed as negative (weak/no staining) and 
positive (moderate/strong staining). Following assessment of the slides no significant 
differential expression between radiosensistive and radioresistant samples was observed. 
9.7 Discussion 
9.7.1 The 26S Proteasome in the Protein Ubiquitin Pathway 
In order to maintain normal cellular homeostasis and subsequently prevent cancer cell 
survival and proliferation, a careful balance between protein synthesis and degradation is 
required. The protein ubiquitination pathway (section 8.3.3.4), consisting of a ubiquitin-
conjugating system and the 26S Proteasome is the principle mechanism for protein 
degradation and functions to destroy not only damaged or redundant proteins, but also 
those proteins involved in several important biological pathways such as p53, MDM2, 
p21
WAF1
, p27, DNA-PKc, BCL2 and BAX. It can therefore be hypothesised that alterations 
to proteins involved within this pathway may contribute to therapy resistance.  
In order for a protein to be recognised for subsequent degradation by the 26S 
Proteasome, it must first be attached to a polyubiquitin chain, a process carried out by 3 
distinct enzymes namely, the ubiquitin-activating enzyme (E1), the ubiquitin-conjugating 
enzyme (E2) and the ubiquitin-ligase enzyme (E3). All function together in a sequential 
manner to attach 1 ubiquitin molecule to the target substrate via a thioester linkage. This 
process is repeated until a polyubiquitin chain is formed. It is this polyubiquitin chain, 
made of at least 4 ubiquitin monomers, that allows for subsequent protein recognition and 
destruction by the 26S Proteasome (Pickart, 2001, Miller and Gordon, 2005, Voorhees and 
Orlowski, 2006) (Figure 72). 
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Figure 72: The ubiquitination cascade 
Through an ATP-dependent reaction, ubiquitin (Ub) is first conjugated to a Ub-activating 
enzyme (E1). This activated Ub moiety is then transferred to a Ub-conjugating enzyme 
(E2). Finally, a Ub-ligase enzyme (E3) works in concert with E2 to attach the activated Ub 
to the target substrate. This process occurs several times to form a polyubiquitin chain that 
then ‘flags’ the protein for proteasomal degradation. 
 
The 26S Proteasome is a 2000 kDa multisubunit complex comprised of a 20S catalytic core 
(20S proteasome) which is capped at one or both ends by a 19S regulatory particle (PA700) 
(Figure 73A). It is the 19S regulatory particles, encoded by the PSMC and PSMD genes 
that are responsible for recognition and cleavage of the polyubiquitin chain from the protein 
substrate. The protein is then unfolded and translocated into the 20S catalytic core for 
destruction. The 20S core is made up of 4 stacked heptameric rings arranged around an 
inner catalytic chamber. Each outer ring contains 7 α-subunits (1-7) encoded by the PSMA 
genes, and each inner ring contains 7 β-subunits (1-7) encoded by the PSMB genes (Smith 
et al., 2007) (Figure 73B). The β rings perform all catalytic processes, with each containing 
3 proteolytic sites, all differing in substrate specificity; caspases-like (PSMB1 subunit), 
trypsin-like (PSMB2 subunit) and chymotrypsin-like (PSMB5 subunit) (Voges et al., 1999, 
Adams, 2003). 
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Figure 73: Structure of the 26S Proteasome 
A: The 20S proteasome (core) is a barrel shaped complex consisting of 4 stacked 
heptameric rings arranged around an inner catalytic chamber. The complex is capped at 
each end by the 19S regulatory particles. 
B: Each outer ring contains 7 α subunits (1-7) encoded by the PSMA genes, and each inner 
ring contains 7 β subunits (1-7) encoded by the PSMB genes. 
 
Due to the number of proteasomal subunits identified during the biomarker discovery phase 
and subsequently mapped onto the protein ubiqutiniation pathway during data mining, the 
26S Proteasome was the first candidate selected for confirmation. Western blotting had 
previously confirmed the down-regulation of the 26S Proteasome (specific to the 20S 
catalytic core) in 3/3 breast RR cell lines (Smith et al., 2009), and confirmation carried out 
during the course of this thesis also observed this significant down-regulation in 2/2 oral 
RR cell lines (PJ41RR and PJ49RR). However, significant up-regulation of the 26S 
Proteasome was observed in 1/2 rectal RR sublines (SW837). This trend was seen in the 2
nd
 
rectal RR subline (HRA-19) however did not meet significance. To assess the clinical 
relevance of the 26S Proteasome in breast cancer, a small pilot study was performed using 
archival breast tissue. Weak cytoplamsic staining was associated with the radioresistant 
tumours (p=0.018) therefore confirming the decreased expression/down-regulation of the 
26S Proteasome in RR breast cancer cells. Work previously carried out in this laboratory 
utilised this antibody in the immunohistochemical study of archival laryngeal carcinomas to 
also demonstrate decreased expression of the 26S Proteasome in radioresistant tumours 
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(p=0.05) (Smith et al., 2009). The up-regulation of the 26S proteasome in 1/2 RR rectal 
cancer cell lines is yet to be assessed in a clinical context. 
 To date, much research has shown the expression of the 26S Proteasome to be 
integral to the development of carcinogenesis due to its degradation of important proteins 
needed to control cell cycle regulation and apoptosis. In order to inhibit the proteasome and 
therefore prevent the continued degradation of such protein mediators, Bortezomib, a 
dipeptide boronic acid analogue was developed and approved by the US Food and Drug 
Administration for the treatment of myeloma patients. Therefore, based on research carried 
out within this laboratory, the clinically confirmed down-regulation of the 26S Proteasome 
in RR breast, and previously in RR laryngeal appears counter-intuitive. However, decreased 
expression of the 26S Proteasome has also been associated with RR cancer initiating cells 
(CICs), with this feature providing a means of monitoring and targeting CICs both in vitro 
and in vivo (Vlashi et al., 2009). It could be hypothesised that a decrease in proteasomal 
expression in a RR phenotype could result in the stabilisation of those proteins required to 
promote cell survival following treatment. In addition, repopulation of a tumour following 
fractionated doses of radiotherapy, maybe due to the reduced destruction of those proteins 
required for effective cellular proliferation.  
9.7.2 DR4 in the Death Receptor Signalling pathway 
Apoptosis is the cell’s intrinsic pathway to cell death and can be initiated by 1 of 2 main 
signalling pathways, namely the intrinsic (mitochondrial) pathway (section 1.2.4.1) or the 
extrinsic (death receptor) pathway (section 1.2.4.2). Both pathways, whilst functioning 
separately rely on the formation of multimeric protein complexes and the initiation of cell 
death by the activation of caspases.  
The extrinsic apoptotic pathway induces cell death through the signalling of death 
receptors (illustrated in Figure 6, Chapter 1). These death receptors, present on the cell’s 
surface, have the ability to transmit apoptotic signals initiated by specific ligands, namely 
FasL, TNF and TRAIL. Binding of ligands to their specific death receptors results in the 
activation of the caspase cascade within seconds, therefore initiation of apoptosis via this 
pathway is very rapid. TRAIL has been shown to induce apoptosis through interaction with 
its death receptors, one of which being DR4. Ligation of TRAIL to DR4 results in 
trimerisation of the receptor and subsequent clustering of its intracellular death domain 
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(DD), enabling the adaptor molecule FADD to bind. Once bound the death inducing 
signalling complex (DISC) is formed and thereby activates pro-caspase 8, which in turn 
activates the downstream effector caspases 3, 6 and 7, thereby converging with the intrinsic 
pathway and initiating apoptosis.  
 DNA damage caused as a result of ionising radiation is believed to mediate 
apoptosis mechanisms through the intrinsic apoptosis pathway via mitochondrial release of 
cytochrome C, functioning independently of the extrinsic death receptor pathway. 
However, biomarker discovery data presented within this thesis found DR4 to be 
differentially expressed in 4/7 radioresistant cell lines hence leading to the selection of DR4 
as a second candidate for confirmation. Whilst DR4 was only discovered in 2/3 RR breast 
and 2/2 RR rectal cancer types during biomarker discovery, western blotting revealed 
differential expression of DR4 in the oral radioresistant cell lines also. The significant 
down-regulation of DR4 was observed in 1/3 breast RR cell lines (MCF-7RR) and 1/2 oral 
RR cell lines (PJ41RR) by western blotting. Significant up-regulation was observed in 1/2 
rectal RR cell lines (SW837RR) by western blotting. DR4 was significantly down-
regulated in radioresistant breast cancer samples following immunohistochemical staining 
(p=0.040; Fishers exact test) (personal communication Miss Dalia ElFadl/Dr Lynn 
Cawkwell). Clinical assessment of DR4 using the pilot series of laryngeal cancer samples 
however did not show any significant differential expression between the radiosensitive and 
radioresistant samples (p=0.1440). This result was not to be unexpected however, as DR4 
was not initially discovered during the biomarker discovery phase for the oral RR cell lines 
as a significant DEP associated with radioresistance. It must also be noted that this 
immunohistochemical analysis only encompassed a small sample number and may 
therefore prove significant on a larger sample series. The up-regulation of DR4 in rectal 
cancer is yet to be clinically assessed.  
 To the best of my knowledge, this is the first time a potential link with radiotherapy 
and the extrinsic death receptor apoptotic pathway has been identified. It could be 
hypothesised that the clinically confirmed decrease in expression of DR4 in radioresistant 
breast cancer, in addition to the confirmation observed in the oral RR cell line by western 
blotting, could be due to the reduced interaction between DR4 and its specific ligand, 
TRAIL, and hence reduced apoptosis by the initiation of the caspase cascade. Hence, 
damaged cells have the ability to continue proliferating and developing. However, whilst 
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this theory explains a potential mechanism for the development of a radioresistant 
phenotype, the link between radiotherapy, DR4 and the extrinsic apoptotic pathway 
remains elusive, and hence requires the need for further future investigation. 
9.8 Conclusion  
To date, the 26S Proteasome complex and DR4 have been taken through all phases of the 
biomarker discovery pipeline. It is important to note that several other proteins from the 
protein ubiquitination pathway and the death receptor signalling pathway also warrant 
further investigation to assess their potential roles as biomarkers of radiotherapy resistance. 
The proteasomal subunits in particular provide a good starting point, as only those subunits 
located within the 20S catalytic core (PSMA and PSMB subunits) have been investigated 
during this chapter. Biomarker discovery data revealed subunits located within the 19S 
regulatory particle (PSMD subunits) to be differentially expressed also (optimisation started 
but not complete). In addition, subunits encoded by the PSME genes have been identified 
during the biomarker discovery phase. These proteins make up an alternative regulatory 
particle to the 19S complex, known as the 11S regulatory particle (PA28) and form part of 
a second proteasome isoform, namely the immunoproteasome. Two isoforms of the 11S 
regulatory particle, PA28α and PA28β encoded by the PSME1 and PSME2 genes 
respectively, were presented as DEPs during this thesis. Their potential role in radiotherapy 
resistance mechanisms however requires further interpretation. Other proteins from the 
death receptor signalling pathway such as TRAIL, the corresponding ligand to DR4 also 
require further research.  
In addition to proteins involved in the 2 selected pathways, those identified in the 
remaining 11 most relevant pathways selected following data mining (Chapter 8) also 
warrant further investigation (see Chapter 10) due to their involvement in key pathways, 
which if malfunctioning, could potentially lead to radiotherapy resistance mechanisms. 
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Chapter 10.  Final conclusions 
Resistance to radiotherapy presents a major problem in the effective treatment of patients 
diagnosed with cancer. Currently, tumour response to radiotherapy cannot be predicted, 
meaning that those patients with resistant tumours endure harmful side effects associated 
with the treatment for no therapeutic gain. The overall aim of this project, was to utilise 
complementary proteomic methodologies for the identification of protein biomarkers 
associated with radiotherapy resistance across three different cancer types (breast, head and 
neck and rectal), using 7 cell line models (3 x breast, 2 x oral, 3 x rectal). These models 
displayed significantly increased resistance to radiotherapy when compared with their 
respective parental counterpart. The resulting phenotypic differences between the cell sub-
line pairs were subsequently reflected in their protein expression patterns, enabling proteins 
which may be associated with radioresistance to be effectively identified and further 
explored. Identification of protein biomarkers may, in the future, enable radiotherapy 
treatment regimens to be tailored on an individual patient basis. In addition this type of 
study will aid our understanding of radiotherapy resistance mechanisms and potentially 
reveal possible therapeutic targets for future treatment protocols. 
10.1 Comparative proteomics for the identification of radioresistance biomarkers 
Proteomic methods have become increasingly popular over recent years, fuelled by the 
various limitations associated with both genomic and transcriptomic approaches. Studying 
at the protein level incorporates posttranslational modifications or alternative splicing 
events that may have occurred through the transitional process from DNA to protein, and 
which may have subsequently had an effect on the behaviour of the final protein product. 
Throughout this thesis, 3 comparative proteomic platforms were exploited namely, 
antibody microarray, 2D-PAGE MS and iTRAQ. Traditionally, 2D-PAGE has been the 
gold standard analysis tool for the identification of differentially expressed proteins, 
however, poor reproducibility, lengthy sample processing, masking of certain proteins and 
its overall low-throughput lead to the employment of antibody microarray and iTRAQ as 
complementary methods. The addition of these methods overall enabled greater proteome 
coverage to be achieved in addition to combating some of the various downfalls associated 
with 2D-PAGE. Through use of these 3 methods a large number of putative protein 
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biomarkers associated with the 7 radioresistant cell line models from across 3 cancer types 
were identified.  
A manual review of the biomarker discovery data identified 70 DEPs, 8 DEPs and 
19 DEPs to be identified in 2 or more of the 7 radioresistant cell lines by antibody 
microarray, 2D MS or iTRAQ respectively. Overall a total of 3 DEPs (KRT8, KRT19 and 
SIAH2) were common across all 3 cancer types. 
 Data mining was subsequently carried out on all discovery phase data using IPA. A 
total of 339 canonical pathways were identified. From these, 13 of the most relevant 
pathways were selected for further interpretation (Chapter 8). Based on these 13 pathways 
the complementarity of the 3 proteomic platforms was assessed to reveal that overall, 70% 
of DEPs were identified by antibody microarray analysis. Of the 13 pathways selected, all 
except the protein ubiquitination pathway were dominated by DEPs identified by antibody 
microarray. From these 13 pathways, encompassing 101 unique DEPs, only 1 DEP 
(HSPB1) was identified by all 3 proteomic platforms hence reinforcing the complementary 
nature of the 3 methods when discovering DEPs relating to radioresistance. Each of the 3 
cancer types was then assessed based on the 13 pathways selected. Analysis revealed that 
from the 101 DEPs mapped in total, 21 were identified in 2/3 cancer types however, no 
DEP was identified across all 3.  
 Overall the 13 pathways identified and subsequently selected following IPA were 
not unexpected based on the nature of this project, and on the whole included pathways and 
proteins that could conceivably play a role in the development of radioresistance. However, 
one pathway in particular namely the death receptor signalling pathway (or extrinsic 
pathway) was an unexpected finding, due to radiotherapy typically inducing apoptosis via 
the intrinsic (mitochondrial) pathway. 
 Following assessment of the 3 individual cancer types, data from the literature was 
analysed in order to see if, or how it supported the data presented within this thesis. The 
protein ubiquitination pathway in particular was supported and developed the most 
following input from the literature, hence reinforcing its potential role in radiotherapy 
resistance mechanisms and subsequently strengthening the reasons for taking this pathway 
forward for further investigation. 
 The first protein candidate selected for confirmation included the 26S proteasome, 
of which several of its subunits were mapped onto the protein ubiquitination pathway 
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during IPA. The differential expression of the 26S Proteasome was confirmed in all 3 
cancer types by western blotting. Assessment of the 26S proteasome in a clinical context 
revealed significant down-regulation to be associated with radiotherapy resistance in breast 
cancer. This finding was also observed in radioresistant laryngeal cancer (Smith et al., 2009) 
however, the role of the 26S proteasome is yet to be clinically assessed in rectal cancer. 
 The second protein candidate selected for confirmation was DR4. DR4 was 
identified in 4/7 RR cell lines during the biomarker phase and was mapped onto the death 
receptor signalling pathway in IPA.  The repeated identification of DR4 was an unexpected 
finding during this project due to its involvement in the extrinsic apoptotic pathway 
however, the differential expression of DR4 was confirmed in all 3 cancer types by western 
blotting. Clinical assessment revealed the down-regulation of DR4 to be associated with 
radioresistance in breast cancer (personal communication with Miss Dalia ElFadl/ Dr Lynn 
Cawkwell) however, no significant change in expression was observed clinically in 
laryngeal cancer. The role of DR4 is yet to be clinically assessed in rectal cancer. 
10.2 Future perspectives 
10.2.1 Increasing biomarker discovery data 
Combining 3 different proteomic platforms, all with different merits for protein discovery, 
will generate a larger number of DEPs associated with radiotherapy resistance than the use 
of one method alone, however this number can be increased further using a combination of 
approaches.  
 
Cell line models and clinical samples 
This thesis has involved the use of 7 established radioresistant cell line models for the 
identification of protein biomarkers. Cell line models provide a good starting point for 
initial in-vitro experiments due to them being a standardised homogenous collection of 
cells, which are easy to culture and manipulate, readily available and have well 
characterised genotypes and phenotypes. Therefore, additional proteomic analysis using 
different established cell line models, derived from various different tumour types would be 
one option to increase the number of DEPs associated with radiotherapy resistance. In 
addition, analysis of clinical samples including tumour tissue, will also expand the number 
of protein candidates for further interpretation. Whilst research using cell line models has 
 241 
 
many advantages it can be argued that they are not an accurate representation of the tumour 
in its correct microenvironment, and therefore results generated from cell line research are 
often questioned as to their true correlation with the in vivo scenario. However, despite the 
obvious benefits of using clinical samples, proteomic investigation of tumour tissue 
presents a number of technical limitations. Clinical tissue specimens are often small and 
therefore result in a limited amount of material to effectively analyse by proteomic 
methods. The acquisition of tissue samples requires ethical approval and patient consent. 
The study of clinical material relies on a good communication network between the 
researcher and surgical team providing the specimen. Clinical tissue samples represent a 
heterogeneous group of cells and may therefore require microdissection in order to gain a 
sample that is densely populated with tumour cells. To date, work presented by Allal and 
co-workers is the only proteomic study to have utilised radioresistant clinical tissue (Allal 
et al., 2004) however, within our laboratory, a recent proteomic study analysing clinical 
tissue from rectal cancer patients is underway in order to identify further biomarkers of 
radioresistance. 
 
Modifications to the proteomic platform  
One of the major limitations of both 2D-PAGE and iTRAQ experiments is the masking of 
less abundant proteins (which are often the proteins of particular interest) by the more 
abundant proteins within the sample. Such issues may be prevented by the use of a series of 
depletion steps to remove the more abundant proteins enabling greater access to the less 
abundant proteins. Subcellular pre-fractionation steps using different buffers to exploit 
differences in protein solubility could also help to reduce complex protein mixtures prior to 
analysis, allowing for better protein separation to take place. Each fraction could be 
analysed individually to enable a clearer representation of the proteome. For 2D-PAGE 
based experiments, the use of larger format gels and multiple narrow overlapping pH range 
IPG strips can provide a greater resolution and hence prevent the masking of the smaller 
protein spots. Increased resolution would also enable protein spots to be excised more 
accurately. However, whilst a number of variables can be exploited to increase the number 
of DEPs identified by 2D-PAGE and iTRAQ, the options are much more limiting for 
antibody microarray analysis due to protein identification being limited to the 725 pre-
selected antibodies spotted onto the (Sigma Aldrich) microarray slide. Such a limitation 
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therefore requires antibody microarray to be accompanied by at least one of the MS-based 
methods if a larger and more diverse range of potential DEPs are to be identified. 
10.2.2 Prioritisation for further confirmation and clinical validation of DEPs  
There are several other DEPs highlighted by IPA that warrant further research. Such 
candidates include the remaining proteasomal subunits that were not encompassed within 
the 26S Proteasome antibody. TRAIL, the corresponding ligand to DR4 would also be a 
potential candidate for further investigation. It would be interesting to identify if the same 
direction of differential expression was observed as with DR4, hence highlighting if the 
decreased levels of apoptosis, possibly contributing to radioresistance, were solely 
determined by the down-regulation of DR4 expression or if the entire TRAIL/DR4 complex 
was decreased overall. Another potentially interesting protein could include HSPB1. This 
protein has involvement as a chaperone in the protein ubiquitination pathway and also plays 
a role in the inhibition of apoptosis pathways. HSPB1 is also involved in cellular stress 
resistance and cellular proliferation processes, all of which could conceivably play a role in 
the development of radioresistance. Additionally, proteins involved in the remaining 11 
most relevant pathways also require investigation. Initial protein candidates may include 
ATM, MAPK8 and RAF1 due to their involvement in several of the 13 most relevant 
pathways. Other candidates may also include those listed in Table 1 (proteins that could 
conceivably play a role in the development of radioresistance), such as CHEK1, BCL2 and 
APAF1 in addition to those discussed in Chapter 2 (‘classic’ biomarkers of 
radioresistance), such as EGFR.  
It is also important to determine how, and on which samples to clinically validate 
protein targets. For example, radioresistance biomarkers could be validated using a large 
immunohistochemical sample cohort and remain discrete to only 1 specific cancer type 
(e.g. breast cancer). However this would be a low through-put approach and extremely time 
consuming. A second option therefore may involve the initial confirmation of a series of 
biomarkers which could then be screened for in a high through-put experiment using a 
tissue microarray (TMA) incorporating several different tumour types. Through use of this 
approach it may be possible to determine an overall biomarker of radioresistance that 
would be clinically relevant to a number of different cancer types. However, one drawback 
of this approach includes the significant effort and collaboration needed in order to identify 
 243 
 
a large and suitable series with the associated clinical radiotherapy response data. One 
further option may therefore involve testing a series of biomarkers, which have been 
validated previously on a small immunohistochemical pilot series, in a clinical trial setting 
therefore enabling the validation of such biomarkers on a much larger scale using a larger 
sample series. 
Through employment of such thorough validation methods in addition to extensive 
data mining, for example using IPA, issues such as RIDEPs identified from both 2D and 
array-based methods, in addition to keratin proteins which could in fact be contaminants 
from human investigators themselves, will hopefully be resolved and reveal the true 
potential of such proteins as biomarkers of radiotherapy resistance. 
10.2.3 Radiosensitisers and molecularly targeted inhibitors 
As discussed, a large number of tumours are resistant to the effects of radiotherapy 
meaning that unless proteins predictive of response are identified, patients with resistant 
tumours undergo unnecessary treatment for no therapeutic gain. Novel avenues for 
treatment will be required for patients who harbour a radioresistant tumour. Various options 
are available to manipulate proteins in order to improve treatment efficacy with 
radiotherapy. One such approach involves the use of radiosensitisers in combination with 
ionising radiation with common examples including cisplatin and 5-fluorouracil (5-FU) in 
addition to gemcitabine, capecitabine and fludarabine. Resistant tumours can also be 
sensitised by the use of molecularly targeted inhibitors in combination with radiotherapy. 
Common clinical regimens include the inhibition of EGFR signalling by cetuximab or 
gefitinib and also the inhibition of VEGF mediated angiogenesis by bevacizumab (Kvols, 
2005, Vallerga et al., 2004).  
The biomarker discovery data generated within this project has revealed a number 
of putative protein biomarkers which were both up- or down-regulated in the radioresistant 
phenotype. One possible option for future work therefore may be to target and subsequently 
inhibit the up-regulated protein markers whilst trying to stimulate the expression of those 
down-regulated protein biomarkers in order to improve the radiosensitivity of the cell line. 
By carrying out such investigation using cell line models a greater understanding of the role 
that those particular proteins play in radiotherapy resistance mechanisms could be achieved, 
in addition to potentially revealing novel therapeutic targets for future intervention.  
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10.2.4 Proteomics – the future relevance for the clinic 
Although the identification of predictive biomarkers of radioresistance will benefit both 
patients and clinicians immensely by enabling treatment regimes to be tailored on an 
individual patient basis, any information gained highlighting the existence of a potential 
biomarker must be interpreted with care. Radioresistance may be associated with the 
increased/decreased expression of a certain protein, but inhibition/up-regulation of this 
protein may not necessarily translate into increased radiosensitivity, and hence the 
radioresistance may be due to underlying conditions, for example tumour hypoxia. In 
addition, the determination of predictive markers of radiotherapy response is a complex 
process and has the potential to differ amongst tumour types. One protein which predicts 
radioresistance in one tumour type many not necessarily predict radioresistance in a 
different tumour type. It must also be considered that the expression of only one protein 
marker may be relatively trivial in the prediction of overall radioresistance however, when 
expressed in addition to several other molecular markers may be highly significant and play 
a substantial role in determining whether or not a tumour would benefit from treatment with 
ionising radiation. However ultimately, the overall aim is to identify a panel of 
differentially expressed proteins between radioresistant and radiosensitive tumours, and 
determine how their functions differ between the two phenotypes. In doing this it is hoped 
that promising biomarkers identified from experimental studies can be confirmed clinically 
in randomised controlled trials and used for routine screening in the clinic, hence 
identifying which patients will respond positively to radiotherapy at the point of diagnosis. 
It is unlikely that the proteomic methods utilised within this thesis will provide a clinically 
attractive approach for routine screening due to both the skill and time required to carry out 
one experiment, in addition to the associated cost implications. Whilst biomarker discovery 
methods such as those described in this thesis will be required to initially identify 
biomarkers of interest it is hoped that a panel of the most promising proteins can be put 
together in a screening assay that can be utilised within the clinical setting. Such assays 
may include mini antibody microarrays, reverse phase arrays or multiplex ELISA assays. 
Any assay developed for use within the clinic must be quick, reliable, standardised, 
inexpensive and easy to operate. Ultimately it is hoped that at some point in the near future 
such assays can be developed and utilised routinely at the point of diagnosis to predict 
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radiotherapy response either for specific tumour types or for tumours in general that receive 
a treatment regimen that includes radiotherapy.  
 Whilst there are a number of other methods that could be employed to identify 
biomarkers, such as studying at the DNA/RNA level, a lack of radioresistance biomarkers 
discovered at these levels has triggered the move towards a proteomics based approach.  
Once protein biomarkers have been identified, a further possible future development could 
include the non-invasive screening of a patient blood sample, in order to screen for protein 
biomarkers which may be expressed on the surface of circulating tumour cells or on tumour 
microparticles. Tumour microparticles are membrane-bound sacs derived from the surface 
of a tumour and provide an antigenic imprint of a tumour in the extracellular environment. 
Therefore, improved strategies to identify and isolate such microparticles may positively 
benefit patients with cancer and help to individualise patient treatment in the future 
(D'Souza-Schorey and Clancy, 2012). However, in order for an assay of this nature to be 
introduced into the clinic, issues of biomarker sensitivity (a measure of positives that are 
identified as true positives) and specificity (a measure of negatives that are correctly 
identified as true negatives) must be addressed in order to ensure the highest level of 
accuracy is maintained. 
 
  
To conclude, the identification of a panel of biomarkers, predictive of radiotherapy 
response which could be used within the clinical setting to screen patients at the point of 
diagnosis, would be a major breakthrough for the treatment of cancer patients today. 
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Appendix A: Human proteins (arranged alphabetically by NCBI gene name) which have been identified as significant DEPs in 
radiotherapy resistant cell lines using a variety of comparative proteomic approaches.  
Accession numbers given in the source manuscripts have been reviewed where possible in the NCBI database. To ensure accurate protein 
identification tandem MS data has been reported here and PMF has been included only if further confirmation or validation was performed. 
All putative biomarkers which were confirmed by independent techniques are highlighted ‘¶’. Differentially expressed proteins indicated by 
‘*’ are found in the “Top 15” human RIDEP list (section 3.3.3). Differentially expressed proteins that were validated using clinical samples 
are highlighted (§). Proteins identified by (Smith et al., 2009), represents previous work carried out by this group and these proteins have 
been further analysed within this thesis.  
 
Gene name 
 
Putative Protein 
Biomarker 
RR Cell Line 
(cancer type) 
Discovery 
Method 
Confirmation 
Method 
Validation 
Method 
Reference 
ACSF3 Acyl-CoA synthetase 
family member 3 
MCF-7RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
ACTB Actin, beta MCF-7RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
H69/R38 (SCLC) 2-DE & MS/MS --- --- (Henness et al., 2004). 
ACTN4 Actinin, alpha 4 MDA-MB-231RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
AHNAK AHNAK nucleoprotein MDA-MB-231RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
AKR1A1 ¶ Aldo-keto reductase 
family 1, member A1 
(aldehyde reductase) 
RR-HEp-2 
(larynx) 
2-DE & MALDI-
TOF-MS 
WB --- 
(Kim et al., 2010) 
 
ALDOA ¶ Aldolase A, fructose-
bisphosphate 
 
T47DRR (breast) 2-DE & MALDI-
TOF-MS 
WB --- 
(Smith et al., 2009) 
MCF-7RR iTRAQ & 
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(breast) MALDI-
TOF/TOF-MS 
ANXA2 Annexin A2 LNCaP-IRR 
(prostate) 
PC3-IRR 
(prostate) 
Du145-IRR RR 
(prostate) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsova et al., 2008). 
 
ANXA3 Annexin A3 LNCaP-IRR 
(prostate) 
PC3-IRR 
(prostate) 
Du145-IRR RR 
(prostate) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsova et al., 2008). 
 
APEX1 ¶ APEX nuclease 
(multifunctional DNA 
repair enzyme) 1 (APE1) 
(REF1) 
LNCaP-IRR 
(prostate) 
PC3-IRR 
(prostate) 
Du145-IRR RR 
(prostate) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
WB 
siRNA 
--- 
(Skvortsova et al., 2008). 
 
APRT ¶ Adenine 
phosphoribosyltransferase 
RR-HEp-2 
(larynx) 
2-DE & MALDI-
TOF-MS 
WB --- (Kim et al., 2010) 
 
ATP5B * ATP synthase, H+ 
transporting, 
mitochondrial F1 
complex, beta 
polypeptide 
MCF-7RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
ATXN3 Ataxin 3 T47DRR (breast) iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
CFL1 Cofilin 1 H69/R38 (SCLC) 2-DE & MS/MS --- --- (Henness et al., 2004). 
 
CKMT1A Creatine kinase, CNE2-IR (NPC) 2-DE & MS/MS --- --- (Feng et al., 2010) 
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mitochondrial 1A  
CLIC1 ¶ Chloride intracellular 
channel 1 
RR-HEp-2 
(larynx) 
2-DE & MALDI-
TOF-MS 
WB 
RTqPCR 
--- (Kim et al., 2010) 
 
CRMP1 Collapsin response 
mediator protein 1 
LNCaP-IRR 
(prostate) 
PC3-IRR 
(prostate) 
Du145-IRR RR 
(prostate) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsova et al., 2008). 
 
DARS ¶ Aspartyl-tRNA 
synthetase 
T47DRR (breast) 2-DE & MALDI-
TOF-MS 
WB --- 
(Smith et al., 2009) 
MDA-MB-231RR 
(breast) 
MCF-7RR 
(breast) 
DDX52 DEAD (Asp-Glu-Ala-
Asp) box polypeptide 52 
LNCaP-IRR 
(prostate) 
PC3-IRR 
(prostate) 
Du145-IRR RR 
(prostate) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsova et al., 2008). 
 
DUT Deoxyuridine 5’-
triphosphate 
nucleotidohydrolase, 
mitochondrial precursor 
FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
 
EBP1 Proliferation-associated 
protein 2G4 
FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
 
ECH1 ¶ Enoyl CoA hydratase 1 RR-HEp-2 
(larynx) 
2-DE & MALDI-
TOF-MS 
WB --- (Kim et al., 2010) 
 
EF1G Elongation factor 1-
gamma 
FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
 
EIF4A1 Eukaryotic translation T47DRR (breast) 2-DE & MALDI- --- --- (Smith et al., 2009) 
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initiation factor 4A1 TOF/TOF-MS 
ENO1 * Enolase 1 (alpha) H69/R38 (SCLC) 2-DE & MS/MS --- --- (Henness et al., 2004) 
LNCaP-IRR 
(prostate) 
PC3-IRR 
(prostate) 
Du145-IRR RR 
(prostate) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsova et al., 2008). 
 
FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- (Skvortsov et al., 2011) 
 
EZR ¶ Ezrin FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
WB --- 
(Skvortsov et al., 2011) 
FAM50A Family with sequence 
similarity 50, member A 
LNCaP-IRR 
(prostate) 
PC3-IRR 
(prostate) 
Du145-IRR RR 
(prostate) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsova et al., 2008). 
FASN Fatty acid synthase MCF-7RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
FLNA Filamin A, alpha MCF-7RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
MDA-MB-231RR 
(breast) 
FSCN1 Fascin FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
FUT8 Fucosyltransferase 8 MCF-7RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
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GAPDH Glyceraldehyde-3-
phosphate dehydrogenase 
LNCaP-IRR 
(prostate) 
PC3-IRR 
(prostate) 
Du145-IRR RR 
(prostate) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsova et al., 2008). 
GDF15 ¶ Growth differentiation 
factor 15 
OECM1-RR 
(HNC) 
KB-RR (HNC) 
1-DE & MALDI-
TOF-MS 
RT-PCR --- 
(Lin et al., 2010). 
GFM1 G elongation factor G, 
mitochondrial 1 
T47DRR (breast) 2-DE & MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
GLO1 Glyoxalase I CNE2-IR (NPC) 2-DE & MS/MS --- --- (Feng et al., 2010) 
GNB1 Guanine nucleotide 
binding protein (G 
protein), beta polypeptide 
1 
H69/R38 (SCLC) 2-DE & MS/MS --- --- 
(Henness et al., 2004). 
 
GSTM3 ¶ Glutathione S-transferase 
mu 3 
MCF-7RR 
(breast) 
2-DE & MALDI-
TOF-MS 
WB 
qPCR 
--- 
(Smith et al., 2009) 
GSTP1 Glutathione-S-transferase 
π 1 
H69/R38 (SCLC) 2-DE & MS/MS --- --- (Henness et al., 2004). 
FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
HINT1 Histidine triad nucleotide-
binding protein 1 
FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
HNRPAB Heterogeneous nuclear 
ribonucleoprotein A/B 
FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
HNRNPA2B1 Heterogeneous nuclear 
ribonucleoprotein A2/B1 
MCF-7RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
HNRNPH1 Heterogeneous nuclear 
ribonucleoprotein H1 
LNCaP-IRR 
(prostate) 
2D-DIGE & 
MALDI-
--- --- 
(Skvortsova et al., 2008). 
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PC3-IRR 
(prostate) 
Du145-IRR RR 
(prostate) 
TOF/TOF-MS 
CNE2-IR (NPC) 2-DE & MS/MS --- --- (Feng et al., 2010) 
HSP90AA1 Heat shock protein 90kDa 
alpha, class A member 1 
MCF-7RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
HSP90AB1 Heat shock protein 90kDa 
alpha, class B member 1 
T47DRR (breast) 2-DE & MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
HSP90B1 ¶ Heat shock protein 90kDa 
beta (GRP94) (GP96), 
member 1 
MCF-7RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
OECM1-RR 
(HNC) 
KB-RR (HNC) 
1-DE & MALDI-
TOF-MS 
RT-PCR 
siRNA 
--- 
(Lin et al., 2010). 
HSPA1A Heat shock 70kDa protein 
1A 
MCF-7RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
HSPA5 § 
 
Heat shock 70kDa protein 
5 (glucose-regulated 
protein, 78KDa / GRP78) 
MCF-7RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
WB --- 
(Smith et al., 2009) 
MDA-MB-231RR 
(breast) 
OECM1-RR 
(HNC) 
KB-RR (HNC) 
1-DE & MALDI-
TOF-MS 
RT-PCR --- 
(Lin et al., 2010). 
FaDu-IRR 
SCC25-IRR 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
CNE2-IR (NPC) 2-DE & MS/MS WB IHC (Feng et al., 2010) 
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HSPA8 ¶ * Heat shock 70KDa 
protein 8 (HSC71) 
LNCaP-IRR 
(prostate) 
PC3-IRR 
(prostate) 
Du145-IRR RR 
(prostate) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
WB --- 
(Skvortsova et al., 2008). 
 
CNE2-IR (NPC) 2-DE & MS/MS --- --- (Lin et al., 2010) 
HSPA9 Heat shock 70KDa 
protein 9 (mortalin) 
H69/R38 (SCLC) 2-DE & MS/MS --- --- (Henness et al., 2004) 
LNCaP-IRR 
(prostate) 
PC3-IRR 
(prostate) 
Du145-IRR RR 
(prostate) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsova et al., 2008) 
MCF-7RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
HSPA9B HSP70 protein, 
mitochondrial precursor 
FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
HSPB1 * Heat shock 27kDa protein 
1 
CNE2-IR (NPC) 2-DE & MS/MS --- --- (Feng et al., 2010) 
HSPD1 ¶ Heat shock 60kDa protein 
1 / Chaperonin 
MCF-7RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
Smith et al., 2009) 
OECM1-RR 
(HNC) 
KB-RR (HNC) 
1-DE & MALDI-
TOF-MS 
RT-PCR --- 
(Lin et al., 2010). 
HSPF4 DNAJ homolog sub 
family A member 1 
FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
HYOU1 Hypoxia up-regulated 1 CNE2-IR (NPC) 2-DE & MS/MS --- --- (Feng et al., 2010) 
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IFI16 Interferon, gamma-
inducible protein 16 
CNE2-IR (NPC) 2-DE & MS/MS --- --- 
(Feng et al., 2010) 
KHSRP KH-type splicing 
regulatory protein 
LNCaP-IRR 
(prostate) 
PC3-IRR 
(prostate) 
Du145-IRR RR 
(prostate) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsova et al., 2008). 
KRT8* Keratin 8 MCF-7RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
KRT10 Keratin 10 FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
KRT17 Keratin 17 CNE2-IR (NPC) 2-DE & MS/MS --- --- (Feng et al., 2010) 
KRT18 Keratin 18 MCF-7RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
KRT19 Keratin 19 MCF-7RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
CNE2-IR (NPC) 2-DE & MS/MS --- --- (Feng et al., 2010) 
FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
LASP1 LIM and SH3 protein 1 LNCaP-IRR 
(prostate) 
2D-DIGE & 
MALDI-
--- --- 
(Skvortsova et al., 2008) 
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PC3-IRR 
(prostate) 
Du145-IRR RR 
(prostate) 
TOF/TOF-MS 
LCP1 ¶ Lymphocyte cytosolic 
protein 1 (L-Plastin) 
MCF-7RR 
(breast) 
2-DE & MALDI-
TOF-MS 
WB --- 
(Smith et al., 2009) 
LMNA Lamin A/C MCF-7RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
M2BP Galectin-3-binding 
protein precursor 
FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
MAPRE1 ¶ Microtubule-associated 
protein, RP/EB family, 
member 1 
RR-HEp-2 
(larynx) 
2-DE & MALDI-
TOF-MS 
WB --- (Kim et al., 2010) 
FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
MAT2A S-adenosylmethionine 
synthetase isoform type-2 
FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
MDH2 Malate dehydrogenase 2, 
NAD 
MCF-7RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
MDM2 Mdm2 p53 binding 
protein 
CNE2-IR (NPC) 2-DE & MS/MS --- --- (Feng et al., 2010) 
MIF Macrophage migration 
inhibitory factor 
(glycosylation-inhibiting 
factor) 
H69/R38 (SCLC) 2-DE & MS/MS --- --- 
(Henness et al., 2004). 
MRPS12 Mitochondrial ribosomal 
protein S12 
CNE2-IR (NPC) 2-DE & MS/MS --- --- 
(Feng et al., 2010) 
MSN ¶ Moesin MDA-MB-231RR 
(breast) 
2-DE & MALDI-
TOF-MS 
WB --- 
(Smith et al., 2009) 
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FaDu-IRR 
SCC25-IRR 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
MYH9 Myosin, heavy chain 9 MDA-MB-231RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
NCL Nucleolin MCF-7RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
NDUFS1 NADH dehydrogenase 
(ubiquinone) Fe-S protein 
1, 75kDa (NADH-
coenzyme Q reductase) 
CNE2-IR (NPC) 2-DE & MS/MS --- --- 
(Feng et al., 2010) 
NME1 ¶ Non-metastatic cells 1, 
protein (NM23A) 
expressed in 
LNCaP-IRR 
(prostate) 
PC3-IRR 
(prostate) 
Du145-IRR RR 
(prostate) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
WB --- 
(Skvortsova et al., 2008). 
 
NPM1 Nucleophosmin FaDu-IRR 
SCC25-IRR 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- (Skvortsova et al., 2008). 
 
OS9 Osteosarcoma amplified 9 T47DRR (breast) iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
P4HB Prolyl 4-hydroxylase, 
beta polypeptide 
MCF-7RR 
(breast) 
 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
PAWR PRKC, apoptosis, WT1, 
regulator 
T47DRR (breast) iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
PCBP1 Poly(rC) binding protein 
1 
LNCaP-IRR 
(prostate) 
2D-DIGE & 
MALDI-
--- --- (Skvortsova et al., 2008). 
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PC3-IRR 
(prostate) 
Du145-IRR RR 
(prostate) 
TOF/TOF-MS  
PCBP2 ¶ Poly(rC) binding protein 
2 
RR-HEp-2 
(larynx) 
2-DE & MALDI-
TOF-MS 
WB --- (Kim et al., 2010) 
PDCD6IP Programmed cell death 6 
interacting protein 
LNCaP-IRR 
(prostate) 
PC3-IRR 
(prostate) 
Du145-IRR RR 
(prostate) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsova et al., 2008). 
 
PDIA1 Protein disulfide 
isomerase precursor 
FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
PDIA3 Protein disulfide 
isomerase family A, 
member 3 
MCF-7RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
PDIA6 Protein disulfide 
isomerase family A, 
member 6 
CNE2-IR (NPC) 2-DE & MS/MS --- --- 
(Feng et al., 2010) 
PFN1 Profilin-1 FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
PGAM1 Phosphoglycerate mutase 
1 
FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
PGAM2 Phosphoglycerate mutase 
2 
FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
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PGK1 Phosphoglycerate kinase 
1 
LNCaP-IRR 
(prostate) 
PC3-IRR 
(prostate) 
Du145-IRR RR 
(prostate) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsova et al., 2008). 
 
PHGDH D-3-phosphoglycerate 
dehydrogenas 
FaDu-IRR 
SCC25-IRR 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
PKM2 * Pyruvate kinase MCF-7RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
PLEC Plectin MDA-MB-231RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
PNP ¶ Purine nucleoside 
phosphorylase 
RR-HEp-2 
(larynx) 
2-DE & MALDI-
TOF-MS 
WB --- (Kim et al., 2010) 
PPP1R8 Protein phosphatase 1, 
regulatory (inhibitor) 
subunit 8 
MCF-7RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
PRDX1 * Peroxiredoxin 1 H69/R38 (SCLC) 2-DE & MS/MS --- --- (Henness et al., 2004) 
CNE2-IR (NPC) 2-DE & MS/MS --- --- (Feng et al., 2010) 
PRDX2 ¶ * Peroxiredoxin 2 MCF+FIR30 2-DE & MS/MS WB 
siRNA 
--- 
(Wang et al., 2005). 
RR-HEp-2 
(larynx) 
2-DE & MALDI-
TOF-MS 
WB --- (Kim et al., 2010) 
PRDX4 Peroxiredoxin 4 CNE2-IR (NPC) 2-DE & MS/MS --- --- (Feng et al., 2010) 
PRPF19 PRP19/PSO4 pre-mRNA 
processing factor 19 
homolog 
LNCaP-IRR 
(prostate) 
PC3-IRR 
(prostate) 
Du145-IRR RR 
(prostate) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsova et al., 2008). 
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PRPS2 ¶ Phosphoribosyl 
pyrophosphate synthetase 
2 
RR-HEp-2 
(larynx) 
2-DE & MALDI-
TOF-MS 
WB --- 
(Kim et al., 2010) 
PSMA1 ¶ Proteasome (prosome, 
macropain) subunit, alpha 
type, 1 
RR-HEp-2 
(larynx) 
2-DE & MALDI-
TOF-MS 
WB --- 
(Kim et al., 2010) 
PSMA2 § Proteasome (prosome, 
macropain) subunit, alpha 
type, 2 
MDA-MB-231RR 
(breast) 
2-DE & MALDI-
TOF/TOF-MS 
--- IHC 
(Smith et al., 2009) 
PSMA7 § Proteasome (prosome, 
macropain) subunit, alpha 
type, 7 
MDA-MB-231RR 
(breast) 
 
2-DE & MALDI-
TOF/TOF-MS 
WB IHC 
(Smith et al., 2009) 
PSMB1 Proteasome (prosome, 
macropain) subunit, beta 
type, 1 
LNCaP-IRR 
(prostate) 
PC3-IRR 
(prostate) 
Du145-IRR RR 
(prostate) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsova et al., 2008). 
 
PSMC2 Proteasome (prosome, 
macropain) 26S subunit, 
ATPase, 2 
CNE2-IR (NPC) 2-DE & MS/MS --- --- 
(Feng et al., 2010) 
PSMC3 Proteasome (prosome, 
macropain) 26S subunit, 
ATPase, 3 
CNE2-IR (NPC) 2-DE & MS/MS --- --- 
(Feng et al., 2010) 
PSMD14 26S-proteasome non-
ATPase regulatory 
subunit 14 
FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
PSME1 ¶ Proteasome (prosome, 
macropain) activator 
subunit 1 (PA28 alpha) 
MCF-7RR 
(breast) 
2-DE & MALDI-
TOF-MS 
RTqPCR --- 
(Smith et al., 2009) 
FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
PSME2 ¶ Proteasome (prosome, MCF-7RR 2-DE & MALDI- RTqPCR --- (Smith et al., 2009) 
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macropain) activator 
subunit 2 (PA28 beta) 
(breast) TOF-MS 
FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
QARS Glutaminyl-tRNA 
synthetase 
MDA-MB-231RR 
(breast) 
2-DE & MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
RAB11A ¶ RAB11A, member RAS 
oncogene family 
LNCaP-IRR 
(prostate) 
PC3-IRR 
(prostate) 
Du145-IRR RR 
(prostate) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
WB --- 
(Skvortsova et al., 2008). 
 
RAB40B ¶ RAB40B, member RAS 
oncogene family 
OECM1-RR 
(HNC) 
KB-RR (HNC) 
1-DE & MALDI-
TOF-MS 
RT-PCR --- 
(Lin et al., 2010). 
RAN RAN, member RAS 
oncogene family 
LNCaP-IRR 
(prostate) 
PC3-IRR 
(prostate) 
Du145-IRR RR 
(prostate) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsova et al., 2008). 
 
FaDu-IRR 
SCC25-9RR 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
RBM14 RNA binding motif 
protein 14 
LNCaP-IRR 
(prostate) 
PC3-IRR 
(prostate) 
Du145-IRR RR 
(prostate) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsova et al., 2008). 
 
RDX Radixin FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
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ROCK2 Rho-associated protein 
kinase 2 
FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
RRM1 Ribonucleotide reductase 
M1 
MCF-7RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
S100A10 Protein S100-A10 FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
SEPT11 Septin 11 LNCaP-IRR 
(prostate) 
PC3-IRR 
(prostate) 
Du145-IRR RR 
(prostate) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsova et al., 2008). 
 
SERBP1 ¶ SERPINE1 mRNA 
binding protein 1 
LNCaP-IRR 
(prostate) 
PC3-IRR 
(prostate) 
Du145-IRR RR 
(prostate) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
WB --- 
(Skvortsova et al., 2008). 
 
SERPINB5 § Serpin B5 precursor FaDu-IRR 
SCC25-9RR 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
CNE2-IR (NPC) 2-DE & MS/MS WB IHC (Feng et al., 2010) 
SET Template-activating 
factor 1 
CNE2-IR (NPC) 2-DE & MS/MS --- --- (Feng et al., 2010) 
FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
SFN § 14-3-3 Sigma protein FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
CNE2-IR (NPC) 2-DE & MS/MS WB/siRNA IHC (Feng et al., 2010) 
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SFRS2 Splicing factor, 
arginine/serine rich 2 
FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
SFRS3 Splicing factor, 
arginine/serine rich 3 
FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
SHMT2 Serine 
hydroxymethyltransferase 
2 
LNCaP-IRR 
(prostate) 
PC3-IRR 
(prostate) 
Du145-IRR RR 
(prostate) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsova et al., 2008). 
 
SMC3 Structural maintenance of 
chromosomes 3 
T47DRR (breast) iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
SOD2 § Superoxide dismutase 2 
(Mn-SOD) 
CNE2-IR (NPC) 2-DE & MS/MS WB 
 
IHC 
(Feng et al., 2010) 
SURF1 Surfeit 1 T47DRR (breast) iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
TAGLN2 Transgelin-2 FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
TALDO1 Transaldolase FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
TDP43 TAR DNA-binding 
protein 43 
FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
TF Transferrin CNE2-IR (NPC) 2-DE & MS/MS --- --- (Feng et al., 2010) 
TPI1 ¶ * Triosephosphate 
isomerase 1 
H69/R38 (SCLC) 2-DE & MS/MS --- --- (Henness et al., 2004) 
MDA-MB-231RR 
(breast) 
2-DE & MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
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MCF-7RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
RR-HEp-2 
(larynx) 
2-DE & MALDI-
TOF-MS 
WB --- (Kim et al., 2010) 
FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011) 
TPT1 Tumor protein, 
translationally-controlled 
1 
CNE2-IR (NPC) 2-DE & MS/MS --- --- 
(Feng et al., 2010) 
TRAP1 ¶ TNF receptor-associated 
protein 1 
T47DRR (breast) 2-DE & MALDI-
TOF/TOF-MS 
WB --- 
(Smith et al., 2009) 
TRMT112 ¶ tRNA methyltransferase 
11-2 homolog 
RR-HEp-2 
(larynx) 
2-DE & MALDI-
TOF-MS 
WB --- (Kim et al., 2010) 
TSG101 Tumour susceptibility 
gene 101 protein 
FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011 
TUBA1A Tubulin, alpha 1a T47DRR (breast) 2-DE & MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
UBA1 ¶ Ubiquitin-like modifier 
activating enzyme 1 
T47DRR (breast) 2-DE & MALDI-
TOF/TOF-MS 
WB --- 
(Smith et al., 2009) 
USP17L1P Ubiquitin-specific 
protease 17-like protein 
MCF-7RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
VDAC3 Voltage-dependent anion 
channel 3 
CNE2-IR (NPC) 2-DE & MS/MS --- --- 
(Feng et al., 2010) 
VIM * Vimentin MDA-MB-231RR 
(breast) 
iTRAQ & 
MALDI-
TOF/TOF-MS 
--- --- 
(Smith et al., 2009) 
CNE2-IR (NPC) 2-DE & MS/MS --- --- (Feng et al., 2010) 
WARS Tryptophanyl-tRNA 
synthetase 
CNE2-IR (NPC) 2-DE & MS/MS --- --- 
(Feng et al., 2010) 
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ZNF185 Zink finger protein 185 FaDu-IRR (HNC) 
SCC25-IRR 
(HNC) 
2D-DIGE & 
MALDI-
TOF/TOF-MS 
--- --- 
(Skvortsov et al., 2011 
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Appendix B: Buffers and reagents 
Cell culture medium 
1 bottle of RPMI 1640 culture media (#31870, Invitrogen) 
Or 
1 bottle of DMEM culture media (#31053, Invitrogen) 
50ml Fetal Bovine Serum (#10106, Invitrogen) 
5ml L-glutamine (#25030, Invitrogen) 
5ml Fungizone – Amphotericin B (#15290, Invitrogen) 
5ml Penicillin/Streptomycin (PenStrep) (#15140, Invitrogen) 
 
Freezing medium 
5ml Dimethyl Sulphoxide (DMSO) 
45ml RPMI/DMEM cell culture medium 
 
2D extraction buffer 
1.26g Urea  
0.456g Thiourea 
0.12g CHAPS 
0.0231g Dithiothreitol (DTT) 
30µl Bio-Lyte 3/10 Ampholyte (#163-1113, Bio-Rad) 
6µl 1% Bromophenol Blue 
1.65ml dH2O 
30µl Protease Inhibitor (#80-6501-23, Amersham Biosciences) 
30µl Phosphatase Inhibitor Cocktail 1 (#P2850, Sigma Aldrich) 
30µl Phosphatase Inhibitor Cocktail 2 (#P5726, Sigma Aldrich) 
 
 
Equilibration buffer 
Stock       Equilibration Buffer 1 
6.7ml 1.5M Tris-HCl pH 8.8    0.1g DTT for every 10ml of stock 
72.07 g Urea 
69ml 87% Glycerol     Equilibration Buffer 2 
4.0g SDS      0.25g IAA for every 10ml of stock 
Trace Bromophenol Blue Salt 
Made up to 200ml with dH2O 
 
1% Overlay Agarose 
1g Agarose 
100ml 1x Tris-glycine running buffer (#161-0772, Bio-Rad) 
Trace Bromophenol Blue 
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Western blot (WB) extraction buffer 
4ml dH2O 
1ml 0.5M Tris:HCl pH 6.8 
0.8ml glycerol 
1.6ml 10% SDS 
200µl 0.05% Bromophenol Blue 
 
 
TBS-Tween20 
TBS Stock (concentrated)                  
121g Trizma Base (#93304, Fluka)       
170g Sodium Chloride (#S3014, Sigma Aldrich)  
Made to 1 litre with dH2O     
Adjusted to pH 7.6 with conc HCl 
 
Working Solution 
250 ml TBS stock 
4750 ml dH20 
2.5 ml Tween20 (#P5972, Sigma Aldrich) 
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Appendix C: Additional information for the 7 commercially purchased cancer cell lines. 
It is not known as to whether any of the cell lines had previously undergone irradiation.  
 
Name of cell line       Established Additional Characteristics Additional references 
MCF-7 
Caucasian female 69 years  
(1970) 
 
p53 wild type (Alkhalaf and El-Mowafy, 2003) 
MDA-MB-231 (MDA) 
Caucasian female 51 years  
(1973) 
 
p53 mutant (Majumder et al., 2002) 
T47D 
Caucasian female 54 years   
(1979) 
 
p53 mutant (Lim et al., 2009) 
PE/CAPJ41 (PJ41) 
Caucasian female 67 years  
(Unknown year)  
 
--- --- 
PE/CAPJ49 (PJ49) 
Caucasian male 57 years   
(Unknown year) 
 
--- --- 
SW837 
Caucasian male 53 years 
(1976) 
 
Duke stage: C 
Established from: IV tumour 
CEA status: High 
(van Erk et al., 2005) 
www.hpacultures.org.uk 
Cat # 91031104 
HRA-19 
Male 66 years 
(1986) 
 
Duke stage: B 
Established from: Primary tumour 
CEA status: Negative 
www.hpacultures.org.uk 
Cat # 10012802 
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Appendix D: 725 Antibodies (Panorama Antibody Microarray XPRESS Profiler) 
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Appendix E: Raw data for the SW837 rectal cancer cell line 
 
SW837 Dose Response Curves - Colonies (Mean of 2 observers) 
 1st experiment 2nd experiment 
Dose  1 2 3 Mean 1 2 3 Mean 
0 566 604 501 557 328 341 339 336 
2 266 263 250 259 332 205 346 294 
4 91 79 104 91 119 75 70 88 
6 61 39 38 46 26 31 11 22 
8 1 5 2 2 7 9 4 6 
10 0 1 1 0 0 0 3 1 
 
SW837 Dose Response Curves - Plating Efficiency (Mean of 2 observers) 
 1st experiment 2nd experiment 
Dose  1 2 3 Mean 1 2 3 Mean 
0 56.6 60.4 50.1 55.7 32.8 34.1 33.9 33.6 
2 26.6 26.3 25.0 25.9 33.2 20.5 24.6 29.4 
4 9.1 7.9 10.4 9.1 11.9 7.5 7.0 8.8 
6 6.1 3.9 3.8 4.6 2.6 3.1 1.1 2.2 
8 0.1 0.5 0.2 0.2 0.7 0.9 0.4 0.6 
10 0 0.1 0.1 0 0 0 0.3 0.1 
 
SW837 Dose Response Curves – Survival Fraction (Mean of 2 observers) 
 1st experiment 2nd experiment 
Dose  1 2 3 Mean 1 2 3 Mean 
0 1 1 1 1 1 1 1 1 
2 0.469 0.435 0.499 0.467 1.012 0.601 1.02 0.877 
4 0.16 0.13 0.207 0.165 0.362 0.219 0.206 0.262 
6 0.107 0.064 0.075 0.082 0.079 0.09 0.032 0.067 
8 0.001 0.008 0.003 0.004 0.021 0.026 0.011 0.019 
10 0 0.001 0.001 0.001 0 0 0.008 0.002 
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Appendix F: Raw data for the SW837RR rectal cancer cell line 
 
SW837RR Dose Response Curves - Colonies (Mean of 2 observers) 
 1st experiment 2nd experiment 
Dose  1 2 3 Mean 1 2 3 Mean 
0 413 402 482 432 442 629 592 554 
2 313 329 336 326 310 340 322 324 
4 182 167 174 174 148 170 138 152 
6 76 50 60 62 94 96 78 89 
8 21 23 22 22 30 22 45 32 
10 12 10 11 11 20 17 25 21 
 
SW837RR Dose Response Curves - Plating Efficiency (Mean of 2 observers) 
 1st experiment 2nd experiment 
Dose  1 2 3 Mean 1 2 3 Mean 
0 41.3 40.2 48.2 43.2 44.2 62.9 59.2 55.4 
2 31.3 32.9 33.6 32.6 31.0 34.0 32.2 32.4 
4 18.2 16.7 17.4 17.4 14.8 17.0 13.8 15.2 
6 7.6 5.0 6.0 6.2 9.4 9.6 7.8 8.9 
8 2.1 2.3 2.2 2.2 3.0 2.2 4.5 3.2 
10 1.2 1.0 1.1 1.1 2.0 1.7 2.5 2.1 
 
SW837RR Dose Response Curves – Survival Fraction (Mean of 2 observers) 
 1st experiment 2nd experiment 
Dose  1 2 3 Mean 1 2 3 Mean 
0 1 1 1 1 1 1 1 1 
2 0.757 0.818 0.697 0.757 0.701 0.54 0.543 0.594 
4 0.44 0.415 0.36 0.405 0.334 0.27 0.233 0.279 
6 0.184 0.124 0.124 0.144 0.212 0.152 0.131 0.165 
8 0.05 0.057 0.045 0.05 0.067 0.034 0.076 0.059 
10 0.029 0.024 0.022 0.025 0.045 0.027 0.042 0.038 
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Appendix G: Raw data for the HRA-19 rectal cancer cell line 
 
HRA-19 Dose Response Curves - Colonies (Mean of 2 observers) 
 1st experiment 2nd experiment 
Dose  1 2 3 Mean 1 2 3 Mean 
0 95 96 104 98 54 64 53 57 
2 51 42 46 46 35 29 27 30 
4 10 2 7 6 4 9 12 8 
6 0 1 1 1 5 3 3 4 
8 0 1 0 0 2 2 2 2 
10 0 0 0 0 0 0 0 0 
 
HRA-19 Dose Response Curves - Plating Efficiency (Mean of 2 observers) 
 1st experiment 2nd experiment 
Dose  1 2 3 Mean 1 2 3 Mean 
0 9.5 9.6 10.4 9.8 5.4 6.4 5.3 5.7 
2 5.1 4.2 4.6 4.6 3.5 2.9 2.7 3.0 
4 1.0 0.2 0.7 0.6 0.4 0.9 1.2 0.8 
6 0 0.1 0.1 0.1 0.5 0.3 0.3 0.4 
8 0 0.1 0 0 0.2 0.2 0.2 0.2 
10 0 0 0 0 0 0 0 0 
 
HRA-19 Dose Response Curves – Survival Fraction (Mean of 2 observers) 
 1st experiment 2nd experiment 
Dose  1 2 3 Mean 1 2 3 Mean 
0 1 1 1 1 1 1 1 1 
2 0.536 0.437 0.442 0.472 0.648 0.453 0.509 0.537 
4 0.105 0.02 0.067 0.064 0.074 0.141 0.226 0.147 
6 0 0.01 0.009 0.006 0.092 0.046 0.056 0.065 
8 0 0.01 0 0.003 0.037 0.031 0.037 0.035 
10 0 0 0 0 0 0 0 0 
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Appendix H: Raw data for the HRA-19RR rectal cancer cell line 
 
HRA-19RR Dose Response Curves - Colonies (Mean of 2 observers) 
 1st experiment 2nd experiment 
Dose  1 2 3 Mean 1 2 3 Mean 
0 64 51 54 56 168 173 152 164 
2 27 31 32 30 109 123 105 112 
4 21 18 11 17 54 47 44 48 
6 5 10 8 8 18 23 13 18 
8 4 5 7 5 12 12 8 11 
10 1 10 3 5 6 3 6 5 
 
HRA-19RR Dose Response Curves - Plating Efficiency (Mean of 2 observers) 
 1st experiment 2nd experiment 
Dose  1 2 3 Mean 1 2 3 Mean 
0 6.4 5.1 5.4 5.6 16.8 17.3 15.2 16.4 
2 2.7 3.1 3.2 3.0 10.9 12.3 10.5 11.2 
4 2.1 1.8 1.1 1.7 5.4 4.7 4.4 4.8 
6 0.5 1.0 0.8 0.8 1.8 2.3 1.3 1.8 
8 0.4 0.5 0.7 0.5 1.2 1.2 0.8 1.1 
10 0.1 1.0 0.3 0.5 0.6 0.3 0.6 0.5 
 
HRA-19RR Dose Response Curves – Survival Fraction (Mean of 2 observers) 
 1st experiment 2nd experiment 
Dose  1 2 3 Mean 1 2 3 Mean 
0 1 1 1 1 1 1 1 1 
2 0.421 0.607 0.592 0.540 0.648 0.710 0.690 0.683 
4 0.328 0.352 0.203 0.294 0.321 0.271 0.289 0.294 
6 0.078 0.196 0.148 0.141 0.107 0.132 0.085 0.108 
8 0.062 0.098 0.129 0.096 0.071 0.069 0.052 0.064 
10 0.015 0.196 0.055 0.089 0.035 0.017 0.039 0.030 
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Appendix I: 2D-PAGE MALDI-TOF/TOF MS data obtained for the RR oral cancer cell lines. 
All protein identification data obtained from the analysis of both RR cell lines (PJ41RR and PJ49RR). Spectra for each protein identification 
were submitted to MASCOT and searched against the SwissProt human protein database. 
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Appendix J: iTRAQ data obtained for the PJ41RR oral cancer cell line. 
All protein identification data obtained from the analysis of the PJ41RR oral cancer cell line. Spectra for each protein identification were 
submitted to MASCOT and searched against the SwissProt human protein database. 
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Appendix K: iTRAQ data obtained for the PJ49RR oral cancer cell line. 
All protein identification data obtained from the analysis of the PJ49RR oral cancer cell line. Spectra for each protein identification were 
submitted to MASCOT and searched against the SwissProt human protein database. 
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Appendix L: 2D-PAGE MALDI-TOF/TOF MS data obtained for the RR Rectal cancer cell lines. 
All protein identification data obtained from the analysis of both RR cell lines (SW837RR and HRA-19RR). Spectra for each protein 
identification were submitted to MASCOT and searched against the SwissProt human protein database. 
 
 
 
 
 
 300 
 
 
 
 301 
 
 
 
 
 302 
 
 
 
 
 
 
 
 
 
 
 303 
 
Appendix M: DEPs associated with the MCF-7RR, MDARR and T47DRR breast 
cell lines, identified by previous antibody microarray. 
Antibody microarray analysis was carried out as per section 4.5 (by Miss Dalia ElFadl). 
Those values that represent a significant fold change in expression (≥ 1.8) have been 
highlighted in bold. Supporting data ≥ 1.5 has also been included for proteins with a ≥ 1.8 
fold in expression. Protein fold changes that did not meet the level of significance (---) or 
did not pass analysis criteria () are also highlighted. Those proteins which were not linked 
to a specific gene name are labelled (ns) and RIDEPs (section 3.5.1) are labelled (*). 
 
Ab# Protein Name Gene Name MCF7RR 
 
MDARR 
 
T47DRR 
Z0377 Zyxin * ZYX 1.7 3.07 2.99 
D3813 DR4 TNFRSF10A 4.84 1.66 5.01 
I9658 Importin alpha 1 KPNA2 3.77 1.65 2.1 
S4945 SynCAM CADM1 2.18 1.73 2.3 
S7945 Siah2 * SIAH2 1.5 1.92 2.05 
G6670 Growth Factor Independence-1 GFI1 2.3 2.49  
P9498 PIAS-x PIAS2 --- 2.21 2.4 
M9934 MyD88 * MYD88 2.02 --- 2.08 
S3934 Smad4 (DPC4) * SMAD4 1.96 1.81 --- 
S8316 SUV39H1 Histone 
Methyltransferase 
SUV39H1 1.88 --- 2.03 
A5979 ARP3 ACTR3 1.83 2.21 --- 
C9358 Chk1 CHEK1 1.54 2.19 -- 
S9568 SKM1 Sodium Channel SCN4A --- 1.51 2.03 
M0445 MDMX MDM4 2.23 1.73 --- 
G6160 beta COP COPB1 2.1 1.55 --- 
G4170 GRP75 HSPA9  1.84 1.64 
R6278 hnRNP-U HNRNPU 3.64 --- --- 
C8616 phospho beta Catenin (pThr41) CTNNB1 2.74 --- --- 
C6974 CaM Kinase II alpha CAMK2A 2.63 --- --- 
B0561 BUB1 BUB1 --- --- 2.51 
P6834 Proliferating Cell Protein Ki-67 MKI67 --- --- 2.44 
T1076 TAP NXF1 -- 2.41 --- 
M7431 MAP Kinase 2 (ERK-2) MAPK1 --- --- 2.39 
P7482 PTEN PTEN 2.36 --- --- 
A4721 ARNO (Cytohesin-2) CYTH2 --- --- 2.26 
B1310 BACH1 BRIP1 --- --- 2.18 
C6987 Cortactin  CTTN --- 2.12 --- 
S7320 Spred-2 SPRED2 --- 2.11 --- 
R5275 RAIDD CRADD --- --- 2.08 
A2105 AP Endonuclease APEX1 2.06 ---  
U5258 Ubiquitin C-terminal UCHL1 2.06 --- --- 
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Hydrolase L1 
G7670 GRK2 ADRBK1 --- 2.03 --- 
E2520 Epidermal Growth Factor EGF --- --- 2.03 
M2820 MSH6 MSH6 --- --- 2.01 
C2542 N-cadherin CDH2 2.1 --- --- 
P8825 Proliferating cell nuclear 
antigen 
PCNA --- 2.01  
R3529 Rnase L RNASEL --- 2.0 --- 
M3566 MTBP MTBP --- --- 1.99 
B7806 Bcl-10 BCL10 --- --- 1.97 
E8767 c-erbB-3 ERBB3 --- --- 1.95 
E2777 c-erbB-2 ERBB2 --- --- 1.92 
C4864 Delta Catenin/NPRAP CTNND2 --- 1.92 --- 
H8163 Histone Deacetylase 5  HDAC5 1.92 --- --- 
M8432 p38 MAP Kinase  MAPK14 --- 1.92  
R6775 Retinoblastoma RB1 1.89 --- --- 
P0244 PKR EIF2AK2 --- --- 1.89 
B1684 Bmf BMF --- --- 1.89 
A4471 ARTS SEPT4 --- --- 1.88 
P9109 Protein Tyrosine Phosphatase 
PEST 
PTPN12 --- 1.87 --- 
C1862 Coilin COIL --- --- 1.87 
L4793 LDS1 KDM1A --- --- 1.87 
F9051 phospho FAK (pSer772) PTK2 --- --- 1.82 
R6028 ROCK-1 ROCK1 1.82 --- --- 
H2287 HDAC6 HDAC6 1.81 --- --- 
A8103 hABH1 ALKBH1 1.8 --- --- 
C9987 Cdk3 CDK3 1.8 --- --- 
G9038 Glutamate Receptor 
NMDAR2A 
GRIN2A 1.8 --- --- 
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Appendix N: DEPs associated with the MCF-7RR, MDARR and T47DRR breast 
cancer cell lines, identified previously by 2D-PAGE MALDI-TOF MS. 
DEPs were identified using the method previously described by Smith and colleagues 
(Smith et al., 2009).  Those proteins which are up-regulated (↑) and down-regulated (↓) in 
the radioresistant (RR) phenotype are highlighted. Proteins (≥2-fold in expression change) 
are listed alphabetically by gene name. Proteins identified as RIDEPs (section 3.3.3) are 
highlighted (*). 
 
RR cell line Protein name Gene name 
Direction of 
expression 
change in RR 
T47DRR Fructose-bisphosphate aldolase A ALDOA ↑ 
MDARR Aspartyl-tRNA synthetase (DARS) DARS ↓ 
T47DRR Aspartyl-tRNA synthetase (DARS) DARS ↑ 
T47DRR Eukaryotic translation initiation factor 
4A, isoform 1 
EIF4A1 ↑ 
T47DRR G elongation factor, mitochondrial 1 GFM1 ↑ 
MCF-7RR Glutathione S-transferase M3 GSTM3 ↓ 
T47DRR Heat shock 90-kDa protein 1 beta HSP90AB1 ↑ 
MCF-7RR L-Plastin LCP1 ↓ 
MDARR Moesin MSN ↓ 
MDARR Proteasome subunit, alpha type, 2 PSMA2 ↓ 
MDARR Proteasome subunit, alpha type 7 PSMA7 ↓ 
MCF-7RR Proteasome activator subunit 1, 
isoform 2 
PSME1 ↓ 
MCF-7RR Proteasome activator subunit 2 (PA28 
beta) 
PSME2 ↓ 
MDARR Glutaminyl-tRNA synthetase QARS ↑ 
MDARR Triosephosphate isomerise 1 * TPI1 ↓ 
T47DRR TRAP1 (HSP75) TRAP1 ↑ 
T47DRR α-Tubulin TUBA1A ↓ 
T47DRR Ubiquitin-activating enzyme E1 UBA1 ↑ 
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Appendix O: DEPs associated with the MCF-7RR, MDARR and T47DRR breast 
cancer cell lines, identified previously by iTRAQ. 
DEPs were identified using the method previously described by Smith and colleagues 
(Smith et al., 2009).  Those proteins which are up-regulated (↑) and down-regulated (↓) in 
the radioresistant (RR) phenotype are highlighted. Significantly expressed proteins (≥ 2-
fold) are listed alphabetically by gene name along with their corresponding fold change 
value. 
 
RR cell line Protein name Gene name 
Direction of 
expression 
change in RR 
MCF-7RR ACSF3 protein ACSF3 ↑ 3.0 
MCF-7RR ACTB protein ACTB ↓ 2.2 
MDARR Actinin, alpha 4 ACTN4 ↓ 2.0 
MDARR Desmoyokin AHNAK ↓ 2.4 
MCF-7RR Aldolase A ALDOA ↓ 2.1 
MCF-7RR Mitochondrial ATP synthase beta subunit 
precursor 
ATP5B ↓ 2.3 
T47DRR Josephin MJD1 ATXN3 ↓ 2.0 
MCF-7RR Fatty acid synthase FASN ↓ 2.4 
MCF-7RR Filamin A, alpha (actin binding protein 
280) 
FLNA 
↓ 2.8 
MDARR ↓ 2.7 
MCF-7RR alpha1,6 Fucosyltransferase FUT8 ↑ 2.0 
MCF-7RR Heterogeneous nuclear ribonucleoprotein 
A2/B1 isoform B1 
HNRNPA2B
1 
↓ 2.2 
MCF-7RR Heat shock protein 90-alpha HSP90AA1 ↓ 2.9 
MCF-7RR Heat shock protein 90-kDa beta (Grp94), 
member 1 
HSP90B1 ↓ 2.2 
MCF-7RR Heat Shock 70-kDa protein 1A HSPA1A ↓ 3.2 
MCF-7RR 
Glucose regulated protein (GRP78) HSPA5 
↓ 3.3 
MDARR ↓ 2.0 
MCF-7RR Heat shock 70-kDa protein 9 precursor HSPA9 ↓ 2.5 
MCF-7RR Chaperonin 60, Hsp60 HSPD1 ↓ 2.3 
MCF-7RR Cytokeratin 18 (424 AA) KRT18 ↓ 3.1 
MCF-7RR Keratin 19 KRT19 ↓ 3.6 
MCF-7RR Keratin 8 KRT8 ↓ 6.2 
MCF-7RR Lamin A/C transcript variant 1 LMNA ↓ 2.3 
MCF-7RR TPA: ubiquitin-specific protease 17-like 
protein 
LOC401447 ↑ 2.0 
MCF-7RR MDH2 MDH2 ↓ 2.0 
MDARR MYH9 MYH9 ↓ 2.3 
MCF-7RR Nucleolin NCL ↓ 2.7 
T47DRR OS9 OS9 ↓ 2.4 
MCF-7RR Prolyl 4-hydroxylase, beta polypeptide P4HB ↓ 2.3 
T47DRR PRKC, apoptosis, WT1, regulator PAWR ↑ 2.4 
MCF-7RR ER-60 protein PDIA3 ↓ 2.1 
MCF-7RR Pyruvate kinase, muscle PKM2 ↓ 2.1 
MDARR Plectin 1 isoform 3 PLEC1 ↓ 2.8 
MCF-7RR Protein phosphatase 1, regulatory PPP1R8 ↑ 2.1 
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(inhibitor) subunit 8 
MCF-7RR Ribonucleotide reductase M1 RRM1 ↑ 2.0 
T47DRR Structural maintenance of chromosomes 3 SMC3 ↓ 2.5 
T47DRR Surfeit 1 SURF1 ↓ 2.2 
MCF-7RR Triosephosphate isomerise 1 TPI1 ↓ 2.0 
MDARR Vimentin VIM ↓ 3.5 
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Appendix P: DEPs associated with the PJ41RR and PJ49RR cell lines, identified by 
previous antibody microarray analysis. 
Antibody microarray analysis was carried out as per section 4.5 (by Miss Dalia ElFadl). 
Those values that represent a significant fold change in expression (≥ 1.8) have been 
highlighted in bold. Supporting data ≥ 1.5 has also been included for proteins with a ≥ 1.8 
fold in expression. Protein fold changes that did not meet the level of significance (---) or 
did not pass analysis criteria () are also highlighted. Those proteins which were not linked 
to a specific gene name are labelled (ns) and RIDEPs (section 3.5.1) are labelled (*). 
 
Ab # Protein name Gene name PJ41 PJ49 
P7484 Serine/Threonine Protein Phosphatase 1 beta PPP1CB 3.07 
A4475 Annexin VII ANXA7 3.61 3.74 
B9310 BUBR1 BUB1B 2.58 1.84 
P5359 Serine/Threonine Protein Phosphatase 2 A/B 
gamma 
PPP2R2C 2.48 2.08 
B3183 BID * BID 2.05 2.33 
P7609 Serine/Threonine Protein Phosphatase 1 
gamma 1 
PPP1CC 2.25 3.64 
R8029 RAD17 RAD17 2.19 2.01 
C8035 Chondroitin Sulphate ACAN 2.30 1.98 
T9700 TWEAK Receptor TNFRSF12A 2.10 1.69 
B0686 BTK BTK 2.10 1.62 
H9787 hBRM hSNF 2a SMRCA2 1.69 2.38 
M3566 MTBP MTBP 1.62 2.05 
A6218 ATM ATM 1.55 2.00 
T9283 Tropomyosin TPM1 1.96 1.64 
C7055 Calmodulin CALM1 1.78 1.89 
C7034 Cytokeratin 8 12 ns 1.61 1.86 
S4191 SLIPR MAGI3 * MAGI3 1.84  1.77 
N2280 Nitric Oxide Synthase bNOS NOS1  8.88 
H4538 HDAC5 HDAC5 4.17 --- 
D3191 DAP Kinase 2 DAPK2  2.67 
N3279 Nerve Growth Factor b NGF  2.46 
I6139 IKKa * CHUK --- 2.29 
S5188 SGK SGK1 --- 2.19 
I9783 Importin a3 KPNA4  2.03 
S2532 S-100 Beta Subunit S100B --- 2.02 
P5704 Protein Kinase C PKC * PRKCB 2.10 --- 
P1601 Protein Kinase B alpha AKT1 --- 2.01 
S7945 Siah2 * SIAH2 2.10  
T9191 TRAIL TNFSF10 2.07 --- 
P2996 PRMT6 PRMT6  1.83 
F9301 FAK Phospho pSer910 PTK2 1.80  
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Appendix Q: IPA Legend. 
Any shape appearing in grey, represents the focus gene identifiers uploaded from the 
dataset. 
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Appendix R: The support of the literature on 8/13 most relevant pathways identified by IPA
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